<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacotherapy for post traumatic stress disorder (PTSD) - Williams, T - 2022 | Cochrane Library</title> <meta content="Pharmacotherapy for post traumatic stress disorder (PTSD) - Williams, T - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002795.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacotherapy for post traumatic stress disorder (PTSD) - Williams, T - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002795.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002795.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacotherapy for post traumatic stress disorder (PTSD)" name="citation_title"/> <meta content="Taryn Williams" name="citation_author"/> <meta content="University of Cape Town" name="citation_author_institution"/> <meta content="Nicole J Phillips" name="citation_author"/> <meta content="University of Cape Town" name="citation_author_institution"/> <meta content="Dan J Stein" name="citation_author"/> <meta content="University of Cape Town" name="citation_author_institution"/> <meta content="dan.stein@uct.ac.za" name="citation_author_email"/> <meta content="Jonathan C Ipser" name="citation_author"/> <meta content="University of Cape Town" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD002795.pub3" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/03/02" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002795.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002795.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002795.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amitriptyline [therapeutic use]; Antidepressive Agents [therapeutic use]; Antidepressive Agents, Tricyclic [therapeutic use]; *Antipsychotic Agents [therapeutic use]; Mirtazapine [therapeutic use]; Paroxetine [therapeutic use]; Selective Serotonin Reuptake Inhibitors [therapeutic use]; *Stress Disorders, Post-Traumatic [drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002795.pub3&amp;doi=10.1002/14651858.CD002795.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="sogqpCtr";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002795\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002795\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002795\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002795\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","pt","ms","ja","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002795.pub3",title:"Pharmacotherapy for post traumatic stress disorder (PTSD)",firstPublishedDate:"Mar 2, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Common Mental Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=sogqpCtr&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002795.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002795.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002795.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002795.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002795.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002795.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002795.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002795.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002795.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002795.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>15146 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002795.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#CD002795-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#CD002795-sec-0123"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#CD002795-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#CD002795-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#CD002795-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#CD002795-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#CD002795-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#CD002795-sec-0115"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/appendices#CD002795-sec-0128"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/supinfo/CD002795StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/supinfo/CD002795StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacotherapy for post traumatic stress disorder (PTSD)</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/information#CD002795-cr-0004">Taryn Williams</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/information#CD002795-cr-0005">Nicole J Phillips</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/information#CD002795-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Dan J Stein</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002795.pub3/information#CD002795-cr-0007">Jonathan C Ipser</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/information/en#CD002795-sec-0152">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 02 March 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002795.pub3">https://doi.org/10.1002/14651858.CD002795.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002795-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002795-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002795-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002795-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002795-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002795-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002795-abs-0001" lang="en"> <section id="CD002795-sec-0001"> <h3 class="title" id="CD002795-sec-0001">Background</h3> <p>Posttraumatic stress disorder (PTSD) is a prevalent and disabling disorder. Evidence that PTSD is characterised by specific psychobiological dysfunctions has contributed to a growing interest in the use of medication in its treatment. </p> </section> <section id="CD002795-sec-0002"> <h3 class="title" id="CD002795-sec-0002">Objectives</h3> <p>To assess the effects of medication for reducing PTSD symptoms in adults with PTSD.</p> </section> <section id="CD002795-sec-0003"> <h3 class="title" id="CD002795-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL; Issue 11, November 2020); MEDLINE (1946‐), Embase (1974‐), PsycINFO (1967‐) and PTSDPubs (all available years) either directly or via the Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR). We also searched international trial registers. The date of the latest search was 13 November 2020. </p> </section> <section id="CD002795-sec-0004"> <h3 class="title" id="CD002795-sec-0004">Selection criteria</h3> <p>All randomised controlled trials (RCTs) of pharmacotherapy for adults with PTSD.</p> </section> <section id="CD002795-sec-0005"> <h3 class="title" id="CD002795-sec-0005">Data collection and analysis</h3> <p>Three review authors (TW, JI, and NP) independently assessed RCTs for inclusion in the review, collated trial data, and assessed trial quality. We contacted investigators to obtain missing data. We stratified summary statistics by medication class, and by medication agent for all medications. We calculated dichotomous and continuous measures using a random‐effects model, and assessed heterogeneity. </p> </section> <section id="CD002795-sec-0006"> <h3 class="title" id="CD002795-sec-0006">Main results</h3> <p>We include 66 RCTs in the review (range: 13 days to 28 weeks; 7442 participants; age range 18 to 85 years) and 54 in the meta‐analysis.  </p> <p>For the primary outcome of treatment response, we found evidence of beneficial effect for selective serotonin reuptake inhibitors (SSRIs) compared with placebo (risk ratio (RR) 0.66, 95% confidence interval (CI) 0.59 to 0.74; 8 studies, 1078 participants), which improved PTSD symptoms in 58% of SSRI participants compared with 35% of placebo participants, based on moderate‐certainty evidence.  </p> <p>For this outcome we also found evidence of beneficial effect for the noradrenergic and specific serotonergic antidepressant (NaSSA) mirtazapine: (RR 0.45, 95% CI 0.22 to 0.94; 1 study, 26 participants) in 65% of people on mirtazapine compared with 22% of placebo participants, and for the tricyclic antidepressant (TCA) amitriptyline (RR 0.60, 95% CI 0.38 to 0.96; 1 study, 40 participants) in 50% of amitriptyline participants compared with 17% of placebo participants, which improved PTSD symptoms. These outcomes are based on low‐certainty evidence. There was however no evidence of beneficial effect for the number of participants who improved with the antipsychotics (RR 0.51, 95% CI 0.16 to 1.67; 2 studies, 43 participants) compared to placebo, based on very low‐certainty evidence. </p> <p>For the outcome of treatment withdrawal, we found evidence of a harm for the individual SSRI agents compared with placebo (RR 1.41, 95% CI 1.07 to 1.87; 14 studies, 2399 participants). Withdrawals were also higher for the separate SSRI paroxetine group compared to the placebo group (RR 1.55, 95% CI 1.05 to 2.29; 5 studies, 1101 participants). Nonetheless, the absolute proportion of individuals dropping out from treatment due to adverse events in the SSRI groups was low (9%), based on moderate‐certainty evidence. For the rest of the medications compared to placebo, we did not find evidence of harm for individuals dropping out from treatment due to adverse events. </p> </section> <section id="CD002795-sec-0007"> <h3 class="title" id="CD002795-sec-0007">Authors' conclusions</h3> <p>The findings of this review support the conclusion that SSRIs improve PTSD symptoms; they are first‐line agents for the pharmacotherapy of PTSD, based on moderate‐certainty evidence. The NaSSA mirtazapine and the TCA amitriptyline may also improve PTSD symptoms, but this is based on low‐certainty evidence. In addition, we found no evidence of benefit for the number of participants who improved following treatment with the antipsychotic group compared to placebo, based on very low‐certainty evidence. There remain important gaps in the evidence base, and a continued need for more effective agents in the management of PTSD. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002795-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002795-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002795-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002795-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002795-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD002795-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002795-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD002795-abs-0014">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD002795-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002795-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002795-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD002795-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002795-abs-0002" lang="en"> <h3>Medication for posttraumatic stress disorder</h3> <p><b>Why is this review important?</b> </p> <p>Posttraumatic stress disorder (PTSD) occurs after exposure to significant trauma and results in enormous personal and societal costs. Although it has traditionally been treated with psychotherapy, medication treatments have proven effective in PTSD treatment. </p> <p><b>Who will be interested in this review?</b> </p> <p>‐ People with PTSD.<br/>‐ Families and friends of people who suffer from PTSD.<br/>‐ General practitioners, psychiatrists, psychologists, and pharmacists. </p> <p><b>What question does this review aim to answer?</b> </p> <p>‐ Is pharmacotherapy effective for reducing PTSD symptoms in adults with PTSD?<br/>  </p> <p><b>Which studies were included in the review?</b> </p> <p>We included studies comparing medication with placebo or a control, or both, for the treatment of PTSD in adults.<br/>We included 66 trials in the review, with a total of 7442 participants. </p> <p><b>What does the evidence from the review tell us?</b> </p> <p>There was evidence of a beneficial effect that selective serotonin reuptake inhibitors (SSRIs) improve PTSD symptoms compared to placebo, based on moderate‐certainty evidence. There was also evidence of a benefit for the noradrenergic and specific serotonergic antidepressant (NaSSA) mirtazapine and the tricyclic antidepressant (TCA) amitriptyline, in improving PTSD symptoms, based on low‐certainty evidence. We also found no evidence of benefit for the number of participants who improved following treatment with the antipsychotic group compared to placebo, based on very low‐certainty evidence. For the remaining medication classes, we did not observe evidence of a benefit for improving PTSD symptoms. </p> <p>There was evidence of a harm that more people taking individual SSRI agents dropped out due to side effects than did those taking placebo, but absolute withdrawal rates were low for the SSRI groups. </p> <p><b>What should happen next?</b> </p> <p>Most evidence for pharmacotherapy efficacy is related to SSRIs for acute treatment. There is an ongoing need to develop new pharmacotherapeutic treatments of PTSD. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002795-sec-0123" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002795-sec-0123"></div> <h3 class="title" id="CD002795-sec-0124">Implications for practice</h3> <section id="CD002795-sec-0124"> <p>Medication treatments can be effective in PTSD, acting to increase treatment response and to reduce symptoms, and should be considered as part of the treatment of this disorder. The existing evidence base of RCTs includes a heterogeneous sample of participants with a range of different traumas, trauma duration and severity, and comorbidity. The greatest number of trials showing efficacy so far, as well as the largest, have been with the SSRIs. </p> </section> <h3 class="title" id="CD002795-sec-0125">Implications for research</h3> <section id="CD002795-sec-0125"> <p>Given the prevalence and costs of PTSD, there is a need for improved study design and controlled clinical trials for the treatment of this disorder. The varying efficacy and tolerability of different classes of medication, including a range of newer agents potentially useful in this disorder, requires further study. Questions for future research also include the precise effects of medication on quality‐of‐life measures, appropriate dose and duration of medication, and determining factors which predict response to medication. Further research on the value of medication in PTSD in different trauma groups, in paediatric and geriatric recipients, in patients with comorbid substance use, and in treatment of refractory patients is needed. Clinical trials to determine the possible benefits of early (prophylactic), combined (with psychotherapy), and long‐term (maintenance) interventions in PTSD may also be valuable. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002795-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002795-sec-0008"></div> <div class="table" id="CD002795-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Comparison 1: Alpha‐blockers versus placebo for posttraumatic stress disorder (PTSD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 1: Alpha‐blockers versus placebo for posttraumatic stress disorder (PTSD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population</b> : adults (aged 18‐85)<br/><b>Settings</b> : multi‐centre trials<br/><b>Intervention</b> : alpha‐blocker<br/><b>Comparison</b>: placebo </p> <p><b>Follow‐up:</b> not specified </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With alpha‐blockers</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies that looked at the number of participants who responded to prazosin compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment tolerability, as measured by Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.99</b><br/>(0.91 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>304<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No evidence of a difference in dropout rates were found in the alpha‐blocker group (13%) and placebo group (12%) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>118 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>117 per 1000</b><br/>(108 to 128) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>118 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>117 per 1000</b><br/>(107 to 127) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : confidence interval;<b>RR</b> : risk ratio. <b>N/A:</b> Not applicable. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to serious risk of bias (concerns with randomisation procedures). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002795-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Comparison 2: Antipsychotics versus placebo for posttraumatic stress disorder (PTSD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 2: Antipsychotics versus placebo for posttraumatic stress disorder (PTSD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population</b> : adults (aged 18‐85)<br/><b>Settings</b> : single and multi‐centre trials<br/><b>Intervention</b> : antipsychotics<br/><b>Comparison</b>: placebo </p> <p><b>Follow‐up</b>: not specified </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With</b> antipsychotics </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.51</b> <br/>(0.16 to 1.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>43<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no evidence of a benefit of the number of participants in the antipsychotic groups (71%) compared to the placebo groups (37%) who responded and improved on the CGI‐I scale </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>368 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>188 per 1000</b><br/>(59 to 615) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>443 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>226 per 1000</b><br/>(71 to 740) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment tolerability, as measured by Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.98</b> <br/>(0.92 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>348<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Twice as many participants withdrew from the antipsychotic groups (16%) compared to the placebo groups (7%), but no important difference in dropout rates was found </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>66 per 1000</b><br/>(60 to 73) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to serious risk of bias (concerns with randomisation procedures).<br/><sup>b</sup>Downgraded by one level due to serious imprecision (wide confidence intervals).<br/><sup>c</sup>Downgraded by one level due to moderate heterogeneity (I<sup>2</sup> of 50%). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002795-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Comparison 3: MAOIs versus placebo for posttraumatic stress disorder (PTSD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 3: MAOIs versus placebo for posttraumatic stress disorder (PTSD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population</b> : adults (aged 18‐85)<br/><b>Settings</b> : multi‐centre trial<br/><b>Intervention</b> : MAOI<br/><b>Comparison</b>: placebo </p> <p><b>Follow‐up</b>: not specified </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With MAOIs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies that looked at the number of participants who responded to phenelzine versus placebo. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment tolerability, as measured by Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.14</b> <br/>(0.90 to 1.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>37<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>More participants dropped out from the placebo group (17%) compared to the MAOI group (5%), but we found no difference in dropout rates </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>190 per 1000</b><br/>(150 to 238) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>190 per 1000</b><br/>(150 to 239) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : confidence interval;<b>RR</b> : risk ratio. <b>N/A:</b> Not applicable. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to serious risk of bias (concerns with randomisation procedures).<br/><sup>b</sup>Downgraded by one level due to serious imprecision (wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002795-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Comparison 4: NaSSAs versus placebo for posttraumatic stress disorder (PTSD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 4: NaSSAs versus placebo for posttraumatic stress disorder (PTSD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population</b> : adults (aged 18‐85)<br/><b>Settings</b> : single‐centre trial<br/><b>Intervention</b> : NaSSA<br/><b>Comparison</b>: placebo </p> <p><b>Follow‐up:</b> not specified </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With NaSSAs</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment efficacy ‐ Treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.45</b> <br/>(0.22 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>26<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence of a benefit for the number of participants with PTSD who responded to treatment (65%) compared to placebo (22%). This is also indicated by the Risk Ratio of 0.45 which indicates that there is a statistically significantly greater number of people in the NaSSA group compared to the placebo group who improved on the CGI‐I scale </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/>(49 to 209) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/>(49 to 209) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment tolerability, as measured by Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.87</b> <br/>(0.68 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>36<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The proportion of dropouts due to adverse events was high in participants receiving the NaSSA (18%) relative to placebo (5%), but there was no </p> <p>evidence of a harm between the numbers of participants that dropped out due to adverse events </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b><br/>(20 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>178 per 1000</b><br/>(20 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>CAPS:</b> Clinically Administered PTSD Scale;<b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to serious risk of bias (concerns with randomisation procedures).<br/><sup>b</sup>Downgraded by one level due to serious imprecision (wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002795-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Comparison 5: SNRIs versus placebo for posttraumatic stress disorder (PTSD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 5: SNRIs versus placebo for posttraumatic stress disorder (PTSD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population</b> : adults (aged 18‐85)<br/><b>Settings</b> : multi‐centre trials<br/><b>Intervention</b> : SNRIs<br/><b>Comparison</b>: placebo </p> <p><b>Follow‐up:</b> for one study at week 24 or at the time of discontinuation if before week 24; the remaining study did not specify follow‐up </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With SNRIs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies that looked at the number of participants who responded to venlafaxine versus placebo. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment tolerability, as measured by Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.98</b> <br/>(0.88 to 1.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>687<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Dropout rates due to adverse events were low in the SNRI (4%) and placebo groups (3%)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b><br/>(23 to 29) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b><br/>(24 to 30) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : confidence interval;<b>RR</b> : risk ratio. <b>N/A:</b> Not applicable. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to serious risk of bias (concerns with randomisation procedures).<br/><sup>b</sup>Downgraded by two levels due to considerable heterogeneity (I<sup>2</sup> of 92%). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002795-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Comparison 6: SSRIs versus placebo for posttraumatic stress disorder (PTSD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 6: SSRIs versus placebo for posttraumatic stress disorder (PTSD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population</b> : adults (aged 18‐85)<br/><b>Settings</b> : single and multi‐centre trials<br/><b>Intervention</b> : SSRIs<br/><b>Comparison</b>: placebo </p> <p><b>Follow‐up:</b> for 1 study at week 10 and for another study 14 days after the last dose of study drug; the remaining studies did not specify follow‐up </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With SSRIs</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.66</b> <br/>(0.59 to 0.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1078<br/>(8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence of a benefit for the number of participants with PTSD who responded to treatment for the SSRI group (58%) compared to the placebo group (35%). This is also indicated by the Risk Ratio of 0.66 which indicates that there is a statistically significantly greater number of people in the SSRI group compared to the placebo group who improved on the CGI‐I scale </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>348 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>229 per 1000</b><br/>(205 to 257) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>328 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>216 per 1000</b><br/>(194 to 243) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment tolerability, as measured by Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.98</b> <br/>(0.96 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2399<br/>(14 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>A similar proportion withdrew due to treatment adverse events (9% versus 7%)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>66 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b><br/>(64 to 66) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b><br/>(48 to 50) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to serious risk of bias (concerns with randomisation procedures). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002795-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Comparison 7: TCAs versus placebo for posttraumatic stress disorder (PTSD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 7: TCAs versus placebo for posttraumatic stress disorder (PTSD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population</b> : adults (aged 18‐85)<br/><b>Settings</b> : single and multi‐centre trials<br/><b>Intervention</b> : TCAs<br/><b>Comparison</b>: placebo </p> <p><b>Follow‐up:</b> not specified </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With TCAs</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.60</b> <br/>(0.38 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>40<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence of a benefit for the number of participants with PTSD who responded to treatment in the TCA group (50%) compared to the placebo group (17%). This is also indicated by the Risk Ratio of 0.60, which indicates that there is a statistically significantly greater number of people in the TCA group compared to the placebo group who improved on the CGI‐I scale </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/>(63 to 160) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/>(63 to 160) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment tolerability, as measured by Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.92</b> <br/>(0.81 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>141<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>We found no evidence of a difference in dropout rates between the TCA groups (23%) and placebo groups (18%) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b><br/>(147 to 191) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale;<b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to serious risk of bias (concerns with randomisation procedures).<br/><sup>b</sup>Downgraded by one level due to serious imprecision (wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002795-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002795-sec-0009"></div> <section id="CD002795-sec-0010"> <h3 class="title" id="CD002795-sec-0010">Description of the condition</h3> <p>Although the phenomenon of posttraumatic stress disorder (PTSD) has long been recognised (for example as "shell shock" or "combat neurosis"), this disorder was only officially recognised in the psychiatric nomenclature in 1980 (<a href="./references#CD002795-bbs2-0155" title="American Psychiatric Association.Diagnostic and statistical manual of mental disorders (DSM-III). 3rd edition. Washington, DC: American Psychiatric Association, 1980.">APA 1980</a>). Diagnostic criteria for PTSD provided by the 3rd edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM‐III) encouraged research on the epidemiology, psychobiology, and treatment of PTSD. The latest version of the Diagnostic and Statistical Manual (i.e. DSM‐5) has made a number of notable revisions. First, PTSD is now classified in a new category, Trauma‐ and Stressor‐Related Disorders, in which the onset of every disorder has been preceded by exposure to a traumatic or otherwise adverse environmental event (<a href="./references#CD002795-bbs2-0222" title="FriedmanMJ .PTSD: National Center for PTSD. U.S Department of Veterans Affairs2016.">Friedman 2016</a>). Second, a fourth cluster of symptoms has been included (i.e. negative cognitions and mood) (<a href="./references#CD002795-bbs2-0157" title="American Psychiatric Association.Diagnostic and statistical manual of mental Disorders, fifth edition. Arlington, VA: American Psychiatric Publishing, 2013.">APA 2013</a>). </p> <p>DSM‐5 criteria for PTSD are as follows. The "A" criterion states that a person must be exposed to a catastrophic event involving actual or threatened death or injury, or a threat to the physical integrity of him/herself or others (for example, sexual violence) for the event to be regarded as a trauma. The "B" criterion (i.e. intrusive recollection) includes symptoms that are distinctive and readily identifiable, like panic, terror, dread, grief, or despair. These symptoms manifest during the daytime as intrusive images, traumatic nightmares, and flashbacks. The "C" criterion (i.e. avoidance criterion) consists of behavioural strategies used by people with PTSD to reduce trauma‐related events. Symptoms included in the "D" criterion reflect negative cognitions and moods that have developed after exposure to the traumatic event (i.e. blame, anger, guilt, or shame). Symptoms included in the "E" criterion are from alterations in arousal or reactivity such as hypervigilance or paranoia. The "F" or duration criterion stipulates that symptoms must persist for at least one month before PTSD may be diagnosed. Within the "G" criterion (i.e. functional significance criterion) the survivor must experience significant social, occupational, or other distress as a result of these symptoms, and in the "H" criterion (or exclusion criterion), these symptoms cannot be due to medication use, substance use, or other illnesses (<a href="./references#CD002795-bbs2-0157" title="American Psychiatric Association.Diagnostic and statistical manual of mental Disorders, fifth edition. Arlington, VA: American Psychiatric Publishing, 2013.">APA 2013</a>). </p> <p>Further, epidemiological research using DSM criteria for PTSD has determined that the disorder is highly prevalent in a wide range of settings, particularly in those people who have been exposed to significant traumas (<a href="./references#CD002795-bbs2-0174" title="BreslauN , DavisGC , AndreskiP .Traumatic events and post traumatic stress disorder in an urban population of young adults. Archives of General Psychiatry1991;48(3):216-22.">Breslau 1991</a>; <a href="./references#CD002795-bbs2-0250" title="KesslerRC , SonnegaA , BrometE , HughesM , NelsonCB .Posttraumatic stress disorder in the National Comorbidity Survey. Archives of General Psychiatry1995;52(12):1048-60.">Kessler 1995</a>; <a href="./references#CD002795-bbs2-0253" title="KoenenKC , RatanatharathornA , NgL , McLaughlinKA , BrometEJ , SteinDJ , et al.Posttraumatic stress disorder in the World Mental Health Surveys. Psychological Medicine2017;47(13):2260–74. [DOI: 10.1017/S0033291717000708]">Koenen 2017</a>). Estimates from the National Comorbidity Survey Replication indicate lifetime PTSD prevalence rates of 3.6% and 9.7%, among men and women in the USA, respectively (<a href="./references#CD002795-bbs2-0251" title="KesslerRC , ChiuWT , DemlerO , MerikangasKR , WaltersEE .Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry2005;62:617-27. [DOI: 10.1001/archpsyc.62.6.617]">Kessler 2005</a>). In the World Mental Health Survey (WMHS), prevalence rates are high in low‐, middle‐, and high‐income countries, with differences in gender prevalence again seen (<a href="./references#CD002795-bbs2-0253" title="KoenenKC , RatanatharathornA , NgL , McLaughlinKA , BrometEJ , SteinDJ , et al.Posttraumatic stress disorder in the World Mental Health Surveys. Psychological Medicine2017;47(13):2260–74. [DOI: 10.1017/S0033291717000708]">Koenen 2017</a>). Higher rates of PTSD have been reported in post‐conflict settings (<a href="./references#CD002795-bbs2-0206" title="De JongJ , KomproeTV , IvanH , Von OmmerenM , El MasriM , ArayaM , et al.Lifetime events and posttraumatic stress disorder in 4 postconflict settings. JAMA2001;286(5):555-62. [DOI: 10.1001/jama.286.5.555]">De Jong 2001</a>). </p> <p>There is growing evidence that PTSD results in enormous personal and societal costs; this is based on chronicity of symptoms, high comorbidity of psychiatric and medical disorders, marked functional impairment, and estimations of economic costs (<a href="./references#CD002795-bbs2-0177" title="BrunelloN , DavidsonJR , DeahlM , KesslerRC , MendlewiczJ , RacagniG , et al.Posttraumatic stress disorder: diagnosis and epidemiology, comorbidity and social consequences, biology and treatment. Neuropsychobiology2001;43(3):150-62.">Brunello 2001</a>; <a href="./references#CD002795-bbs2-0253" title="KoenenKC , RatanatharathornA , NgL , McLaughlinKA , BrometEJ , SteinDJ , et al.Posttraumatic stress disorder in the World Mental Health Surveys. Psychological Medicine2017;47(13):2260–74. [DOI: 10.1017/S0033291717000708]">Koenen 2017</a>; <a href="./references#CD002795-bbs2-0285" title="SolomonSD , DavidsonJR .Trauma: prevalence, impairment, service use, and cost. Journal of Clinical Psychiatry1997;58(Suppl 5):1-11.">Solomon 1997</a>). Furthermore, PTSD may be characterised by specific psychobiological dysfunctions mediated by neurobiological mechanisms, which may in turn be targeted by specific preventive and therapeutic pharmacological interventions (<a href="./references#CD002795-bbs2-0154" title="AmosT , SteinDJ , IpserJC .Pharmacological interventions for preventing post-traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews2014, Issue Issue 7. Art. No.: CD006239. Art. No: CD006239. [DOI: 10.1002/14651858.CD006239.pub2]">Amos 2014</a>; <a href="./references#CD002795-bbs2-0167" title="BernardyNC , FriedmanMJ .Pharmacological management of posttraumatic stress disorder. Current Opinion in Psychology2017;14:116-21. [DOI: doi.org/10.1016/j.copsyc.2017.01.003]">Bernardy 2017</a>; <a href="./references#CD002795-bbs2-0183" title="CharneyDS , DeutchAY , KrystalJH , SouthwickSM , DavisM .Psychobiologic mechanisms of posttraumatic stress disorder. Archives of General Psychiatry1993;50(4):294-306.">Charney 1993</a>). There is certainly growing evidence in PTSD for specific dysregulations of neurotransmitter systems (including the serotonin, noradrenaline, and dopamine systems) and neuroendocrine systems (including the hypothalamus‐pituitary‐adrenal axis), as well as for structural and functional neuroanatomical abnormalities (<a href="./references#CD002795-bbs2-0173" title="BremnerJD , VermettenE .Neuroanatomical changes associated with pharmacotherapy in posttraumatic stress disorder. Annals of the New York Academy of Science2004;1032:154-7.">Bremner 2004</a>; <a href="./references#CD002795-bbs2-0181" title="CaniveJM , LewineJD , Orrison WW Jr, EdgarCJ , ProvencalSL , DavisJT , et al.MRI reveals gross structural abnormalities in PTSD. Annals of the New York Academy of Sciences1997;821:512-5.">Canive 1997</a>; <a href="./references#CD002795-bbs2-0183" title="CharneyDS , DeutchAY , KrystalJH , SouthwickSM , DavisM .Psychobiologic mechanisms of posttraumatic stress disorder. Archives of General Psychiatry1993;50(4):294-306.">Charney 1993</a>; <a href="./references#CD002795-bbs2-0186" title="ConnorKM , DavidsonJR .The role of serotonin in posttraumatic stress disorder: neurobiology and pharmacotherapy. CNS Spectrums1998;3(7S2):43-51.">Connor 1998</a>; <a href="./references#CD002795-bbs2-0283" title="SherinJE , NemeroffCB .Post-traumatic stress disorder: the neurobiological impact of psychological trauma. Dialogues in Clinical Neuroscience2011;13(3):263-78.">Sherin 2011</a>; <a href="./references#CD002795-bbs2-0297" title="YehudaR , McFarlaneAC .Conflict between current knowledge about posttraumatic stress disorder and its original conceptual basis. American Journal of Psychiatry1995;152(12):1705-13.">Yehuda 1995</a>). </p> <p>Prior psychological trauma plays a causal role in PTSD, and psychotherapy has been widely deployed in its management. Although psychodynamic psychotherapy has long been the mainstay of treatment, there have been few controlled studies of this modality (<a href="./references#CD002795-bbs2-0175" title="BromD , KleberRJ , DefaresPB .Brief psychotherapy for posttraumatic stress disorders. Journal of Consulting and Clinical Psychology1989;57(5):607-12.">Brom 1989</a>; <a href="./references#CD002795-bbs2-0223" title="GersonsBP , CarlierIV , LambertsRD , Van der KolkBA .Randomized clinical trial of brief eclectic psychotherapy for police officers with posttraumatic stress disorder. Journal of Trauma Stress2000;13(2):333-47.">Gersons 2000</a>; <a href="./references#CD002795-bbs2-0224" title="Gilboa-SchechtmanE , FoaEB , ShafranN , AderkaIM , PowersMB , RachamimL , et al.Prolonged exposure versus dynamic therapy for adolescent PTSD: a pilot randomized controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry2010;49(10):1034-42. [DOI: 10.1016/j.jaac.2010.07.014]">Gilboa‐Schechtman 2010</a>). The value of so‐called psychological debriefing in the immediate aftermath of trauma remains to be proven (<a href="./references#CD002795-bbs2-0277" title="RoseS , BissonJ .Brief early psychological interventions following trauma: a systematic review of the literature. Journal of Traumatic Stress1998;11(4):697-710.">Rose 1998</a>; <a href="./references#CD002795-bbs2-0278" title="RoseS , BissonJ , WesselyS .Psychological debriefing for preventing post traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews2002, Issue 2. Art. No: CD000560. [DOI: 10.1002/14651858.CD000560]">Rose 2002</a>). Indeed, there is evidence that acute post‐trauma debriefing may worsen PTSD symptoms, prompting guidelines to advise against its use (<a href="./references#CD002795-bbs2-0225" title="GistR .Psychological debriefing. In: Encyclopaedia of Clinical Psychology. Chichester: John Wiley &amp; Sons, Inc, 2015.">Gist 2015</a>). Nevertheless, there is a growing body of evidence demonstrating that cognitive‐behavioural and similar psychotherapies are indeed effective in the treatment of PTSD (<a href="./references#CD002795-bbs2-0168" title="BissonJI , AndrewM .Psychological treatment of post-traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews2007, Issue 12. Art. No: CD003388. [DOI: 10.1002/14651858.CD003388.pub3]">Bisson 2007</a>; <a href="./references#CD002795-bbs2-0172" title="BradleyR , GreeneJ , RussE , DutraL , WestenD .A multidimensional meta-analysis of psychotherapy for PTSD. American Journal of Psychiatry2005;162(2):214-27.">Bradley 2005</a>; <a href="./references#CD002795-bbs2-0235" title="HarveyAG , BryantRA , TarrierN .Cognitive behaviour therapy for posttraumatic stress disorder. Clinical Psychology Review2003;23(3):501-22.">Harvey 2003</a>; <a href="./references#CD002795-bbs2-0271" title="NICE.Post-traumatic stress disorder: management (NG116). Clinical guideline Published: December 2018. National Institute for Health and Care Excellence2018.">NICE 2018</a>; <a href="./references#CD002795-bbs2-0292" title="WatkinsLE , SprangKR , RothbaumBO .Treating PTSD: a review of evidence-based psychotherapy interventions. Frontiers in Behavioral Neuroscience2018;12:258. [DOI: doi:10.3389/fnbeh.2018.00258]">Watkins 2018</a>). </p> <p>Whereas in older models medications might be valuable primarily as an adjunct to psychotherapy techniques in post‐traumatic reactions (<a href="./references#CD002795-bbs2-0280" title="SargentWW , SlaterE .Acute war neuroses. Lancet1940;140:1-2.">Sargent 1940</a>), contemporary psychobiological theory speculates that comorbid substance use in PTSD may represent an attempt at 'self‐medication' and that prescribed medication may be able to play a primary role in preventing or reversing the dysfunctions of PTSD (<a href="./references#CD002795-bbs2-0183" title="CharneyDS , DeutchAY , KrystalJH , SouthwickSM , DavisM .Psychobiologic mechanisms of posttraumatic stress disorder. Archives of General Psychiatry1993;50(4):294-306.">Charney 1993</a>; <a href="./references#CD002795-bbs2-0184" title="CharneyD .Psychobiological mechanisms of resilience and vulnerability: Implications for successful adaptation to extreme stress. American Journal of Psychiatry2004;161(2):195-216.">Charney 2004</a>; <a href="./references#CD002795-bbs2-0275" title="ResslerKJ .Alpha-adrenergic receptors in PTSD -failure or time for precision medicine?New England Journal of Medicine2018;378:575-6. [DOI: 10.1056/NEJMe1716724]">Ressler 2018</a>). PTSD frequently includes comorbid disorders such as major affective disorders, dysthymia, alcohol or substance abuse disorders, anxiety disorders, or personality disorders (<a href="./references#CD002795-bbs2-0222" title="FriedmanMJ .PTSD: National Center for PTSD. U.S Department of Veterans Affairs2016.">Friedman 2016</a>). Certain of these comorbid conditions are known to respond to medication (<a href="./references#CD002795-bbs2-0250" title="KesslerRC , SonnegaA , BrometE , HughesM , NelsonCB .Posttraumatic stress disorder in the National Comorbidity Survey. Archives of General Psychiatry1995;52(12):1048-60.">Kessler 1995</a>; <a href="./references#CD002795-bbs2-0251" title="KesslerRC , ChiuWT , DemlerO , MerikangasKR , WaltersEE .Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry2005;62:617-27. [DOI: 10.1001/archpsyc.62.6.617]">Kessler 2005</a>). Indeed, the position that medication treatment may be useful in PTSD seems to have gained gradually increasing acceptance (<a href="./references#CD002795-bbs2-0158" title="AsnisGM , KohnSR , HendersonM , BrownNL .SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations. Drugs2004;64(4):383-404.">Asnis 2004</a>; <a href="./references#CD002795-bbs2-0161" title="BaldwinDS , AndersonIM , NuttDJ , AllgulanderC , BandelowB , Den BoerJA .Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. Journal of Psychopharmacology2014;28(5):403-39. [DOI: 10.1177/0269881114525674]">Baldwin 2014</a>; <a href="./references#CD002795-bbs2-0186" title="ConnorKM , DavidsonJR .The role of serotonin in posttraumatic stress disorder: neurobiology and pharmacotherapy. CNS Spectrums1998;3(7S2):43-51.">Connor 1998</a>; <a href="./references#CD002795-bbs2-0191" title="CyrM , FarrarMK .Treatment for posttraumatic stress disorder. Annals of Pharmacotherapy2000;34(3):366-76.">Cyr 2000</a>; <a href="./references#CD002795-bbs2-0199" title="DavidsonJR .Pharmacotherapy of posttraumatic stress disorder: treatment options, long term follow-up, and predictors of outcome. Journal of Clinical Psychiatry2000;61(Suppl 5):52-6.">Davidson 2000</a>; <a href="./references#CD002795-bbs2-0218" title="FoaEB , DavidsonJR , FrancesA .The expert consensus guideline series: treatment of posttraumatic stress disorder: the expert consensus panel for PTSD. Journal of Clinical Psychiatry1999;60(Suppl. 16):1-75.">Foa 1999</a>; <a href="./references#CD002795-bbs2-0262" title="MarshallRD , SteinDJ , LiebowitzMR , YehudaR .Psychopharmacology of posttraumatic stress disorder. Psychiatric Annals1996;26:217-26.">Marshall 1996</a>; <a href="./references#CD002795-bbs2-0263" title="MarshallRD , DavidsonJR , YehudaR .Pharmacotherapy in the treatment of posttraumatic stress disorder and other trauma-related disorders. In: YehudaR , editors(s). Psychological Trauma. Washington, DC: American Psychiatric Press, 1998:133-77.">Marshall 1998a</a>; <a href="./references#CD002795-bbs2-0265" title="MarshallRD , PierceD .Implications of recent findings in posttraumatic stress disorder and the role of pharmacotherapy. Harvard Review of Psychiatry2000;7(5):247-56.">Marshall 2000</a>; <a href="./references#CD002795-bbs2-0290" title="UrsanoRJ , BellC , EthS , FriedmanM , NorwoodA , PfefferbaumB , et al.Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. American Journal of Psychiatry2004;161(11 Suppl):3-31.">Ursano 2004</a>; <a href="./references#CD002795-bbs2-0281" title="ShalevA , BonneE , EthS .Treatment of posttraumatic stress disorder: a review. Psychosomatic Medicine1996;58(2):162-82.">Shalev 1996</a>). </p> </section> <section id="CD002795-sec-0011"> <h3 class="title" id="CD002795-sec-0011">Description of the intervention</h3> <p>Early reports of the pharmacotherapy of PTSD focused on the tricyclic antidepressants (TCAs) and the irreversible monoamine oxidase inhibitors (MAOIs) (<a href="./references#CD002795-bbs2-0165" title="BasogluM , MarksIM , SenguenS .Amitriptyline for PTSD in a torture survivor: a case study. Journal of Traumatic Stress1992;5:77-83.">Basoglu 1992</a>; <a href="./references#CD002795-bbs2-0171" title="BleichA , SiegelB , GarbR , LererB .Post-traumatic stress disorder following combat exposure: clinical features and psychopharmacological treatment. British Journal of Psychiatry1986;149:365-9.">Bleich 1986</a>; <a href="./references#CD002795-bbs2-0178" title="BursteinA .Treatment of posttraumatic stress disorder with imipramine. Psychosomatics1984;25(9):681-7.">Burstein 1984</a>; <a href="./references#CD002795-bbs2-0185" title="ChenC .The obsessive quality and clomipramine treatment of PTSD. American Journal of Psychiatry1991;148(8):1087-8.">Chen 1991</a>; <a href="./references#CD002795-bbs2-0192" title="DavidsonJ , WalkerI , KiltsC .A pilot study of phenelzine in the treatment of post-traumatic stress disorder. British Journal of Psychiatry1987;150:252-5.">Davidson 1987</a>; <a href="./references#CD002795-bbs2-0193" title="DavidsonJR , NemeroffCB .Pharmacotherapy in posttraumatic stress disorder: historical and clinical considerations and future directions. Psychopharmacology Bulletin1989;25(3):422-5.">Davidson 1989</a>; <a href="./references#CD002795-bbs2-0213" title="FalconS , RyanC , ChamberlainK , CurtisG .Tricyclics: possible treatment for post-traumatic stress disorder. Journal of Clinical Psychiatry1985;46(9):385-9.">Falcon 1985</a>; <a href="./references#CD002795-bbs2-0085" title="FrankJB , KostenTR , Giller EL Jr, DanE .A randomized clinical trial of phenelzine and imipramine for post-traumatic stress disorder. American Journal of Psychiatry1988;145(10):1289-91. ">Frank 1988</a>; <a href="./references#CD002795-bbs2-0241" title="HogbenGL , CornfieldRB .Treatment of traumatic war neurosis with phenelzine. Archives of General Psychiatry1981;38(4):440-5.">Hogben 1981</a>; <a href="./references#CD002795-bbs2-0247" title="IrwinM , Van-PuttenT , GuzeB , MarderSR .Pharmacologic treatment of veterans with posttraumatic stress disorder and concomitant affective disorder. Annals of Clinical Psychiatry1989;1(2):127-30.">Irwin 1989</a>; <a href="./references#CD002795-bbs2-0032" title="KostenTR , FrankJB , DanE , McDougleCJ , Giller EL Jr.Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease1991;179(6):366–70. ">Kosten 1991</a>; <a href="./references#CD002795-bbs2-0256" title="LererB , BleichA , KotlerM , GarbR , HertzbergM , LevinB .Posttraumatic stress disorder in Israeli combat veterans: effect of phenelzine treatment. Archives of General Psychiatry1987;44(11):976-81.">Lerer 1987</a>; <a href="./references#CD002795-bbs2-0272" title="OliveraAT , FeroD .Affective disorders, DST, and treatment in PTSD patients: clinical observations. Journal of Traumatic Stress1990;3:407-14.">Olivera 1990</a>; <a href="./references#CD002795-bbs2-0266" title="MilanesF , MackC .Phenelzine treatment of post-vietnam stress syndrome. VA Practitioner1984;1:40-9.">Milanes 1984</a>; <a href="./references#CD002795-bbs2-0052" title="ReistC , KauffmannCD , Chicz DemetA , ChenCC , DemetEM .REM latency, dexamethasone suppression test, and thyroid releasing hormone stimulation test in posttraumatic stress disorder. Progress in Neuropsychopharmacology and Biological Psychiatry1995;19(3):433-43. ReistC , KauffmannCD , HaierRJ , SangdahlC , DeMetEM , Chicz-DeMetA , et al.A controlled trial of desipramine in 18 men with posttraumatic stress disorder. American Journal of Psychiatry1989;146(4):513-6. ">Reist 1989</a>; <a href="./references#CD002795-bbs2-0279" title="RubinMR , SoltV , Chen C-J, et al.Anafranil's effect on the obsessions and sleep in PTSD. In: Proceedings and Abstracts of the 146th Annual Meeting of the American Psychiatric Association, San Francisco, CA. 1993:102.">Rubin 1993</a>; <a href="./references#CD002795-bbs2-0054" title="ShestatzkyM , GreenbergD , LererB .A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatric Research1988;24(2):149-55. ">Shestatzky 1988</a>; <a href="./references#CD002795-bbs2-0296" title="WhiteNS .Post-traumatic stress disorder. Hospital and Community Psychiatry1983;34(11):1061-2.">White 1983</a>). More recent work has focused on the selective serotonin reuptake inhibitors (SSRIs) (<a href="./references#CD002795-bbs2-0004" title="BradyK , PearlsteinT , AsnisGM , BakerD , RothbaumB , SikesCR , et al.Efficacy and safety of sertraline treatment of posttraumatic stress disorder. Archives of General Psychiatry2000;283(14):1837-44. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry2001;158(12):1974-81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. GaffneyM .Factor analysis of treatment response in posttraumatic stress disorder. Journal of Traumatic Stress2003;16(1):77-80. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59-65. RapaportMH , FarfelG , ClaryCM .Quality of life improvement in PTSD with sertraline treatment: results of a multicenter, placebo-controlled trial. International Journal of Neuropsychopharmacology2000;3(Suppl 1):294. ">Brady 2000</a>; <a href="./references#CD002795-bbs2-0013" title="DavidsonJ , LondborgP , PearlsteinT , RothbaumB , BradyK , FarfelG .Double-blind, randomized, 28-week continuation study of sertraline and placebo in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):292. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry2001;158(12):1974-81. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59-65. ">Davidson 2001b</a>; <a href="./references#CD002795-bbs2-0029" title="HertzbergMA , FeldmanME , BeckhamJC , KudlerHS , DavidsonJR .Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Annals of Clinical Psychiatry2000;12(2):101-5. ">Hertzberg 2000</a>; <a href="./references#CD002795-bbs2-0264" title="MarshallRD , SchneierFR , FallonBA , KnightCB , AbbateLA , GoetzD , et al.An open trial of paroxetine in patients with noncombat-related posttraumatic stress disorder. Journal of Clinical Psychopharmacology1998;18(1):10-8.">Marshall 1998b</a>; <a href="./references#CD002795-bbs2-0036" title="MartenyiF , BrownEB , ZhangH , PrakashA , KokeSC .Fluoxetine versus placebo in posttraumatic stress disorder. Journal of Clinical Psychiatry2002;63(3):199-206. ">Martenyi 2002a</a>; <a href="./references#CD002795-bbs2-0057" title="SmajkicA , WeineS , Djuric-BijedicZ , BoskailoE , LewisJ , PavkovicI .Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms. Journal of Traumatic Stress2001;14(3):445-52. ">Smajkic 2001</a>; <a href="./references#CD002795-bbs2-0059" title="GlaxoSmithKline.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). GSK - Clinical Study Register [www.gsk-clinicalstudyregister.com]2000:Study ID:GSK 29060/648. TuckerP , ZaninelliR , YehudaR , RuggieroL , DillinghamK , PittsCD .Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry2001;62(11):860-8. ">Tucker 2001</a>; <a href="./references#CD002795-bbs2-0060" title="TuckerP , Potter-KimballR , WyattDB , ParkerDE , BurginC , JonesDE , et al.Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. General Psychopharmacology2003;37(3):135-49. ">Tucker 2003</a>; <a href="./references#CD002795-bbs2-0066" title="AmitalD , ZoharJ , KotlerM , BleichA , MiodovnikH , NevoA , et al.A placebo-controlled study of sertraline in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):269. AmitalD , ZoharJ , KotlerM , BleichA , MiodovnikH , NevoA , et al.A placebo-controlled trial pilot study of sertraline in PTSD. In: Annual Meeting of the American Psychiatric Association. American Psychiatric Association, 1999:157. ZoharJ , AmitalD , MiodownikC , KotlerM , BleichA , LaneRM .Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. Journal of Clinical Psychopharmacology2002;22(2):190-5. ">Zohar 2002</a>), selective serotonin and norepinephrine reuptake inhibitors (SNRIs) (<a href="./references#CD002795-bbs2-0016" title="DavidsonJ , BaldwinD , SteinDJ , KuperE , BenattiaI , AhmedS , et al.Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Archives of General Psychiatry2006;63(10):1158-65. ">Davidson 2006a</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>) and the serotonin antagonists and reuptake inhibitors (SARIs) (<a href="./references#CD002795-bbs2-0019" title="DavisLL , AmbroseS , EnglishB , DaforeME , FarleyJ , Bartolucci Al, et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder. In: 20th Annual Meeting, International Society for Traumatic Stress Studies, December 6 - 9, New Orleans, LA. 2001. DavisLL , JewellME , AmbroseS , FarleyJ , EnglishB , BartolucciA , et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. Journal of Clinical Psychopharmacology2004;24(3):291-7. [DOI: 10.1097/01.jcp.0000125685.82219.1a]">Davis 2004</a>; <a href="./references#CD002795-bbs2-0236" title="HertzbergMA , FeldmanME , BeckhamJC , DavidsonJR .Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design. Journal of Clinical Psychopharmacology1996;16(4):294-8.">Hertzberg 1996</a>; <a href="./references#CD002795-bbs2-0237" title="HertzbergMA , FeldmanME , BeckhamJC , MooreSD , DavidsonJR .Open trial of nefazodone for combat-related posttraumatic stress disorder. Journal of Clinical Psychiatry1998;59(9):460-4.">Hertzberg 1998</a>; <a href="./references#CD002795-bbs2-0238" title="HidalgoR .Nefazodone in posttraumatic stress: results from six open-label trials. International Clinical Psychopharmacology1999;14(2):61-8.">Hidalgo 1999</a>; <a href="./references#CD002795-bbs2-0258" title="LiebowitzNR , El MallakhRS .Trazodone for the treatment of anxiety symptoms in substance abusers. Journal of Clinical Psychopharmacology1989;9(8):449-51.">Liebowitz 1989</a>). </p> <p>Several other antidepressants have also been studied (<a href="./references#CD002795-bbs2-0002" title="BakerDG , DiamondBI , GilletteG , HamnerM , KatzelnickD , KellerT , et al.A double-blind randomized placebo-controlled multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology1995;122(4):386-9. ConnorKM , HidalgoRB , CrockettB , MalikM , KatzRJ , DavidsonJR .Predictors of treatment response in patients with posttraumatic stress disorder. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2001;25(2):337-45. ">Baker 1995</a>; <a href="./references#CD002795-bbs2-0182" title="CaniveJM , ClarkRD , CalaisLA , QuallsC , TuasonVB .Bupropion treatment in veterans with posttraumatic stress disorder: an open study. Journal of Clinical Psychopharmacology1998;18(5):379-83.">Canive 1998</a>; <a href="./references#CD002795-bbs2-0187" title="ConnorKM , DavidsonJR , WeislerRH , AhearnE .A pilot study of mirtazapine in post-traumatic stress disorder. International Clinical Psychopharmacology1999;14(1):29-31.">Connor 1999b</a>; <a href="./references#CD002795-bbs2-0198" title="DavidsonJR , WeislerRH , MalikM , TuplerLA .Fluvoxamine in civilians with posttraumatic stress disorder. Journal of Clinical Psychopharmacology1998;18(1):93-5.">Davidson 1998</a>; <a href="./references#CD002795-bbs2-0014" title="DavidsonJR , WeislerRH , ButterfieldMI , CasatCD , ConnorKM , BarnettS , et al.Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biological Psychiatry2003;53(2):188-91. ">Davidson 2003</a>; <a href="./references#CD002795-bbs2-0201" title="DavisLL , NugentAL , MurrayJ , KramerGL , PettyF .Nefazodone treatment for chronic posttraumatic stress disorder: an open trial. Journal of Clinical Psychopharmacology2000;20(2):159-64.">Davis 2000</a>; <a href="./references#CD002795-bbs2-0020" title="DavisLL , DavidsonJR , WardC , BartolucciA , BowdenCL , PettyF .Divalproex in the treatment of posttraumatic tress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. Journal of Clinical Psychopharmacology2008;28(21):84–8. [DOI: 10.1097/jcp.0b013e318160f83b]">Davis 2008</a>; <a href="./references#CD002795-bbs2-0233" title="HamnerMB , FruehBC .Response to venlafaxine in a previously antidepressant treatment-resistant combat veteran with post-traumatic stress disorder. International Clinical Psychopharmacology1998;13(5):233-4.">Hamner 1998</a>; <a href="./references#CD002795-bbs2-0031" title="ConnorKM , HidalgoRB , CrockettB , MalikM , KatzRJ , DavidsonJR .Predictors of treatment response in patients with posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2001;25(2):337–45. KatzRJ , LottMH , ArbusP , CrocqL , HerlobsenP , LingjaerdeO , et al.Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety1994;1(4):169–74. [DOI: https://doi.org/10.1002/anxi.3070010404 ]">Katz 1994</a>; <a href="./references#CD002795-bbs2-0270" title="NealLA , ShaplandW , FoxC .An open trial of moclobemide in the treatment of post-traumatic stress disorder. International Clinical Psychopharmacology1997;12(4):231-7.">Neal 1997</a>). In addition, benzodiazepines (<a href="./references#CD002795-bbs2-0005" title="BraunP , GreenbergD , DasbergH , LererB .Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. Journal of Clinical Psychiatry1990;51(6):236-8. ">Braun 1990</a>; <a href="./references#CD002795-bbs2-0211" title="DunnerFJ , EdwardsWP , CopelandPC .Clinical efficacy of alprazolam in PTSD patients. In: 138th Annual Meeting of the American Psychiatric Association, Los Angeles, CA. 1985.">Dunner 1985</a>; <a href="./references#CD002795-bbs2-0261" title="LowensteinRJ , HornsteinN , FarberB .Open trial of clonazepam in the treatment of post traumatic stress symptoms in multiple personality disorder. Dissociation1988;1:3-12.">Lowenstein 1988</a>), beta‐blockers (<a href="./references#CD002795-bbs2-0214" title="FamularoR , KinscherffR , FentonT .Propranolol treatment for childhood posttraumatic stress disorder, acute type. A pilot study. American Journal of Diseases of Children1988;142(11):1244-7.">Famularo 1988</a>; <a href="./references#CD002795-bbs2-0254" title="KolbLC , BurrisBC , GriffithsS .Propranolol and clonidine in the treatment of the chronic post-traumatic stress disorders of war. In: Van der KolkBA , editors(s). Post-traumatic Stress Disorder: Psychological and Biological Sequelae. Washington, DC: American Psychiatric Press, 1984:98-105.">Kolb 1984</a>), buspirone (<a href="./references#CD002795-bbs2-0209" title="DuffyJD .Rapid response to buspirone in a case of post-traumatic stress disorder. Annals of Clinical Psychiatry1992;4:193-6.">Duffy 1992</a>; <a href="./references#CD002795-bbs2-0210" title="DuffyJD , MalloyPF .Efficacy of buspirone in the treatment of posttraumatic stress disorder: An open trial. Annals of Clinical Psychiatry1994;6(1):33-7.">Duffy 1994</a>; <a href="./references#CD002795-bbs2-0255" title="LaPortaLD , WareMR .Buspirone in the treatment of posttraumatic stress disorder. Journal of Clinical Psychopharmacology1992;12(2):133-4.">LaPorta 1992</a>; <a href="./references#CD002795-bbs2-0217" title="FichtnerCG , AroraRC , O'ConnorFL , CraytonJW .Platelet paroxetine binding and fluoxetine pharmacotherapy in posttraumatic stress disorder: preliminary observations on a possible predictor of clinical treatment response. Life Sciences1994;54(3):39-44.">Fichtner 1994</a>; <a href="./references#CD002795-bbs2-0284" title="SimpsonMA .Buspirone, benzodiazepines, and post-traumatic stress disorder. Journal of Traumatic Stress1991;4:305-8.">Simpson 1991</a>; <a href="./references#CD002795-bbs2-0295" title="WellsGB , ChuC , JohnsonR , NasdahlC , AyubiMA , SewellE , et al.Buspirone in the treatment of post-traumatic stress disorder and dream anxiety disorder. Military Medicine1991;11(4):340-3.">Wells 1991</a>), clonidine (<a href="./references#CD002795-bbs2-0234" title="HarmonRJ , RiggsPD .Clonidine for posttraumatic stress disorder in preschool children. Journal of the American Academy of Child &amp; Adolescent Psychiatry1996;35(9):1247-9.">Harmon 1996</a>; <a href="./references#CD002795-bbs2-0254" title="KolbLC , BurrisBC , GriffithsS .Propranolol and clonidine in the treatment of the chronic post-traumatic stress disorders of war. In: Van der KolkBA , editors(s). Post-traumatic Stress Disorder: Psychological and Biological Sequelae. Washington, DC: American Psychiatric Press, 1984:98-105.">Kolb 1984</a>; <a href="./references#CD002795-bbs2-0252" title="KinzieJD , LeungP .Clonidine in Cambodian patients with post traumatic stress disorder. Journal of Nervous and Mental Disease1989;177(9):546-50.">Kinzie 1989</a>), guanfacine (<a href="./references#CD002795-bbs2-0020" title="DavisLL , DavidsonJR , WardC , BartolucciA , BowdenCL , PettyF .Divalproex in the treatment of posttraumatic tress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. Journal of Clinical Psychopharmacology2008;28(21):84–8. [DOI: 10.1097/jcp.0b013e318160f83b]">Davis 2008</a>; <a href="./references#CD002795-bbs2-0244" title="HorriganJP .Guanfacine for PTSD nightmares. Journal of the American Academy of Child &amp; Adolescent Psychiatry1996;35(8):975-6.">Horrigan 1996</a>), cyprohepadine (<a href="./references#CD002795-bbs2-0176" title="BrophyMH .Cyproheptadine for combat nightmares in post-traumatic stress disorder and dream anxiety disorder. Military Medicine1991;156(2):100-1.">Brophy 1991</a>; <a href="./references#CD002795-bbs2-0227" title="GuptaS , PopliA , BathurstE , HennigL , DroneyT , KellerP .Efficacy of cyproheptadine for nightmares associated with posttraumatic stress disorder. Comprehensive Psychiatry1998;39(3):160-4.">Gupta 1998</a>), d‐cycloserine (<a href="./references#CD002795-bbs2-0093" title="Heresco-LevyU , KremerI , JavittDC , GoichmanR , ReshefA , BlanaruM , et al.Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. International Journal of Neuropsychopharmacology2002;5(4):301-7. ">Heresco‐Levy 2002</a>), inositol (<a href="./references#CD002795-bbs2-0030" title="KaplanZ , AmirM , SwartzM , LevineJ .Inositol treatment of posttraumatic stress disorder. Anxiety1996;2(1):51–2. [DOI: 10.1002/(SICI)1522-7154(1996)2:1&lt;51::AID-ANXI8&gt;3.0.CO;2-G]">Kaplan 1996</a>), mood‐stabilisers (<a href="./references#CD002795-bbs2-0215" title="FeslerFA .Valproate in combat-related posttraumatic stress disorder. Journal of Clinical Psychiatry1991;52(9):361-4.">Fesler 1991</a>; <a href="./references#CD002795-bbs2-0216" title="FichtnerCG , KuhlmanDT , GruenfeldMJ , HughesJR .Decreased episodic violence and increased control of dissociation in a carbamazepine-treated case of multiple personality. Biological Psychiatry1990;27(9):1045-52.">Fichtner 1990</a>; <a href="./references#CD002795-bbs2-0219" title="FordN .The use of anticonvulsants in posttraumatic stress disorder: case study and overview. Journal of Traumatic Stress1996;9(4):857-63.">Ford 1996</a>; <a href="./references#CD002795-bbs2-0220" title="ForsterPL , SchoenfieldFB , MarmarCR , LangAJ .Lithium for irritability in post-traumatic stress disorder. Journal of Traumatic Stress1994;8(1):143-9.">Forster 1994</a>; <a href="./references#CD002795-bbs2-0028" title="HertzbergMA , ButterfieldMI , FeldmanME , BeckhamJC , SutherlandSM , ConnorKM , et al.A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biological Psychiatry1999;45(9):1226-9. ">Hertzberg 1999</a>; <a href="./references#CD002795-bbs2-0249" title="KeckPE , McElroySL , FriedmanLM .Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders. Journal of Clinical Psychopharmacology1992;12(1S):36-41.">Keck 1992</a>; <a href="./references#CD002795-bbs2-0260" title="LooffD , GrimleyP , KullerF , MartinA , ShonfieldL .Carbamazepine for PTSD. Journal of the American Academy of Child &amp; Adolescent Psychiatry1995;34(6):703-4.">Looff 1995</a>; <a href="./references#CD002795-bbs2-0288" title="SzymanskiHV , OlympiaJ .Divalproex in posttraumatic stress disorder. American Journal of Psychiatry1991;148(8):1086-7.">Szymanski 1991</a>), typical (<a href="./references#CD002795-bbs2-0171" title="BleichA , SiegelB , GarbR , LererB .Post-traumatic stress disorder following combat exposure: clinical features and psychopharmacological treatment. British Journal of Psychiatry1986;149:365-9.">Bleich 1986</a>; <a href="./references#CD002795-bbs2-0207" title="DillardML , BendfeldtF , JerniganP .Use of thioridazine in post-traumatic stress disorder. Southern Medical Journal1993;86(11):1276-8.">Dillard 1993</a>) and atypical neuroleptics (<a href="./references#CD002795-bbs2-0006" title="ButterfieldMI , BeckerME , ConnorKM , SutherlandS , ChurchillLE , DavidsonJR .Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. International Clinical Psychopharmacology2001;16(4):197-203. ">Butterfield 2001</a>; <a href="./references#CD002795-bbs2-0179" title="BurtonJK , MarshallRD .Categorizing fear: the role of trauma in a clinical formulation. American Journal of Psychiatry1999;156(5):761-6.">Burton 1999</a>; <a href="./references#CD002795-bbs2-0232" title="HamnerMB .Clozapine treatment for a veteran with comorbid psychosis and PTSD (letter). American Journal of Psychiatry1996;153(6):841.">Hamner 1996</a>; <a href="./references#CD002795-bbs2-0248" title="IzrayelitL .Schizoaffective disorder and PTSD successfully treated with olanzapine and supportive psychotherapy. Psychiatric Annals1998;28(8):424-6.">Izrayelit 1998</a>; <a href="./references#CD002795-bbs2-0257" title="LeybaCM , WamplerTP .Risperidone in PTSD. Psychiatric Services1998;49(2):245-6.">Leyba 1998</a>), opioids (<a href="./references#CD002795-bbs2-0226" title="GloverH .A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder. Israel Journal of Psychiatry and Related Sciences1993;30(4):255-63.">Glover 1993</a>), and the alpha‐blocker prazosin (<a href="./references#CD002795-bbs2-0049" title="RaskindMA , PeskindER , ChowB , HarrisC , Davis-KarimA , HolmesHA , et al.Trial of prazosin for post-traumatic stress disorder in military veterans. New England Journal of Medicine2018;378(6):507-17. [DOI: 10.1056/NEJMoa1507598]">Raskind 2018</a>) have also received attention. </p> </section> <section id="CD002795-sec-0012"> <h3 class="title" id="CD002795-sec-0012">How the intervention might work</h3> <p>SSRIs and SNRIs are considered first‐line agents for the treatment of PTSD (<a href="./references#CD002795-bbs2-0161" title="BaldwinDS , AndersonIM , NuttDJ , AllgulanderC , BandelowB , Den BoerJA .Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. Journal of Psychopharmacology2014;28(5):403-39. [DOI: 10.1177/0269881114525674]">Baldwin 2014</a>; <a href="./references#CD002795-bbs2-0164" title="BandelowB , ZoharJ , HollanderE , KasperS , Möller H-J, WFSBP Task Force on Treatment Guidelines for Anxiety Obsessive-compulsive Post-traumatic Stress Disorders, et al.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-raumatic tress disorders –first revision. World Journal of Biological Psychiatry2008;9(4):248-312. [DOI: https://doi.org/10.1080/15622970802465807]">Bandelow 2008</a>; <a href="./references#CD002795-bbs2-0246" title="IpserJC , SteinDJ .Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). International Journal of Neuropsychopharmacology2012;15(6):825–40. [DOI: org/10.1017/S1461145711001209]">Ipser 2012</a>). These antidepressants increase serotonin output by blocking the serotonin transporter (SERT) and are effective in reducing symptoms of anxiety and fear (<a href="./references#CD002795-bbs2-0287" title="StahlSM .Stahl’s essential psychopharmacology. Neuroscientific Basis and Practical Application. Fourth Edition. Cambridge, UK: Cambridge University Press, 2013.">Stahl 2013</a>). There are currently six SSRIs globally available for the treatment of PTSD symptoms: namely, sertraline, paroxetine, fluoxetine, fluvoxamine, citalopram, and escitalopram. Only two (sertraline and paroxetine) are FDA‐approved (<a href="./references#CD002795-bbs2-0274" title="RavindranLN , SteinMB .Pharmacotherapy of PTSD: premises, principles, and priorities. Brain Research2009;1293:24–39. [DOI: 10.1016/j.brainres.2009.03.037]">Ravindran 2009</a>). Similarly, the serotonin 1A (5HT1A) partial agonist, buspirone, has potential anxiolytic actions. These could theoretically be due to this agent's 5HT1A partial agonist actions at both presynaptic and postsynaptic 5HT1A receptors, with actions at both sites resulting in enhanced serotonergic activity in projections to the amygdala, prefrontal cortex, striatum, and thalamus. SSRIs and SNRIs theoretically operate using similar mechanisms. Since the onset of anxiolytic action for buspirone is delayed, this has led to the belief that 5HT1A agonists exert their therapeutic effects by adaptive neuronal events and receptor events, rather than simply by the acute occupancy of 5HT1A receptors. In this way, the presumed mechanism of action of 5HT1A partial agonists is analogous to the SSRIs, which also demonstrate delayed onset of action, and are also presumed to act by adaptations in neurotransmitter receptors. These delayed medication effects can be compared to the relatively rapid effect of the benzodiazepine anxiolytics, which act relatively acutely by occupying benzodiazepine receptors (<a href="./references#CD002795-bbs2-0287" title="StahlSM .Stahl’s essential psychopharmacology. Neuroscientific Basis and Practical Application. Fourth Edition. Cambridge, UK: Cambridge University Press, 2013.">Stahl 2013</a>). The serotonin antagonist and reuptake inhibitor, nefazodone, is an older antidepressant that is thought to work through post‐synaptic 5‐HT2A receptor antagonism, inhibition of presynaptic serotonin and norepinephrine (NE) reuptake, and through blocking α1 receptors. Nefazodone is now rarely used, due to concerns of hepatotoxicity (<a href="./references#CD002795-bbs2-0274" title="RavindranLN , SteinMB .Pharmacotherapy of PTSD: premises, principles, and priorities. Brain Research2009;1293:24–39. [DOI: 10.1016/j.brainres.2009.03.037]">Ravindran 2009</a>). <a href="./references#CD002795-bbs2-0258" title="LiebowitzNR , El MallakhRS .Trazodone for the treatment of anxiety symptoms in substance abusers. Journal of Clinical Psychopharmacology1989;9(8):449-51.">Liebowitz 1989</a> reviewed the clinical efficacy of trazodone (50 – 250 mg/day) in treating 22 patients with a dual diagnosis of substance abuse and anxiety symptoms. A substantial number of people suffered from symptoms of posttraumatic stress disorder (PTSD). Improvement was noted in all participants within the first month of treatment, and most reported symptomatic improvement after each dose of trazodone, resulting in an as‐needed pattern of usage. </p> <p>Benzodiazepines, as a class, work on the central nervous system (CNS) through their effects on the GABAA receptors. Activation at the special benzodiazepine receptor site on the GABAA receptor promotes enhanced activity of the inhibitory neurotransmitter γ‐aminobutyric acid (GABA), thus resulting in various effects including: anxiolysis, sedation, muscle relaxation, cognitive effects, and anticonvulsant actions. These functions, and particularly the first two, would seem to have benefits for PTSD (<a href="./references#CD002795-bbs2-0274" title="RavindranLN , SteinMB .Pharmacotherapy of PTSD: premises, principles, and priorities. Brain Research2009;1293:24–39. [DOI: 10.1016/j.brainres.2009.03.037]">Ravindran 2009</a>). </p> <p>Anti‐adrenergic agents or beta‐blockers or both target putative noradrenergic alterations seen in PTSD. Clonidine, for example, is commonly used as an antihypertensive agent, and is a centrally‐acting α2 adrenergic agonist that works to decrease sympathetic tone. As such, it was theorised to have potential effects on the hyperarousal symptoms seen in PTSD. Guanfacine, another α2 adrenergic agonist with a similar mechanism of action, has also been investigated, but no benefit has been reported (<a href="./references#CD002795-bbs2-0020" title="DavisLL , DavidsonJR , WardC , BartolucciA , BowdenCL , PettyF .Divalproex in the treatment of posttraumatic tress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. Journal of Clinical Psychopharmacology2008;28(21):84–8. [DOI: 10.1097/jcp.0b013e318160f83b]">Davis 2008</a>; <a href="./references#CD002795-bbs2-0110" title="NeylanTC , LenociM , SamuelsonKW , MetzlerTJ , Henn-HaaseC , HierholzerRW , et al.No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. American Journal of Psychiatry2006;163(12):2186–8. ">Neylan 2006</a>). The use of β‐adrenergic antagonists has also been investigated in PTSD, but primarily for a role in the secondary prevention of this disorder. <a href="./references#CD002795-bbs2-0180" title="CahillL , PrinsB , WeberM , McGaughJL .β-adrenergic activation and memory for emotional events. Nature1994;371(6499):702–4. [DOI: 10.1038/371702a0]">Cahill 1994</a> demonstrated that a single dose of propranolol administered to healthy humans impaired subsequent recall of an emotionally‐arousing story but not for an emotionally‐neutral one, thus lending support for the theory that memory for emotional experiences involved the β‐ adrenergic system. Based on this, it was theorised that administration of a β‐adrenergic antagonist in the peritraumatic period might have a beneficial effect in blocking consolidation of the traumatic memory and thus prevent development of PTSD (<a href="./references#CD002795-bbs2-0274" title="RavindranLN , SteinMB .Pharmacotherapy of PTSD: premises, principles, and priorities. Brain Research2009;1293:24–39. [DOI: 10.1016/j.brainres.2009.03.037]">Ravindran 2009</a>). </p> <p>Anticonvulsant medications, with their putative anti‐kindling effects, have been investigated for PTSD, although most of the evidence for use of these agents (e.g. carbamazepine and divalproex) is not well researched (<a href="./references#CD002795-bbs2-0274" title="RavindranLN , SteinMB .Pharmacotherapy of PTSD: premises, principles, and priorities. Brain Research2009;1293:24–39. [DOI: 10.1016/j.brainres.2009.03.037]">Ravindran 2009</a>; <a href="./references#CD002795-bbs2-0275" title="ResslerKJ .Alpha-adrenergic receptors in PTSD -failure or time for precision medicine?New England Journal of Medicine2018;378:575-6. [DOI: 10.1056/NEJMe1716724]">Ressler 2018</a>). </p> <p>TCAs are non‐specific in their actions on specific neurotransmitters, with their primary mechanism of action involving varying degrees of serotonin and NE reuptake inhibition. MAOIs, on the other hand, work by irreversibly inhibiting the enzyme monoamine oxidase, normally involved in metabolism of serotonin and NE. Both medication classes are generally considered second‐ or third‐line treatments due to their adverse event profile and need for dietary restriction (i.e. MAOIs) (<a href="./references#CD002795-bbs2-0274" title="RavindranLN , SteinMB .Pharmacotherapy of PTSD: premises, principles, and priorities. Brain Research2009;1293:24–39. [DOI: 10.1016/j.brainres.2009.03.037]">Ravindran 2009</a>). </p> <p>Only a small number of controlled trials have investigated the adjunctive use of antipsychotic agents (which include olanzapine, risperidone, quetiapine, ziprasidone, and aripiprazole) in PTSD, and even fewer have explored their use as monotherapy (<a href="./references#CD002795-bbs2-0274" title="RavindranLN , SteinMB .Pharmacotherapy of PTSD: premises, principles, and priorities. Brain Research2009;1293:24–39. [DOI: 10.1016/j.brainres.2009.03.037]">Ravindran 2009</a>). Other agents like D‐cycloserine (DCS), a partial agonist at the NMDA receptor, have also been investigated as a potential treatment for PTSD. Arguing that the presence of flashbacks and intrusive memories in PTSD may be a function of extinction failure, and that learning and memory are both glutamate‐dependent processes, <a href="./references#CD002795-bbs2-0093" title="Heresco-LevyU , KremerI , JavittDC , GoichmanR , ReshefA , BlanaruM , et al.Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. International Journal of Neuropsychopharmacology2002;5(4):301-7. ">Heresco‐Levy 2002</a> and colleagues argued that enhancing glutamate transmission could facilitate the learning of new memories to replace the traumatic ones (as cited in <a href="./references#CD002795-bbs2-0274" title="RavindranLN , SteinMB .Pharmacotherapy of PTSD: premises, principles, and priorities. Brain Research2009;1293:24–39. [DOI: 10.1016/j.brainres.2009.03.037]">Ravindran 2009</a>). The addition of cyproheptadine, taken orally at night, has also been shown to control and decrease the intensity and frequency of nightmares (<a href="./references#CD002795-bbs2-0176" title="BrophyMH .Cyproheptadine for combat nightmares in post-traumatic stress disorder and dream anxiety disorder. Military Medicine1991;156(2):100-1.">Brophy 1991</a>; <a href="./references#CD002795-bbs2-0227" title="GuptaS , PopliA , BathurstE , HennigL , DroneyT , KellerP .Efficacy of cyproheptadine for nightmares associated with posttraumatic stress disorder. Comprehensive Psychiatry1998;39(3):160-4.">Gupta 1998</a>). Similarly, 18 chronic posttraumatic stress disorder combat veterans who received the opioid nalmefene showed a favourable response, with a marked decrease of emotional numbing and other symptoms of PTSD, including startle response, nightmares, flashbacks, intrusive thoughts, rage and vulnerability as the dosage increased (<a href="./references#CD002795-bbs2-0226" title="GloverH .A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder. Israel Journal of Psychiatry and Related Sciences1993;30(4):255-63.">Glover 1993</a>). There was also evidence reported by studies assessing the mood‐stabilisers carbamazepine (<a href="./references#CD002795-bbs2-0259" title="LipperS , DavidsonJR , GradyTA , EdingerJD , HammettEB , MahorneySL , et al.Preliminary study of carbamazepine in post traumatic stress disorder. Psychosomatics1986;27(12):849-54.">Lipper 1986</a>), valproate (<a href="./references#CD002795-bbs2-0215" title="FeslerFA .Valproate in combat-related posttraumatic stress disorder. Journal of Clinical Psychiatry1991;52(9):361-4.">Fesler 1991</a>), lithium (<a href="./references#CD002795-bbs2-0220" title="ForsterPL , SchoenfieldFB , MarmarCR , LangAJ .Lithium for irritability in post-traumatic stress disorder. Journal of Traumatic Stress1994;8(1):143-9.">Forster 1994</a>), lamotrigine (<a href="./references#CD002795-bbs2-0028" title="HertzbergMA , ButterfieldMI , FeldmanME , BeckhamJC , SutherlandSM , ConnorKM , et al.A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biological Psychiatry1999;45(9):1226-9. ">Hertzberg 1999</a>), and prazosin (<a href="./references#CD002795-bbs2-0049" title="RaskindMA , PeskindER , ChowB , HarrisC , Davis-KarimA , HolmesHA , et al.Trial of prazosin for post-traumatic stress disorder in military veterans. New England Journal of Medicine2018;378(6):507-17. [DOI: 10.1056/NEJMoa1507598]">Raskind 2018</a>). There was, however, no significant difference found in the improvement score for inositol compared to placebo (<a href="./references#CD002795-bbs2-0030" title="KaplanZ , AmirM , SwartzM , LevineJ .Inositol treatment of posttraumatic stress disorder. Anxiety1996;2(1):51–2. [DOI: 10.1002/(SICI)1522-7154(1996)2:1&lt;51::AID-ANXI8&gt;3.0.CO;2-G]">Kaplan 1996</a>). </p> </section> <section id="CD002795-sec-0013"> <h3 class="title" id="CD002795-sec-0013">Why it is important to do this review</h3> <p>A systematic review of studies of pharmacotherapy for PTSD is useful in tackling several questions for the field. First, is pharmacotherapy in fact an effective form of treatment in PTSD? Given the preponderance of psychological models and evidence for the efficacy of certain forms of psychotherapy in PTSD (<a href="./references#CD002795-bbs2-0169" title="BissonJI , RobertsNP , AndrewM , CooperR , LewisC .Psychological therapies for chronic post‐traumatic stress disorder (PTSD) in adults. Cochrane Database of Systematic Reviews2013, Issue 12. Art. No: CD003388. [DOI: 10.1002/14651858.CD003388.pub4]">Bisson 2013</a>), the role of pharmacotherapy remains debatable for many. In a recently‐published guideline for the treatment of PTSD, the National Institute for Health and Care Excellence (NICE) recommends that preference be given to trauma‐focused psychological therapy over pharmacotherapy as a routine first‐line treatment for this disorder (<a href="./references#CD002795-bbs2-0271" title="NICE.Post-traumatic stress disorder: management (NG116). Clinical guideline Published: December 2018. National Institute for Health and Care Excellence2018.">NICE 2018</a>). </p> <p>Second, are certain medication classes more effective in the treatment of symptoms and/or more acceptable to the patient in terms of adverse events than others? The use of novel agents (such as prazosin) for PTSD in recent years raises the question of how these compare with older agents. Early recommendations, such as the expert consensus guideline series for the treatment of posttraumatic stress disorder (<a href="./references#CD002795-bbs2-0218" title="FoaEB , DavidsonJR , FrancesA .The expert consensus guideline series: treatment of posttraumatic stress disorder: the expert consensus panel for PTSD. Journal of Clinical Psychiatry1999;60(Suppl. 16):1-75.">Foa 1999</a>), suggested that the SSRIs, the serotonin modulator nefazodone, and the SNRI venlafaxine are first‐line medications for the treatment of PTSD, with benzodiazepines and mood‐stabilisers having a role in people with certain kinds of symptoms. More recent recommendations have highlighted paroxetine, mirtazapine, amitriptyline and phenelzine (<a href="./references#CD002795-bbs2-0271" title="NICE.Post-traumatic stress disorder: management (NG116). Clinical guideline Published: December 2018. National Institute for Health and Care Excellence2018.">NICE 2018</a>). Support for such recommendations requires ongoing assessment of the literature on RCTs. </p> <p>Third, can a systematic review of RCTs provide information about the most important factors affecting pharmacotherapy response? Clinical factors, such as the kind of pre‐existing trauma (e.g. combat‐related or not) and the presence of comorbid depression have all been suggested to play a role (<a href="./references#CD002795-bbs2-0194" title="DavidsonJR , KudlerHS , SaundersWB , EricksonL , SmithRD , SteinRM , et al.Predicting response to amitriptyline in posttraumatic stress disorder. American Journal of Psychiatry1993;150(7):1024-9.">Davidson 1993</a>; <a href="./references#CD002795-bbs2-0199" title="DavidsonJR .Pharmacotherapy of posttraumatic stress disorder: treatment options, long term follow-up, and predictors of outcome. Journal of Clinical Psychiatry2000;61(Suppl 5):52-6.">Davidson 2000</a>; <a href="./references#CD002795-bbs2-0264" title="MarshallRD , SchneierFR , FallonBA , KnightCB , AbbateLA , GoetzD , et al.An open trial of paroxetine in patients with noncombat-related posttraumatic stress disorder. Journal of Clinical Psychopharmacology1998;18(1):10-8.">Marshall 1998b</a>; <a href="./references#CD002795-bbs2-0062" title="Van der KolkBA , DreyfussD , MichaelsM , SheraD , BerkowitzR , FislerR , et al.Fluoxetine treatment in posttraumatic stress disorder. Journal of Clinical Psychiatry1994;55(12):517-22. ">Van der Kolk 1994</a>). It is possible that the database of RCTs in PTSD may include information about these variables. </p> <p>Several reviews of the pharmacotherapy of PTSD have indeed been published in recent years (<a href="./references#CD002795-bbs2-0152" title="AlbucherRC , LiberzonI .Psychopharmacological treatment in PTSD: a critical review. Journal of Psychiatric Research2002;36(6):355-67.">Albucher 2002</a>; <a href="./references#CD002795-bbs2-0158" title="AsnisGM , KohnSR , HendersonM , BrownNL .SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations. Drugs2004;64(4):383-404.">Asnis 2004</a>; <a href="./references#CD002795-bbs2-0245" title="HoskinsM , PearceJ , BethellA , DankovaL , BarbuiC , TolWA , et al.Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. British Journal of Psychiatry2015;206(2):93–100. [DOI: 10.1192/bjp.bp.114.148551]">Hoskins 2015</a>; <a href="./references#CD002795-bbs2-0246" title="IpserJC , SteinDJ .Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). International Journal of Neuropsychopharmacology2012;15(6):825–40. [DOI: org/10.1017/S1461145711001209]">Ipser 2012</a>). These reviews have been useful in summarising the existing research, pointing to methodological flaws, and outlining areas for future research. Nevertheless, not all reviews have employed a systematic search strategy, and it has been suggested that even MEDLINE searches may miss over half of all RCTs in specialised health care journals (<a href="./references#CD002795-bbs2-0242" title="HopewellS , ClarkeM , LusherA , LefebvreC , WestbyM .A comparison of handsearching versus MEDLINE searching to identify reports of randomized controlled trials. Statistics in Medicine2002;21(11):1625-34.">Hopewell 2002</a>). Furthermore, not all studies have provided estimates of the effects of medication (<a href="./references#CD002795-bbs2-0195" title="DavidsonJR , MalikML , SutherlandSN .Response characteristics to antidepressants and placebo in post-traumatic stress disorder. International Clinical Psychopharmacology1997;12(6):291-6.">Davidson 1997a</a>; <a href="./references#CD002795-bbs2-0273" title="PenavaSJ , OttoMW , PollackMH , RosenbaumJF .Current status of pharmacotherapy for PTSD: an effect size analysis of controlled studies. Depression and Anxiety1996;4(5):240-2.">Penava 1996</a>). Finally, not all reviews in this area have adhered to Cochrane Collaboration (<a href="./references#CD002795-bbs2-0269" title="MulrowCD , OxmanAD .Cochrane Collaboration Handbook. Oxford: Update Software, 1997.">Mulrow 1997</a>) or similar (<a href="./references#CD002795-bbs2-0267" title="MoherD , CookDJ , EastwoodS , OlkinI , RennieD , StroupDF .Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Lancet1999;354(9193):1896-900.">Moher 1999</a>) guidelines for systematic identification of trials, investigation of sources of heterogeneity, measurement of methodological quality, and estimation of the effects of intervention. </p> <p>The authors therefore updated a systematic review of RCTs of the pharmacotherapy of PTSD in adults, previously published in 2000 and 2006 (<a href="./references#CD002795-bbs2-0298" title="SteinDJ , Zungu‐DirwayiN , van derLindenG , SeedatS .Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews2000, Issue 4. Art. No: CD002795. [DOI: 10.1002/14651858.CD002795]">Stein 2000</a>; <a href="./references#CD002795-bbs2-0299" title="SteinDJ , IpserJC , SeedatS , SagerC , AmosT .Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews2006, Issue 1. Art. No: CD002795. [DOI: 10.1002/14651858.CD002795.pub2]">Stein 2006</a>), following Cochrane guidelines and software (<a href="./references#CD002795-bbs2-0240" title="HigginsJP , GreensS , editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>; <a href="./references#CD002795-bbs2-0276" title="Review Manager 5 (RevMan 5).Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">RevMan 2020</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002795-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002795-sec-0014"></div> <p>To assess the effects of medication for reducing PTSD symptoms in adults with PTSD.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002795-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002795-sec-0015"></div> <section id="CD002795-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002795-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered randomised controlled trials (placebo‐controlled and comparative trials) for inclusion. We also considered unpublished reports, abstracts, and brief and preliminary reports. We did not use differences between trials (for example, sample size, trial duration or language) to exclude studies. We also included cluster‐randomised controlled trials, cross‐over trials and multiple treatment trials in the analyses. </p> </section> <section id="CD002795-sec-0018"> <h4 class="title">Types of participants</h4> <p><b>Participant characteristics</b> </p> <p>We included all studies of adult participants (aged 18 to 85 years) diagnosed with PTSD (as determined by the study author), irrespective of diagnostic criteria and measure, duration and severity of PTSD symptoms, and gender. These descriptors were, however, tabulated in order to address the question of their possible impact on the effects of medication. </p> <p>We included adults on concomitant medications in the review, but we excluded adults on concomitant psychotherapy. </p> <p><b>Comorbidities</b> </p> <p>We placed no restrictions on the presence of comorbid disorders secondary to PTSD.</p> <p><b>Setting</b> </p> <p>We placed no restrictions by setting.</p> <p><b>Subsets of participants</b> </p> <p>We excluded studies that reported a subset of participants that met the review inclusion criteria, to preserve randomisation. </p> </section> <section id="CD002795-sec-0019"> <h4 class="title">Types of interventions</h4> <p>The review focuses only on medication treatments, in which the comparator was a placebo (active or non‐active) or other medication (i.e. control group). A parallel review of the psychotherapy of PTSD has been completed by a Cochrane team (<a href="./references#CD002795-bbs2-0168" title="BissonJI , AndrewM .Psychological treatment of post-traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews2007, Issue 12. Art. No: CD003388. [DOI: 10.1002/14651858.CD003388.pub3]">Bisson 2007</a>; <a href="./references#CD002795-bbs2-0169" title="BissonJI , RobertsNP , AndrewM , CooperR , LewisC .Psychological therapies for chronic post‐traumatic stress disorder (PTSD) in adults. Cochrane Database of Systematic Reviews2013, Issue 12. Art. No: CD003388. [DOI: 10.1002/14651858.CD003388.pub4]">Bisson 2013</a>). More recently, a Cochrane review of RCTs of medication prophylaxis for PTSD has been published (<a href="./references#CD002795-bbs2-0154" title="AmosT , SteinDJ , IpserJC .Pharmacological interventions for preventing post-traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews2014, Issue Issue 7. Art. No.: CD006239. Art. No: CD006239. [DOI: 10.1002/14651858.CD006239.pub2]">Amos 2014</a>). </p> <p>This review classifies medications based on their putative mechanisms of action (taken from CCMD antidepressant classification map) (<a href="./references#CD002795-bbs2-0200" title="DaviesSJ , ChampionC , DawsonS , SharpJ , ChurchillR .The Subway Map - a new way to visualize antidepressant classification (a Cochrane CCDAN initiative). In: 14th ICGP and 19th JSNP Joint Congress; 3 October. Tsukuba, Japan, 2014: 78. [Abstract P14]. 2015.">Davies 2015</a>), and they do not necessarily map onto the drug classification schemes used in other reviews. </p> <p><b>Experimental interventions</b> </p> <p>We grouped specific pharmacological interventions by medication class, listed below:</p> <p> <ul id="CD002795-list-0001"> <li> <p>Alpha‐blockers (e.g. prazosin)</p> </li> <li> <p>Anticonvulsants (e.g. tiagabine, divalproex, lamotrigine, and topiramate)</p> </li> <li> <p>Antihistamines (e.g. hydroxyzine)</p> </li> <li> <p>Antipsychotics (e.g. olanzapine, risperidone and quetiapine)</p> </li> <li> <p>Benzodiazepines (e.g. alprazolam)</p> </li> <li> <p>Dopamine beta‐hydroxylase inhibitors (e.g. nepicastat)</p> </li> <li> <p>Hypnotics (e.g. eszopiclone)</p> </li> <li> <p>Mono‐amine oxidase inhibitors (MAOIs, e.g. phenelzine)</p> </li> <li> <p>NK‐1 receptor antagonists (e.g. orvepitant)</p> </li> <li> <p>NMDA receptor antagonists (e.g. ketamine)</p> </li> <li> <p>Norepinephrine and dopamine reuptake inhibitors (NDRIs, bupropion SR)</p> </li> <li> <p>Noradrenaline reuptake inhibitors (NARs, e.g. reboxetine)</p> </li> <li> <p>Noradrenergic and specific serotonergic antidepressants (NaSSAs, e.g. mirtazapine)</p> </li> <li> <p>Other medications (e.g. ganaxolone, GR205171, GSK561679)</p> </li> <li> <p>Reversible inhibitor of monoamine oxidase A (RIMA, e.g. brofaromine)</p> </li> <li> <p>Second messenger system precursors (e.g. inositol)</p> </li> <li> <p>Selective serotonin reuptake inhibitors (SSRIs, e.g. paroxetine, fluvoxamine, sertraline, fluoxetine, and citalopram) </p> </li> <li> <p>Serotonin and norepinephrine reuptake inhibitor (SNRI, e.g. venlafaxine)</p> </li> <li> <p>Serotonin antagonist and reuptake inhibitors (SARI, e.g. nefazodone)</p> </li> <li> <p>Tricyclic antidepressants (TCAs, e.g. amitriptyline, desipramine and imipramine)</p> </li> </ul> </p> <p><b>Comparator interventions</b> </p> <p> <ul id="CD002795-list-0002"> <li> <p>Placebo (active or non‐active)</p> </li> <li> <p>Medication (control)</p> </li> </ul> </p> <p>We placed no restrictions on timing, dosage, duration, or co‐interventions.</p> </section> <section id="CD002795-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD002795-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD002795-list-0003"> <li> <p><b>Treatment efficacy</b> </p> <ul id="CD002795-list-0004"> <li> <p>Treatment response (responders versus non‐responders) was determined from the Clinical Global Impressions Scale ‐ Improvement Item (CGI‐I). The CGI‐I ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). In this review, responders were defined on the CGI‐I as those with a score of 1 = "very much" or 2 = "much" improved (<a href="./references#CD002795-bbs2-0229" title="GuyW .ECDEU assessment manual for psychopharmacology. Washington, DC: U.S. National Institute of Health, 1976.">Guy 1976</a>). Given that the CGI‐I is a widely‐used global outcome measure in RCTs of PTSD, this instrument served as a robust measure of the clinical value of treatment in PTSD (<a href="./references#CD002795-bbs2-0196" title="DavidsonJR .Biological therapies for posttraumatic stress disorder: an overview. Journal of Clinical Psychiatry1997;58(Suppl 9):33-6.">Davidson 1997b</a>). </p> </li> </ul> </li> <li> <p><b>Treatment tolerability ‐ dropouts due to treatment‐emergent adverse events</b> </p> <ul id="CD002795-list-0005"> <li> <p>The total proportion of participants who withdrew from the RCTs due to treatment‐emergent adverse events was included in the analysis as a surrogate measure of medication acceptability, in the absence of other more direct indicators of acceptability. </p> </li> </ul> </li> </ul> </p> </section> <section id="CD002795-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD002795-list-0006"> <li> <p><b>Reduction of PTSD symptoms</b> </p> <ul id="CD002795-list-0007"> <li> <p>Reduction in PTSD symptoms was determined from the total score on the Clinician Administered PTSD Scale (CAPS) (<a href="./references#CD002795-bbs2-0170" title="BlakeDD , WeathersFW , NagyLM , KaloupekDG , GusmanFD , CharneyDS , et al.A clinician rating scale for assessing current and lifetime PTSD: The CAPS-1. Behavior Therapy1990;21:187-8.">Blake 1990</a>), a symptom‐severity measure that is increasingly used in RCTs of PTSD. The CAPS is designed to make a categorical PTSD diagnosis which corresponds to the DSM‐IV criteria. A "1, 2" rule is used to determine a diagnosis, whereby a frequency score of 1 (scale 0 = "none of the time" to 4 = "most or all of the time") and an intensity score of 2 (scale 0 = "none" to 4 = "extreme") is required in order to meet specific symptom criteria (<a href="./references#CD002795-bbs2-0293" title="WeathersFW , RuscioAM , KeaneTM .Psychometric properties of nine scoring rules for the Clinician-Administered Posttraumatic Stress Disorder Scale. Psychological Assessment1999;11:124-33.">Weathers 1999</a>, as cited in the International Society for Traumatic Stress Studies). </p> </li> <li> <p>PTSD symptom reduction was assessed for those trials which used other continuous measures of symptom severity besides the CAPS, as well as from summary statistics from self‐rated scales such as the Impact of Events Scale (IES) (<a href="./references#CD002795-bbs2-0243" title="HorowitzM , WilnerN , AlvarezW .Impact of Event Scale: a measure of subjective stress. Psychosomatic Medicine1979;41(3):209-18.">Horowitz 1979</a>), and the Davidson Trauma Scale (DTS) (<a href="./references#CD002795-bbs2-0197" title="DavidsonJR , BookSW , ColketL , TuplerLA , RothS , DavidD , et al.Assessment of a new self-rating scale for posttraumatic stress disorder. Psychological Medicine1997;27(1):153-60.">Davidson 1997c</a>). The IES evaluates the distress that is caused by traumatic events and is centred around two subscales (i.e. intrusion and avoidance). The IES is a 22‐item self‐report scale in which respondents choose options from 1 to 5. The DTS is a 17‐item self‐report measure that assesses the 17 DSM‐IV symptoms of PTSD. Items are rated on a 5‐point frequency (0 = "not at all" to 4 = "every day") and severity scale (0 = "not at all distressing" to 4 = "extremely distressing"). The scores range from 0 to 136. </p> </li> <li> <p>Self‐rated scales were frequently the only outcome measures used in older trials and may continue to have a role in clinical practice. The efficacy of medication in alleviating symptoms within the three symptom clusters characteristic of PTSD (re‐experiencing/intrusion, avoidance/numbing, and hyperarousal) was determined using the CAPS‐B, CAPS‐C, and CAPS‐D subscales of the CAPS, as well as the relevant subscales of the self‐rated outcome measures. </p> </li> </ul> </li> <li> <p><b>Reduction in depressive symptoms</b> </p> <ul id="CD002795-list-0008"> <li> <p>The reduction of comorbid symptoms was measured by depression scales, such as the Beck Depression Inventory (BDI) (<a href="./references#CD002795-bbs2-0166" title="BeckAT , WardCH , MendelsonM , MockJ , ErbaughJ .An inventory for measuring depression. Archives of General Psychiatry1961;4:561-71.">Beck 1961</a>), the Hamilton Depression scale (HAM‐D) (<a href="./references#CD002795-bbs2-0231" title="HamiltonM .A rating scale for depression. Journal of Neurology, Neurosurgery &amp; Psychiatry1960;23:56-62.">Hamilton 1960</a>), and the Montgomery‐Asberg Depression Rating Scale (MADRS) (<a href="./references#CD002795-bbs2-0268" title="MontgomerySA , AsbergM .A new depression scale designed to be sensitive to change. British Journal of Psychiatry1979;134:382-9.">Montgomery 1979</a>). </p> </li> <li> <p>The Beck Depression Inventory (BDI) is a 21‐question multiple‐choice self‐report, one of the most widely used psychometric tests for measuring the severity of depression. A score of 0 to 9 indicates minimal depression, 10 to 18 mild depression, 19 to 29 moderate depression, and 30 to 63 severe depression. The Hamilton Depression scale (HAM‐D) is a multiple‐item questionnaire with 17 to 29 items (depending on the version). Patients are rated on a 3‐ or 5‐point scale. A score of 0 to 7 is normal and a score of 20 or higher moderate, severe, or very severe. The MADRS is a 10‐item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall scores range from 0 to 60. Usual cut‐off points are 0 to 6 ‐ normal/symptom absent; 7 to 19 ‐ mild depression; 20 to 34 ‐ moderate depression; and more than 34 ‐ severe depression. </p> </li> </ul> </li> <li> <p><b>Reduction in anxiety symptoms</b> </p> <ul id="CD002795-list-0009"> <li> <p>The reduction of comorbid symptoms was measured by anxiety scales, such as the Covi Anxiety Scale (CAS) (<a href="./references#CD002795-bbs2-0188" title="CoviL , LipmanRS .Primary depression or primary anxiety: a possible psychometric approach to a diagnostic dilemma. Clinical Neuropharmacology1984;7:S502-3.">Covi 1984</a>) and the Hamilton Anxiety scale (HAM‐A) (<a href="./references#CD002795-bbs2-0230" title="HamiltonM .The assessment of anxiety states by rating. British Journal of Medical Psychology1959;32(1):50-5.">Hamilton 1959</a>). </p> </li> <li> <p>The Covi Anxiety Scale is a three‐item scale along with three separate dimensions: verbal report, behaviour, and somatic symptoms of anxiety, and each dimension is rated on a 1‐to‐5 spectrum (1 = “not at all” to 5 = “very much”). The HAM‐A consists of 14 items and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0 to 56, where less than 17 indicates mild severity, 18 to 24 mild‐to‐moderate severity, and 25 to 30 moderate‐to‐severe. </p> </li> </ul> </li> <li> <p><b>Functional disability</b> </p> <ul id="CD002795-list-0010"> <li> <p>Functional disability as measured by the Sheehan Disability Scale (SDS), which includes subscales to assess work, social and family‐related impairment (<a href="./references#CD002795-bbs2-0282" title="SheehanDV , Harnett-SheehanK , RajBA .The measurement of disability. International Clinical Psychopharmacology1996;11 Suppl 3:89-95.">Sheehan 1996</a>), was also included, when provided, to address the question of medication effectiveness. The Sheehan Disability Scale is a composite of three self‐rated items designed to measure the extent to which three major sectors in the patient’s life are impaired by panic, anxiety, phobic, or depressive symptoms. The patient rates the extent to which his or her 1) work, 2) social life or leisure activities, and 3) home life or family responsibilities are impaired by his or her symptoms on a 10‐point visual analogue scale. The numerical ratings of 0‐to‐10 can be translated into a percentage if desired. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). </p> </li> </ul> </li> <li> <p><b>Treatment tolerability ‐ dropouts due to any cause</b> </p> <ul id="CD002795-list-0011"> <li> <p>Dropout rates due to any cause were also compared in order to provide some indication of treatment effectiveness. </p> </li> </ul> </li> </ul> </p> <section id="CD002795-sec-0023"> <h6 class="title">Main comparisons</h6> <p>We assessed the following outcomes and grouped them by specific pharmacological interventions according to medication class: </p> <p> <ul id="CD002795-list-0012"> <li> <p>Comparison 1: Alpha‐blockers versus placebo.</p> </li> <li> <p>Comparison 2: Anticonvulsants versus placebo.</p> </li> <li> <p>Comparison 3: Antipsychotics versus placebo.</p> </li> <li> <p>Comparison 4: Benzodiazepines versus placebo.</p> </li> <li> <p>Comparison 5: Dopamine beta‐hydroxylase inhibitors versus placebo.</p> </li> <li> <p>Comparison 6: Ganaxolone versus placebo.</p> </li> <li> <p>Comparison 7: GR205171 versus placebo.</p> </li> <li> <p>Comparison 8: GSK561679 versus placebo.</p> </li> <li> <p>Comparison 9: Hypnotics versus placebo</p> </li> <li> <p>Comparison 10: MAOIs versus placebo.</p> </li> <li> <p>Comparison 11: NaSSAs versus placebo.</p> </li> <li> <p>Comparison 12: NK‐1 receptor antagonists versus placebo.</p> </li> <li> <p>Comparison 13: RIMAs versus placebo.</p> </li> <li> <p>Comparison 14: SARIs versus placebo.</p> </li> <li> <p>Comparison 15: SNRIs versus placebo.</p> </li> <li> <p>Comparison 16: SSRIs versus placebo.</p> </li> <li> <p>Comparison 17: TCAs versus placebo.</p> </li> <li> <p>Comparison 18: Total effect of medication versus placebo.</p> </li> <li> <p>Comparison 19: Head‐to‐head comparisons.</p> </li> <li> <p>Comparison 20: Subgroup analyses ‐ Methodological criteria.</p> </li> <li> <p>Comparison 21: Subgroup analyses ‐ Clinical criteria.</p> </li> <li> <p>Comparison 22: Sensitivity analyses.</p> </li> <li> <p>Comparison 23: Publication bias.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD002795-sec-0024"> <h3 class="title">Search methods for identification of studies</h3> <p><b>Cochrane Specialised Register (CCMDCTR)</b><br/>The Cochrane Common Mental Disorders Group maintains a comprehensive, specialised register of randomised controlled trials, the CCMDCTR (to 13 November 2020). The register contains over 39,000 reference records (reports of RCTs) for anxiety disorders, depression, bipolar disorder, eating disorders, self‐harm and other mental disorders within the scope of this Group. The CCMDCTR is a partially studies‐based register with more than 50% of reference records tagged to about 12,500 individually PICO‐coded study records. Reports of trials for inclusion in the register were collated from (weekly) generic searches of MEDLINE (1950‐), Embase (1974‐) and PsycINFO (1967‐), quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) and review‐specific searches of additional databases. Reports of trials were also sourced from international trial registries, drug companies, the handsearching of key journals, conference proceedings and other (non‐Cochrane) systematic reviews and meta‐analyses. Details of CCMD’s core search strategies (used to identify RCTs) can be found on the Group’s website with an example of the core MEDLINE search displayed in <a href="./appendices#CD002795-sec-0129">Appendix 1</a>. </p> <section id="CD002795-sec-0025"> <h4 class="title">Electronic searches</h4> <p>An information specialist with the Cochrane Common Mental Disorders Group searched the following databases using keywords, subject headings and search syntax appropriate to each resource. The date of the latest, full search is 13 November 2020. </p> <p> <ul id="CD002795-list-0013"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2020, issue 11) in the Cochrane Library (searched 13 November 2020); </p> </li> <li> <p>Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR) (all years to June 2016); </p> </li> <li> <p>Embase Ovid (1974 to 2020 Week 46);</p> </li> <li> <p>MEDLINE ALL, Ovid (1946 to November 13, 2020);</p> </li> <li> <p>PsycINFO Ovid (all years to November Week 46 2020);</p> </li> <li> <p>PTSDPubs Proquest (previously PILOTS: Published International Literature On Traumatic Stress) (all years to 16 November 2020); </p> </li> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">https://clinicaltrials.gov/</a>); </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>). </p> </li> </ul> </p> <p>The searches have been through a number of iterations over the years, initially concentrating on terms for population and intervention (+ RCT filter), across the main bibliographic databases either directly or via the Cochrane Common Mental Disorders Controlled Trials Register (<a href="./appendices#CD002795-sec-0129">Appendix 1</a>). </p> <p>As the number of different pharmacological interventions used to treat PTSD expanded beyond the traditional psychotropic drugs, an information specialist ran searches for population only, RCTs (CCMDCTR, all available years; key bibliographic databases, 2014 onwards) (<a href="./appendices#CD002795-sec-0133">Appendix 2</a>). The search results were pre‐sifted (in duplicate), to weed out the non‐RCTs, prior to passing on the records on to the author team. The population only search, was designed to capture studies for a number of reviews within the CCMD group, for the treatment or prevention of PTSD. </p> <p>We (the author team) undertook our own searches, initially using a broad strategy to find not only RCTs, but also open‐label trials, as well as journal and chapter reviews of the pharmacotherapy of PTSD in adults (<a href="./appendices#CD002795-sec-0134">Appendix 3</a>). </p> </section> <section id="CD002795-sec-0026"> <h4 class="title">Searching other resources</h4> <p><b>Reference Lists</b> </p> <p>We sought additional RCTs in reference lists of the retrieved articles.</p> <p><b>Personal communication</b> </p> <p>We also obtained published and unpublished trials from key researchers, who were identified by the frequency with which they were cited in the bibliographies of RCTs and open‐label studies. </p> </section> </section> <section id="CD002795-sec-0027"> <h3 class="title" id="CD002795-sec-0027">Data collection and analysis</h3> <p>We used Review Manager 5 (RevMan 5) to perform all analyses reported in this review (<a href="./references#CD002795-bbs2-0276" title="Review Manager 5 (RevMan 5).Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">RevMan 2020</a>). </p> <section id="CD002795-sec-0028"> <h4 class="title">Selection of studies</h4> <p>RCTs identified from the search were independently assessed for inclusion by three review authors (TW, JI and NP), based on information included in the abstract or the main body of the trial report, or both. We collated RCTs which we regarded as satisfying the inclusion criteria specified in the <a href="#CD002795-sec-0029">Data extraction and management</a> and <a href="#CD002795-sec-0016">Criteria for considering studies for this review</a>. Studies for which additional information was required in order to determine their suitability for inclusion in the review have been listed in the <a href="./references#CD002795-sec-0160" title="">Characteristics of studies awaiting classification</a> table, pending the availability of this information. We resolved any disagreements in assessment and collation by discussion with a fourth review author (DS). </p> </section> <section id="CD002795-sec-0029"> <h4 class="title">Data extraction and management</h4> <p>We designed spreadsheet forms to record descriptive information, summary statistics of the outcome measures, the quality scale ratings, and associated commentary. </p> <p>We collated the following information from each trial (additional information can be found in the <a href="./references#CD002795-sec-0158" title="">Characteristics of included studies</a> tables, but not all extracted data are reported in this review): </p> <p> <ul id="CD002795-list-0014"> <li> <p>Description of the trials, including the primary researcher, the year of publication, and the source of funding. </p> </li> <li> <p>Characteristics of the interventions, including the number of participants randomised to the treatment and control groups, the number of total dropouts per group as well as the number that dropped out due to adverse effects, the dose of medication and the period over which it was administered, and the name and class of the medication (e.g. SSRIs, TCAs, MAOIs and 'other medication). </p> </li> <li> <p>Characteristics of trial methodology, including the diagnostic (e.g. DSM‐IV (<a href="./references#CD002795-bbs2-0156" title="American Psychiatric Association.Diagnostic and statistical manual of mental disorders (DSM-IV). 4th edition. Washington, DC: American Psychiatric Association, 1994.">APA 1994</a>)) and exclusion criteria used, the screening instrument used (e.g. the Structured Clinical Interview for DSM‐IV (SCID) (<a href="./references#CD002795-bbs2-0286" title="SpitzerR , WilliamsJ , GibbonsM .Instructional manual for the structured clinical interview for DSM-IV. New York. NY: New York State Psychiatric Institute, 1996.">Spitzer 1996</a>)) for both the primary and comorbid diagnoses, the presence of comorbid major depressive disorders (MDDs), the use of a placebo run‐in or of a minimal severity criterion, the number of centres involved, and the trial's methodological quality (see below). </p> </li> <li> <p>Characteristics of participants, including gender distribution and mean and range of ages, mean length of time with PTSD symptoms, whether they had been treated with the medication in the past (treatment naïvety), the number of participants in the sample with MDD, the number who experienced combat trauma, and the baseline severity of PTSD, as assessed by the trial's primary outcome measure or another commonly‐used scale. </p> </li> <li> <p>Outcome measures employed (primary and secondary), and summary continuous (means and standard deviations (SD)) and dichotomous (number of responders) data. Additional information included whether data reflected the intention‐to‐treat (ITT) with last observation carried forward (LOCF) or mixed methods (MM) sample, or whether a completer/observed cases (OC) sample was reported. </p> </li> </ul> </p> <p>Where information was missing, the review authors contacted investigators by email to obtain this information. </p> </section> <section id="CD002795-sec-0030"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risks of bias of each included study using the Cochrane risk of bias tool (<a href="./references#CD002795-bbs2-0240" title="HigginsJP , GreensS , editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>), based on consideration of the following six domains: </p> <p> <ul id="CD002795-list-0015"> <li> <p>Random sequence generation: did investigators use a random‐number table or a computerised random‐number generator? </p> </li> <li> <p>Allocation concealment: was the medication sequentially numbered, sealed, and placed in opaque envelopes? </p> </li> <li> <p>Blinding of participants, personnel, and outcome assessors for each main outcome or class of outcomes: was knowledge of the allocated treatment or assessment adequately blinded during the study? </p> </li> <li> <p>Incomplete outcome data for each main outcome or class of outcomes: were missing or excluded outcome data adequately addressed? </p> </li> <li> <p>Selective outcome reporting: were the reports of the study free of suggestion of selective outcome reporting? Such a judgement could only be made based on the availability of the protocol. </p> </li> <li> <p>Other sources of bias: was the study apparently free of other problems that could put it at a high risk of bias? </p> </li> </ul> </p> <p>Three independent review authors (TW, JI and NP) assessed and extracted the risks of bias for the included studies. We discussed any disagreements with a fourth review author (DS). Where necessary, we contacted the authors of the studies for further information. The review authors made a judgement on the risk of bias for each domain within and across studies, based on the following three categories: ’low’ risk of bias, ’unclear’ risk of bias, and ’high’ risk of bias. All risk of bias data are graphically presented and described in the text. </p> </section> <section id="CD002795-sec-0031"> <h4 class="title">Measures of treatment effect</h4> <p><b>Categorical data</b> </p> <p>Relative risk (RR) of failure to respond to treatment was used as the summary statistic for the dichotomous outcome of interest (CGI‐I or related measure). We used the RR instead of the odds ratio, as odd ratios tend to underestimate the size of the treatment effect when the occurrence of the adverse outcome of interest is common (as was the case in this review, with an anticipated non‐response greater than 20%) (<a href="./references#CD002795-bbs2-0204" title="DeeksJ , HigginsJ , AltmanD .Cochrane Reviewers’ Handbook 4.2.1 (updated December 2003). In: AldersonP , GreenS , HigginsJ , editors(s). The Cochrane Library. Chichester, UK: John Wiley &amp; Sons, Ltd., 2003.">Deeks 2003</a>; <a href="./references#CD002795-bbs2-0205" title="DeeksJJ , AltmanDG , BradburnMJ .Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey SG, Altman DG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. BMJ Publication Group, 2008:285–12.">Deeks 2011</a>), and because of the greater ease with which this statistic can be interpreted. </p> <p><b>Continuous data</b> </p> <p>We calculated weighted mean differences (WMDs) for continuous summary data obtained from studies that used the CAPS. Alternatively, in cases in which a range of scales were used, such as in the assessment of symptom severity on the self‐rated IES and DTS scales, we determined the standardised mean difference (SMD). This method of analysis standardises the differences between the means of the treatment and control groups in terms of the variability observed in the trial. </p> <p>In the case of data from trials using multiple fixed doses of medication, we avoided the bias introduced through comparing the summary statistics for multiple groups against the same placebo control by pooling the means and standard deviations across all the treatment arms as a function of the number of participants in each arm. In addition, when including summary statistics from the self‐rated scales, we preferred data from the DTS over the IES in trials which used both scales, given the inclusion in the former of a subscale assessing the hyperarousal symptom cluster (<a href="./references#CD002795-bbs2-0294" title="WeissDS , MarmarCR .The Impact of Event Scale—Revised. In: WilsonJP , KeaneTM , editors(s). Assessing psychological trauma and PTSD: a handbook for practitioners. New York, NY: Guilford Press, 1997:399-411.">Weiss 1997</a>), and concerns about the psychometric properties of the IES subscales (<a href="./references#CD002795-bbs2-0189" title="CreamerM , BellR , FaillaS .Psychometric properties of the Impact of Event Scale—Revised. Behaviour Research and Therapy2003;41(12):1489–96.">Creamer 2003</a>). </p> </section> <section id="CD002795-sec-0032"> <h4 class="title">Unit of analysis issues</h4> <p><b>Cluster‐randomised trials</b> </p> <p>In cluster‐randomised trials, groups of individuals, rather than individuals themselves, are randomised to different interventions. Analysing treatment response in cluster‐randomised trials without taking these groupings into account could be problematic, as participants within any one cluster often tend to respond in a similar manner, and thus analyses cannot assume that participants’ data are independent of the rest of the cluster. Cluster‐randomised trials also face additional risk‐of‐bias issues including recruitment bias, baseline imbalance, loss of clusters, and non‐comparability with trials randomising individuals (<a href="./references#CD002795-bbs2-0240" title="HigginsJP , GreensS , editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). No cluster‐randomised trials were eligible for inclusion in this review. </p> <p><b>Cross‐over trials</b> </p> <p>Cross‐over trials were only included in the calculation of summary statistics when it was (a) possible to extract medication and placebo/comparator data from the first treatment period alone, or (b) when the inclusion of data from both treatment periods was justified through a wash‐out period of sufficient duration as to minimise the risk of carry‐over effects (a minimum of two weeks or longer in the case of trials assessing the efficacy of agents with extended half‐lives, such as the SSRI, fluoxetine (<a href="./references#CD002795-bbs2-0228" title="GuryC , CousinF .Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability. Encephale1999;25(5):470-6.">Gury 1999</a>)). In the latter case, data from both periods were only included when it was possible to determine the correlation between participants' responses to the interventions in the different phases (<a href="./references#CD002795-bbs2-0212" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA .Meta-analyses involving cross-over trials: Methodological issues. International Journal of Epidemiology2002;31(1):140-9.">Elbourne 2002</a>). </p> <p><b>Multiple treatment groups</b> </p> <p>A few trials included in this review compared more than two intervention groups or multiple doses of the same medication against placebo. Including data from the same placebo group for these studies repeatedly in the same comparison would result in a unit‐of‐analysis error (<a href="./references#CD002795-bbs2-0240" title="HigginsJP , GreensS , editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). To prevent these errors for trials comparing multiple dosages of the same agent to placebo, we averaged the mean and standard deviation of the outcome of interest across dosage groups. We included outcome data from multiple treatment arms in the same comparison if the agents tested were from different medication classes. We turned off the subtotals of the outcome if the placebo group appeared twice in the analysis to accommodate the second medication. In the case of trials testing multiple agents from the same classes, and in calculating the total effect across all medication classes, we restricted data from multi‐arm RCTs to the agent that was least represented in the database. </p> </section> <section id="CD002795-sec-0033"> <h4 class="title">Dealing with missing data</h4> <p>All analyses of dichotomous data were intention‐to‐treat (ITT) and data from trials providing information on the original group size (prior to dropouts) were included in the analyses of treatment efficacy. We preferred within studies the inclusion of summary statistics for continuous outcome measures derived from mixed‐effects models, followed by last observation carried forward (LOCF) and observed cases (OC) summary statistics, in that order. This is in line with evidence that mixed‐effects methods are more robust to bias than LOCF analyses (<a href="./references#CD002795-bbs2-0291" title="VerbekeM , MolenberghsG .Linear mixed models for longitudinal data. New York: Springer2000.">Verbeke 2000</a>). </p> </section> <section id="CD002795-sec-0034"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity of treatment response, i.e. whether the differences between the results of trials were greater than would be expected by chance alone, visually from the forest plot of the RR. It was also determined by means of the Chi<sup>2</sup> test of heterogeneity, with a significance level of less than 0.10 interpreted as evidence of heterogeneity, given the low power of the Chi<sup>2</sup> statistic when the number of trials is small (<a href="./references#CD002795-bbs2-0204" title="DeeksJ , HigginsJ , AltmanD .Cochrane Reviewers’ Handbook 4.2.1 (updated December 2003). In: AldersonP , GreenS , HigginsJ , editors(s). The Cochrane Library. Chichester, UK: John Wiley &amp; Sons, Ltd., 2003.">Deeks 2003</a>). </p> <p>In addition, we used the I<sup>2</sup> heterogeneity statistic reported by RevMan to test the robustness of the Chi<sup>2</sup> statistic to differences in the number of trials included in the groups being compared within each subgroup analysis (<a href="./references#CD002795-bbs2-0239" title="HigginsJT , ThompsonSG , DeeksJJ , AltmanDG .Measuring inconsistency in meta-analyses. BMJ2003;327(6):557-60.">Higgins 2003</a>). Differences in treatment response on the CGI‐I were determined by whether the confidence intervals for the effect sizes of the subgroups overlapped. We chose this method in preference to the stratified test, due to inaccuracies in the calculation in RevMan of the Chi<sup>2</sup> statistic for dichotomous measures (<a href="./references#CD002795-bbs2-0204" title="DeeksJ , HigginsJ , AltmanD .Cochrane Reviewers’ Handbook 4.2.1 (updated December 2003). In: AldersonP , GreenS , HigginsJ , editors(s). The Cochrane Library. Chichester, UK: John Wiley &amp; Sons, Ltd., 2003.">Deeks 2003</a>; <a href="./references#CD002795-bbs2-0205" title="DeeksJJ , AltmanDG , BradburnMJ .Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey SG, Altman DG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. BMJ Publication Group, 2008:285–12.">Deeks 2011</a>). </p> <p>Thresholds for the interpretation of I<sup>2</sup> can be misleading, since the importance of inconsistency depends on several factors. The review follows a rough guide for interpretation: </p> <p> <ul id="CD002795-list-0016"> <li> <p>0% to 40%: might not be important.</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity.</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity.</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD002795-sec-0035"> <h4 class="title">Assessment of reporting biases</h4> <p>Funnel plots provide a graphic illustration of the effect estimates of an intervention from individual studies against some measure of the precision of that estimate. We determined publication bias by visual inspection of a funnel plot of treatment response, with the consideration of confounding selection bias, poor methodological quality, true heterogeneity, artefact, and chance. Given that this calculation is dependent on having 10 trials per outcome, we could only calculate this for the SSRIs. </p> </section> <section id="CD002795-sec-0036"> <h4 class="title">Data synthesis</h4> <p>We obtained summary statistics for categorical and continuous measures from a random‐effects model; this includes both within‐study sampling error and between‐studies variation in determining the precision of the confidence interval (CI) around the overall effect size, whereas the fixed‐effect model takes only within‐study variation into account. The summary statistics were expressed as an average effect size for each subgroup, as well as by means of 95% CIs. </p> </section> <section id="CD002795-sec-0037"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We conducted subgroup analyses (<a href="./references#CD002795-bbs2-0289" title="ThomsonSG .Why sources of heterogeneity in meta-analysis should be investigated. BMJ1994;309(6965):1351-5.">Thomson 1994</a>) in order to assess the degree to which methodological differences between trials might have systematically influenced differences observed in the primary treatment outcomes. </p> <p>We grouped the trials according to the following methodological sources of heterogeneity:</p> <p> <ul id="CD002795-list-0017"> <li> <p>The involvement of participants from a single centre or multiple centres. Single‐centre trials are more likely to be associated with lower sample size but with less variability in clinician ratings. </p> </li> <li> <p>Whether or not trials were industry‐funded. In general, published trials which are sponsored by pharmaceutical companies appear more likely to report positive findings than trials which are not supported by for‐profit companies (<a href="./references#CD002795-bbs2-0153" title="Als-NielsenB , ChenW , GluudC , KjaergardLL .Association of funding and conclusions in randomized drug trials - A reflection of treatment effect or adverse events?JAMA2003;290(7):921-8.">Als‐Nielsen 2003</a>; <a href="./references#CD002795-bbs2-0160" title="BakerCB , JohnsrudMT , CrismonML , RosenheckRA , WoodsSW .Quantitative analysis of sponsorship bias in economic studies of antidepressants. British Journal of Psychiatry2003;183:498-506.">Baker 2003</a>). </p> </li> </ul> </p> <p>In addition, we used the following criteria to assess the extent of clinical sources of heterogeneity: </p> <p> <ul id="CD002795-list-0018"> <li> <p>Whether or not the sample included combat veterans (this subgroup has been regarded as more resistant to treatment and is arguably more likely to have more chronic and severe symptoms, to have comorbid depression, and to be male). For the purposes of this review, those trials for which 10% or fewer of the sample consisted of war veterans were classified as non‐combat veteran RCTs. </p> </li> <li> <p>Whether or not the sample included participants diagnosed with major depression. Such an analysis might assist in determining the extent to which the efficacy of a medication agent in treating PTSD is independent of its ability to reduce symptoms of depression, an important consideration given the classification of many of these medications as antidepressants. </p> </li> </ul> </p> </section> <section id="CD002795-sec-0038"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses, which determine the robustness of the review authors' conclusion and methodological assumptions made in conducting the meta‐analysis. Sensitivity analyses were conducted to determine whether treatment response on the CGI‐I differed as a result of: </p> <p> <ul id="CD002795-list-0019"> <li> <p>Treatment response versus non‐response as the unit of comparison in determining medication efficacy. This comparison is regarded as necessary, given concerns that the former may result in less consistent summary statistics than the latter (<a href="./references#CD002795-bbs2-0203" title="DeeksJJ .Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine2002;21(11):1575-600.">Deeks 2002</a>). </p> </li> <li> <p>The exclusion of participants who were lost to follow‐up (LTF). This was determined through a 'worst case/best case' scenario (<a href="./references#CD002795-bbs2-0204" title="DeeksJ , HigginsJ , AltmanD .Cochrane Reviewers’ Handbook 4.2.1 (updated December 2003). In: AldersonP , GreenS , HigginsJ , editors(s). The Cochrane Library. Chichester, UK: John Wiley &amp; Sons, Ltd., 2003.">Deeks 2003</a>). In the worst case, all the missing data for the treatment group were recorded as non‐responders, whereas in the best case, all missing data in the control group were treated as non‐responders (In the case of the one SSRI (<a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a>) and MAOI trial (<a href="./references#CD002795-bbs2-0002" title="BakerDG , DiamondBI , GilletteG , HamnerM , KatzelnickD , KellerT , et al.A double-blind randomized placebo-controlled multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology1995;122(4):386-9. ConnorKM , HidalgoRB , CrockettB , MalikM , KatzRJ , DavidsonJR .Predictors of treatment response in patients with posttraumatic stress disorder. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2001;25(2):337-45. ">Baker 1995</a>) which only reported total LTF, the ratio of participants who dropped out in the medication and placebo groups was determined from the average ratio between these groups for those RCTs in the respective classes which did provide this information). Should the conclusions about treatment efficacy not differ between these two comparisons, we can assume that missing data in trial reports do not have a significant influence on outcome. </p> </li> </ul> </p> </section> <section id="CD002795-sec-0039"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>The review authors compiled summary of findings tables to present the evidence for the primary outcomes of the review (i.e. number of responders and dropouts due to treatment‐emergent side effects). In addition, the following comparisons were prioritised and are presented in the summary of findings tables: </p> <p> <ul id="CD002795-list-0020"> <li> <p>Comparison 1: Alpha‐blockers versus placebo.</p> </li> <li> <p>Comparison 2: Antipsychotics versus placebo.</p> </li> <li> <p>Comparison 3: MAOIs versus placebo.</p> </li> <li> <p>Comparison 4: NaSSAs versus placebo.</p> </li> <li> <p>Comparison 5: SNRIs versus placebo.</p> </li> <li> <p>Comparison 6: SSRIs versus placebo.</p> </li> <li> <p>Comparison 7: TCAs versus placebo.</p> </li> </ul> </p> <p>We used the following six elements (<a href="./references#CD002795-bbs2-0240" title="HigginsJP , GreensS , editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>) to report this: </p> <p> <ul id="CD002795-list-0021"> <li> <p>A list of all important outcomes, both desirable and undesirable;</p> </li> <li> <p>A measure of the typical burden of these outcomes (e.g. illustrative risk, or illustrative mean, on control intervention); </p> </li> <li> <p>Absolute and relative magnitude of effect (if both are appropriate);</p> </li> <li> <p>Numbers of participants and studies addressing these outcomes</p> </li> <li> <p>A grade of the overall quality of the body of evidence for each outcome</p> </li> <li> <p>Space for comments.</p> </li> </ul> </p> <p>The downgrading of the evidence rating for outcomes was based on five factors. Reasons for downgrading the evidence were classified as ’serious’ (downgrading the quality rating by one level) or ’very serious’ (downgrading the quality grade by two levels). </p> <p> <ul id="CD002795-list-0022"> <li> <p>Limitations in the design and implementation of the trial.</p> </li> <li> <p>Indirectness of evidence.</p> </li> <li> <p>Unexplained heterogeneity or inconsistency of results.</p> </li> <li> <p>Imprecision of results.</p> </li> <li> <p>High probability of publication bias.</p> </li> </ul> </p> <p>The review authors classified the quality of evidence for each outcome according to the following categories: </p> <p> <ul id="CD002795-list-0023"> <li> <p>High quality: further research is very unlikely to change our confidence in the estimate of effect; </p> </li> <li> <p>Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; </p> </li> <li> <p>Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; </p> </li> <li> <p>Very low quality: we are very uncertain about the estimate.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002795-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002795-sec-0040"></div> <section id="CD002795-sec-0041"> <h3 class="title">Description of studies</h3> <section id="CD002795-sec-0042"> <h4 class="title">Results of the search</h4> <p>We found a total of 23,309 studies through the search process (CCMDCTR 3660; MEDLINE 2489; PsycINFO 6222; <a href="http://ClinicalTrials.org" target="_blank">ClinicalTrials.org</a> 2371; Embase 1984; PILOTS 792; Proquest PTSDpubs 194; PubMed 5597). After the removal of 3052 duplicates, we scanned 20,257 titles and abstracts (if provided) for eligibility, and of these, we ruled out 20,126 studies. One hundred and thirty one studies initially seemed relevant, but after independent review of the full‐text studies, 65 failed to meet our inclusion criteria (see <a href="./references#CD002795-sec-0159" title="">Characteristics of excluded studies</a>), leaving 66 RCTs eligible for inclusion in the review (see <a href="./references#CD002795-sec-0158" title="">Characteristics of included studies</a> and <a href="#CD002795-fig-0001">Figure 1</a>). Of the 66 trials, the review included 54 RCTs in the meta‐analysis. Eighteen studies are awaiting classification, and one study is ongoing (see <a href="./references#CD002795-sec-0160" title="">Characteristics of studies awaiting classification</a> and <a href="./references#CD002795-sec-0161" title="">Characteristics of ongoing studies</a>). </p> <div class="figure" id="CD002795-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD002795-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD002795-sec-0043"> <h4 class="title">Included studies</h4> <p>The review includes 66 RCTs of PTSD (7442 participants, age range: 18 to 82 years), four of which contained a maintenance component (<a href="./references#CD002795-bbs2-0012" title="DavidsonJ , LondborgP , PearlsteinT , RothbaumB , BradyK , FarfelG .Double-blind, randomized, 28-week continuation study of sertraline and placebo in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):292. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo controlled study. American Journal of Psychiatry2001;158(12):1974–81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. DavidsonJR , RothbaumBO , Van der KolkBA , SikesCR , FarfelGM .Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Archives of General Psychiatry2001;58(5):485-92. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59–65. ">Davidson 2001a</a>, <a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a>, <a href="./references#CD002795-bbs2-0036" title="MartenyiF , BrownEB , ZhangH , PrakashA , KokeSC .Fluoxetine versus placebo in posttraumatic stress disorder. Journal of Clinical Psychiatry2002;63(3):199-206. ">Martenyi 2002a</a>, <a href="./references#CD002795-bbs2-0063" title="Van der Kolk, SpinazzolaJ , BlausteinM , HopperJ , HopperE , KornD , et al.A randomized clinical trial of EMDR, fluoxetine and pill placebo in the treatment of PTSD: treatment effects and long-term maintenance. Draft manuscript2004. Van der KolkBA , SpinazzolaJ , BlausteinME , HopperJW , HopperEK , KornDL , et al.A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. Journal of Clinical Psychiatry2007;68(1):37-46. ">Van der Kolk 2007</a>). Of the 66 trials, 58 were published, and all of these publications were in English. Pharmaceutical companies contributed funding for 35 of these trials. Twenty‐one studies were single‐centre trials, and 38 studies took place in multiple‐centres. There was insufficient information to determine the setting for the remaining seven trials. A placebo comparison group was used in all but six of the trials (<a href="./references#CD002795-bbs2-0041" title="McRaeAL , BradyKT , MellmanTA , SonnSC , KilleenTK , TimmermanMA , et al.Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depression and Anxiety2004;19(3):190–6. [DOI: 10.1002/da.20008]">McRae 2004</a> and <a href="./references#CD002795-bbs2-0053" title="SayginMZ , SungurMZ , SabolEU , CetinkayaP .Nefazodone versus sertraline in treatment of posttraumatic stress disorder. Bulletin of Clinical Psychopharmacology2002;12(1):1-5. ">Saygin 2002</a> compared nefazodone with the SSRI sertraline, while <a href="./references#CD002795-bbs2-0057" title="SmajkicA , WeineS , Djuric-BijedicZ , BoskailoE , LewisJ , PavkovicI .Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms. Journal of Traumatic Stress2001;14(3):445-52. ">Smajkic 2001</a> compared the efficacy of the SSRIs sertraline, paroxetine and the SNRI venlafaxine). <a href="./references#CD002795-bbs2-0008" title="ChungMY , MinKH , JunYJ , KimSS , KimWC , JunEM .Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Human Psychopharmacology2004;19(7):489–94. [DOI: 10.1002/hup.615]">Chung 2004</a> assessed the efficacy and tolerability of mirtazapine against that of sertraline, <a href="./references#CD002795-bbs2-0024" title="FederA , ParidesMK , MurroughJW , PerezAM , MorganJE , SaxenaS , et al.Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder. A randomized clinical trial. JAMA Psychiatry2014;71(6):681-8. [DOI: 10.1001/jamapsychiatry.2014.62]">Feder 2014</a> compared ketamine to midazolam (fixed 0.045 mg), and <a href="./references#CD002795-bbs2-0058" title="SpivakB , StrousRD , ShakedG , ShabashE , KotlerM , WeizmanA .Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. Journal of Clinical Psychopharmacology2006;26(2):152–6. [DOI: 10.1097/01.jcp.0000203195.65710.f0]">Spivak 2006</a> compared reboxetine (fixed 8 mg) to fluvoxamine (fixed 150 mg)). Of the remaining 60 RCTs, 26 of the trials included a SSRI treatment arm (one citalopram, dose range: 20 to 50 mg; eight fluoxetine, dose range: 10 to 80 mg; six paroxetine, dose range: 10 to 60 mg; 11 sertraline, dose range: 15 to 200 mg), two trials an alpha‐blocker intervention (prazosin, dose range: 1 to 15 mg; one of the trials included the antihistamine hydroxyzine, dose range: 10 to 100 mg), seven trials an anticonvulsant intervention (e.g. two tiagabine, dose range: 2 to 16 mg; two divalproex, dose range: 500 to 3000 mg; one lamotrigine, dose range: 25 to 500 mg; two topiramate, dose range: 25 to 400 mg), five trials an antipsychotic intervention (e.g. two olanzapine, dose range: 5 to 20 mg; two risperidone, dose range: 0.5 to 6 mg; one quetiapine, dose range: 25 to 800 mg), and three trials an experimental intervention (one ganaxolone, dose range: 200 to 600 mg; one GR205171, fixed 5 mg; one GSK561679, fixed 350 mg). The review also includes two trials with a MAOI intervention (phenelzine, dose range: 15 to 75 mg), one trial with a NaSSA intervention (mirtazapine, dose range: 15 to 50 mg); two trials with a RIMA intervention (brofaromine, dose range: 50 to 150 mg), one trial with a SNRI intervention (venlafaxine, dose range: 75 to 300 mg), and three trials with a TCA intervention (one amitriptyline, dose range: 50 to 200 mg; one desipramine, dose range: 50 to 200 mg; one imipramine, dose range: 50 to 300 mg). Single trials included a benzodiazepine (alprazolam, dose range: 1.5 to 6 mg) treatment arm, a dopamine beta‐hydroxylase inhibitor (nepicastat, dose range: 100 to 800 mg) treatment arm, a NK‐1 receptor antagonist (orvepitant, fixed 60 mg) treatment arm, a hypnotic (eszopiclone, dose 3 mg) treatment arm, and a second messenger system precursor (inositol, fixed 12 grams) treatment arm. The review also includes one trial investigating the norepinephrine and dopamine reuptake inhibitor bupropion SR (dose range: 100 to 300 mg). </p> <p>None of the six RCTs which used a cross‐over design (<a href="./references#CD002795-bbs2-0005" title="BraunP , GreenbergD , DasbergH , LererB .Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. Journal of Clinical Psychiatry1990;51(6):236-8. ">Braun 1990</a>; <a href="./references#CD002795-bbs2-0024" title="FederA , ParidesMK , MurroughJW , PerezAM , MorganJE , SaxenaS , et al.Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder. A randomized clinical trial. JAMA Psychiatry2014;71(6):681-8. [DOI: 10.1001/jamapsychiatry.2014.62]">Feder 2014</a>; <a href="./references#CD002795-bbs2-0030" title="KaplanZ , AmirM , SwartzM , LevineJ .Inositol treatment of posttraumatic stress disorder. Anxiety1996;2(1):51–2. [DOI: 10.1002/(SICI)1522-7154(1996)2:1&lt;51::AID-ANXI8&gt;3.0.CO;2-G]">Kaplan 1996</a>; <a href="./references#CD002795-bbs2-0050" title="RasmussonAM , MarxCE , JainS , FarfelGM , TsaiJ , SunX , et al.A randomized controlled trial of ganaxolone in posttraumatic stress disorder. Psychopharmacology2017;234(15):2245–57. [DOI: 10.1007/s00213-017-4649-y]">Rasmusson 2017</a>; <a href="./references#CD002795-bbs2-0052" title="ReistC , KauffmannCD , Chicz DemetA , ChenCC , DemetEM .REM latency, dexamethasone suppression test, and thyroid releasing hormone stimulation test in posttraumatic stress disorder. Progress in Neuropsychopharmacology and Biological Psychiatry1995;19(3):433-43. ReistC , KauffmannCD , HaierRJ , SangdahlC , DeMetEM , Chicz-DeMetA , et al.A controlled trial of desipramine in 18 men with posttraumatic stress disorder. American Journal of Psychiatry1989;146(4):513-6. ">Reist 1989</a>; <a href="./references#CD002795-bbs2-0054" title="ShestatzkyM , GreenbergD , LererB .A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatric Research1988;24(2):149-55. ">Shestatzky 1988</a>) provided enough information for inclusion of data in the meta‐analysis. These trials were all small and of poor quality, so their inclusion/exclusion is unlikely to have had a significant effect on the primary outcomes of the meta‐analysis. In brief, <a href="./references#CD002795-bbs2-0005" title="BraunP , GreenbergD , DasbergH , LererB .Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. Journal of Clinical Psychiatry1990;51(6):236-8. ">Braun 1990</a> compared an intervention of alprazolam with placebo using a sample of 16 outpatients over a period of 12 weeks. <a href="./references#CD002795-bbs2-0024" title="FederA , ParidesMK , MurroughJW , PerezAM , MorganJE , SaxenaS , et al.Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder. A randomized clinical trial. JAMA Psychiatry2014;71(6):681-8. [DOI: 10.1001/jamapsychiatry.2014.62]">Feder 2014</a> compared ketamine and midazolam over 13 days amongst 41 participants. <a href="./references#CD002795-bbs2-0030" title="KaplanZ , AmirM , SwartzM , LevineJ .Inositol treatment of posttraumatic stress disorder. Anxiety1996;2(1):51–2. [DOI: 10.1002/(SICI)1522-7154(1996)2:1&lt;51::AID-ANXI8&gt;3.0.CO;2-G]">Kaplan 1996</a> investigated the efficacy of inositol for a sample of 13 participants from two different outpatient clinics. <a href="./references#CD002795-bbs2-0050" title="RasmussonAM , MarxCE , JainS , FarfelGM , TsaiJ , SunX , et al.A randomized controlled trial of ganaxolone in posttraumatic stress disorder. Psychopharmacology2017;234(15):2245–57. [DOI: 10.1007/s00213-017-4649-y]">Rasmusson 2017</a> included 112 participants in an open‐label trial followed by a double‐blind trial investigating the experiential medication ganaxolone. <a href="./references#CD002795-bbs2-0052" title="ReistC , KauffmannCD , Chicz DemetA , ChenCC , DemetEM .REM latency, dexamethasone suppression test, and thyroid releasing hormone stimulation test in posttraumatic stress disorder. Progress in Neuropsychopharmacology and Biological Psychiatry1995;19(3):433-43. ReistC , KauffmannCD , HaierRJ , SangdahlC , DeMetEM , Chicz-DeMetA , et al.A controlled trial of desipramine in 18 men with posttraumatic stress disorder. American Journal of Psychiatry1989;146(4):513-6. ">Reist 1989</a> conducted a cross‐over trial of the TCA desipramine, in treating 27 combat veterans over a period of 10 weeks. <a href="./references#CD002795-bbs2-0054" title="ShestatzkyM , GreenbergD , LererB .A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatric Research1988;24(2):149-55. ">Shestatzky 1988</a> assessed the efficacy of the MAOI phenelzine in a 12‐week trial of 13 PTSD outpatients. </p> <p>In determining the long‐term effects of medication, <a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a> conducted a 10‐week trial of paroxetine and found continued reduction in PTSD symptoms after an additional maintenance period of 12 weeks, while <a href="./references#CD002795-bbs2-0063" title="Van der Kolk, SpinazzolaJ , BlausteinM , HopperJ , HopperE , KornD , et al.A randomized clinical trial of EMDR, fluoxetine and pill placebo in the treatment of PTSD: treatment effects and long-term maintenance. Draft manuscript2004. Van der KolkBA , SpinazzolaJ , BlausteinME , HopperJW , HopperEK , KornDL , et al.A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. Journal of Clinical Psychiatry2007;68(1):37-46. ">Van der Kolk 2007</a> assessed the efficacy of fluoxetine in 59 participants over five weeks followed by a six‐month maintenance phase. In a relapse‐prevention trial of sertraline, <a href="./references#CD002795-bbs2-0013" title="DavidsonJ , LondborgP , PearlsteinT , RothbaumB , BradyK , FarfelG .Double-blind, randomized, 28-week continuation study of sertraline and placebo in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):292. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry2001;158(12):1974-81. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59-65. ">Davidson 2001b</a> set out to determine whether 50 participants who were randomised to a placebo control for 28 weeks were more likely to experience clinical deterioration or relapse than the 46 randomised to a sertraline intervention for the same period. Participants in the relapse‐prevention phase of this trial had completed a 12‐week RCT of sertraline, and had also met responder criteria following the subsequent open‐label administration of this medication for a period of six months. In another relapse‐prevention trial, <a href="./references#CD002795-bbs2-0036" title="MartenyiF , BrownEB , ZhangH , PrakashA , KokeSC .Fluoxetine versus placebo in posttraumatic stress disorder. Journal of Clinical Psychiatry2002;63(3):199-206. ">Martenyi 2002a</a> re‐randomised 131 responders to a 12‐week short‐term RCT of fluoxetine to an additional 24 weeks of placebo or medication. </p> <p>We noted a great deal of clinical heterogeneity across participants in the RCTs of this review. Of the 53 trials that provided information on the nature of the index trauma for PTSD, eight were composed exclusively of war veterans (<a href="./references#CD002795-bbs2-0008" title="ChungMY , MinKH , JunYJ , KimSS , KimWC , JunEM .Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Human Psychopharmacology2004;19(7):489–94. [DOI: 10.1002/hup.615]">Chung 2004</a>; <a href="./references#CD002795-bbs2-0011" title="DavidsonJR , KudlerH , SmithR , MahorneySL , LipperS , HammettE , et al.Treatment of posttraumatic stress disorder with amitriptyline and placebo. Archives of General Psychiatry1990;47(3):259-66. DavidsonJR , KudlerHS , SaundersWB , EricksonL , SmithRD , SteinRM , et al.Predicting response to amitriptyline in posttraumatic stress disorder. American Journal of Psychiatry1993;150(7):1024-9. ">Davidson 1990</a>; <a href="./references#CD002795-bbs2-0029" title="HertzbergMA , FeldmanME , BeckhamJC , KudlerHS , DavidsonJR .Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Annals of Clinical Psychiatry2000;12(2):101-5. ">Hertzberg 2000</a>; <a href="./references#CD002795-bbs2-0032" title="KostenTR , FrankJB , DanE , McDougleCJ , Giller EL Jr.Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease1991;179(6):366–70. ">Kosten 1991</a>; <a href="./references#CD002795-bbs2-0042" title="NCT00659230.Nepicastat for Posttraumatic Stress Disorder (PTSD) in OIF/OEF Veterans (Nepicastat). clinicaltrials.gov/ct2/show/NCT00659230 (first received 06 May 2008). ">NCT00659230</a>; <a href="./references#CD002795-bbs2-0048" title="Food and Drug Adminstration (FDA).Review and evaluation of clinical data [Pfizer NDA application: Sertraline (Zoloft) for PTSD]. www.accessdata.fda.gov/drugsatfda_docs/nda/99/19-839S026_Zoloft_Clinr_P1.pdf1999;(accessed 28 November 2021). FriedmanMJ , MarmarCR , BakerDG , SikesCR , FarfelGM .Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. Journal of Clinical Psychiatry2007;68(5):711-20. Pfizer.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. ">Pfizer589</a>; <a href="./references#CD002795-bbs2-0049" title="RaskindMA , PeskindER , ChowB , HarrisC , Davis-KarimA , HolmesHA , et al.Trial of prazosin for post-traumatic stress disorder in military veterans. New England Journal of Medicine2018;378(6):507-17. [DOI: 10.1056/NEJMoa1507598]">Raskind 2018</a>; <a href="./references#CD002795-bbs2-0052" title="ReistC , KauffmannCD , Chicz DemetA , ChenCC , DemetEM .REM latency, dexamethasone suppression test, and thyroid releasing hormone stimulation test in posttraumatic stress disorder. Progress in Neuropsychopharmacology and Biological Psychiatry1995;19(3):433-43. ReistC , KauffmannCD , HaierRJ , SangdahlC , DeMetEM , Chicz-DeMetA , et al.A controlled trial of desipramine in 18 men with posttraumatic stress disorder. American Journal of Psychiatry1989;146(4):513-6. ">Reist 1989</a>), 15 contained individuals exposed to 'civilian' traumas, such as car accidents, earthquakes, domestic violence and child molestation (<a href="./references#CD002795-bbs2-0001" title="AhmadpanahM , SabzeieeP , Mohammad HosseiniS , TorabianS , HaghighiM , JahangardL , et al.Comparing the effect of prazosin and hydroxyzine on sleep quality in patients suffering from posttraumatic stress disorder. Neuropsychobiology2014;69(4):235–42. [10.1159/000362243]">Ahmadpanah 2014</a>; <a href="./references#CD002795-bbs2-0003" title="BeckerME , HertzbergMA , MooreSD , DennisMF , BukenyaDS , BeckhamJC .A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. Journal of Clinical Psychopharmacology2007;27(2):193-7. [DOI: 10.1097/JCP.0b013e318032eaed]">Becker 2007</a>; <a href="./references#CD002795-bbs2-0004" title="BradyK , PearlsteinT , AsnisGM , BakerD , RothbaumB , SikesCR , et al.Efficacy and safety of sertraline treatment of posttraumatic stress disorder. Archives of General Psychiatry2000;283(14):1837-44. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry2001;158(12):1974-81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. GaffneyM .Factor analysis of treatment response in posttraumatic stress disorder. Journal of Traumatic Stress2003;16(1):77-80. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59-65. RapaportMH , FarfelG , ClaryCM .Quality of life improvement in PTSD with sertraline treatment: results of a multicenter, placebo-controlled trial. International Journal of Neuropsychopharmacology2000;3(Suppl 1):294. ">Brady 2000</a>; <a href="./references#CD002795-bbs2-0009" title="BarnettSD , TharwaniHM , HertzbergMA , SutherlandSM , ConnorKM , DavidsonJR .Tolerability of fluoxetine in posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2002;26(2):363-7. ConnorKM , SutherlandSM , TuplerLA , MalikML , DavidsonJR .Fluoxetine in post-traumatic stress disorder: randomized, double-blind study. British Journal of Psychiatry1999;175:17-22. MalikML , ConnorKM , SutherlandSM , SmithRD , DavisonRM , DavidsonJR .Quality-of-life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo- controlled trial of fluoxetine. Journal of Traumatic Stress1999;12(2):387-93. ">Connor 1999a</a>; <a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a>; <a href="./references#CD002795-bbs2-0041" title="McRaeAL , BradyKT , MellmanTA , SonnSC , KilleenTK , TimmermanMA , et al.Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depression and Anxiety2004;19(3):190–6. [DOI: 10.1002/da.20008]">McRae 2004</a>; <a href="./references#CD002795-bbs2-0043" title="NCT01000493.Orvepitant (GW823296) in adult Post Traumatic Stress Disorder. clinicaltrials.gov/ct2/show/NCT01000493 (first received 23 October 2009). ">NCT01000493</a>; <a href="./references#CD002795-bbs2-0045" title="PadalaPR , MadisonJ , MonnahanM , MarcilW , PriceP , RamaswamyS , et al.Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. International Clinical Psychopharmacology2006;21(5):275–80. ">Padala 2006</a>; <a href="./references#CD002795-bbs2-0047" title="Food and Drug Administration (FDA).Review and evaluation of clinical data [Pfizer NDA application: Sertraline (Zoloft) for PTSD]. www.accessdata.fda.gov/drugsatfda_docs/nda/99/19-839S026_Zoloft_Clinr_P1.pdf1999;(accessed 28 November 2021). Pfizer.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. ">Pfizer588</a>; <a href="./references#CD002795-bbs2-0051" title="ReichDB , WinternitzS , HennenJ , WattsT , StanculescuC .A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. Journal of Clinical Psychiatry2004;65(12):1601-5. ">Reich 2004</a>; <a href="./references#CD002795-bbs2-0053" title="SayginMZ , SungurMZ , SabolEU , CetinkayaP .Nefazodone versus sertraline in treatment of posttraumatic stress disorder. Bulletin of Clinical Psychopharmacology2002;12(1):1-5. ">Saygin 2002</a>; <a href="./references#CD002795-bbs2-0057" title="SmajkicA , WeineS , Djuric-BijedicZ , BoskailoE , LewisJ , PavkovicI .Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms. Journal of Traumatic Stress2001;14(3):445-52. ">Smajkic 2001</a>; <a href="./references#CD002795-bbs2-0058" title="SpivakB , StrousRD , ShakedG , ShabashE , KotlerM , WeizmanA .Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. Journal of Clinical Psychopharmacology2006;26(2):152–6. [DOI: 10.1097/01.jcp.0000203195.65710.f0]">Spivak 2006</a>; <a href="./references#CD002795-bbs2-0061" title="TuckerP , TrautmanRP , WyattDB , ThompsonJ , WuSC , CapeceJA , et al.Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2007;68(2):201-6. ">Tucker 2007</a>; <a href="./references#CD002795-bbs2-0065" title="YehMS , MariJJ , CostaMC , AndreoliSB , BressanRA , MelloMF .A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neuroscience and Therapeutics2011;17(5):305–10. [DOI: 10.1111/j.1755-5949.2010.00188.x]">Yeh 2011</a>) and 30 contained people exposed to both combat‐related and civilian traumas (<a href="./references#CD002795-bbs2-0002" title="BakerDG , DiamondBI , GilletteG , HamnerM , KatzelnickD , KellerT , et al.A double-blind randomized placebo-controlled multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology1995;122(4):386-9. ConnorKM , HidalgoRB , CrockettB , MalikM , KatzRJ , DavidsonJR .Predictors of treatment response in patients with posttraumatic stress disorder. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2001;25(2):337-45. ">Baker 1995</a>; <a href="./references#CD002795-bbs2-0005" title="BraunP , GreenbergD , DasbergH , LererB .Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. Journal of Clinical Psychiatry1990;51(6):236-8. ">Braun 1990</a>; <a href="./references#CD002795-bbs2-0006" title="ButterfieldMI , BeckerME , ConnorKM , SutherlandS , ChurchillLE , DavidsonJR .Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. International Clinical Psychopharmacology2001;16(4):197-203. ">Butterfield 2001</a>; <a href="./references#CD002795-bbs2-0012" title="DavidsonJ , LondborgP , PearlsteinT , RothbaumB , BradyK , FarfelG .Double-blind, randomized, 28-week continuation study of sertraline and placebo in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):292. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo controlled study. American Journal of Psychiatry2001;158(12):1974–81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. DavidsonJR , RothbaumBO , Van der KolkBA , SikesCR , FarfelGM .Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Archives of General Psychiatry2001;58(5):485-92. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59–65. ">Davidson 2001a</a>; <a href="./references#CD002795-bbs2-0014" title="DavidsonJR , WeislerRH , ButterfieldMI , CasatCD , ConnorKM , BarnettS , et al.Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biological Psychiatry2003;53(2):188-91. ">Davidson 2003</a>; <a href="./references#CD002795-bbs2-0015" title="DavidsonJT , ConnorKM , HertzbergMA , WeislerRH , WilsonWH , PayneVM .Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study. Journal of Clinical Psychopharmacology2005;25(2):166–9. [DOI: 10.1097/01.jcp.0000155817.21467.6c]">Davidson 2005</a>; <a href="./references#CD002795-bbs2-0016" title="DavidsonJ , BaldwinD , SteinDJ , KuperE , BenattiaI , AhmedS , et al.Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Archives of General Psychiatry2006;63(10):1158-65. ">Davidson 2006a</a>; <a href="./references#CD002795-bbs2-0019" title="DavisLL , AmbroseS , EnglishB , DaforeME , FarleyJ , Bartolucci Al, et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder. In: 20th Annual Meeting, International Society for Traumatic Stress Studies, December 6 - 9, New Orleans, LA. 2001. DavisLL , JewellME , AmbroseS , FarleyJ , EnglishB , BartolucciA , et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. Journal of Clinical Psychopharmacology2004;24(3):291-7. [DOI: 10.1097/01.jcp.0000125685.82219.1a]">Davis 2004</a>; <a href="./references#CD002795-bbs2-0020" title="DavisLL , DavidsonJR , WardC , BartolucciA , BowdenCL , PettyF .Divalproex in the treatment of posttraumatic tress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. Journal of Clinical Psychopharmacology2008;28(21):84–8. [DOI: 10.1097/jcp.0b013e318160f83b]">Davis 2008</a>; <a href="./references#CD002795-bbs2-0021" title="DavisLL , PilkintonP , LinC , ParkerP , EstesS , BartolucciA .A randomized, placebo-controlled trial of mirtazapine for the treatment of posttraumatic stress disorder in v eterans. Journal of Clinical Psychiatry2020;81(6):e1-8. [DOI: 10.4088/JCP.20m13267]">Davis 2020</a>; <a href="./references#CD002795-bbs2-0022" title="DowdSM , ZaltaAK , BurgessHJ , AdkinsEC , Valdespino-HaydenZ , PollackMH .Double-blind randomized controlled study of the efficacy, safety and tolerability of eszopiclone vs placebo for the treatment of patients with post-traumatic stress disorder and insomnia. World Journal of Psychiatry2020;10(3):21-8. [DOI: 10.5498/wjp.v10.i3.21]">Dowd 2020</a>; <a href="./references#CD002795-bbs2-0023" title="DunlopBW , BinderEB , IosifescuD , MathewSJ , NeylanTC , PapeJC , et al.Corticotropin-releasing factor receptor 1 antagonism Is ineffective for women with posttraumatic stress disorder. Biological Psychiatry2017;82(12):866–74. [DOI: http://dx.doi.org/10.1016/j.biopsych.2017.06.024]">Dunlop 2017</a>; <a href="./references#CD002795-bbs2-0024" title="FederA , ParidesMK , MurroughJW , PerezAM , MorganJE , SaxenaS , et al.Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder. A randomized clinical trial. JAMA Psychiatry2014;71(6):681-8. [DOI: 10.1001/jamapsychiatry.2014.62]">Feder 2014</a>; <a href="./references#CD002795-bbs2-0028" title="HertzbergMA , ButterfieldMI , FeldmanME , BeckhamJC , SutherlandSM , ConnorKM , et al.A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biological Psychiatry1999;45(9):1226-9. ">Hertzberg 1999</a>; <a href="./references#CD002795-bbs2-0030" title="KaplanZ , AmirM , SwartzM , LevineJ .Inositol treatment of posttraumatic stress disorder. Anxiety1996;2(1):51–2. [DOI: 10.1002/(SICI)1522-7154(1996)2:1&lt;51::AID-ANXI8&gt;3.0.CO;2-G]">Kaplan 1996</a>; <a href="./references#CD002795-bbs2-0031" title="ConnorKM , HidalgoRB , CrockettB , MalikM , KatzRJ , DavidsonJR .Predictors of treatment response in patients with posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2001;25(2):337–45. KatzRJ , LottMH , ArbusP , CrocqL , HerlobsenP , LingjaerdeO , et al.Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety1994;1(4):169–74. [DOI: https://doi.org/10.1002/anxi.3070010404 ]">Katz 1994</a>; <a href="./references#CD002795-bbs2-0033" title="LiW , Ma Y-B, YangQ , LiBL , Meng Q-G, ZhangY .Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study. International Journal of Psychiatry in Clinical Practice2017;21(2):151-5. [DOI: 10.1080/13651501.2017.1291838]">Li 2017</a>; <a href="./references#CD002795-bbs2-0034" title="Food and Drugs Administration (FDA).Paxil (paroxetine) [NDA 20-031/S-029 Paxil (Paroxetine hydrochloride) tablets; GlaxoSmithKline; Post-traumatic Stress Disorder]. www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf (accessed 26 November 2021). GlaxoSmithKline.A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Posttraumatic Stress Disorder (PTSD). GSK - clinical study register [www.gsk-clinicalstudyregister.com]:Study ID: PAR 29060 651 (BRL-02960). MarshallRD , BeebeKL , OldhamM , ZaninelliR .Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. American Journal of Psychiatry2001;158(12):1982-8. ">Marshall 2001</a>; <a href="./references#CD002795-bbs2-0036" title="MartenyiF , BrownEB , ZhangH , PrakashA , KokeSC .Fluoxetine versus placebo in posttraumatic stress disorder. Journal of Clinical Psychiatry2002;63(3):199-206. ">Martenyi 2002a</a>; <a href="./references#CD002795-bbs2-0038" title="MartenyiF , BrownEB , CaldwellCB .Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study. Journal of Clinical Psychopharmacology2007;27(2):166–70. [DOI: 10.1097/JCP.0b013e31803308ce]">Martenyi 2007</a>; <a href="./references#CD002795-bbs2-0039" title="MathewSJ , VythilingamM , MurroughaJW , ZarateCA , FederaA , LuckenbaughDA , et al.A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. European Neuropsychopharmacology2011;21(3):221–9. ">Mathew 2011</a>; <a href="./references#CD002795-bbs2-0046" title="PanahiY , MoghaddamBR , SahebkarA , NazariMA , BeiraghdarF , KaramiG , et al.A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder. Psychological Medicine2011;41(10):2159–66. [DOI: 10.1017/S0033291711000201]">Panahi 2011</a>; <a href="./references#CD002795-bbs2-0050" title="RasmussonAM , MarxCE , JainS , FarfelGM , TsaiJ , SunX , et al.A randomized controlled trial of ganaxolone in posttraumatic stress disorder. Psychopharmacology2017;234(15):2245–57. [DOI: 10.1007/s00213-017-4649-y]">Rasmusson 2017</a>; <a href="./references#CD002795-bbs2-0054" title="ShestatzkyM , GreenbergD , LererB .A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatric Research1988;24(2):149-55. ">Shestatzky 1988</a>; <a href="./references#CD002795-bbs2-0059" title="GlaxoSmithKline.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). GSK - Clinical Study Register [www.gsk-clinicalstudyregister.com]2000:Study ID:GSK 29060/648. TuckerP , ZaninelliR , YehudaR , RuggieroL , DillinghamK , PittsCD .Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry2001;62(11):860-8. ">Tucker 2001</a>; <a href="./references#CD002795-bbs2-0060" title="TuckerP , Potter-KimballR , WyattDB , ParkerDE , BurginC , JonesDE , et al.Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. General Psychopharmacology2003;37(3):135-49. ">Tucker 2003</a>; <a href="./references#CD002795-bbs2-0062" title="Van der KolkBA , DreyfussD , MichaelsM , SheraD , BerkowitzR , FislerR , et al.Fluoxetine treatment in posttraumatic stress disorder. Journal of Clinical Psychiatry1994;55(12):517-22. ">Van der Kolk 1994</a>; <a href="./references#CD002795-bbs2-0063" title="Van der Kolk, SpinazzolaJ , BlausteinM , HopperJ , HopperE , KornD , et al.A randomized clinical trial of EMDR, fluoxetine and pill placebo in the treatment of PTSD: treatment effects and long-term maintenance. Draft manuscript2004. Van der KolkBA , SpinazzolaJ , BlausteinME , HopperJW , HopperEK , KornDL , et al.A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. Journal of Clinical Psychiatry2007;68(1):37-46. ">Van der Kolk 2007</a>; <a href="./references#CD002795-bbs2-0064" title="VillarrealG , HamnerMB , CañiveJM , RobertS , CalaisLA , DurklaskiV , et al.Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. American Journal of Psychiatry2016;173(12):1205-12. [DOI: 10.1176/appi.ajp.2016.15070967]">Villarreal 2016</a>; <a href="./references#CD002795-bbs2-0066" title="AmitalD , ZoharJ , KotlerM , BleichA , MiodovnikH , NevoA , et al.A placebo-controlled study of sertraline in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):269. AmitalD , ZoharJ , KotlerM , BleichA , MiodovnikH , NevoA , et al.A placebo-controlled trial pilot study of sertraline in PTSD. In: Annual Meeting of the American Psychiatric Association. American Psychiatric Association, 1999:157. ZoharJ , AmitalD , MiodownikC , KotlerM , BleichA , LaneRM .Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. Journal of Clinical Psychopharmacology2002;22(2):190-5. ">Zohar 2002</a>). Of the 36 RCTs that provided information on comorbid psychopathology, 32 reported that the participants in the trials were diagnosed with other anxiety disorders besides PTSD, as classified according to DSM III, DSM III‐R, DSM‐IV DSM‐IV‐TR or DSM‐5 criteria (<a href="./references#CD002795-bbs2-0001" title="AhmadpanahM , SabzeieeP , Mohammad HosseiniS , TorabianS , HaghighiM , JahangardL , et al.Comparing the effect of prazosin and hydroxyzine on sleep quality in patients suffering from posttraumatic stress disorder. Neuropsychobiology2014;69(4):235–42. [10.1159/000362243]">Ahmadpanah 2014</a>; <a href="./references#CD002795-bbs2-0003" title="BeckerME , HertzbergMA , MooreSD , DennisMF , BukenyaDS , BeckhamJC .A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. Journal of Clinical Psychopharmacology2007;27(2):193-7. [DOI: 10.1097/JCP.0b013e318032eaed]">Becker 2007</a>; <a href="./references#CD002795-bbs2-0004" title="BradyK , PearlsteinT , AsnisGM , BakerD , RothbaumB , SikesCR , et al.Efficacy and safety of sertraline treatment of posttraumatic stress disorder. Archives of General Psychiatry2000;283(14):1837-44. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry2001;158(12):1974-81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. GaffneyM .Factor analysis of treatment response in posttraumatic stress disorder. Journal of Traumatic Stress2003;16(1):77-80. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59-65. RapaportMH , FarfelG , ClaryCM .Quality of life improvement in PTSD with sertraline treatment: results of a multicenter, placebo-controlled trial. International Journal of Neuropsychopharmacology2000;3(Suppl 1):294. ">Brady 2000</a>; <a href="./references#CD002795-bbs2-0005" title="BraunP , GreenbergD , DasbergH , LererB .Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. Journal of Clinical Psychiatry1990;51(6):236-8. ">Braun 1990</a>; <a href="./references#CD002795-bbs2-0006" title="ButterfieldMI , BeckerME , ConnorKM , SutherlandS , ChurchillLE , DavidsonJR .Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. International Clinical Psychopharmacology2001;16(4):197-203. ">Butterfield 2001</a>; <a href="./references#CD002795-bbs2-0007" title="CareyP , SulimanS , GanesanK , SeedatS , SteinDJ .Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Human Psychopharmacology Clinical and Experimental2012;27:386–91. [DOI: 10.1002/hup.2238]">Carey 2012</a>; <a href="./references#CD002795-bbs2-0011" title="DavidsonJR , KudlerH , SmithR , MahorneySL , LipperS , HammettE , et al.Treatment of posttraumatic stress disorder with amitriptyline and placebo. Archives of General Psychiatry1990;47(3):259-66. DavidsonJR , KudlerHS , SaundersWB , EricksonL , SmithRD , SteinRM , et al.Predicting response to amitriptyline in posttraumatic stress disorder. American Journal of Psychiatry1993;150(7):1024-9. ">Davidson 1990</a>; <a href="./references#CD002795-bbs2-0012" title="DavidsonJ , LondborgP , PearlsteinT , RothbaumB , BradyK , FarfelG .Double-blind, randomized, 28-week continuation study of sertraline and placebo in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):292. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo controlled study. American Journal of Psychiatry2001;158(12):1974–81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. DavidsonJR , RothbaumBO , Van der KolkBA , SikesCR , FarfelGM .Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Archives of General Psychiatry2001;58(5):485-92. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59–65. ">Davidson 2001a</a>; <a href="./references#CD002795-bbs2-0014" title="DavidsonJR , WeislerRH , ButterfieldMI , CasatCD , ConnorKM , BarnettS , et al.Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biological Psychiatry2003;53(2):188-91. ">Davidson 2003</a>; <a href="./references#CD002795-bbs2-0018" title="DavidsonJR , BradyK , MellmanTA , SteinMB , PollackMH .The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. Journal of Clinical Psychopharmacology2007;27(1):85–8. [DOI: 10.1097/JCP.0b013e31802e5115]">Davidson 2007</a>; <a href="./references#CD002795-bbs2-0019" title="DavisLL , AmbroseS , EnglishB , DaforeME , FarleyJ , Bartolucci Al, et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder. In: 20th Annual Meeting, International Society for Traumatic Stress Studies, December 6 - 9, New Orleans, LA. 2001. DavisLL , JewellME , AmbroseS , FarleyJ , EnglishB , BartolucciA , et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. Journal of Clinical Psychopharmacology2004;24(3):291-7. [DOI: 10.1097/01.jcp.0000125685.82219.1a]">Davis 2004</a>; <a href="./references#CD002795-bbs2-0021" title="DavisLL , PilkintonP , LinC , ParkerP , EstesS , BartolucciA .A randomized, placebo-controlled trial of mirtazapine for the treatment of posttraumatic stress disorder in v eterans. Journal of Clinical Psychiatry2020;81(6):e1-8. [DOI: 10.4088/JCP.20m13267]">Davis 2020</a>; <a href="./references#CD002795-bbs2-0022" title="DowdSM , ZaltaAK , BurgessHJ , AdkinsEC , Valdespino-HaydenZ , PollackMH .Double-blind randomized controlled study of the efficacy, safety and tolerability of eszopiclone vs placebo for the treatment of patients with post-traumatic stress disorder and insomnia. World Journal of Psychiatry2020;10(3):21-8. [DOI: 10.5498/wjp.v10.i3.21]">Dowd 2020</a>; <a href="./references#CD002795-bbs2-0023" title="DunlopBW , BinderEB , IosifescuD , MathewSJ , NeylanTC , PapeJC , et al.Corticotropin-releasing factor receptor 1 antagonism Is ineffective for women with posttraumatic stress disorder. Biological Psychiatry2017;82(12):866–74. [DOI: http://dx.doi.org/10.1016/j.biopsych.2017.06.024]">Dunlop 2017</a>; <a href="./references#CD002795-bbs2-0027" title="HamnerMB , FaldowskiRA , RobertS , UlmerHG , HornerMD , LorberbaumJP .A preliminary controlled trial of divalproex in posttraumatic stress disorder. Annals of Clinical Psychiatry2008;21(2):89-94. ">Hamner 2008</a>; <a href="./references#CD002795-bbs2-0029" title="HertzbergMA , FeldmanME , BeckhamJC , KudlerHS , DavidsonJR .Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Annals of Clinical Psychiatry2000;12(2):101-5. ">Hertzberg 2000</a>; <a href="./references#CD002795-bbs2-0030" title="KaplanZ , AmirM , SwartzM , LevineJ .Inositol treatment of posttraumatic stress disorder. Anxiety1996;2(1):51–2. [DOI: 10.1002/(SICI)1522-7154(1996)2:1&lt;51::AID-ANXI8&gt;3.0.CO;2-G]">Kaplan 1996</a>; <a href="./references#CD002795-bbs2-0033" title="LiW , Ma Y-B, YangQ , LiBL , Meng Q-G, ZhangY .Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study. International Journal of Psychiatry in Clinical Practice2017;21(2):151-5. [DOI: 10.1080/13651501.2017.1291838]">Li 2017</a>; <a href="./references#CD002795-bbs2-0034" title="Food and Drugs Administration (FDA).Paxil (paroxetine) [NDA 20-031/S-029 Paxil (Paroxetine hydrochloride) tablets; GlaxoSmithKline; Post-traumatic Stress Disorder]. www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf (accessed 26 November 2021). GlaxoSmithKline.A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Posttraumatic Stress Disorder (PTSD). GSK - clinical study register [www.gsk-clinicalstudyregister.com]:Study ID: PAR 29060 651 (BRL-02960). MarshallRD , BeebeKL , OldhamM , ZaninelliR .Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. American Journal of Psychiatry2001;158(12):1982-8. ">Marshall 2001</a>; <a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a>; <a href="./references#CD002795-bbs2-0039" title="MathewSJ , VythilingamM , MurroughaJW , ZarateCA , FederaA , LuckenbaughDA , et al.A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. European Neuropsychopharmacology2011;21(3):221–9. ">Mathew 2011</a>; <a href="./references#CD002795-bbs2-0040" title="McCallWV , YoussefN , BranchF , NollaT , McCloudL , MoraczewskiJ , et al.A randomized controlled trial (RCT) of prazosin versus placebo for suicidal posttraumatic stress disorder (PTSD) patients with nightmares-a pilot study. Sleep2018;41(Supplement 1):A351-2. [DOI: 10.1097/JCP.0000000000000968]">McCall 2018</a>; <a href="./references#CD002795-bbs2-0046" title="PanahiY , MoghaddamBR , SahebkarA , NazariMA , BeiraghdarF , KaramiG , et al.A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder. Psychological Medicine2011;41(10):2159–66. [DOI: 10.1017/S0033291711000201]">Panahi 2011</a>; <a href="./references#CD002795-bbs2-0048" title="Food and Drug Adminstration (FDA).Review and evaluation of clinical data [Pfizer NDA application: Sertraline (Zoloft) for PTSD]. www.accessdata.fda.gov/drugsatfda_docs/nda/99/19-839S026_Zoloft_Clinr_P1.pdf1999;(accessed 28 November 2021). FriedmanMJ , MarmarCR , BakerDG , SikesCR , FarfelGM .Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. Journal of Clinical Psychiatry2007;68(5):711-20. Pfizer.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. ">Pfizer589</a>; <a href="./references#CD002795-bbs2-0049" title="RaskindMA , PeskindER , ChowB , HarrisC , Davis-KarimA , HolmesHA , et al.Trial of prazosin for post-traumatic stress disorder in military veterans. New England Journal of Medicine2018;378(6):507-17. [DOI: 10.1056/NEJMoa1507598]">Raskind 2018</a>; <a href="./references#CD002795-bbs2-0050" title="RasmussonAM , MarxCE , JainS , FarfelGM , TsaiJ , SunX , et al.A randomized controlled trial of ganaxolone in posttraumatic stress disorder. Psychopharmacology2017;234(15):2245–57. [DOI: 10.1007/s00213-017-4649-y]">Rasmusson 2017</a>; <a href="./references#CD002795-bbs2-0051" title="ReichDB , WinternitzS , HennenJ , WattsT , StanculescuC .A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. Journal of Clinical Psychiatry2004;65(12):1601-5. ">Reich 2004</a>; <a href="./references#CD002795-bbs2-0053" title="SayginMZ , SungurMZ , SabolEU , CetinkayaP .Nefazodone versus sertraline in treatment of posttraumatic stress disorder. Bulletin of Clinical Psychopharmacology2002;12(1):1-5. ">Saygin 2002</a>; <a href="./references#CD002795-bbs2-0054" title="ShestatzkyM , GreenbergD , LererB .A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatric Research1988;24(2):149-55. ">Shestatzky 1988</a>; <a href="./references#CD002795-bbs2-0059" title="GlaxoSmithKline.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). GSK - Clinical Study Register [www.gsk-clinicalstudyregister.com]2000:Study ID:GSK 29060/648. TuckerP , ZaninelliR , YehudaR , RuggieroL , DillinghamK , PittsCD .Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry2001;62(11):860-8. ">Tucker 2001</a>; <a href="./references#CD002795-bbs2-0060" title="TuckerP , Potter-KimballR , WyattDB , ParkerDE , BurginC , JonesDE , et al.Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. General Psychopharmacology2003;37(3):135-49. ">Tucker 2003</a>; <a href="./references#CD002795-bbs2-0061" title="TuckerP , TrautmanRP , WyattDB , ThompsonJ , WuSC , CapeceJA , et al.Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2007;68(2):201-6. ">Tucker 2007</a>). The most commonly‐reported comorbid anxiety was panic disorder, with or without agoraphobia, which was reported for nine of the 13 studies that distinguished between individual anxiety disorder diagnostic categories (<a href="./references#CD002795-bbs2-0005" title="BraunP , GreenbergD , DasbergH , LererB .Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. Journal of Clinical Psychiatry1990;51(6):236-8. ">Braun 1990</a>; <a href="./references#CD002795-bbs2-0006" title="ButterfieldMI , BeckerME , ConnorKM , SutherlandS , ChurchillLE , DavidsonJR .Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. International Clinical Psychopharmacology2001;16(4):197-203. ">Butterfield 2001</a>; <a href="./references#CD002795-bbs2-0011" title="DavidsonJR , KudlerH , SmithR , MahorneySL , LipperS , HammettE , et al.Treatment of posttraumatic stress disorder with amitriptyline and placebo. Archives of General Psychiatry1990;47(3):259-66. DavidsonJR , KudlerHS , SaundersWB , EricksonL , SmithRD , SteinRM , et al.Predicting response to amitriptyline in posttraumatic stress disorder. American Journal of Psychiatry1993;150(7):1024-9. ">Davidson 1990</a>; <a href="./references#CD002795-bbs2-0019" title="DavisLL , AmbroseS , EnglishB , DaforeME , FarleyJ , Bartolucci Al, et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder. In: 20th Annual Meeting, International Society for Traumatic Stress Studies, December 6 - 9, New Orleans, LA. 2001. DavisLL , JewellME , AmbroseS , FarleyJ , EnglishB , BartolucciA , et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. Journal of Clinical Psychopharmacology2004;24(3):291-7. [DOI: 10.1097/01.jcp.0000125685.82219.1a]">Davis 2004</a>; <a href="./references#CD002795-bbs2-0021" title="DavisLL , PilkintonP , LinC , ParkerP , EstesS , BartolucciA .A randomized, placebo-controlled trial of mirtazapine for the treatment of posttraumatic stress disorder in v eterans. Journal of Clinical Psychiatry2020;81(6):e1-8. [DOI: 10.4088/JCP.20m13267]">Davis 2020</a>; <a href="./references#CD002795-bbs2-0034" title="Food and Drugs Administration (FDA).Paxil (paroxetine) [NDA 20-031/S-029 Paxil (Paroxetine hydrochloride) tablets; GlaxoSmithKline; Post-traumatic Stress Disorder]. www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf (accessed 26 November 2021). GlaxoSmithKline.A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Posttraumatic Stress Disorder (PTSD). GSK - clinical study register [www.gsk-clinicalstudyregister.com]:Study ID: PAR 29060 651 (BRL-02960). MarshallRD , BeebeKL , OldhamM , ZaninelliR .Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. American Journal of Psychiatry2001;158(12):1982-8. ">Marshall 2001</a>; <a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a>; <a href="./references#CD002795-bbs2-0053" title="SayginMZ , SungurMZ , SabolEU , CetinkayaP .Nefazodone versus sertraline in treatment of posttraumatic stress disorder. Bulletin of Clinical Psychopharmacology2002;12(1):1-5. ">Saygin 2002</a>; <a href="./references#CD002795-bbs2-0060" title="TuckerP , Potter-KimballR , WyattDB , ParkerDE , BurginC , JonesDE , et al.Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. General Psychopharmacology2003;37(3):135-49. ">Tucker 2003</a>). Twenty‐two studies included individuals with major depressive disorder (MDD), while MDD was an exclusion criterion for seven trials. We were unable to determine whether individuals with MDD could take part in the remaining trials, due to insufficient information. </p> <p>Twenty trials assessed our primary efficacy outcome – the number of participants with PTSD who responded to treatment – using the CGI–I Scale (<a href="./references#CD002795-bbs2-0004" title="BradyK , PearlsteinT , AsnisGM , BakerD , RothbaumB , SikesCR , et al.Efficacy and safety of sertraline treatment of posttraumatic stress disorder. Archives of General Psychiatry2000;283(14):1837-44. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry2001;158(12):1974-81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. GaffneyM .Factor analysis of treatment response in posttraumatic stress disorder. Journal of Traumatic Stress2003;16(1):77-80. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59-65. RapaportMH , FarfelG , ClaryCM .Quality of life improvement in PTSD with sertraline treatment: results of a multicenter, placebo-controlled trial. International Journal of Neuropsychopharmacology2000;3(Suppl 1):294. ">Brady 2000</a>; <a href="./references#CD002795-bbs2-0007" title="CareyP , SulimanS , GanesanK , SeedatS , SteinDJ .Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Human Psychopharmacology Clinical and Experimental2012;27:386–91. [DOI: 10.1002/hup.2238]">Carey 2012</a>; <a href="./references#CD002795-bbs2-0008" title="ChungMY , MinKH , JunYJ , KimSS , KimWC , JunEM .Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Human Psychopharmacology2004;19(7):489–94. [DOI: 10.1002/hup.615]">Chung 2004</a>; <a href="./references#CD002795-bbs2-0011" title="DavidsonJR , KudlerH , SmithR , MahorneySL , LipperS , HammettE , et al.Treatment of posttraumatic stress disorder with amitriptyline and placebo. Archives of General Psychiatry1990;47(3):259-66. DavidsonJR , KudlerHS , SaundersWB , EricksonL , SmithRD , SteinRM , et al.Predicting response to amitriptyline in posttraumatic stress disorder. American Journal of Psychiatry1993;150(7):1024-9. ">Davidson 1990</a>; <a href="./references#CD002795-bbs2-0012" title="DavidsonJ , LondborgP , PearlsteinT , RothbaumB , BradyK , FarfelG .Double-blind, randomized, 28-week continuation study of sertraline and placebo in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):292. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo controlled study. American Journal of Psychiatry2001;158(12):1974–81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. DavidsonJR , RothbaumBO , Van der KolkBA , SikesCR , FarfelGM .Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Archives of General Psychiatry2001;58(5):485-92. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59–65. ">Davidson 2001a</a>; <a href="./references#CD002795-bbs2-0015" title="DavidsonJT , ConnorKM , HertzbergMA , WeislerRH , WilsonWH , PayneVM .Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study. Journal of Clinical Psychopharmacology2005;25(2):166–9. [DOI: 10.1097/01.jcp.0000155817.21467.6c]">Davidson 2005</a>; <a href="./references#CD002795-bbs2-0018" title="DavidsonJR , BradyK , MellmanTA , SteinMB , PollackMH .The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. Journal of Clinical Psychopharmacology2007;27(1):85–8. [DOI: 10.1097/JCP.0b013e31802e5115]">Davidson 2007</a>; <a href="./references#CD002795-bbs2-0025" title="Eli Lilly.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. FriedmanMJ , MarmarCR , BakerDG , SikesCR , FarfelGM .Randomised, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. Journal of Clinical Psychiatry2007;68(5):711-20. ">Friedman 2007</a>; <a href="./references#CD002795-bbs2-0026" title="GSK 29060 627.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). https://www.gsk-studyregister.com/en/trial-details/?id=29060/648. ">GSK 29060 627</a>; <a href="./references#CD002795-bbs2-0034" title="Food and Drugs Administration (FDA).Paxil (paroxetine) [NDA 20-031/S-029 Paxil (Paroxetine hydrochloride) tablets; GlaxoSmithKline; Post-traumatic Stress Disorder]. www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf (accessed 26 November 2021). GlaxoSmithKline.A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Posttraumatic Stress Disorder (PTSD). GSK - clinical study register [www.gsk-clinicalstudyregister.com]:Study ID: PAR 29060 651 (BRL-02960). MarshallRD , BeebeKL , OldhamM , ZaninelliR .Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. American Journal of Psychiatry2001;158(12):1982-8. ">Marshall 2001</a>; <a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a>; <a href="./references#CD002795-bbs2-0046" title="PanahiY , MoghaddamBR , SahebkarA , NazariMA , BeiraghdarF , KaramiG , et al.A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder. Psychological Medicine2011;41(10):2159–66. [DOI: 10.1017/S0033291711000201]">Panahi 2011</a>; <a href="./references#CD002795-bbs2-0047" title="Food and Drug Administration (FDA).Review and evaluation of clinical data [Pfizer NDA application: Sertraline (Zoloft) for PTSD]. www.accessdata.fda.gov/drugsatfda_docs/nda/99/19-839S026_Zoloft_Clinr_P1.pdf1999;(accessed 28 November 2021). Pfizer.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. ">Pfizer588</a>; <a href="./references#CD002795-bbs2-0048" title="Food and Drug Adminstration (FDA).Review and evaluation of clinical data [Pfizer NDA application: Sertraline (Zoloft) for PTSD]. www.accessdata.fda.gov/drugsatfda_docs/nda/99/19-839S026_Zoloft_Clinr_P1.pdf1999;(accessed 28 November 2021). FriedmanMJ , MarmarCR , BakerDG , SikesCR , FarfelGM .Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. Journal of Clinical Psychiatry2007;68(5):711-20. Pfizer.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. ">Pfizer589</a>; <a href="./references#CD002795-bbs2-0049" title="RaskindMA , PeskindER , ChowB , HarrisC , Davis-KarimA , HolmesHA , et al.Trial of prazosin for post-traumatic stress disorder in military veterans. New England Journal of Medicine2018;378(6):507-17. [DOI: 10.1056/NEJMoa1507598]">Raskind 2018</a>; <a href="./references#CD002795-bbs2-0053" title="SayginMZ , SungurMZ , SabolEU , CetinkayaP .Nefazodone versus sertraline in treatment of posttraumatic stress disorder. Bulletin of Clinical Psychopharmacology2002;12(1):1-5. ">Saygin 2002</a>; <a href="./references#CD002795-bbs2-0054" title="ShestatzkyM , GreenbergD , LererB .A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatric Research1988;24(2):149-55. ">Shestatzky 1988</a>; <a href="./references#CD002795-bbs2-0055" title="Food and Drug Administration (FDA).NDA 20-031/S-029 Paxil (paroxetine hydrochloride) tablets; GlaxoSmithKline; Post-traumatic Stress Disorder. www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf;(accessed 28 November 2021). GlaxoSmithKline.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). GSK - clinical study register [www.gsk-clinicalstudyregister.com]:Study ID: 29060/627. SmithKline Beecham.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. SteinDJ , DavidsonJ , SeedatS , BeebeK .Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies. Expert Opinion on Pharmacotherapy2003;4(10):1829-38. ">SKB627</a>; <a href="./references#CD002795-bbs2-0059" title="GlaxoSmithKline.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). GSK - Clinical Study Register [www.gsk-clinicalstudyregister.com]2000:Study ID:GSK 29060/648. TuckerP , ZaninelliR , YehudaR , RuggieroL , DillinghamK , PittsCD .Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry2001;62(11):860-8. ">Tucker 2001</a>; <a href="./references#CD002795-bbs2-0066" title="AmitalD , ZoharJ , KotlerM , BleichA , MiodovnikH , NevoA , et al.A placebo-controlled study of sertraline in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):269. AmitalD , ZoharJ , KotlerM , BleichA , MiodovnikH , NevoA , et al.A placebo-controlled trial pilot study of sertraline in PTSD. In: Annual Meeting of the American Psychiatric Association. American Psychiatric Association, 1999:157. ZoharJ , AmitalD , MiodownikC , KotlerM , BleichA , LaneRM .Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. Journal of Clinical Psychopharmacology2002;22(2):190-5. ">Zohar 2002</a>), whilst 16 other trials assessed this outcome as a secondary measure using the same scale (<a href="./references#CD002795-bbs2-0002" title="BakerDG , DiamondBI , GilletteG , HamnerM , KatzelnickD , KellerT , et al.A double-blind randomized placebo-controlled multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology1995;122(4):386-9. ConnorKM , HidalgoRB , CrockettB , MalikM , KatzRJ , DavidsonJR .Predictors of treatment response in patients with posttraumatic stress disorder. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2001;25(2):337-45. ">Baker 1995</a>; <a href="./references#CD002795-bbs2-0006" title="ButterfieldMI , BeckerME , ConnorKM , SutherlandS , ChurchillLE , DavidsonJR .Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. International Clinical Psychopharmacology2001;16(4):197-203. ">Butterfield 2001</a>; <a href="./references#CD002795-bbs2-0010" title="ConnorKM , DavidsonJR , WeislerRH , ZhangW , AbrahamK .Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology2006;184:21–5. [DOI: 10.1007/s00213-005-0265-3]">Connor 2006</a>; <a href="./references#CD002795-bbs2-0019" title="DavisLL , AmbroseS , EnglishB , DaforeME , FarleyJ , Bartolucci Al, et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder. In: 20th Annual Meeting, International Society for Traumatic Stress Studies, December 6 - 9, New Orleans, LA. 2001. DavisLL , JewellME , AmbroseS , FarleyJ , EnglishB , BartolucciA , et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. Journal of Clinical Psychopharmacology2004;24(3):291-7. [DOI: 10.1097/01.jcp.0000125685.82219.1a]">Davis 2004</a>; <a href="./references#CD002795-bbs2-0021" title="DavisLL , PilkintonP , LinC , ParkerP , EstesS , BartolucciA .A randomized, placebo-controlled trial of mirtazapine for the treatment of posttraumatic stress disorder in v eterans. Journal of Clinical Psychiatry2020;81(6):e1-8. [DOI: 10.4088/JCP.20m13267]">Davis 2020</a>; <a href="./references#CD002795-bbs2-0024" title="FederA , ParidesMK , MurroughJW , PerezAM , MorganJE , SaxenaS , et al.Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder. A randomized clinical trial. JAMA Psychiatry2014;71(6):681-8. [DOI: 10.1001/jamapsychiatry.2014.62]">Feder 2014</a>; <a href="./references#CD002795-bbs2-0027" title="HamnerMB , FaldowskiRA , RobertS , UlmerHG , HornerMD , LorberbaumJP .A preliminary controlled trial of divalproex in posttraumatic stress disorder. Annals of Clinical Psychiatry2008;21(2):89-94. ">Hamner 2008</a>; <a href="./references#CD002795-bbs2-0031" title="ConnorKM , HidalgoRB , CrockettB , MalikM , KatzRJ , DavidsonJR .Predictors of treatment response in patients with posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2001;25(2):337–45. KatzRJ , LottMH , ArbusP , CrocqL , HerlobsenP , LingjaerdeO , et al.Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety1994;1(4):169–74. [DOI: https://doi.org/10.1002/anxi.3070010404 ]">Katz 1994</a>; <a href="./references#CD002795-bbs2-0036" title="MartenyiF , BrownEB , ZhangH , PrakashA , KokeSC .Fluoxetine versus placebo in posttraumatic stress disorder. Journal of Clinical Psychiatry2002;63(3):199-206. ">Martenyi 2002a</a>; <a href="./references#CD002795-bbs2-0037" title="MartenyiF , BrownEB , ZhangH , KokeSC , PrakashA .Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. British Journal of Psychiatry2002;181:315-20. ">Martenyi 2002b</a>; <a href="./references#CD002795-bbs2-0039" title="MathewSJ , VythilingamM , MurroughaJW , ZarateCA , FederaA , LuckenbaughDA , et al.A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. European Neuropsychopharmacology2011;21(3):221–9. ">Mathew 2011</a>; <a href="./references#CD002795-bbs2-0049" title="RaskindMA , PeskindER , ChowB , HarrisC , Davis-KarimA , HolmesHA , et al.Trial of prazosin for post-traumatic stress disorder in military veterans. New England Journal of Medicine2018;378(6):507-17. [DOI: 10.1056/NEJMoa1507598]">Raskind 2018</a>; <a href="./references#CD002795-bbs2-0050" title="RasmussonAM , MarxCE , JainS , FarfelGM , TsaiJ , SunX , et al.A randomized controlled trial of ganaxolone in posttraumatic stress disorder. Psychopharmacology2017;234(15):2245–57. [DOI: 10.1007/s00213-017-4649-y]">Rasmusson 2017</a>; <a href="./references#CD002795-bbs2-0061" title="TuckerP , TrautmanRP , WyattDB , ThompsonJ , WuSC , CapeceJA , et al.Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2007;68(2):201-6. ">Tucker 2007</a>; <a href="./references#CD002795-bbs2-0064" title="VillarrealG , HamnerMB , CañiveJM , RobertS , CalaisLA , DurklaskiV , et al.Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. American Journal of Psychiatry2016;173(12):1205-12. [DOI: 10.1176/appi.ajp.2016.15070967]">Villarreal 2016</a>; <a href="./references#CD002795-bbs2-0065" title="YehMS , MariJJ , CostaMC , AndreoliSB , BressanRA , MelloMF .A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neuroscience and Therapeutics2011;17(5):305–10. [DOI: 10.1111/j.1755-5949.2010.00188.x]">Yeh 2011</a>). Forty‐seven trials used the CAPS to assess the reduction in PTSD symptoms, while 23 used the CGI‐S, 25 used the DTS and 14 used the IES. The most common measures used to assess depression were the HAM‐D (n = 22) and the MADRS (n = 16). Eighteen trials assessed the reduction of anxiety symptoms with the HAM‐A (<a href="./references#CD002795-bbs2-0005" title="BraunP , GreenbergD , DasbergH , LererB .Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. Journal of Clinical Psychiatry1990;51(6):236-8. ">Braun 1990</a>; <a href="./references#CD002795-bbs2-0010" title="ConnorKM , DavidsonJR , WeislerRH , ZhangW , AbrahamK .Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology2006;184:21–5. [DOI: 10.1007/s00213-005-0265-3]">Connor 2006</a>; <a href="./references#CD002795-bbs2-0011" title="DavidsonJR , KudlerH , SmithR , MahorneySL , LipperS , HammettE , et al.Treatment of posttraumatic stress disorder with amitriptyline and placebo. Archives of General Psychiatry1990;47(3):259-66. DavidsonJR , KudlerHS , SaundersWB , EricksonL , SmithRD , SteinRM , et al.Predicting response to amitriptyline in posttraumatic stress disorder. American Journal of Psychiatry1993;150(7):1024-9. ">Davidson 1990</a>; <a href="./references#CD002795-bbs2-0012" title="DavidsonJ , LondborgP , PearlsteinT , RothbaumB , BradyK , FarfelG .Double-blind, randomized, 28-week continuation study of sertraline and placebo in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):292. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo controlled study. American Journal of Psychiatry2001;158(12):1974–81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. DavidsonJR , RothbaumBO , Van der KolkBA , SikesCR , FarfelGM .Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Archives of General Psychiatry2001;58(5):485-92. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59–65. ">Davidson 2001a</a>; <a href="./references#CD002795-bbs2-0019" title="DavisLL , AmbroseS , EnglishB , DaforeME , FarleyJ , Bartolucci Al, et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder. In: 20th Annual Meeting, International Society for Traumatic Stress Studies, December 6 - 9, New Orleans, LA. 2001. DavisLL , JewellME , AmbroseS , FarleyJ , EnglishB , BartolucciA , et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. Journal of Clinical Psychopharmacology2004;24(3):291-7. [DOI: 10.1097/01.jcp.0000125685.82219.1a]">Davis 2004</a>; <a href="./references#CD002795-bbs2-0011" title="DavidsonJR , KudlerH , SmithR , MahorneySL , LipperS , HammettE , et al.Treatment of posttraumatic stress disorder with amitriptyline and placebo. Archives of General Psychiatry1990;47(3):259-66. DavidsonJR , KudlerHS , SaundersWB , EricksonL , SmithRD , SteinRM , et al.Predicting response to amitriptyline in posttraumatic stress disorder. American Journal of Psychiatry1993;150(7):1024-9. ">Davidson 1990</a>; <a href="./references#CD002795-bbs2-0025" title="Eli Lilly.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. FriedmanMJ , MarmarCR , BakerDG , SikesCR , FarfelGM .Randomised, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. Journal of Clinical Psychiatry2007;68(5):711-20. ">Friedman 2007</a>; <a href="./references#CD002795-bbs2-0030" title="KaplanZ , AmirM , SwartzM , LevineJ .Inositol treatment of posttraumatic stress disorder. Anxiety1996;2(1):51–2. [DOI: 10.1002/(SICI)1522-7154(1996)2:1&lt;51::AID-ANXI8&gt;3.0.CO;2-G]">Kaplan 1996</a>; <a href="./references#CD002795-bbs2-0032" title="KostenTR , FrankJB , DanE , McDougleCJ , Giller EL Jr.Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease1991;179(6):366–70. ">Kosten 1991</a>; <a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a>; <a href="./references#CD002795-bbs2-0036" title="MartenyiF , BrownEB , ZhangH , PrakashA , KokeSC .Fluoxetine versus placebo in posttraumatic stress disorder. Journal of Clinical Psychiatry2002;63(3):199-206. ">Martenyi 2002a</a>; <a href="./references#CD002795-bbs2-0037" title="MartenyiF , BrownEB , ZhangH , KokeSC , PrakashA .Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. British Journal of Psychiatry2002;181:315-20. ">Martenyi 2002b</a>; <a href="./references#CD002795-bbs2-0041" title="McRaeAL , BradyKT , MellmanTA , SonnSC , KilleenTK , TimmermanMA , et al.Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depression and Anxiety2004;19(3):190–6. [DOI: 10.1002/da.20008]">McRae 2004</a>; <a href="./references#CD002795-bbs2-0045" title="PadalaPR , MadisonJ , MonnahanM , MarcilW , PriceP , RamaswamyS , et al.Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. International Clinical Psychopharmacology2006;21(5):275–80. ">Padala 2006</a>; <a href="./references#CD002795-bbs2-0052" title="ReistC , KauffmannCD , Chicz DemetA , ChenCC , DemetEM .REM latency, dexamethasone suppression test, and thyroid releasing hormone stimulation test in posttraumatic stress disorder. Progress in Neuropsychopharmacology and Biological Psychiatry1995;19(3):433-43. ReistC , KauffmannCD , HaierRJ , SangdahlC , DeMetEM , Chicz-DeMetA , et al.A controlled trial of desipramine in 18 men with posttraumatic stress disorder. American Journal of Psychiatry1989;146(4):513-6. ">Reist 1989</a>; <a href="./references#CD002795-bbs2-0058" title="SpivakB , StrousRD , ShakedG , ShabashE , KotlerM , WeizmanA .Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. Journal of Clinical Psychopharmacology2006;26(2):152–6. [DOI: 10.1097/01.jcp.0000203195.65710.f0]">Spivak 2006</a>; <a href="./references#CD002795-bbs2-0061" title="TuckerP , TrautmanRP , WyattDB , ThompsonJ , WuSC , CapeceJA , et al.Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2007;68(2):201-6. ">Tucker 2007</a>; <a href="./references#CD002795-bbs2-0064" title="VillarrealG , HamnerMB , CañiveJM , RobertS , CalaisLA , DurklaskiV , et al.Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. American Journal of Psychiatry2016;173(12):1205-12. [DOI: 10.1176/appi.ajp.2016.15070967]">Villarreal 2016</a>). Only 13 trials assessed functional disability using the SDS (<a href="./references#CD002795-bbs2-0007" title="CareyP , SulimanS , GanesanK , SeedatS , SteinDJ .Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Human Psychopharmacology Clinical and Experimental2012;27:386–91. [DOI: 10.1002/hup.2238]">Carey 2012</a>; <a href="./references#CD002795-bbs2-0009" title="BarnettSD , TharwaniHM , HertzbergMA , SutherlandSM , ConnorKM , DavidsonJR .Tolerability of fluoxetine in posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2002;26(2):363-7. ConnorKM , SutherlandSM , TuplerLA , MalikML , DavidsonJR .Fluoxetine in post-traumatic stress disorder: randomized, double-blind study. British Journal of Psychiatry1999;175:17-22. MalikML , ConnorKM , SutherlandSM , SmithRD , DavisonRM , DavidsonJR .Quality-of-life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo- controlled trial of fluoxetine. Journal of Traumatic Stress1999;12(2):387-93. ">Connor 1999a</a>; <a href="./references#CD002795-bbs2-0016" title="DavidsonJ , BaldwinD , SteinDJ , KuperE , BenattiaI , AhmedS , et al.Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Archives of General Psychiatry2006;63(10):1158-65. ">Davidson 2006a</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>; <a href="./references#CD002795-bbs2-0018" title="DavidsonJR , BradyK , MellmanTA , SteinMB , PollackMH .The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. Journal of Clinical Psychopharmacology2007;27(1):85–8. [DOI: 10.1097/JCP.0b013e31802e5115]">Davidson 2007</a>; <a href="./references#CD002795-bbs2-0021" title="DavisLL , PilkintonP , LinC , ParkerP , EstesS , BartolucciA .A randomized, placebo-controlled trial of mirtazapine for the treatment of posttraumatic stress disorder in v eterans. Journal of Clinical Psychiatry2020;81(6):e1-8. [DOI: 10.4088/JCP.20m13267]">Davis 2020</a>; <a href="./references#CD002795-bbs2-0026" title="GSK 29060 627.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). https://www.gsk-studyregister.com/en/trial-details/?id=29060/648. ">GSK 29060 627</a>; <a href="./references#CD002795-bbs2-0034" title="Food and Drugs Administration (FDA).Paxil (paroxetine) [NDA 20-031/S-029 Paxil (Paroxetine hydrochloride) tablets; GlaxoSmithKline; Post-traumatic Stress Disorder]. www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf (accessed 26 November 2021). GlaxoSmithKline.A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Posttraumatic Stress Disorder (PTSD). GSK - clinical study register [www.gsk-clinicalstudyregister.com]:Study ID: PAR 29060 651 (BRL-02960). MarshallRD , BeebeKL , OldhamM , ZaninelliR .Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. American Journal of Psychiatry2001;158(12):1982-8. ">Marshall 2001</a>; <a href="./references#CD002795-bbs2-0039" title="MathewSJ , VythilingamM , MurroughaJW , ZarateCA , FederaA , LuckenbaughDA , et al.A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. European Neuropsychopharmacology2011;21(3):221–9. ">Mathew 2011</a>; <a href="./references#CD002795-bbs2-0041" title="McRaeAL , BradyKT , MellmanTA , SonnSC , KilleenTK , TimmermanMA , et al.Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depression and Anxiety2004;19(3):190–6. [DOI: 10.1002/da.20008]">McRae 2004</a>; <a href="./references#CD002795-bbs2-0056" title="SmithKline Beecham.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. ">SKB650</a>; <a href="./references#CD002795-bbs2-0059" title="GlaxoSmithKline.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). GSK - Clinical Study Register [www.gsk-clinicalstudyregister.com]2000:Study ID:GSK 29060/648. TuckerP , ZaninelliR , YehudaR , RuggieroL , DillinghamK , PittsCD .Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry2001;62(11):860-8. ">Tucker 2001</a>; <a href="./references#CD002795-bbs2-0061" title="TuckerP , TrautmanRP , WyattDB , ThompsonJ , WuSC , CapeceJA , et al.Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2007;68(2):201-6. ">Tucker 2007</a>). Post‐treatment follow‐up assessments ranged from two weeks in <a href="./references#CD002795-bbs2-0026" title="GSK 29060 627.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). https://www.gsk-studyregister.com/en/trial-details/?id=29060/648. ">GSK 29060 627</a> to six months in <a href="./references#CD002795-bbs2-0063" title="Van der Kolk, SpinazzolaJ , BlausteinM , HopperJ , HopperE , KornD , et al.A randomized clinical trial of EMDR, fluoxetine and pill placebo in the treatment of PTSD: treatment effects and long-term maintenance. Draft manuscript2004. Van der KolkBA , SpinazzolaJ , BlausteinME , HopperJW , HopperEK , KornDL , et al.A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. Journal of Clinical Psychiatry2007;68(1):37-46. ">Van der Kolk 2007</a>. See <a href="./references#CD002795-sec-0158" title="">Characteristics of included studies</a> for more details. </p> </section> <section id="CD002795-sec-0044"> <h4 class="title">Excluded studies</h4> <p>We excluded 65 studies from the review (see <a href="./references#CD002795-sec-0159" title="">Characteristics of excluded studies</a>). The most common reason for trials being considered ineligible was the augmentation of medication or psychotherapy within groups, or both (<a href="./references#CD002795-bbs2-0067" title="AerniA , TraberR , HockC , RoozendaalB , SchellingG , PapassotiropoulosA , et al.Low-dose cortisol for symptoms of posttraumatic stress disorder. American Journal of Psychiatry2004;161(8):1488-90. ">Aerni 2004</a>; <a href="./references#CD002795-bbs2-0069" title="BackSE , McCauleyJL , KorteKJ , GrosDF , LeavittV , GrayKM , et al.A double-blind, randomized, controlled pilot trial of N-Acetylcysteine in veterans with posttraumatic stress disorder and substance use disorders. Journal of Clinical Psychiatry2016;77(11):e1439-46. [DOI: 10.4088/JCP.15m10239]">Back 2016</a>; <a href="./references#CD002795-bbs2-0071" title="BartzokisG , LuPH , TurnerJ , MintzJ , SaundersCS .Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biological Psychiatry2005;57(5):474-9. ">Bartzokis 2005</a>; <a href="./references#CD002795-bbs2-0072" title="BatkiSL , PenningtonDL , LasherB , NeylanTC , MetzlerT , WaldropA , et al.Topiramate treatment of alcohol use disorder in veterans with PTSD: a randomized controlled pilot trial. Alcoholism: Clinical and Experimental Research2014;38(8):2169–77. [DOI: doi:10.1111/acer.12496]">Batki 2014</a>; <a href="./references#CD002795-bbs2-0075" title="BountressKE , BadourC , FlanaganJ , GilmoreAK , BackSE .Treatment of co-occurring posttraumatic stress disorder and substance use: does order of onset influence outcomes?Psychological Trauma: Theory, Research, Practice and Policy2018;10(6):662-5. [DOI: 10.1037/tra0000309]">Bountress 2018</a>; <a href="./references#CD002795-bbs2-0078" title="BrunetA , SaumierD , LiuA , StreinerDL , TremblayJ , PitmanRK .Reduction of PTSD symptoms with pre-reactivation propranolol therapy: a randomized controlled trial. American Journal of Psychiatry2018;175(5):427-33. [DOI: 10.1176/appi.ajp.2017.17050481]">Brunet 2018</a>; <a href="./references#CD002795-bbs2-0079" title="BuhmannCB , NordentoftM , EkstroemM , CarlssonJ , MortensenEL .Long-term treatment effect of trauma-affected refugees with flexible cognitive behavioural therapy and antidepressants. Psychiatry Research2018;264:217-23. [DOI: 10.1016/j.psychres.2018.03.069]">Buhmann 2018</a>; <a href="./references#CD002795-bbs2-0082" title="FederA , CostiS , RutterSB , CollinsAB , GovindarajuluU , JhaMK , et al.A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. American Journal of Psychiatry2021;178(2):193–202. [DOI: 10.1176/appi.ajp.2020.20050596]">Feder 2021</a>; <a href="./references#CD002795-bbs2-0090" title="HamnerM , UlmerH , HorneD .Buspirone potentiation of antidepressants in the treatment of PTSD. Depression and Anxiety1997;5(3):137-9. ">Hamner 1997</a>; <a href="./references#CD002795-bbs2-0092" title="HamnerMB , FaldowskiRA , UlmerHG , FruehBC , HuberMG , AranaGW .Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. International Clinical Psychopharmacology2003;18(1):1-8. ">Hamner 2003</a>; <a href="./references#CD002795-bbs2-0093" title="Heresco-LevyU , KremerI , JavittDC , GoichmanR , ReshefA , BlanaruM , et al.Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. International Journal of Neuropsychopharmacology2002;5(4):301-7. ">Heresco‐Levy 2002</a>; <a href="./references#CD002795-bbs2-0100" title="MonnellyEP , CirauloDA , KnappC , KeaneT .Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. Journal of Clinical Psychopharmacology2003;23(2):193-6. ">Monnelly 2003</a>; <a href="./references#CD002795-bbs2-0110" title="NeylanTC , LenociM , SamuelsonKW , MetzlerTJ , Henn-HaaseC , HierholzerRW , et al.No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. American Journal of Psychiatry2006;163(12):2186–8. ">Neylan 2006</a>; <a href="./references#CD002795-bbs2-0106" title="NCT01325168.The effect of intranasal oxytocin on emphatic abilities in patients with post traumatic stress disorder (PTSD). clinicaltrials.gov/ct2/show/record/NCT01325168 (first received 29 March 2011). ">NCT01325168</a>; <a href="./references#CD002795-bbs2-0107" title="NCT01449955.Rapamycin as a means of interference with reconsolidation of posttraumatic stress disorder-related traumatic memory. clinicaltrials.gov/ct2/show/record/NCT01449955 (first received 10 October 2011). ">NCT01449955</a>; <a href="./references#CD002795-bbs2-0108" title="NCT01477762.Cortisol suppression and startle responses in posttraumatic stress disorder (PTSD) (CSS). clinicaltrials.gov/ct2/show/record/NCT01477762 (first received 18 April 2017). ">NCT01477762</a>; <a href="./references#CD002795-bbs2-0111" title="OttoMW , HintonD , KorblyNB , CheaA , BaP , GershunyBS , et al.Treatment of pharmacotherapy-refractory posttraumatic stress disorder among Cambodian refugees: a pilot study of combination treatment with cognitive-behavior therapy vs sertraline alone. Behaviour Research and Therapy2003;41(11):1271-6. ">Otto 2003</a>; <a href="./references#CD002795-bbs2-0118" title="RamaswamyS , DriscollD , ReistC , SmithLM , AlbersLJ , RoseJR .A double-blind, placebo-controlled randomized trial of vilazodone in the treatment of posttraumatic stress disorder and comorbid depression. Primary Care Companion for CNS Disorders2017;19(4):17m02138. [DOI: https://doi.org/10.4088/PCC.17m02138]">Ramaswamy 2017</a>; <a href="./references#CD002795-bbs2-0120" title="RaskindMA , PeskindER , KanterED , PetrieEC , RadantA , ThompsonCE , et al.Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. American Journal of Psychiatry2003;160(2):371-3. ">Raskind 2003</a>; <a href="./references#CD002795-bbs2-0121" title="RaskindMA , PeskindER , HoffDJ , HartKL , HolmesHA , WarrenD .A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Society of Biological Psychiatry2007;61:928–34. [DOI: 10.1016/j.biopsych.2006.06.032]">Raskind 2007</a>; <a href="./references#CD002795-bbs2-0128" title="SteinMB , KlineNA , MatloffJL .Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. American Journal of Psychiatry2002;159(10):1777-9. ">Stein 2002</a>; <a href="./references#CD002795-bbs2-0129" title="SurisA , HollidayR , AdinoffB , HolderN , NorthCS .Facilitating fear-based memory extinction with dexamethasone: a randomized controlled trial in male veterans with combat-related PTSD. Psychiatry2017;80(4):399-410. [DOI: 10.1080/00332747.2017.1286892]">Suris 2017</a>). Psychometric studies were also excluded (<a href="./references#CD002795-bbs2-0077" title="BremnerJD , InnisRB , NgCK , StaibLH , SalomonRM , BronenRA , et al.Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder. Archives of General Psychiatry1997;54(3):246-54. ">Bremner 1997</a>; <a href="./references#CD002795-bbs2-0080" title="CouplandNJ , LillywhiteA , BellCE , PotokarJP , NuttDJ .A pilot controlled study of the effects of flumazenil in posttraumatic stress disorder. Biological Psychiatry1997;41(9):988-90. ">Coupland 1997</a>; <a href="./references#CD002795-bbs2-0091" title="HamnerMB , UlmerHG , HorneDF , GeorgeMS , AranaGW .Procaine administration and behavioral responsivity in post-traumatic stress disorder: a pilot study of tolerability. Human Psychopharmacology1999;14(2):105-11. ">Hamner 1999</a>; <a href="./references#CD002795-bbs2-0096" title="KanterED , WilkinsonCW , RadantAD , PetrieEC , DobieDJ , McFallME , et al.Glucocorticoid feedback sensitivity and adrenocortical responsiveness in posttraumatic stress disorder. Biological Psychiatry2001;50(4):238-45. ">Kanter 2001</a>; <a href="./references#CD002795-bbs2-0097" title="KellnerM , WiedemannK , YassouridisA , LevengoodR , GuoLS , HolsboerF , et al.Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder. Biological Psychiatry2000;47(2):107-11. ">Kellner 2000</a>; <a href="./references#CD002795-bbs2-0101" title="Morgan CA 3rd, GrillonC , SouthwickSM , NagyLM , DavisM , KrystalJH , et al.Yohimbine facilitated acoustic startle in combat veterans with post-traumatic stress disorder. Psychopharmacology1995;117(4):466-71. ">Morgan 1995</a>; <a href="./references#CD002795-bbs2-0114" title="PitmanRK , Van der KolkBA , OrrSP , GreenbergMS .Naloxone-reversible analgesic response to combat-related stimuli in posttraumatic stress disorder. Archives of General Psychiatry1990;47(6):541-4. ">Pitman 1990</a>; <a href="./references#CD002795-bbs2-0119" title="RandallPK , BremnerJD , KrystalJH , NagyLM , HeningerGR , NicolaouAL , et al.Effects of the benzodiazepine antagonist flumazenil in PTSD. Biological Psychiatry1995;38(5):319-24. ">Randall 1995</a>; <a href="./references#CD002795-bbs2-0123" title="ReistC , KauffmannCD , Chicz DemetA , ChenCC , DemetEM .REM latency, dexamethasone suppression test, and thyroid releasing hormone stimulation test in posttraumatic stress disorder. Progress in Neuropsychopharmacology and Biological Psychiatry1995;19(3):433-43. ">Reist 1995</a>; <a href="./references#CD002795-bbs2-0124" title="ReistC , DuffyJG , FujimotoK , CahillL .Beta-adrenergic blockade and emotional memory in PTSD. International Journal of Neuropsychopharmacology2001;4(4):377-83. ">Reist 2001</a>; <a href="./references#CD002795-bbs2-0127" title="SouthwickSM , KrystalJH , BremnerJD , Morgan CA 3rd, NicolaouAL , NagyLM , et al.Noradrenergic and serotonergic function in posttraumatic stress disorder. Archives of General Psychiatry1997;54(8):749-58. ">Southwick 1997</a>; <a href="./references#CD002795-bbs2-0130" title="VaivaG , DucrocqF , JezequelK , AverlandB , LestavelP , BrunetA , et al.Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biological Psychiatry2003;54(9):947-9. ">Vaiva 2003</a>; <a href="./references#CD002795-bbs2-0131" title="Van der KolkBA , GreenbergMS , OrrSP , PitmanRK .Endogenous opioids, stress induced analgesia, and posttraumatic stress disorder. Psychopharmacology Bulletin1989;25(3):417-21. ">Van der Kolk 1989</a>). We excluded eight trials with a primary diagnosis other than PTSD (<a href="./references#CD002795-bbs2-0068" title="AngelidisA , KyrgiouA , Van der WeeN , Van der DoesW , PutmanP .P.3.26 Effects of hydrocortisone on cognitive performance and threat-interference under acute stress in highly anxious females. European Neuropsychopharmacology2019;29(Supplement 2):S698-9. [DOI: http://dx.doi.org/10.1016/j.euroneuro.2019.01.088]">Angelidis 2019</a>; <a href="./references#CD002795-bbs2-0070" title="BackSE , FlanaganJC , JonesJL , AugurI , PetersonAL , Young-McCaughanS , et al.Doxazosin for the treatment of co-occurring PTSD and alcohol use disorder: design and methodology of a randomized controlled trial in military veterans. Contemporary Clinical Trials2018;73:8-15. [DOI: 10.1016/j.cct.2018.08.009]">Back 2018</a>; <a href="./references#CD002795-bbs2-0084" title="FlanaganJC , AllanNP , CalhounCD , BadourCL , Moran-Santa MariaM , BradyKT , et al.Effects of oxytocin on stress reactivity and craving in veterans with co-occurring PTSD and alcohol use disorder. Experimental and Clinical Psychopharmacology2019;27(1):45-54. [DOI: https://dx.doi.org/10.1037/pha0000232]">Flanagan 2019</a>; <a href="./references#CD002795-bbs2-0095" title="Jacobs-RebhunS , SchnurrPP , FriedmanMJ , PeckR , BrophyM , FullerD .Posttraumatic stress disorder and sleep difficulty. American Journal of Psychiatry2000;157(9):1525-6. ">Jacobs‐Rebhun 2000</a>; <a href="./references#CD002795-bbs2-0102" title="NaylorJC , DolberTR , StraussJL , KiltsJD , StraumanTJ , BradfordDW , et al.A pilot randomized controlled trial with paroxetine for subthreshold PTSD in operation enduring freedom/operation Iraqi freedom era veterans. Psychiatry Research Journal2013;206(0):318–20. [DOI: 10.1016/j.psychres.2012.11.008]">Naylor 2013</a>; <a href="./references#CD002795-bbs2-0113" title="PetrakisIL , PolingJ , LevinsonC , NichC , CarrollK , RalevskiE , et al.Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder. Biological Psychiatry2006;60(7):777-83. [DOI: 10.1016/j.biopsych.2006.03.074]">Petrakis 2006</a>; <a href="./references#CD002795-bbs2-0125" title="RoacheJD , RajJJ , BlountT , HaleW , Mintz, J, MurffWR .SSRI treatment of dual diagnosis PTSD and alcohol dependence In veterans: opposite effects of sertraline In EOA and LOA subtypes. In: UT Health Science Center at San Antonio and South Texas Veterans Health Care System, San Antonio, TX, USA. 2017. ">Roache 2017</a>; <a href="./references#CD002795-bbs2-0132" title="VerplaetseTL , RalevskiE , RobertsW , GueorguievaR , McKeeSA , PetrakisIL .Alcohol abstainer status and prazosin treatment in association with changes in posttraumatic stress disorder symptoms in veterans with comorbid alcohol use disorder and posttraumatic stress disorder. Alcoholism: Clinical and Experimental Research2019;43(4):741-6. [DOI: //dx.doi.org/10.1111/acer.13969]">Verplaetse 2019</a>), and seven trials with the absence of a control comparator (<a href="./references#CD002795-bbs2-0081" title="EftekhariA , MillerH , ZoellnerL , FeenyN .Prolonged exposure vs. sertraline: Secondary outcomes in PTSD treatment. In: 20th Annual Meeting, International Society for Traumatic Stress Studies, November 14 - November 18, New Orleans, LA. 2004. ">Eftekhari 2004</a>; <a href="./references#CD002795-bbs2-0087" title="FrommbergerU , NybergE , RichterH , StieglitzRD , BergerM .Paroxetine vs. cognitive-behavioral therapy in the treatment of depression in PTSD patients. In: XXIst Collegium Internationale Neuro psychopharmacologicum, Glasgow, Scotland. 12th 16th July. 1998. ">Frommberger 1998</a>; <a href="./references#CD002795-bbs2-0089" title="GrahamB , GarciaNM , BurtonMS , CooperAA , Roy-ByrnePP , MavissakalianMR .High expectancy and early response produce optimal effects in sertraline treatment for post-traumatic stress disorder. British Journal of Psychiatry2018;213(6):704-8. [DOI: dx.doi.org/10.1192/bjp.2018.211]">Graham 2018</a>; <a href="./references#CD002795-bbs2-0094" title="InslichtS , NilesA , MetzlerT , MiladM , OrrSP , MarmarC , et al.Randomized controlled trial of hydrocortisone and D-cycloserine on fear extinction in PTSD. Biological Psychiatry2018;83(9 Supplement 1):S352. ">Inslicht 2018</a>; <a href="./references#CD002795-bbs2-0098" title="LeQA , DoctorJN , ZoellnerLA , FeenyNC .Effects of treatment, choice, and preference on health-related quality-of-life outcomes in patients with posttraumatic stress disorder (PTSD). Quality of Life Research2018;27(6):1555-62. [DOI: https://dx.doi.org/10.1007/s11136-018-1833-4]">Le 2018</a>; <a href="./references#CD002795-bbs2-0116" title="PollackMH , HogeEA , WorthingtonJJ , MoshierSJ , WechslerRS , BrandesM , et al.Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2011;72(7):892-7. [DOI: 10.4088/JCP.09m05607gry]">Pollack 2011</a>; <a href="./references#CD002795-bbs2-0117" title="RamaswamyS , DriscollD , SmithLM , BhatiaSC , PettyF .Failed efficacy of ziprasidone in the treatment of post-traumatic stress disorder. Contemporary Clinical Trials Communications2016;2:1-5. [DOI: https://dx.doi.org/10.1016/j.conctc.2015.12.003]">Ramaswamy 2016</a>). <a href="./references#CD002795-bbs2-0073" title="BoroughsMS , EhlingerPP , BatchelderAW , SafrenSA , O'CleirighC .Posttraumatic stress symptoms and emerging adult sexual minority men: implications for assessment and treatment of childhood sexual abuse. Journal of Traumatic Stress2018;31(5):665-75. [DOI: 10.1002/jts.22335]">Boroughs 2018</a>, <a href="./references#CD002795-bbs2-0085" title="FrankJB , KostenTR , Giller EL Jr, DanE .A randomized clinical trial of phenelzine and imipramine for post-traumatic stress disorder. American Journal of Psychiatry1988;145(10):1289-91. ">Frank 1988</a> and <a href="./references#CD002795-bbs2-0122" title="RaskindMA , PetersonK , WilliamsT , HoffDJ , HartK , HolmesH , et al.A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. American Journal of Psychiatry2013;170(9):1003-10. [DOI: 10.1176/appi.ajp.2013.12081133]">Raskind 2013</a> were excluded because these trials were secondary analyses of previous studies, <a href="./references#CD002795-bbs2-0099" title="MelloMF , YehMS , NetoJB , BragaLL , FiksJP , MendesDD , et al.A randomized, double-blind, placebo-controlled trial to assess the efficacy of topiramate in the treatment of post-traumatic stress disorder. BMC Psychiatry2009;9(28):1-20. [DOI: 10.1186/1471-244X-9-28]">Mello 2009</a> because this study is a protocol, <a href="./references#CD002795-bbs2-0083" title="FlanaganJC , HandA , JarneckeAM , Moran-Santa MariaMM , BradyKT , JosephJE .Effects of oxytocin on working memory and executive control system connectivity in posttraumatic stress disorder. Experimental and Clinical Psychopharmacology2018;26(4):391-402. [DOI: 10.1037/pha0000197]">Flanagan 2018</a> because it is an imaging study, and <a href="./references#CD002795-bbs2-0112" title="PapeJC , Carrillo-RoaT , RothbaumBO , NemeroffCB , CzamaraD , ZannasAS , et al.DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder. Clinical Epigenetics2018;10(1):136. [DOI: http://dx.doi.org/10.1186/s13148-018-0569-x]">Pape 2018</a> a genetic study. PTSD prevention studies were also excluded (<a href="./references#CD002795-bbs2-0074" title="Borrelli J Jr, StarrA , DownsDL , NorthCS .Prospective study of the effectiveness of paroxetine on the onset of posttraumatic stress disorder, depression, and health and functional outcomes after trauma. Journal of Orthopaedic Trauma2019;33(2):e58-e63. [DOI: https://dx.doi.org/10.1097/BOT.0000000000001342]">Borrelli 2019</a>, <a href="./references#CD002795-bbs2-0086" title="FrijlingJL .Preventing PTSD with oxytocin: effects of oxytocin administration on fear neurocircuitry and PTSD symptom development in recently trauma-exposed individuals. European Journal of Psychotraumatology2017;8(1):1302652. [DOI: http://dx.doi.org/10.1080/20008198.2017.1302652]">Frijling 2017</a>; <a href="./references#CD002795-bbs2-0088" title="GelpinE , BonneO , PeriT , BrandesD , ShalevAY .Treatment of recent trauma survivors with benzodiazepines: a prospective study. Journal of Clinical Psychiatry1996;57(9):390-4. ">Gelpin 1996</a>; <a href="./references#CD002795-bbs2-0115" title="PitmanRK , SandersKM , ZusmanRM , HealyAR , CheemaF , LaskoNB , et al.Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biological Psychiatry2002;51(2):189-92. ">Pitman 2002</a>; <a href="./references#CD002795-bbs2-0126" title="SchellingG , KilgerE , RoozendaalB , deQuervainDJ , BriegelJ , DaggeA , et al.Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: a randomized study. Biological Psychiatry2004;55(6):627-33. ">Schelling 2004</a>). Four trials have been withdrawn and are no longer in effect due to difficulty in achieving target enrolment numbers (<a href="./references#CD002795-bbs2-0103" title="NCT00557622.Clinical evaluation of BRL29060A (paroxetine hydrochloride hydrate) in posttraumatic stress disorder (PTSD). clinicaltrials.gov/ct2/show/record/ NCT00557622 (first received 14 November 2007). ">NCT00557622</a>; <a href="./references#CD002795-bbs2-0104" title="NCT00648375.Effectiveness of propranolol for treating people with post-traumatic stress disorder. clinicaltrials.gov/ct2/show/record/NCT00648375 (first received 01 April 2008). ">NCT00648375</a>; <a href="./references#CD002795-bbs2-0105" title="NCT00706173.Trial of hydrocortisone for post-traumatic stress disorder (PTSD). clinicaltrials.gov/ct2/show/record/NCT00706173 (first received 27 June 2008). ">NCT00706173</a>; <a href="./references#CD002795-bbs2-0109" title="NCT01664260.Efficacy mechanism of N-acetylcysteine in patients with posttraumatic stress disorder. clinicaltrials.gov/ct2/show/record/NCT01664260 (first received 14 August 2012). ">NCT01664260</a>) and were therefore also excluded. See <a href="./references#CD002795-sec-0159" title="">Characteristics of excluded studies</a> for more details. </p> </section> <section id="CD002795-sec-0045"> <h4 class="title">Studies awaiting classification</h4> <p>Eighteen trials are awaiting classification (<a href="./references#CD002795-bbs2-0133" title="DavisL , PettyF .GABAergic modulation in PTSD and treatment with anticonvulsants. In: In: 19th Annual Meeting, International Society for Traumatic Stress Studies, October 29 - November 1, Chicago, IL. 2003. ">Davis 2003</a>; <a href="./references#CD002795-bbs2-0134" title="">Fluoxetine, Davidson</a>; <a href="./references#CD002795-bbs2-0135" title="">Fluoxetine, Lilly</a>; <a href="./references#CD002795-bbs2-0136" title="NagyLM , SouthwickSM , CharneyDS .Placebo-controlled trial of fluoxetine in PTSD. In: International Society for Traumatic Stress Studies 12th Annual Meeting, San Francisco, CA, November 11. 1996. ">Nagy 1996</a>; <a href="./references#CD002795-bbs2-0137" title="NCT00413296.Levetiracetam in post-traumatic stress disorder (PTSD). clinicaltrials.gov/ct2/show/record/NCT00413296 (first received 19 December 2006). ">NCT00413296</a>; <a href="./references#CD002795-bbs2-0138" title="NCT00672776.Effects of Paxil CR on neural circuits in posttraumatic stress disorder (PTSD). clinicaltrials.gov/ct2/show/record/NCT00672776 (first received 06 May 2008). ">NCT00672776</a>; <a href="./references#CD002795-bbs2-0139" title="NCT01517711.Tramadol Extended-Release (ER) for posttraumatic stress disorder (PTSD). clinicaltrials.gov/ct2/show/record/NCT01517711 (first received 25 January 2012). ">NCT01517711</a>; <a href="./references#CD002795-bbs2-0140" title="NCT02637895.Vortioxetine for posttraumatic stress disorder. clinicaltrials.gov/ct2/show/record/NCT02637895 (first received 22 December 2015). ">NCT02637895</a>; <a href="./references#CD002795-bbs2-0141" title="NCT02709018.A controlled trial of losartan in posttraumatic stress disorder (LOSe-PTSD). clinicaltrials.gov/ct2/show/record/NCT02709018 (first received 15 March 2016). ">NCT02709018</a>; <a href="./references#CD002795-bbs2-0142" title="NCT02933606.Phase II study of BNC210 in PTSD (RESTORE). clinicaltrials.gov/ct2/show/record/NCT02933606 (first received 14 October 2016). ">NCT02933606</a>; <a href="./references#CD002795-bbs2-0143" title="">Nefazodone 1, BMS</a>; <a href="./references#CD002795-bbs2-0144" title="">Nefazodone 2, BMS</a>; <a href="./references#CD002795-bbs2-0145" title="">Olanzapine, Davidson</a>; <a href="./references#CD002795-bbs2-0146" title="">Paroxetine 2 ‐ SB</a>; <a href="./references#CD002795-bbs2-0147" title="">Paroxetine 3 ‐ SB</a>; <a href="./references#CD002795-bbs2-0148" title="">Sertraline 2, Pfizer</a>; <a href="./references#CD002795-bbs2-0149" title="">Sertraline 3, Pfizer</a>; <a href="./references#CD002795-bbs2-0150" title="">Sertraline 4, Pfizer</a>). <a href="./references#CD002795-bbs2-0137" title="NCT00413296.Levetiracetam in post-traumatic stress disorder (PTSD). clinicaltrials.gov/ct2/show/record/NCT00413296 (first received 19 December 2006). ">NCT00413296</a> conducted a study on the effectiveness of levetiracetam in 16 participants with PTSD. <a href="./references#CD002795-bbs2-0138" title="NCT00672776.Effects of Paxil CR on neural circuits in posttraumatic stress disorder (PTSD). clinicaltrials.gov/ct2/show/record/NCT00672776 (first received 06 May 2008). ">NCT00672776</a> assessed paroxetine compared to placebo in participants with PTSD. PET measurement of brain activation before and after paroxetine or placebo treatment also took place in <a href="./references#CD002795-bbs2-0138" title="NCT00672776.Effects of Paxil CR on neural circuits in posttraumatic stress disorder (PTSD). clinicaltrials.gov/ct2/show/record/NCT00672776 (first received 06 May 2008). ">NCT00672776</a>. <a href="./references#CD002795-bbs2-0139" title="NCT01517711.Tramadol Extended-Release (ER) for posttraumatic stress disorder (PTSD). clinicaltrials.gov/ct2/show/record/NCT01517711 (first received 25 January 2012). ">NCT01517711</a> assessed tramadol and placebo in 40 participants with PTSD, as measured by the CAPS, CGI‐S and various other secondary scales, and <a href="./references#CD002795-bbs2-0140" title="NCT02637895.Vortioxetine for posttraumatic stress disorder. clinicaltrials.gov/ct2/show/record/NCT02637895 (first received 22 December 2015). ">NCT02637895</a> investigated vortioxetine for posttraumatic stress disorder. Two trials <a href="./references#CD002795-bbs2-0141" title="NCT02709018.A controlled trial of losartan in posttraumatic stress disorder (LOSe-PTSD). clinicaltrials.gov/ct2/show/record/NCT02709018 (first received 15 March 2016). ">NCT02709018</a> and <a href="./references#CD002795-bbs2-0142" title="NCT02933606.Phase II study of BNC210 in PTSD (RESTORE). clinicaltrials.gov/ct2/show/record/NCT02933606 (first received 14 October 2016). ">NCT02933606</a> assessed losartan and BNC210 compared to placebo in posttraumatic stress disorder, respectively. There was insufficient information provided on the remaining studies awaiting classification. See <a href="./references#CD002795-sec-0160" title="">Characteristics of studies awaiting classification</a> for more details. </p> </section> <section id="CD002795-sec-0046"> <h4 class="title">Ongoing studies</h4> <p>One study is ongoing (<a href="./references#CD002795-bbs2-0151" title="NCT01221792.Carvedilol versus placebo for treatment in post traumatic stress disorder (PTSD). clinicaltrials.gov/ct2/show/record/NCT01221792 (first received 15 October 2010). ">NCT01221792</a>). <a href="./references#CD002795-bbs2-0151" title="NCT01221792.Carvedilol versus placebo for treatment in post traumatic stress disorder (PTSD). clinicaltrials.gov/ct2/show/record/NCT01221792 (first received 15 October 2010). ">NCT01221792</a> will compare carvedilol versus placebo using the DTS and the CAPS to determine levels of PTSD severity in people with PTSD. See <a href="./references#CD002795-sec-0161" title="">Characteristics of ongoing studies</a>. </p> </section> </section> <section id="CD002795-sec-0047"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias was assessed using the Cochrane risk of bias tool for allocation concealment, blinding, incomplete outcome data, selective reporting and other potential sources of bias. Sixteen of the included studies were rated as being at high risk for at least one type of bias (see <a href="#CD002795-fig-0002">Figure 2</a> and <a href="#CD002795-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD002795-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002795-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD002795-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD002795-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD002795-sec-0048"> <h4 class="title">Allocation</h4> <section id="CD002795-sec-0049"> <h5 class="title">Randomisation</h5> <p>The randomisation procedure was described in 22 trials (<a href="./references#CD002795-bbs2-0001" title="AhmadpanahM , SabzeieeP , Mohammad HosseiniS , TorabianS , HaghighiM , JahangardL , et al.Comparing the effect of prazosin and hydroxyzine on sleep quality in patients suffering from posttraumatic stress disorder. Neuropsychobiology2014;69(4):235–42. [10.1159/000362243]">Ahmadpanah 2014</a>; <a href="./references#CD002795-bbs2-0003" title="BeckerME , HertzbergMA , MooreSD , DennisMF , BukenyaDS , BeckhamJC .A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. Journal of Clinical Psychopharmacology2007;27(2):193-7. [DOI: 10.1097/JCP.0b013e318032eaed]">Becker 2007</a>; <a href="./references#CD002795-bbs2-0007" title="CareyP , SulimanS , GanesanK , SeedatS , SteinDJ .Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Human Psychopharmacology Clinical and Experimental2012;27:386–91. [DOI: 10.1002/hup.2238]">Carey 2012</a>; <a href="./references#CD002795-bbs2-0009" title="BarnettSD , TharwaniHM , HertzbergMA , SutherlandSM , ConnorKM , DavidsonJR .Tolerability of fluoxetine in posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2002;26(2):363-7. ConnorKM , SutherlandSM , TuplerLA , MalikML , DavidsonJR .Fluoxetine in post-traumatic stress disorder: randomized, double-blind study. British Journal of Psychiatry1999;175:17-22. MalikML , ConnorKM , SutherlandSM , SmithRD , DavisonRM , DavidsonJR .Quality-of-life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo- controlled trial of fluoxetine. Journal of Traumatic Stress1999;12(2):387-93. ">Connor 1999a</a>; <a href="./references#CD002795-bbs2-0012" title="DavidsonJ , LondborgP , PearlsteinT , RothbaumB , BradyK , FarfelG .Double-blind, randomized, 28-week continuation study of sertraline and placebo in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):292. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo controlled study. American Journal of Psychiatry2001;158(12):1974–81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. DavidsonJR , RothbaumBO , Van der KolkBA , SikesCR , FarfelGM .Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Archives of General Psychiatry2001;58(5):485-92. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59–65. ">Davidson 2001a</a>; <a href="./references#CD002795-bbs2-0015" title="DavidsonJT , ConnorKM , HertzbergMA , WeislerRH , WilsonWH , PayneVM .Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study. Journal of Clinical Psychopharmacology2005;25(2):166–9. [DOI: 10.1097/01.jcp.0000155817.21467.6c]">Davidson 2005</a>; <a href="./references#CD002795-bbs2-0016" title="DavidsonJ , BaldwinD , SteinDJ , KuperE , BenattiaI , AhmedS , et al.Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Archives of General Psychiatry2006;63(10):1158-65. ">Davidson 2006a</a>; <a href="./references#CD002795-bbs2-0019" title="DavisLL , AmbroseS , EnglishB , DaforeME , FarleyJ , Bartolucci Al, et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder. In: 20th Annual Meeting, International Society for Traumatic Stress Studies, December 6 - 9, New Orleans, LA. 2001. DavisLL , JewellME , AmbroseS , FarleyJ , EnglishB , BartolucciA , et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. Journal of Clinical Psychopharmacology2004;24(3):291-7. [DOI: 10.1097/01.jcp.0000125685.82219.1a]">Davis 2004</a>; <a href="./references#CD002795-bbs2-0020" title="DavisLL , DavidsonJR , WardC , BartolucciA , BowdenCL , PettyF .Divalproex in the treatment of posttraumatic tress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. Journal of Clinical Psychopharmacology2008;28(21):84–8. [DOI: 10.1097/jcp.0b013e318160f83b]">Davis 2008</a>; <a href="./references#CD002795-bbs2-0023" title="DunlopBW , BinderEB , IosifescuD , MathewSJ , NeylanTC , PapeJC , et al.Corticotropin-releasing factor receptor 1 antagonism Is ineffective for women with posttraumatic stress disorder. Biological Psychiatry2017;82(12):866–74. [DOI: http://dx.doi.org/10.1016/j.biopsych.2017.06.024]">Dunlop 2017</a>; <a href="./references#CD002795-bbs2-0025" title="Eli Lilly.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. FriedmanMJ , MarmarCR , BakerDG , SikesCR , FarfelGM .Randomised, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. Journal of Clinical Psychiatry2007;68(5):711-20. ">Friedman 2007</a>; <a href="./references#CD002795-bbs2-0030" title="KaplanZ , AmirM , SwartzM , LevineJ .Inositol treatment of posttraumatic stress disorder. Anxiety1996;2(1):51–2. [DOI: 10.1002/(SICI)1522-7154(1996)2:1&lt;51::AID-ANXI8&gt;3.0.CO;2-G]">Kaplan 1996</a>; <a href="./references#CD002795-bbs2-0033" title="LiW , Ma Y-B, YangQ , LiBL , Meng Q-G, ZhangY .Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study. International Journal of Psychiatry in Clinical Practice2017;21(2):151-5. [DOI: 10.1080/13651501.2017.1291838]">Li 2017</a>; <a href="./references#CD002795-bbs2-0036" title="MartenyiF , BrownEB , ZhangH , PrakashA , KokeSC .Fluoxetine versus placebo in posttraumatic stress disorder. Journal of Clinical Psychiatry2002;63(3):199-206. ">Martenyi 2002a</a>; <a href="./references#CD002795-bbs2-0039" title="MathewSJ , VythilingamM , MurroughaJW , ZarateCA , FederaA , LuckenbaughDA , et al.A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. European Neuropsychopharmacology2011;21(3):221–9. ">Mathew 2011</a>; <a href="./references#CD002795-bbs2-0046" title="PanahiY , MoghaddamBR , SahebkarA , NazariMA , BeiraghdarF , KaramiG , et al.A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder. Psychological Medicine2011;41(10):2159–66. [DOI: 10.1017/S0033291711000201]">Panahi 2011</a>; <a href="./references#CD002795-bbs2-0050" title="RasmussonAM , MarxCE , JainS , FarfelGM , TsaiJ , SunX , et al.A randomized controlled trial of ganaxolone in posttraumatic stress disorder. Psychopharmacology2017;234(15):2245–57. [DOI: 10.1007/s00213-017-4649-y]">Rasmusson 2017</a>; <a href="./references#CD002795-bbs2-0058" title="SpivakB , StrousRD , ShakedG , ShabashE , KotlerM , WeizmanA .Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. Journal of Clinical Psychopharmacology2006;26(2):152–6. [DOI: 10.1097/01.jcp.0000203195.65710.f0]">Spivak 2006</a>; <a href="./references#CD002795-bbs2-0061" title="TuckerP , TrautmanRP , WyattDB , ThompsonJ , WuSC , CapeceJA , et al.Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2007;68(2):201-6. ">Tucker 2007</a>; <a href="./references#CD002795-bbs2-0063" title="Van der Kolk, SpinazzolaJ , BlausteinM , HopperJ , HopperE , KornD , et al.A randomized clinical trial of EMDR, fluoxetine and pill placebo in the treatment of PTSD: treatment effects and long-term maintenance. Draft manuscript2004. Van der KolkBA , SpinazzolaJ , BlausteinME , HopperJW , HopperEK , KornDL , et al.A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. Journal of Clinical Psychiatry2007;68(1):37-46. ">Van der Kolk 2007</a>; <a href="./references#CD002795-bbs2-0064" title="VillarrealG , HamnerMB , CañiveJM , RobertS , CalaisLA , DurklaskiV , et al.Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. American Journal of Psychiatry2016;173(12):1205-12. [DOI: 10.1176/appi.ajp.2016.15070967]">Villarreal 2016</a>; <a href="./references#CD002795-bbs2-0065" title="YehMS , MariJJ , CostaMC , AndreoliSB , BressanRA , MelloMF .A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neuroscience and Therapeutics2011;17(5):305–10. [DOI: 10.1111/j.1755-5949.2010.00188.x]">Yeh 2011</a>). Computer‐generated random codes were used in 10 of these trials (<a href="./references#CD002795-bbs2-0009" title="BarnettSD , TharwaniHM , HertzbergMA , SutherlandSM , ConnorKM , DavidsonJR .Tolerability of fluoxetine in posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2002;26(2):363-7. ConnorKM , SutherlandSM , TuplerLA , MalikML , DavidsonJR .Fluoxetine in post-traumatic stress disorder: randomized, double-blind study. British Journal of Psychiatry1999;175:17-22. MalikML , ConnorKM , SutherlandSM , SmithRD , DavisonRM , DavidsonJR .Quality-of-life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo- controlled trial of fluoxetine. Journal of Traumatic Stress1999;12(2):387-93. ">Connor 1999a</a>; <a href="./references#CD002795-bbs2-0012" title="DavidsonJ , LondborgP , PearlsteinT , RothbaumB , BradyK , FarfelG .Double-blind, randomized, 28-week continuation study of sertraline and placebo in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):292. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo controlled study. American Journal of Psychiatry2001;158(12):1974–81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. DavidsonJR , RothbaumBO , Van der KolkBA , SikesCR , FarfelGM .Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Archives of General Psychiatry2001;58(5):485-92. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59–65. ">Davidson 2001a</a>; <a href="./references#CD002795-bbs2-0020" title="DavisLL , DavidsonJR , WardC , BartolucciA , BowdenCL , PettyF .Divalproex in the treatment of posttraumatic tress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. Journal of Clinical Psychopharmacology2008;28(21):84–8. [DOI: 10.1097/jcp.0b013e318160f83b]">Davis 2008</a>; <a href="./references#CD002795-bbs2-0025" title="Eli Lilly.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. FriedmanMJ , MarmarCR , BakerDG , SikesCR , FarfelGM .Randomised, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. Journal of Clinical Psychiatry2007;68(5):711-20. ">Friedman 2007</a>; <a href="./references#CD002795-bbs2-0033" title="LiW , Ma Y-B, YangQ , LiBL , Meng Q-G, ZhangY .Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study. International Journal of Psychiatry in Clinical Practice2017;21(2):151-5. [DOI: 10.1080/13651501.2017.1291838]">Li 2017</a>; <a href="./references#CD002795-bbs2-0036" title="MartenyiF , BrownEB , ZhangH , PrakashA , KokeSC .Fluoxetine versus placebo in posttraumatic stress disorder. Journal of Clinical Psychiatry2002;63(3):199-206. ">Martenyi 2002a</a>; <a href="./references#CD002795-bbs2-0058" title="SpivakB , StrousRD , ShakedG , ShabashE , KotlerM , WeizmanA .Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. Journal of Clinical Psychopharmacology2006;26(2):152–6. [DOI: 10.1097/01.jcp.0000203195.65710.f0]">Spivak 2006</a>; <a href="./references#CD002795-bbs2-0061" title="TuckerP , TrautmanRP , WyattDB , ThompsonJ , WuSC , CapeceJA , et al.Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2007;68(2):201-6. ">Tucker 2007</a>; <a href="./references#CD002795-bbs2-0064" title="VillarrealG , HamnerMB , CañiveJM , RobertS , CalaisLA , DurklaskiV , et al.Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. American Journal of Psychiatry2016;173(12):1205-12. [DOI: 10.1176/appi.ajp.2016.15070967]">Villarreal 2016</a>; <a href="./references#CD002795-bbs2-0065" title="YehMS , MariJJ , CostaMC , AndreoliSB , BressanRA , MelloMF .A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neuroscience and Therapeutics2011;17(5):305–10. [DOI: 10.1111/j.1755-5949.2010.00188.x]">Yeh 2011</a>). Permuted blocks were generated by computer programmes for seven trials (<a href="./references#CD002795-bbs2-0007" title="CareyP , SulimanS , GanesanK , SeedatS , SteinDJ .Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Human Psychopharmacology Clinical and Experimental2012;27:386–91. [DOI: 10.1002/hup.2238]">Carey 2012</a>; <a href="./references#CD002795-bbs2-0016" title="DavidsonJ , BaldwinD , SteinDJ , KuperE , BenattiaI , AhmedS , et al.Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Archives of General Psychiatry2006;63(10):1158-65. ">Davidson 2006a</a>; <a href="./references#CD002795-bbs2-0023" title="DunlopBW , BinderEB , IosifescuD , MathewSJ , NeylanTC , PapeJC , et al.Corticotropin-releasing factor receptor 1 antagonism Is ineffective for women with posttraumatic stress disorder. Biological Psychiatry2017;82(12):866–74. [DOI: http://dx.doi.org/10.1016/j.biopsych.2017.06.024]">Dunlop 2017</a>; <a href="./references#CD002795-bbs2-0039" title="MathewSJ , VythilingamM , MurroughaJW , ZarateCA , FederaA , LuckenbaughDA , et al.A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. European Neuropsychopharmacology2011;21(3):221–9. ">Mathew 2011</a>; <a href="./references#CD002795-bbs2-0040" title="McCallWV , YoussefN , BranchF , NollaT , McCloudL , MoraczewskiJ , et al.A randomized controlled trial (RCT) of prazosin versus placebo for suicidal posttraumatic stress disorder (PTSD) patients with nightmares-a pilot study. Sleep2018;41(Supplement 1):A351-2. [DOI: 10.1097/JCP.0000000000000968]">McCall 2018</a>; <a href="./references#CD002795-bbs2-0050" title="RasmussonAM , MarxCE , JainS , FarfelGM , TsaiJ , SunX , et al.A randomized controlled trial of ganaxolone in posttraumatic stress disorder. Psychopharmacology2017;234(15):2245–57. [DOI: 10.1007/s00213-017-4649-y]">Rasmusson 2017</a>; <a href="./references#CD002795-bbs2-0063" title="Van der Kolk, SpinazzolaJ , BlausteinM , HopperJ , HopperE , KornD , et al.A randomized clinical trial of EMDR, fluoxetine and pill placebo in the treatment of PTSD: treatment effects and long-term maintenance. Draft manuscript2004. Van der KolkBA , SpinazzolaJ , BlausteinME , HopperJW , HopperEK , KornDL , et al.A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. Journal of Clinical Psychiatry2007;68(1):37-46. ">Van der Kolk 2007</a>) and prearranged random codes were used by <a href="./references#CD002795-bbs2-0030" title="KaplanZ , AmirM , SwartzM , LevineJ .Inositol treatment of posttraumatic stress disorder. Anxiety1996;2(1):51–2. [DOI: 10.1002/(SICI)1522-7154(1996)2:1&lt;51::AID-ANXI8&gt;3.0.CO;2-G]">Kaplan 1996</a>, as well as a preassigned set of random numbers by <a href="./references#CD002795-bbs2-0015" title="DavidsonJT , ConnorKM , HertzbergMA , WeislerRH , WilsonWH , PayneVM .Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study. Journal of Clinical Psychopharmacology2005;25(2):166–9. [DOI: 10.1097/01.jcp.0000155817.21467.6c]">Davidson 2005</a>. The review classified all these studies as being at low risk for selection bias, while risk of bias was designated as unclear in the remaining studies. </p> </section> <section id="CD002795-sec-0050"> <h5 class="title">Allocation concealment</h5> <p>Of the 66 RCTs, only 13 trials described adequate allocation concealment (<a href="./references#CD002795-bbs2-0001" title="AhmadpanahM , SabzeieeP , Mohammad HosseiniS , TorabianS , HaghighiM , JahangardL , et al.Comparing the effect of prazosin and hydroxyzine on sleep quality in patients suffering from posttraumatic stress disorder. Neuropsychobiology2014;69(4):235–42. [10.1159/000362243]">Ahmadpanah 2014</a>; <a href="./references#CD002795-bbs2-0007" title="CareyP , SulimanS , GanesanK , SeedatS , SteinDJ .Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Human Psychopharmacology Clinical and Experimental2012;27:386–91. [DOI: 10.1002/hup.2238]">Carey 2012</a>; <a href="./references#CD002795-bbs2-0009" title="BarnettSD , TharwaniHM , HertzbergMA , SutherlandSM , ConnorKM , DavidsonJR .Tolerability of fluoxetine in posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2002;26(2):363-7. ConnorKM , SutherlandSM , TuplerLA , MalikML , DavidsonJR .Fluoxetine in post-traumatic stress disorder: randomized, double-blind study. British Journal of Psychiatry1999;175:17-22. MalikML , ConnorKM , SutherlandSM , SmithRD , DavisonRM , DavidsonJR .Quality-of-life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo- controlled trial of fluoxetine. Journal of Traumatic Stress1999;12(2):387-93. ">Connor 1999a</a>; <a href="./references#CD002795-bbs2-0016" title="DavidsonJ , BaldwinD , SteinDJ , KuperE , BenattiaI , AhmedS , et al.Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Archives of General Psychiatry2006;63(10):1158-65. ">Davidson 2006a</a>; <a href="./references#CD002795-bbs2-0019" title="DavisLL , AmbroseS , EnglishB , DaforeME , FarleyJ , Bartolucci Al, et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder. In: 20th Annual Meeting, International Society for Traumatic Stress Studies, December 6 - 9, New Orleans, LA. 2001. DavisLL , JewellME , AmbroseS , FarleyJ , EnglishB , BartolucciA , et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. Journal of Clinical Psychopharmacology2004;24(3):291-7. [DOI: 10.1097/01.jcp.0000125685.82219.1a]">Davis 2004</a>; <a href="./references#CD002795-bbs2-0020" title="DavisLL , DavidsonJR , WardC , BartolucciA , BowdenCL , PettyF .Divalproex in the treatment of posttraumatic tress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. Journal of Clinical Psychopharmacology2008;28(21):84–8. [DOI: 10.1097/jcp.0b013e318160f83b]">Davis 2008</a>; <a href="./references#CD002795-bbs2-0022" title="DowdSM , ZaltaAK , BurgessHJ , AdkinsEC , Valdespino-HaydenZ , PollackMH .Double-blind randomized controlled study of the efficacy, safety and tolerability of eszopiclone vs placebo for the treatment of patients with post-traumatic stress disorder and insomnia. World Journal of Psychiatry2020;10(3):21-8. [DOI: 10.5498/wjp.v10.i3.21]">Dowd 2020</a>; <a href="./references#CD002795-bbs2-0023" title="DunlopBW , BinderEB , IosifescuD , MathewSJ , NeylanTC , PapeJC , et al.Corticotropin-releasing factor receptor 1 antagonism Is ineffective for women with posttraumatic stress disorder. Biological Psychiatry2017;82(12):866–74. [DOI: http://dx.doi.org/10.1016/j.biopsych.2017.06.024]">Dunlop 2017</a>; <a href="./references#CD002795-bbs2-0024" title="FederA , ParidesMK , MurroughJW , PerezAM , MorganJE , SaxenaS , et al.Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder. A randomized clinical trial. JAMA Psychiatry2014;71(6):681-8. [DOI: 10.1001/jamapsychiatry.2014.62]">Feder 2014</a>; <a href="./references#CD002795-bbs2-0033" title="LiW , Ma Y-B, YangQ , LiBL , Meng Q-G, ZhangY .Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study. International Journal of Psychiatry in Clinical Practice2017;21(2):151-5. [DOI: 10.1080/13651501.2017.1291838]">Li 2017</a>; <a href="./references#CD002795-bbs2-0036" title="MartenyiF , BrownEB , ZhangH , PrakashA , KokeSC .Fluoxetine versus placebo in posttraumatic stress disorder. Journal of Clinical Psychiatry2002;63(3):199-206. ">Martenyi 2002a</a>; <a href="./references#CD002795-bbs2-0041" title="McRaeAL , BradyKT , MellmanTA , SonnSC , KilleenTK , TimmermanMA , et al.Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depression and Anxiety2004;19(3):190–6. [DOI: 10.1002/da.20008]">McRae 2004</a>; <a href="./references#CD002795-bbs2-0050" title="RasmussonAM , MarxCE , JainS , FarfelGM , TsaiJ , SunX , et al.A randomized controlled trial of ganaxolone in posttraumatic stress disorder. Psychopharmacology2017;234(15):2245–57. [DOI: 10.1007/s00213-017-4649-y]">Rasmusson 2017</a>) and were classified as low for risk of bias. A pharmacist or sponsor who prepared and supplied the study medication maintained allocation concealment in 11 trials (<a href="./references#CD002795-bbs2-0001" title="AhmadpanahM , SabzeieeP , Mohammad HosseiniS , TorabianS , HaghighiM , JahangardL , et al.Comparing the effect of prazosin and hydroxyzine on sleep quality in patients suffering from posttraumatic stress disorder. Neuropsychobiology2014;69(4):235–42. [10.1159/000362243]">Ahmadpanah 2014</a>; <a href="./references#CD002795-bbs2-0007" title="CareyP , SulimanS , GanesanK , SeedatS , SteinDJ .Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Human Psychopharmacology Clinical and Experimental2012;27:386–91. [DOI: 10.1002/hup.2238]">Carey 2012</a>; <a href="./references#CD002795-bbs2-0009" title="BarnettSD , TharwaniHM , HertzbergMA , SutherlandSM , ConnorKM , DavidsonJR .Tolerability of fluoxetine in posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2002;26(2):363-7. ConnorKM , SutherlandSM , TuplerLA , MalikML , DavidsonJR .Fluoxetine in post-traumatic stress disorder: randomized, double-blind study. British Journal of Psychiatry1999;175:17-22. MalikML , ConnorKM , SutherlandSM , SmithRD , DavisonRM , DavidsonJR .Quality-of-life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo- controlled trial of fluoxetine. Journal of Traumatic Stress1999;12(2):387-93. ">Connor 1999a</a>; <a href="./references#CD002795-bbs2-0016" title="DavidsonJ , BaldwinD , SteinDJ , KuperE , BenattiaI , AhmedS , et al.Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Archives of General Psychiatry2006;63(10):1158-65. ">Davidson 2006a</a>; <a href="./references#CD002795-bbs2-0019" title="DavisLL , AmbroseS , EnglishB , DaforeME , FarleyJ , Bartolucci Al, et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder. In: 20th Annual Meeting, International Society for Traumatic Stress Studies, December 6 - 9, New Orleans, LA. 2001. DavisLL , JewellME , AmbroseS , FarleyJ , EnglishB , BartolucciA , et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. Journal of Clinical Psychopharmacology2004;24(3):291-7. [DOI: 10.1097/01.jcp.0000125685.82219.1a]">Davis 2004</a>; <a href="./references#CD002795-bbs2-0020" title="DavisLL , DavidsonJR , WardC , BartolucciA , BowdenCL , PettyF .Divalproex in the treatment of posttraumatic tress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. Journal of Clinical Psychopharmacology2008;28(21):84–8. [DOI: 10.1097/jcp.0b013e318160f83b]">Davis 2008</a>; <a href="./references#CD002795-bbs2-0022" title="DowdSM , ZaltaAK , BurgessHJ , AdkinsEC , Valdespino-HaydenZ , PollackMH .Double-blind randomized controlled study of the efficacy, safety and tolerability of eszopiclone vs placebo for the treatment of patients with post-traumatic stress disorder and insomnia. World Journal of Psychiatry2020;10(3):21-8. [DOI: 10.5498/wjp.v10.i3.21]">Dowd 2020</a>; <a href="./references#CD002795-bbs2-0023" title="DunlopBW , BinderEB , IosifescuD , MathewSJ , NeylanTC , PapeJC , et al.Corticotropin-releasing factor receptor 1 antagonism Is ineffective for women with posttraumatic stress disorder. Biological Psychiatry2017;82(12):866–74. [DOI: http://dx.doi.org/10.1016/j.biopsych.2017.06.024]">Dunlop 2017</a>; <a href="./references#CD002795-bbs2-0024" title="FederA , ParidesMK , MurroughJW , PerezAM , MorganJE , SaxenaS , et al.Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder. A randomized clinical trial. JAMA Psychiatry2014;71(6):681-8. [DOI: 10.1001/jamapsychiatry.2014.62]">Feder 2014</a>; <a href="./references#CD002795-bbs2-0033" title="LiW , Ma Y-B, YangQ , LiBL , Meng Q-G, ZhangY .Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study. International Journal of Psychiatry in Clinical Practice2017;21(2):151-5. [DOI: 10.1080/13651501.2017.1291838]">Li 2017</a>; <a href="./references#CD002795-bbs2-0041" title="McRaeAL , BradyKT , MellmanTA , SonnSC , KilleenTK , TimmermanMA , et al.Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depression and Anxiety2004;19(3):190–6. [DOI: 10.1002/da.20008]">McRae 2004</a>). One study maintained concealment with the use of sealed envelopes (<a href="./references#CD002795-bbs2-0036" title="MartenyiF , BrownEB , ZhangH , PrakashA , KokeSC .Fluoxetine versus placebo in posttraumatic stress disorder. Journal of Clinical Psychiatry2002;63(3):199-206. ">Martenyi 2002a</a>), and another with bottles with numbers and codes generated by a computer programme (<a href="./references#CD002795-bbs2-0050" title="RasmussonAM , MarxCE , JainS , FarfelGM , TsaiJ , SunX , et al.A randomized controlled trial of ganaxolone in posttraumatic stress disorder. Psychopharmacology2017;234(15):2245–57. [DOI: 10.1007/s00213-017-4649-y]">Rasmusson 2017</a>). Two trials were classified as being at high risk of bias because of no allocation concealment information (<a href="./references#CD002795-bbs2-0008" title="ChungMY , MinKH , JunYJ , KimSS , KimWC , JunEM .Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Human Psychopharmacology2004;19(7):489–94. [DOI: 10.1002/hup.615]">Chung 2004</a>; <a href="./references#CD002795-bbs2-0057" title="SmajkicA , WeineS , Djuric-BijedicZ , BoskailoE , LewisJ , PavkovicI .Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms. Journal of Traumatic Stress2001;14(3):445-52. ">Smajkic 2001</a>). The remaining trials were classified as unclear because the trials did not provide enough information to determine the adequacy of the concealment used. </p> </section> </section> <section id="CD002795-sec-0051"> <h4 class="title">Blinding</h4> <section id="CD002795-sec-0052"> <h5 class="title">Blinding of participants and personnel</h5> <p>Nine studies included in the review were classified as being at low risk for performance bias, as participants and personnel were explicitly described as blinded in the study report (<a href="./references#CD002795-bbs2-0001" title="AhmadpanahM , SabzeieeP , Mohammad HosseiniS , TorabianS , HaghighiM , JahangardL , et al.Comparing the effect of prazosin and hydroxyzine on sleep quality in patients suffering from posttraumatic stress disorder. Neuropsychobiology2014;69(4):235–42. [10.1159/000362243]">Ahmadpanah 2014</a>; <a href="./references#CD002795-bbs2-0019" title="DavisLL , AmbroseS , EnglishB , DaforeME , FarleyJ , Bartolucci Al, et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder. In: 20th Annual Meeting, International Society for Traumatic Stress Studies, December 6 - 9, New Orleans, LA. 2001. DavisLL , JewellME , AmbroseS , FarleyJ , EnglishB , BartolucciA , et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. Journal of Clinical Psychopharmacology2004;24(3):291-7. [DOI: 10.1097/01.jcp.0000125685.82219.1a]">Davis 2004</a>; <a href="./references#CD002795-bbs2-0021" title="DavisLL , PilkintonP , LinC , ParkerP , EstesS , BartolucciA .A randomized, placebo-controlled trial of mirtazapine for the treatment of posttraumatic stress disorder in v eterans. Journal of Clinical Psychiatry2020;81(6):e1-8. [DOI: 10.4088/JCP.20m13267]">Davis 2020</a>; <a href="./references#CD002795-bbs2-0024" title="FederA , ParidesMK , MurroughJW , PerezAM , MorganJE , SaxenaS , et al.Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder. A randomized clinical trial. JAMA Psychiatry2014;71(6):681-8. [DOI: 10.1001/jamapsychiatry.2014.62]">Feder 2014</a>; <a href="./references#CD002795-bbs2-0032" title="KostenTR , FrankJB , DanE , McDougleCJ , Giller EL Jr.Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease1991;179(6):366–70. ">Kosten 1991</a>; <a href="./references#CD002795-bbs2-0033" title="LiW , Ma Y-B, YangQ , LiBL , Meng Q-G, ZhangY .Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study. International Journal of Psychiatry in Clinical Practice2017;21(2):151-5. [DOI: 10.1080/13651501.2017.1291838]">Li 2017</a>; <a href="./references#CD002795-bbs2-0039" title="MathewSJ , VythilingamM , MurroughaJW , ZarateCA , FederaA , LuckenbaughDA , et al.A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. European Neuropsychopharmacology2011;21(3):221–9. ">Mathew 2011</a>; <a href="./references#CD002795-bbs2-0049" title="RaskindMA , PeskindER , ChowB , HarrisC , Davis-KarimA , HolmesHA , et al.Trial of prazosin for post-traumatic stress disorder in military veterans. New England Journal of Medicine2018;378(6):507-17. [DOI: 10.1056/NEJMoa1507598]">Raskind 2018</a>; <a href="./references#CD002795-bbs2-0065" title="YehMS , MariJJ , CostaMC , AndreoliSB , BressanRA , MelloMF .A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neuroscience and Therapeutics2011;17(5):305–10. [DOI: 10.1111/j.1755-5949.2010.00188.x]">Yeh 2011</a>). Two trials were classified as being at high risk of bias because neither trial blinded their participants and personnel (<a href="./references#CD002795-bbs2-0008" title="ChungMY , MinKH , JunYJ , KimSS , KimWC , JunEM .Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Human Psychopharmacology2004;19(7):489–94. [DOI: 10.1002/hup.615]">Chung 2004</a>; <a href="./references#CD002795-bbs2-0057" title="SmajkicA , WeineS , Djuric-BijedicZ , BoskailoE , LewisJ , PavkovicI .Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms. Journal of Traumatic Stress2001;14(3):445-52. ">Smajkic 2001</a>). The review classified risk of bias for the remaining trials as unclear, despite investigators describing them in the study reports as double‐blinded, as they did not specify the actual parties blinded. </p> </section> <section id="CD002795-sec-0053"> <h5 class="title">Blinding of outcome assessors</h5> <p>Although most of the trials were described as "double‐blind", only 13 of the trials explicitly described the assessment of outcome as blinded (<a href="./references#CD002795-bbs2-0005" title="BraunP , GreenbergD , DasbergH , LererB .Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. Journal of Clinical Psychiatry1990;51(6):236-8. ">Braun 1990</a>; <a href="./references#CD002795-bbs2-0009" title="BarnettSD , TharwaniHM , HertzbergMA , SutherlandSM , ConnorKM , DavidsonJR .Tolerability of fluoxetine in posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2002;26(2):363-7. ConnorKM , SutherlandSM , TuplerLA , MalikML , DavidsonJR .Fluoxetine in post-traumatic stress disorder: randomized, double-blind study. British Journal of Psychiatry1999;175:17-22. MalikML , ConnorKM , SutherlandSM , SmithRD , DavisonRM , DavidsonJR .Quality-of-life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo- controlled trial of fluoxetine. Journal of Traumatic Stress1999;12(2):387-93. ">Connor 1999a</a>; <a href="./references#CD002795-bbs2-0020" title="DavisLL , DavidsonJR , WardC , BartolucciA , BowdenCL , PettyF .Divalproex in the treatment of posttraumatic tress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. Journal of Clinical Psychopharmacology2008;28(21):84–8. [DOI: 10.1097/jcp.0b013e318160f83b]">Davis 2008</a>; <a href="./references#CD002795-bbs2-0024" title="FederA , ParidesMK , MurroughJW , PerezAM , MorganJE , SaxenaS , et al.Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder. A randomized clinical trial. JAMA Psychiatry2014;71(6):681-8. [DOI: 10.1001/jamapsychiatry.2014.62]">Feder 2014</a>; <a href="./references#CD002795-bbs2-0033" title="LiW , Ma Y-B, YangQ , LiBL , Meng Q-G, ZhangY .Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study. International Journal of Psychiatry in Clinical Practice2017;21(2):151-5. [DOI: 10.1080/13651501.2017.1291838]">Li 2017</a>; <a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a>; <a href="./references#CD002795-bbs2-0040" title="McCallWV , YoussefN , BranchF , NollaT , McCloudL , MoraczewskiJ , et al.A randomized controlled trial (RCT) of prazosin versus placebo for suicidal posttraumatic stress disorder (PTSD) patients with nightmares-a pilot study. Sleep2018;41(Supplement 1):A351-2. [DOI: 10.1097/JCP.0000000000000968]">McCall 2018</a>; <a href="./references#CD002795-bbs2-0046" title="PanahiY , MoghaddamBR , SahebkarA , NazariMA , BeiraghdarF , KaramiG , et al.A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder. Psychological Medicine2011;41(10):2159–66. [DOI: 10.1017/S0033291711000201]">Panahi 2011</a>; <a href="./references#CD002795-bbs2-0049" title="RaskindMA , PeskindER , ChowB , HarrisC , Davis-KarimA , HolmesHA , et al.Trial of prazosin for post-traumatic stress disorder in military veterans. New England Journal of Medicine2018;378(6):507-17. [DOI: 10.1056/NEJMoa1507598]">Raskind 2018</a>; <a href="./references#CD002795-bbs2-0050" title="RasmussonAM , MarxCE , JainS , FarfelGM , TsaiJ , SunX , et al.A randomized controlled trial of ganaxolone in posttraumatic stress disorder. Psychopharmacology2017;234(15):2245–57. [DOI: 10.1007/s00213-017-4649-y]">Rasmusson 2017</a>; <a href="./references#CD002795-bbs2-0054" title="ShestatzkyM , GreenbergD , LererB .A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatric Research1988;24(2):149-55. ">Shestatzky 1988</a>; <a href="./references#CD002795-bbs2-0058" title="SpivakB , StrousRD , ShakedG , ShabashE , KotlerM , WeizmanA .Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. Journal of Clinical Psychopharmacology2006;26(2):152–6. [DOI: 10.1097/01.jcp.0000203195.65710.f0]">Spivak 2006</a>; <a href="./references#CD002795-bbs2-0063" title="Van der Kolk, SpinazzolaJ , BlausteinM , HopperJ , HopperE , KornD , et al.A randomized clinical trial of EMDR, fluoxetine and pill placebo in the treatment of PTSD: treatment effects and long-term maintenance. Draft manuscript2004. Van der KolkBA , SpinazzolaJ , BlausteinME , HopperJW , HopperEK , KornDL , et al.A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. Journal of Clinical Psychiatry2007;68(1):37-46. ">Van der Kolk 2007</a>). The extent to which blinding was preserved in those flexible‐dose trials which adjusted dosage based on tolerability is unclear. Indeed, the outcome was assessed independently of medication administration and side‐effect evaluation in only one RCT (<a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a>). Two comparative RCTs did not use any form of blinding (<a href="./references#CD002795-bbs2-0008" title="ChungMY , MinKH , JunYJ , KimSS , KimWC , JunEM .Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Human Psychopharmacology2004;19(7):489–94. [DOI: 10.1002/hup.615]">Chung 2004</a>; <a href="./references#CD002795-bbs2-0057" title="SmajkicA , WeineS , Djuric-BijedicZ , BoskailoE , LewisJ , PavkovicI .Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms. Journal of Traumatic Stress2001;14(3):445-52. ">Smajkic 2001</a>), and it is not clear whether blinding was undertaken in another (<a href="./references#CD002795-bbs2-0053" title="SayginMZ , SungurMZ , SabolEU , CetinkayaP .Nefazodone versus sertraline in treatment of posttraumatic stress disorder. Bulletin of Clinical Psychopharmacology2002;12(1):1-5. ">Saygin 2002</a>). The remaining studies were classified as being at unclear risk. </p> </section> </section> <section id="CD002795-sec-0054"> <h4 class="title">Incomplete outcome data</h4> <p>Thirty‐three studies failed to provide sufficient information to determine whether the medication and placebo groups were comparable for dropout proportions, or for the demographic and clinical characteristics of those who withdrew (<a href="./references#CD002795-bbs2-0001" title="AhmadpanahM , SabzeieeP , Mohammad HosseiniS , TorabianS , HaghighiM , JahangardL , et al.Comparing the effect of prazosin and hydroxyzine on sleep quality in patients suffering from posttraumatic stress disorder. Neuropsychobiology2014;69(4):235–42. [10.1159/000362243]">Ahmadpanah 2014</a>; <a href="./references#CD002795-bbs2-0002" title="BakerDG , DiamondBI , GilletteG , HamnerM , KatzelnickD , KellerT , et al.A double-blind randomized placebo-controlled multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology1995;122(4):386-9. ConnorKM , HidalgoRB , CrockettB , MalikM , KatzRJ , DavidsonJR .Predictors of treatment response in patients with posttraumatic stress disorder. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2001;25(2):337-45. ">Baker 1995</a>; <a href="./references#CD002795-bbs2-0005" title="BraunP , GreenbergD , DasbergH , LererB .Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. Journal of Clinical Psychiatry1990;51(6):236-8. ">Braun 1990</a>; <a href="./references#CD002795-bbs2-0007" title="CareyP , SulimanS , GanesanK , SeedatS , SteinDJ .Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Human Psychopharmacology Clinical and Experimental2012;27:386–91. [DOI: 10.1002/hup.2238]">Carey 2012</a>; <a href="./references#CD002795-bbs2-0008" title="ChungMY , MinKH , JunYJ , KimSS , KimWC , JunEM .Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Human Psychopharmacology2004;19(7):489–94. [DOI: 10.1002/hup.615]">Chung 2004</a>; <a href="./references#CD002795-bbs2-0009" title="BarnettSD , TharwaniHM , HertzbergMA , SutherlandSM , ConnorKM , DavidsonJR .Tolerability of fluoxetine in posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2002;26(2):363-7. ConnorKM , SutherlandSM , TuplerLA , MalikML , DavidsonJR .Fluoxetine in post-traumatic stress disorder: randomized, double-blind study. British Journal of Psychiatry1999;175:17-22. MalikML , ConnorKM , SutherlandSM , SmithRD , DavisonRM , DavidsonJR .Quality-of-life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo- controlled trial of fluoxetine. Journal of Traumatic Stress1999;12(2):387-93. ">Connor 1999a</a>; <a href="./references#CD002795-bbs2-0012" title="DavidsonJ , LondborgP , PearlsteinT , RothbaumB , BradyK , FarfelG .Double-blind, randomized, 28-week continuation study of sertraline and placebo in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):292. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo controlled study. American Journal of Psychiatry2001;158(12):1974–81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. DavidsonJR , RothbaumBO , Van der KolkBA , SikesCR , FarfelGM .Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Archives of General Psychiatry2001;58(5):485-92. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59–65. ">Davidson 2001a</a>; <a href="./references#CD002795-bbs2-0014" title="DavidsonJR , WeislerRH , ButterfieldMI , CasatCD , ConnorKM , BarnettS , et al.Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biological Psychiatry2003;53(2):188-91. ">Davidson 2003</a>; <a href="./references#CD002795-bbs2-0015" title="DavidsonJT , ConnorKM , HertzbergMA , WeislerRH , WilsonWH , PayneVM .Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study. Journal of Clinical Psychopharmacology2005;25(2):166–9. [DOI: 10.1097/01.jcp.0000155817.21467.6c]">Davidson 2005</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>; <a href="./references#CD002795-bbs2-0021" title="DavisLL , PilkintonP , LinC , ParkerP , EstesS , BartolucciA .A randomized, placebo-controlled trial of mirtazapine for the treatment of posttraumatic stress disorder in v eterans. Journal of Clinical Psychiatry2020;81(6):e1-8. [DOI: 10.4088/JCP.20m13267]">Davis 2020</a>; <a href="./references#CD002795-bbs2-0023" title="DunlopBW , BinderEB , IosifescuD , MathewSJ , NeylanTC , PapeJC , et al.Corticotropin-releasing factor receptor 1 antagonism Is ineffective for women with posttraumatic stress disorder. Biological Psychiatry2017;82(12):866–74. [DOI: http://dx.doi.org/10.1016/j.biopsych.2017.06.024]">Dunlop 2017</a>; <a href="./references#CD002795-bbs2-0027" title="HamnerMB , FaldowskiRA , RobertS , UlmerHG , HornerMD , LorberbaumJP .A preliminary controlled trial of divalproex in posttraumatic stress disorder. Annals of Clinical Psychiatry2008;21(2):89-94. ">Hamner 2008</a>; <a href="./references#CD002795-bbs2-0029" title="HertzbergMA , FeldmanME , BeckhamJC , KudlerHS , DavidsonJR .Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Annals of Clinical Psychiatry2000;12(2):101-5. ">Hertzberg 2000</a>; <a href="./references#CD002795-bbs2-0030" title="KaplanZ , AmirM , SwartzM , LevineJ .Inositol treatment of posttraumatic stress disorder. Anxiety1996;2(1):51–2. [DOI: 10.1002/(SICI)1522-7154(1996)2:1&lt;51::AID-ANXI8&gt;3.0.CO;2-G]">Kaplan 1996</a>; <a href="./references#CD002795-bbs2-0034" title="Food and Drugs Administration (FDA).Paxil (paroxetine) [NDA 20-031/S-029 Paxil (Paroxetine hydrochloride) tablets; GlaxoSmithKline; Post-traumatic Stress Disorder]. www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf (accessed 26 November 2021). GlaxoSmithKline.A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Posttraumatic Stress Disorder (PTSD). GSK - clinical study register [www.gsk-clinicalstudyregister.com]:Study ID: PAR 29060 651 (BRL-02960). MarshallRD , BeebeKL , OldhamM , ZaninelliR .Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. American Journal of Psychiatry2001;158(12):1982-8. ">Marshall 2001</a>; <a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a>; <a href="./references#CD002795-bbs2-0036" title="MartenyiF , BrownEB , ZhangH , PrakashA , KokeSC .Fluoxetine versus placebo in posttraumatic stress disorder. Journal of Clinical Psychiatry2002;63(3):199-206. ">Martenyi 2002a</a>; <a href="./references#CD002795-bbs2-0039" title="MathewSJ , VythilingamM , MurroughaJW , ZarateCA , FederaA , LuckenbaughDA , et al.A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. European Neuropsychopharmacology2011;21(3):221–9. ">Mathew 2011</a>; <a href="./references#CD002795-bbs2-0040" title="McCallWV , YoussefN , BranchF , NollaT , McCloudL , MoraczewskiJ , et al.A randomized controlled trial (RCT) of prazosin versus placebo for suicidal posttraumatic stress disorder (PTSD) patients with nightmares-a pilot study. Sleep2018;41(Supplement 1):A351-2. [DOI: 10.1097/JCP.0000000000000968]">McCall 2018</a>; <a href="./references#CD002795-bbs2-0041" title="McRaeAL , BradyKT , MellmanTA , SonnSC , KilleenTK , TimmermanMA , et al.Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depression and Anxiety2004;19(3):190–6. [DOI: 10.1002/da.20008]">McRae 2004</a>; <a href="./references#CD002795-bbs2-0043" title="NCT01000493.Orvepitant (GW823296) in adult Post Traumatic Stress Disorder. clinicaltrials.gov/ct2/show/NCT01000493 (first received 23 October 2009). ">NCT01000493</a>; <a href="./references#CD002795-bbs2-0045" title="PadalaPR , MadisonJ , MonnahanM , MarcilW , PriceP , RamaswamyS , et al.Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. International Clinical Psychopharmacology2006;21(5):275–80. ">Padala 2006</a>; <a href="./references#CD002795-bbs2-0047" title="Food and Drug Administration (FDA).Review and evaluation of clinical data [Pfizer NDA application: Sertraline (Zoloft) for PTSD]. www.accessdata.fda.gov/drugsatfda_docs/nda/99/19-839S026_Zoloft_Clinr_P1.pdf1999;(accessed 28 November 2021). Pfizer.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. ">Pfizer588</a>; <a href="./references#CD002795-bbs2-0048" title="Food and Drug Adminstration (FDA).Review and evaluation of clinical data [Pfizer NDA application: Sertraline (Zoloft) for PTSD]. www.accessdata.fda.gov/drugsatfda_docs/nda/99/19-839S026_Zoloft_Clinr_P1.pdf1999;(accessed 28 November 2021). FriedmanMJ , MarmarCR , BakerDG , SikesCR , FarfelGM .Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. Journal of Clinical Psychiatry2007;68(5):711-20. Pfizer.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. ">Pfizer589</a>; <a href="./references#CD002795-bbs2-0049" title="RaskindMA , PeskindER , ChowB , HarrisC , Davis-KarimA , HolmesHA , et al.Trial of prazosin for post-traumatic stress disorder in military veterans. New England Journal of Medicine2018;378(6):507-17. [DOI: 10.1056/NEJMoa1507598]">Raskind 2018</a>; <a href="./references#CD002795-bbs2-0050" title="RasmussonAM , MarxCE , JainS , FarfelGM , TsaiJ , SunX , et al.A randomized controlled trial of ganaxolone in posttraumatic stress disorder. Psychopharmacology2017;234(15):2245–57. [DOI: 10.1007/s00213-017-4649-y]">Rasmusson 2017</a>; <a href="./references#CD002795-bbs2-0052" title="ReistC , KauffmannCD , Chicz DemetA , ChenCC , DemetEM .REM latency, dexamethasone suppression test, and thyroid releasing hormone stimulation test in posttraumatic stress disorder. Progress in Neuropsychopharmacology and Biological Psychiatry1995;19(3):433-43. ReistC , KauffmannCD , HaierRJ , SangdahlC , DeMetEM , Chicz-DeMetA , et al.A controlled trial of desipramine in 18 men with posttraumatic stress disorder. American Journal of Psychiatry1989;146(4):513-6. ">Reist 1989</a>; <a href="./references#CD002795-bbs2-0053" title="SayginMZ , SungurMZ , SabolEU , CetinkayaP .Nefazodone versus sertraline in treatment of posttraumatic stress disorder. Bulletin of Clinical Psychopharmacology2002;12(1):1-5. ">Saygin 2002</a>; <a href="./references#CD002795-bbs2-0054" title="ShestatzkyM , GreenbergD , LererB .A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatric Research1988;24(2):149-55. ">Shestatzky 1988</a>; <a href="./references#CD002795-bbs2-0055" title="Food and Drug Administration (FDA).NDA 20-031/S-029 Paxil (paroxetine hydrochloride) tablets; GlaxoSmithKline; Post-traumatic Stress Disorder. www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf;(accessed 28 November 2021). GlaxoSmithKline.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). GSK - clinical study register [www.gsk-clinicalstudyregister.com]:Study ID: 29060/627. SmithKline Beecham.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. SteinDJ , DavidsonJ , SeedatS , BeebeK .Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies. Expert Opinion on Pharmacotherapy2003;4(10):1829-38. ">SKB627</a>; <a href="./references#CD002795-bbs2-0056" title="SmithKline Beecham.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. ">SKB650</a>; <a href="./references#CD002795-bbs2-0066" title="AmitalD , ZoharJ , KotlerM , BleichA , MiodovnikH , NevoA , et al.A placebo-controlled study of sertraline in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):269. AmitalD , ZoharJ , KotlerM , BleichA , MiodovnikH , NevoA , et al.A placebo-controlled trial pilot study of sertraline in PTSD. In: Annual Meeting of the American Psychiatric Association. American Psychiatric Association, 1999:157. ZoharJ , AmitalD , MiodownikC , KotlerM , BleichA , LaneRM .Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. Journal of Clinical Psychopharmacology2002;22(2):190-5. ">Zohar 2002</a>). The risk of attrition bias was rated as unclear for these trials. Substantial differences in the proportion of study dropouts between the medication and placebo groups for 11 trials were observed (<a href="./references#CD002795-bbs2-0006" title="ButterfieldMI , BeckerME , ConnorKM , SutherlandS , ChurchillLE , DavidsonJR .Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. International Clinical Psychopharmacology2001;16(4):197-203. ">Butterfield 2001</a>; <a href="./references#CD002795-bbs2-0010" title="ConnorKM , DavidsonJR , WeislerRH , ZhangW , AbrahamK .Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology2006;184:21–5. [DOI: 10.1007/s00213-005-0265-3]">Connor 2006</a>; <a href="./references#CD002795-bbs2-0022" title="DowdSM , ZaltaAK , BurgessHJ , AdkinsEC , Valdespino-HaydenZ , PollackMH .Double-blind randomized controlled study of the efficacy, safety and tolerability of eszopiclone vs placebo for the treatment of patients with post-traumatic stress disorder and insomnia. World Journal of Psychiatry2020;10(3):21-8. [DOI: 10.5498/wjp.v10.i3.21]">Dowd 2020</a>; <a href="./references#CD002795-bbs2-0028" title="HertzbergMA , ButterfieldMI , FeldmanME , BeckhamJC , SutherlandSM , ConnorKM , et al.A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biological Psychiatry1999;45(9):1226-9. ">Hertzberg 1999</a>; <a href="./references#CD002795-bbs2-0032" title="KostenTR , FrankJB , DanE , McDougleCJ , Giller EL Jr.Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease1991;179(6):366–70. ">Kosten 1991</a>; <a href="./references#CD002795-bbs2-0037" title="MartenyiF , BrownEB , ZhangH , KokeSC , PrakashA .Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. British Journal of Psychiatry2002;181:315-20. ">Martenyi 2002b</a>; <a href="./references#CD002795-bbs2-0044" title="NCT01681849.Neural circuits in women with abuse and Posttraumatic Stress Disorder. clinicaltrials.gov/ct2/show/NCT01681849 (first received 10 September 2012). ">NCT01681849</a>; <a href="./references#CD002795-bbs2-0051" title="ReichDB , WinternitzS , HennenJ , WattsT , StanculescuC .A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. Journal of Clinical Psychiatry2004;65(12):1601-5. ">Reich 2004</a>; <a href="./references#CD002795-bbs2-0057" title="SmajkicA , WeineS , Djuric-BijedicZ , BoskailoE , LewisJ , PavkovicI .Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms. Journal of Traumatic Stress2001;14(3):445-52. ">Smajkic 2001</a>; <a href="./references#CD002795-bbs2-0058" title="SpivakB , StrousRD , ShakedG , ShabashE , KotlerM , WeizmanA .Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. Journal of Clinical Psychopharmacology2006;26(2):152–6. [DOI: 10.1097/01.jcp.0000203195.65710.f0]">Spivak 2006</a>; <a href="./references#CD002795-bbs2-0062" title="Van der KolkBA , DreyfussD , MichaelsM , SheraD , BerkowitzR , FislerR , et al.Fluoxetine treatment in posttraumatic stress disorder. Journal of Clinical Psychiatry1994;55(12):517-22. ">Van der Kolk 1994</a>), justifying a rating of high risk. The review rated the remaining 22 studies as being at low risk for this domain, because of comparable dropout rates in each comparison group and no difference in the demographic characteristics. Intention‐to‐treat data for all outcomes were assessed in 33 studies, using LOCF (n = 33), completers (n = 19), observed cases (n = 2) and mixed‐effect models (n = 3) to account for missing data. Three studies did not specify how they addressed the issue of missing data. </p> </section> <section id="CD002795-sec-0055"> <h4 class="title">Selective reporting</h4> <p>It was unclear whether selective reporting took place in 57 trials because the study protocols were not available for the study. Six studies were rated as being at low risk for selective reporting because authors reported on all outcomes as specified in their respective trial protocols (<a href="./references#CD002795-bbs2-0021" title="DavisLL , PilkintonP , LinC , ParkerP , EstesS , BartolucciA .A randomized, placebo-controlled trial of mirtazapine for the treatment of posttraumatic stress disorder in v eterans. Journal of Clinical Psychiatry2020;81(6):e1-8. [DOI: 10.4088/JCP.20m13267]">Davis 2020</a>; <a href="./references#CD002795-bbs2-0023" title="DunlopBW , BinderEB , IosifescuD , MathewSJ , NeylanTC , PapeJC , et al.Corticotropin-releasing factor receptor 1 antagonism Is ineffective for women with posttraumatic stress disorder. Biological Psychiatry2017;82(12):866–74. [DOI: http://dx.doi.org/10.1016/j.biopsych.2017.06.024]">Dunlop 2017</a>; <a href="./references#CD002795-bbs2-0042" title="NCT00659230.Nepicastat for Posttraumatic Stress Disorder (PTSD) in OIF/OEF Veterans (Nepicastat). clinicaltrials.gov/ct2/show/NCT00659230 (first received 06 May 2008). ">NCT00659230</a>; <a href="./references#CD002795-bbs2-0043" title="NCT01000493.Orvepitant (GW823296) in adult Post Traumatic Stress Disorder. clinicaltrials.gov/ct2/show/NCT01000493 (first received 23 October 2009). ">NCT01000493</a>; <a href="./references#CD002795-bbs2-0044" title="NCT01681849.Neural circuits in women with abuse and Posttraumatic Stress Disorder. clinicaltrials.gov/ct2/show/NCT01681849 (first received 10 September 2012). ">NCT01681849</a>; <a href="./references#CD002795-bbs2-0049" title="RaskindMA , PeskindER , ChowB , HarrisC , Davis-KarimA , HolmesHA , et al.Trial of prazosin for post-traumatic stress disorder in military veterans. New England Journal of Medicine2018;378(6):507-17. [DOI: 10.1056/NEJMoa1507598]">Raskind 2018</a>). In <a href="./references#CD002795-bbs2-0020" title="DavisLL , DavidsonJR , WardC , BartolucciA , BowdenCL , PettyF .Divalproex in the treatment of posttraumatic tress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. Journal of Clinical Psychopharmacology2008;28(21):84–8. [DOI: 10.1097/jcp.0b013e318160f83b]">Davis 2008</a>, <a href="./references#CD002795-bbs2-0024" title="FederA , ParidesMK , MurroughJW , PerezAM , MorganJE , SaxenaS , et al.Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder. A randomized clinical trial. JAMA Psychiatry2014;71(6):681-8. [DOI: 10.1001/jamapsychiatry.2014.62]">Feder 2014</a>, and <a href="./references#CD002795-bbs2-0064" title="VillarrealG , HamnerMB , CañiveJM , RobertS , CalaisLA , DurklaskiV , et al.Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. American Journal of Psychiatry2016;173(12):1205-12. [DOI: 10.1176/appi.ajp.2016.15070967]">Villarreal 2016</a>, the prespecified secondary outcomes in the protocol did not appear in the study report, meriting a classification of high risk. </p> </section> <section id="CD002795-sec-0056"> <h4 class="title">Other potential sources of bias</h4> <p>Twenty‐one studies were classified as being at low risk for other potential sources of bias (<a href="./references#CD002795-bbs2-0001" title="AhmadpanahM , SabzeieeP , Mohammad HosseiniS , TorabianS , HaghighiM , JahangardL , et al.Comparing the effect of prazosin and hydroxyzine on sleep quality in patients suffering from posttraumatic stress disorder. Neuropsychobiology2014;69(4):235–42. [10.1159/000362243]">Ahmadpanah 2014</a>; <a href="./references#CD002795-bbs2-0002" title="BakerDG , DiamondBI , GilletteG , HamnerM , KatzelnickD , KellerT , et al.A double-blind randomized placebo-controlled multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology1995;122(4):386-9. ConnorKM , HidalgoRB , CrockettB , MalikM , KatzRJ , DavidsonJR .Predictors of treatment response in patients with posttraumatic stress disorder. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2001;25(2):337-45. ">Baker 1995</a>; <a href="./references#CD002795-bbs2-0005" title="BraunP , GreenbergD , DasbergH , LererB .Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. Journal of Clinical Psychiatry1990;51(6):236-8. ">Braun 1990</a>; <a href="./references#CD002795-bbs2-0009" title="BarnettSD , TharwaniHM , HertzbergMA , SutherlandSM , ConnorKM , DavidsonJR .Tolerability of fluoxetine in posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2002;26(2):363-7. ConnorKM , SutherlandSM , TuplerLA , MalikML , DavidsonJR .Fluoxetine in post-traumatic stress disorder: randomized, double-blind study. British Journal of Psychiatry1999;175:17-22. MalikML , ConnorKM , SutherlandSM , SmithRD , DavisonRM , DavidsonJR .Quality-of-life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo- controlled trial of fluoxetine. Journal of Traumatic Stress1999;12(2):387-93. ">Connor 1999a</a>; <a href="./references#CD002795-bbs2-0011" title="DavidsonJR , KudlerH , SmithR , MahorneySL , LipperS , HammettE , et al.Treatment of posttraumatic stress disorder with amitriptyline and placebo. Archives of General Psychiatry1990;47(3):259-66. DavidsonJR , KudlerHS , SaundersWB , EricksonL , SmithRD , SteinRM , et al.Predicting response to amitriptyline in posttraumatic stress disorder. American Journal of Psychiatry1993;150(7):1024-9. ">Davidson 1990</a>; <a href="./references#CD002795-bbs2-0015" title="DavidsonJT , ConnorKM , HertzbergMA , WeislerRH , WilsonWH , PayneVM .Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study. Journal of Clinical Psychopharmacology2005;25(2):166–9. [DOI: 10.1097/01.jcp.0000155817.21467.6c]">Davidson 2005</a>; <a href="./references#CD002795-bbs2-0021" title="DavisLL , PilkintonP , LinC , ParkerP , EstesS , BartolucciA .A randomized, placebo-controlled trial of mirtazapine for the treatment of posttraumatic stress disorder in v eterans. Journal of Clinical Psychiatry2020;81(6):e1-8. [DOI: 10.4088/JCP.20m13267]">Davis 2020</a>; <a href="./references#CD002795-bbs2-0022" title="DowdSM , ZaltaAK , BurgessHJ , AdkinsEC , Valdespino-HaydenZ , PollackMH .Double-blind randomized controlled study of the efficacy, safety and tolerability of eszopiclone vs placebo for the treatment of patients with post-traumatic stress disorder and insomnia. World Journal of Psychiatry2020;10(3):21-8. [DOI: 10.5498/wjp.v10.i3.21]">Dowd 2020</a>; <a href="./references#CD002795-bbs2-0023" title="DunlopBW , BinderEB , IosifescuD , MathewSJ , NeylanTC , PapeJC , et al.Corticotropin-releasing factor receptor 1 antagonism Is ineffective for women with posttraumatic stress disorder. Biological Psychiatry2017;82(12):866–74. [DOI: http://dx.doi.org/10.1016/j.biopsych.2017.06.024]">Dunlop 2017</a>; <a href="./references#CD002795-bbs2-0024" title="FederA , ParidesMK , MurroughJW , PerezAM , MorganJE , SaxenaS , et al.Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder. A randomized clinical trial. JAMA Psychiatry2014;71(6):681-8. [DOI: 10.1001/jamapsychiatry.2014.62]">Feder 2014</a>; <a href="./references#CD002795-bbs2-0029" title="HertzbergMA , FeldmanME , BeckhamJC , KudlerHS , DavidsonJR .Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Annals of Clinical Psychiatry2000;12(2):101-5. ">Hertzberg 2000</a>; <a href="./references#CD002795-bbs2-0033" title="LiW , Ma Y-B, YangQ , LiBL , Meng Q-G, ZhangY .Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study. International Journal of Psychiatry in Clinical Practice2017;21(2):151-5. [DOI: 10.1080/13651501.2017.1291838]">Li 2017</a>; <a href="./references#CD002795-bbs2-0040" title="McCallWV , YoussefN , BranchF , NollaT , McCloudL , MoraczewskiJ , et al.A randomized controlled trial (RCT) of prazosin versus placebo for suicidal posttraumatic stress disorder (PTSD) patients with nightmares-a pilot study. Sleep2018;41(Supplement 1):A351-2. [DOI: 10.1097/JCP.0000000000000968]">McCall 2018</a>; <a href="./references#CD002795-bbs2-0042" title="NCT00659230.Nepicastat for Posttraumatic Stress Disorder (PTSD) in OIF/OEF Veterans (Nepicastat). clinicaltrials.gov/ct2/show/NCT00659230 (first received 06 May 2008). ">NCT00659230</a>; <a href="./references#CD002795-bbs2-0044" title="NCT01681849.Neural circuits in women with abuse and Posttraumatic Stress Disorder. clinicaltrials.gov/ct2/show/NCT01681849 (first received 10 September 2012). ">NCT01681849</a>; <a href="./references#CD002795-bbs2-0046" title="PanahiY , MoghaddamBR , SahebkarA , NazariMA , BeiraghdarF , KaramiG , et al.A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder. Psychological Medicine2011;41(10):2159–66. [DOI: 10.1017/S0033291711000201]">Panahi 2011</a>; <a href="./references#CD002795-bbs2-0049" title="RaskindMA , PeskindER , ChowB , HarrisC , Davis-KarimA , HolmesHA , et al.Trial of prazosin for post-traumatic stress disorder in military veterans. New England Journal of Medicine2018;378(6):507-17. [DOI: 10.1056/NEJMoa1507598]">Raskind 2018</a>; <a href="./references#CD002795-bbs2-0050" title="RasmussonAM , MarxCE , JainS , FarfelGM , TsaiJ , SunX , et al.A randomized controlled trial of ganaxolone in posttraumatic stress disorder. Psychopharmacology2017;234(15):2245–57. [DOI: 10.1007/s00213-017-4649-y]">Rasmusson 2017</a>; <a href="./references#CD002795-bbs2-0053" title="SayginMZ , SungurMZ , SabolEU , CetinkayaP .Nefazodone versus sertraline in treatment of posttraumatic stress disorder. Bulletin of Clinical Psychopharmacology2002;12(1):1-5. ">Saygin 2002</a>; <a href="./references#CD002795-bbs2-0063" title="Van der Kolk, SpinazzolaJ , BlausteinM , HopperJ , HopperE , KornD , et al.A randomized clinical trial of EMDR, fluoxetine and pill placebo in the treatment of PTSD: treatment effects and long-term maintenance. Draft manuscript2004. Van der KolkBA , SpinazzolaJ , BlausteinME , HopperJW , HopperEK , KornDL , et al.A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. Journal of Clinical Psychiatry2007;68(1):37-46. ">Van der Kolk 2007</a>; <a href="./references#CD002795-bbs2-0065" title="YehMS , MariJJ , CostaMC , AndreoliSB , BressanRA , MelloMF .A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neuroscience and Therapeutics2011;17(5):305–10. [DOI: 10.1111/j.1755-5949.2010.00188.x]">Yeh 2011</a>). The review rated the risk of other bias for the remaining studies as unclear due to industry involvement, whether through funding or provision of study medication. </p> </section> </section> <section id="CD002795-sec-0057"> <h3 class="title" id="CD002795-sec-0057">Effects of interventions</h3> <p>See: <a href="./full#CD002795-tbl-0001"><b>Summary of findings 1</b> Comparison 1: Alpha‐blockers versus placebo for posttraumatic stress disorder (PTSD)</a>; <a href="./full#CD002795-tbl-0002"><b>Summary of findings 2</b> Comparison 2: Antipsychotics versus placebo for posttraumatic stress disorder (PTSD)</a>; <a href="./full#CD002795-tbl-0003"><b>Summary of findings 3</b> Comparison 3: MAOIs versus placebo for posttraumatic stress disorder (PTSD)</a>; <a href="./full#CD002795-tbl-0004"><b>Summary of findings 4</b> Comparison 4: NaSSAs versus placebo for posttraumatic stress disorder (PTSD)</a>; <a href="./full#CD002795-tbl-0005"><b>Summary of findings 5</b> Comparison 5: SNRIs versus placebo for posttraumatic stress disorder (PTSD)</a>; <a href="./full#CD002795-tbl-0006"><b>Summary of findings 6</b> Comparison 6: SSRIs versus placebo for posttraumatic stress disorder (PTSD)</a>; <a href="./full#CD002795-tbl-0007"><b>Summary of findings 7</b> Comparison 7: TCAs versus placebo for posttraumatic stress disorder (PTSD)</a> </p> <p>See summary of findings tables for the main comparisons prioritised based on primary outcomes of medication classes compared to placebo for treating PTSD in adults: <a href="./full#CD002795-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD002795-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD002795-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD002795-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD002795-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD002795-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD002795-tbl-0007">summary of findings Table 7</a>. Please refer to <a href="#CD002795-sec-0020">Types of outcome measures</a> for a description of the scoring systems used in included studies. </p> <section id="CD002795-sec-0058"> <h4 class="title">Comparison 1: Alpha‐blockers versus placebo</h4> <section id="CD002795-sec-0059"> <h5 class="title">Primary outcome measures</h5> <p>We found no studies that looked at the number of participants who responded to prazosin compared to placebo. </p> <p>There was also no evidence of a harm for the number of participants who withdrew due to treatment‐emergent side effects (risk ratio (RR) 0.99, 95% confidence interval (CI) 0.91 to 1.08; 1 study, 304 participants; see <a href="./references#CD002795-fig-0006" title="">Analysis 1.1</a>; <a href="./references#CD002795-bbs2-0049" title="RaskindMA , PeskindER , ChowB , HarrisC , Davis-KarimA , HolmesHA , et al.Trial of prazosin for post-traumatic stress disorder in military veterans. New England Journal of Medicine2018;378(6):507-17. [DOI: 10.1056/NEJMoa1507598]">Raskind 2018</a>), based on moderate‐certainty evidence. </p> </section> <section id="CD002795-sec-0060"> <h5 class="title">Secondary outcome measures</h5> <p>There was no evidence of a benefit of prazosin compared to placebo for the reduction of PTSD symptoms on the CAPS total (mean difference (MD) 0.10 points, 95% CI −5.13 to 5.33; 1 study, 271 participants; see <a href="./references#CD002795-fig-0007" title="">Analysis 1.2</a>; <a href="./references#CD002795-bbs2-0049" title="RaskindMA , PeskindER , ChowB , HarrisC , Davis-KarimA , HolmesHA , et al.Trial of prazosin for post-traumatic stress disorder in military veterans. New England Journal of Medicine2018;378(6):507-17. [DOI: 10.1056/NEJMoa1507598]">Raskind 2018</a>). No evidence of a benefit for prazosin versus placebo was found for one trial that provided data for the reduction of PTSD symptoms on the self‐rated PTSD Checklist–Military Version (PCL‐M): (standardised mean difference (SMD) −0.18 points, 95% CI −0.41 to 0.06; 1 study, 271 participants; <a href="./references#CD002795-fig-0008" title="">Analysis 1.3</a>; <a href="./references#CD002795-bbs2-0049" title="RaskindMA , PeskindER , ChowB , HarrisC , Davis-KarimA , HolmesHA , et al.Trial of prazosin for post-traumatic stress disorder in military veterans. New England Journal of Medicine2018;378(6):507-17. [DOI: 10.1056/NEJMoa1507598]">Raskind 2018</a>). </p> <p>There was no evidence of a benefit of prazosin in reducing depression symptoms on the Patient Health Questionnaire 9‐item depression (PHQ‐9) scale in participants with PTSD compared to placebo (MD −0.60 points, 95% CI −2.11 to 0.91; 1 study, 271 participants; see <a href="./references#CD002795-fig-0009" title="">Analysis 1.4</a>; <a href="./references#CD002795-bbs2-0049" title="RaskindMA , PeskindER , ChowB , HarrisC , Davis-KarimA , HolmesHA , et al.Trial of prazosin for post-traumatic stress disorder in military veterans. New England Journal of Medicine2018;378(6):507-17. [DOI: 10.1056/NEJMoa1507598]">Raskind 2018</a>). </p> <p>A similar proportion of participants withdrew from the prazosin group (20%) compared to the placebo group (19%) (see <a href="./references#CD002795-fig-0010" title="">Analysis 1.5</a>; <a href="./references#CD002795-bbs2-0049" title="RaskindMA , PeskindER , ChowB , HarrisC , Davis-KarimA , HolmesHA , et al.Trial of prazosin for post-traumatic stress disorder in military veterans. New England Journal of Medicine2018;378(6):507-17. [DOI: 10.1056/NEJMoa1507598]">Raskind 2018</a>). </p> </section> </section> <section id="CD002795-sec-0061"> <h4 class="title">Comparison 2: Anticonvulsants versus placebo</h4> <section id="CD002795-sec-0062"> <h5 class="title">Primary outcome measures</h5> <p>There was no evidence of a benefit that lamotrigine, tiagabine or topiramate improves treatment efficacy in participants with PTSD compared to placebo (RR 0.87, 95% CI 0.63 to 1.21; 4 trials, 315 participants (<a href="./references#CD002795-bbs2-0018" title="DavidsonJR , BradyK , MellmanTA , SteinMB , PollackMH .The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. Journal of Clinical Psychopharmacology2007;27(1):85–8. [DOI: 10.1097/JCP.0b013e31802e5115]">Davidson 2007</a>; <a href="./references#CD002795-bbs2-0028" title="HertzbergMA , ButterfieldMI , FeldmanME , BeckhamJC , SutherlandSM , ConnorKM , et al.A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biological Psychiatry1999;45(9):1226-9. ">Hertzberg 1999</a>; <a href="./references#CD002795-bbs2-0061" title="TuckerP , TrautmanRP , WyattDB , ThompsonJ , WuSC , CapeceJA , et al.Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2007;68(2):201-6. ">Tucker 2007</a>; <a href="./references#CD002795-bbs2-0065" title="YehMS , MariJJ , CostaMC , AndreoliSB , BressanRA , MelloMF .A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neuroscience and Therapeutics2011;17(5):305–10. [DOI: 10.1111/j.1755-5949.2010.00188.x]">Yeh 2011</a>). </p> <p>Dropout rates due to adverse events were low in RCTs of divalproex, lamotrigine, tiagabine and topiramate, and were comparable to those observed in the placebo arms (11% versus 9%, respectively) (RR 0.98, 95% CI 0.92 to 1.05; 5 trials, 348 participants; see <a href="./references#CD002795-fig-0012" title="">Analysis 2.2</a>; <a href="./references#CD002795-bbs2-0018" title="DavidsonJR , BradyK , MellmanTA , SteinMB , PollackMH .The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. Journal of Clinical Psychopharmacology2007;27(1):85–8. [DOI: 10.1097/JCP.0b013e31802e5115]">Davidson 2007</a>; <a href="./references#CD002795-bbs2-0027" title="HamnerMB , FaldowskiRA , RobertS , UlmerHG , HornerMD , LorberbaumJP .A preliminary controlled trial of divalproex in posttraumatic stress disorder. Annals of Clinical Psychiatry2008;21(2):89-94. ">Hamner 2008</a>; <a href="./references#CD002795-bbs2-0028" title="HertzbergMA , ButterfieldMI , FeldmanME , BeckhamJC , SutherlandSM , ConnorKM , et al.A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biological Psychiatry1999;45(9):1226-9. ">Hertzberg 1999</a>; <a href="./references#CD002795-bbs2-0061" title="TuckerP , TrautmanRP , WyattDB , ThompsonJ , WuSC , CapeceJA , et al.Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2007;68(2):201-6. ">Tucker 2007</a>; <a href="./references#CD002795-bbs2-0065" title="YehMS , MariJJ , CostaMC , AndreoliSB , BressanRA , MelloMF .A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neuroscience and Therapeutics2011;17(5):305–10. [DOI: 10.1111/j.1755-5949.2010.00188.x]">Yeh 2011</a>). </p> </section> <section id="CD002795-sec-0063"> <h5 class="title">Secondary outcome measures</h5> <p>We assessed data on the reduction of PTSD symptoms, measured by the CAPS (total score), in five studies comparing divalproex, tiagabine and topiramate to placebo (MD −0.35 points, 95% CI −6.54 to −5.84; 5 trials, 411 participants; see <a href="./references#CD002795-fig-0013" title="">Analysis 2.3</a>; <a href="./references#CD002795-bbs2-0018" title="DavidsonJR , BradyK , MellmanTA , SteinMB , PollackMH .The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. Journal of Clinical Psychopharmacology2007;27(1):85–8. [DOI: 10.1097/JCP.0b013e31802e5115]">Davidson 2007</a>; <a href="./references#CD002795-bbs2-0020" title="DavisLL , DavidsonJR , WardC , BartolucciA , BowdenCL , PettyF .Divalproex in the treatment of posttraumatic tress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. Journal of Clinical Psychopharmacology2008;28(21):84–8. [DOI: 10.1097/jcp.0b013e318160f83b]">Davis 2008</a>; <a href="./references#CD002795-bbs2-0027" title="HamnerMB , FaldowskiRA , RobertS , UlmerHG , HornerMD , LorberbaumJP .A preliminary controlled trial of divalproex in posttraumatic stress disorder. Annals of Clinical Psychiatry2008;21(2):89-94. ">Hamner 2008</a>; <a href="./references#CD002795-bbs2-0061" title="TuckerP , TrautmanRP , WyattDB , ThompsonJ , WuSC , CapeceJA , et al.Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2007;68(2):201-6. ">Tucker 2007</a>; <a href="./references#CD002795-bbs2-0065" title="YehMS , MariJJ , CostaMC , AndreoliSB , BressanRA , MelloMF .A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neuroscience and Therapeutics2011;17(5):305–10. [DOI: 10.1111/j.1755-5949.2010.00188.x]">Yeh 2011</a>). We found no evidence of beneficial effect (P = 0.91). Divalproex and topiramate were not superior to placebo on either the re‐experiencing/intrusion subscale (MD 0.20 points, 95% CI −3.74 to 4.13; see <a href="./references#CD002795-fig-0013" title="">Analysis 2.3</a>), avoidance/numbing subscale (MD −0.37 points, 95% CI −8.65 to 7.91; see <a href="./references#CD002795-fig-0013" title="">Analysis 2.3</a>), or hyperarousal subscale (MD 0.21 points, 95% CI −2.57 to 2.99; see <a href="./references#CD002795-fig-0013" title="">Analysis 2.3</a>) of the CAPS in three trials with 141 participants (<a href="./references#CD002795-bbs2-0020" title="DavisLL , DavidsonJR , WardC , BartolucciA , BowdenCL , PettyF .Divalproex in the treatment of posttraumatic tress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. Journal of Clinical Psychopharmacology2008;28(21):84–8. [DOI: 10.1097/jcp.0b013e318160f83b]">Davis 2008</a>; <a href="./references#CD002795-bbs2-0027" title="HamnerMB , FaldowskiRA , RobertS , UlmerHG , HornerMD , LorberbaumJP .A preliminary controlled trial of divalproex in posttraumatic stress disorder. Annals of Clinical Psychiatry2008;21(2):89-94. ">Hamner 2008</a>; <a href="./references#CD002795-bbs2-0065" title="YehMS , MariJJ , CostaMC , AndreoliSB , BressanRA , MelloMF .A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neuroscience and Therapeutics2011;17(5):305–10. [DOI: 10.1111/j.1755-5949.2010.00188.x]">Yeh 2011</a>). We noted substantial and considerable heterogeneity for the re‐experiencing/intrusion and avoidance/numbing subscales, respectively (Chi<sup>2</sup> = 4.19, df = 2 (P = 0.12); I<sup>2</sup>= 52%; Chi<sup>2</sup>= 9.87, df = 2 (P = 0.007); I<sup>2</sup> = 80%). </p> <p>Furthermore, we found no evidence of a benefit for divalproex, lamotrigine, tiagabine or topiramate versus placebo for the reduction of PTSD symptoms on the other symptom severity scales such as the CGI‐S and DGRP (SMD 0.15 points, 95% CI −0.31 to 0.60; 5 trials, 180 participants; see <a href="./references#CD002795-fig-0014" title="">Analysis 2.4</a>; <a href="./references#CD002795-bbs2-0010" title="ConnorKM , DavidsonJR , WeislerRH , ZhangW , AbrahamK .Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology2006;184:21–5. [DOI: 10.1007/s00213-005-0265-3]">Connor 2006</a>; <a href="./references#CD002795-bbs2-0020" title="DavisLL , DavidsonJR , WardC , BartolucciA , BowdenCL , PettyF .Divalproex in the treatment of posttraumatic tress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. Journal of Clinical Psychopharmacology2008;28(21):84–8. [DOI: 10.1097/jcp.0b013e318160f83b]">Davis 2008</a>; <a href="./references#CD002795-bbs2-0027" title="HamnerMB , FaldowskiRA , RobertS , UlmerHG , HornerMD , LorberbaumJP .A preliminary controlled trial of divalproex in posttraumatic stress disorder. Annals of Clinical Psychiatry2008;21(2):89-94. ">Hamner 2008</a>; <a href="./references#CD002795-bbs2-0028" title="HertzbergMA , ButterfieldMI , FeldmanME , BeckhamJC , SutherlandSM , ConnorKM , et al.A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biological Psychiatry1999;45(9):1226-9. ">Hertzberg 1999</a>; <a href="./references#CD002795-bbs2-0061" title="TuckerP , TrautmanRP , WyattDB , ThompsonJ , WuSC , CapeceJA , et al.Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2007;68(2):201-6. ">Tucker 2007</a>), or on the self‐rated DTS and IES (SMD −0.06 points, 95% CI −0.75 to 0.64; 3 trials, 84 participants; see <a href="./references#CD002795-fig-0015" title="">Analysis 2.5</a>; <a href="./references#CD002795-bbs2-0010" title="ConnorKM , DavidsonJR , WeislerRH , ZhangW , AbrahamK .Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology2006;184:21–5. [DOI: 10.1007/s00213-005-0265-3]">Connor 2006</a>; <a href="./references#CD002795-bbs2-0027" title="HamnerMB , FaldowskiRA , RobertS , UlmerHG , HornerMD , LorberbaumJP .A preliminary controlled trial of divalproex in posttraumatic stress disorder. Annals of Clinical Psychiatry2008;21(2):89-94. ">Hamner 2008</a>; <a href="./references#CD002795-bbs2-0061" title="TuckerP , TrautmanRP , WyattDB , ThompsonJ , WuSC , CapeceJA , et al.Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2007;68(2):201-6. ">Tucker 2007</a>), with substantial heterogeneity found for the self‐rated measures (Chi<sup>2</sup> = 4.86, df = 2 (P = 0.09); I<sup>2</sup> = 59%). </p> <p>Similarly, there was no evidence of a benefit of divalproex, tiagabine or topiramate for the reduction in depression symptoms on the BDI, HAM‐D and MADRS for participants with PTSD compared to placebo (SMD −0.22 points, 95% CI −0.57 to 0.12; 3 trials, 131 participants; see <a href="./references#CD002795-fig-0016" title="">Analysis 2.6</a>; <a href="./references#CD002795-bbs2-0010" title="ConnorKM , DavidsonJR , WeislerRH , ZhangW , AbrahamK .Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology2006;184:21–5. [DOI: 10.1007/s00213-005-0265-3]">Connor 2006</a>; <a href="./references#CD002795-bbs2-0020" title="DavisLL , DavidsonJR , WardC , BartolucciA , BowdenCL , PettyF .Divalproex in the treatment of posttraumatic tress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. Journal of Clinical Psychopharmacology2008;28(21):84–8. [DOI: 10.1097/jcp.0b013e318160f83b]">Davis 2008</a>; <a href="./references#CD002795-bbs2-0065" title="YehMS , MariJJ , CostaMC , AndreoliSB , BressanRA , MelloMF .A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neuroscience and Therapeutics2011;17(5):305–10. [DOI: 10.1111/j.1755-5949.2010.00188.x]">Yeh 2011</a>). There was also no evidence of a benefit of divalproex and tiagabine compared to placebo on the reduction of anxiety symptoms on the HAM‐A (MD −0.66 points, 95% CI −3.66 to 2.35; 3 trials, 138 participants; see <a href="./references#CD002795-fig-0017" title="">Analysis 2.7</a>; <a href="./references#CD002795-bbs2-0010" title="ConnorKM , DavidsonJR , WeislerRH , ZhangW , AbrahamK .Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology2006;184:21–5. [DOI: 10.1007/s00213-005-0265-3]">Connor 2006</a>; <a href="./references#CD002795-bbs2-0020" title="DavisLL , DavidsonJR , WardC , BartolucciA , BowdenCL , PettyF .Divalproex in the treatment of posttraumatic tress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. Journal of Clinical Psychopharmacology2008;28(21):84–8. [DOI: 10.1097/jcp.0b013e318160f83b]">Davis 2008</a>; <a href="./references#CD002795-bbs2-0061" title="TuckerP , TrautmanRP , WyattDB , ThompsonJ , WuSC , CapeceJA , et al.Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2007;68(2):201-6. ">Tucker 2007</a>). We found no evidence of beneficial effect for the reduction of anxiety symptoms for ‘other’ measures of anxiety (SMD 0.55 points, 95% CI −0.21 to 1.31; 1 trial, 28 participants; see <a href="./references#CD002795-fig-0018" title="">Analysis 2.8</a>; <a href="./references#CD002795-bbs2-0027" title="HamnerMB , FaldowskiRA , RobertS , UlmerHG , HornerMD , LorberbaumJP .A preliminary controlled trial of divalproex in posttraumatic stress disorder. Annals of Clinical Psychiatry2008;21(2):89-94. ">Hamner 2008</a>). In addition, there was no evidence of a benefit of tiagabine on the reduction of functional disability measured by the SDS in participants with PTSD compared to placebo (MD 0.41 points, 95% CI −1.48 to 2.30; 2 trials, 270 participants; see <a href="./references#CD002795-fig-0019" title="">Analysis 2.9</a>) (<a href="./references#CD002795-bbs2-0018" title="DavidsonJR , BradyK , MellmanTA , SteinMB , PollackMH .The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. Journal of Clinical Psychopharmacology2007;27(1):85–8. [DOI: 10.1097/JCP.0b013e31802e5115]">Davidson 2007</a>; <a href="./references#CD002795-bbs2-0061" title="TuckerP , TrautmanRP , WyattDB , ThompsonJ , WuSC , CapeceJA , et al.Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2007;68(2):201-6. ">Tucker 2007</a>). </p> <p>Similar dropout rates due to any cause were observed in the medication (28%) and placebo (32%) arms for the anticonvulsants (see <a href="./references#CD002795-fig-0020" title="">Analysis 2.10</a>; <a href="./references#CD002795-bbs2-0010" title="ConnorKM , DavidsonJR , WeislerRH , ZhangW , AbrahamK .Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology2006;184:21–5. [DOI: 10.1007/s00213-005-0265-3]">Connor 2006</a>; <a href="./references#CD002795-bbs2-0018" title="DavidsonJR , BradyK , MellmanTA , SteinMB , PollackMH .The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. Journal of Clinical Psychopharmacology2007;27(1):85–8. [DOI: 10.1097/JCP.0b013e31802e5115]">Davidson 2007</a>; <a href="./references#CD002795-bbs2-0020" title="DavisLL , DavidsonJR , WardC , BartolucciA , BowdenCL , PettyF .Divalproex in the treatment of posttraumatic tress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. Journal of Clinical Psychopharmacology2008;28(21):84–8. [DOI: 10.1097/jcp.0b013e318160f83b]">Davis 2008</a>; <a href="./references#CD002795-bbs2-0027" title="HamnerMB , FaldowskiRA , RobertS , UlmerHG , HornerMD , LorberbaumJP .A preliminary controlled trial of divalproex in posttraumatic stress disorder. Annals of Clinical Psychiatry2008;21(2):89-94. ">Hamner 2008</a>; <a href="./references#CD002795-bbs2-0028" title="HertzbergMA , ButterfieldMI , FeldmanME , BeckhamJC , SutherlandSM , ConnorKM , et al.A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biological Psychiatry1999;45(9):1226-9. ">Hertzberg 1999</a>; <a href="./references#CD002795-bbs2-0061" title="TuckerP , TrautmanRP , WyattDB , ThompsonJ , WuSC , CapeceJA , et al.Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry2007;68(2):201-6. ">Tucker 2007</a>; <a href="./references#CD002795-bbs2-0065" title="YehMS , MariJJ , CostaMC , AndreoliSB , BressanRA , MelloMF .A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neuroscience and Therapeutics2011;17(5):305–10. [DOI: 10.1111/j.1755-5949.2010.00188.x]">Yeh 2011</a>). </p> </section> </section> <section id="CD002795-sec-0064"> <h4 class="title">Comparison 3: Antipsychotics versus placebo</h4> <section id="CD002795-sec-0065"> <h5 class="title">Primary outcome measures</h5> <p>There was no evidence of a benefit of effect for olanzapine in participants with PTSD compared to placebo (RR 0.51, 95% CI 0.16 to 1.67; 2 trials, 43 participants; see <a href="./references#CD002795-fig-0021" title="">Analysis 3.1</a>; <a href="./references#CD002795-bbs2-0006" title="ButterfieldMI , BeckerME , ConnorKM , SutherlandS , ChurchillLE , DavidsonJR .Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. International Clinical Psychopharmacology2001;16(4):197-203. ">Butterfield 2001</a>; <a href="./references#CD002795-bbs2-0007" title="CareyP , SulimanS , GanesanK , SeedatS , SteinDJ .Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Human Psychopharmacology Clinical and Experimental2012;27:386–91. [DOI: 10.1002/hup.2238]">Carey 2012</a>), based on very low‐certainty evidence. We noted moderate heterogeneity across these trials (Chi<sup>2</sup> = 1.99, df = 1 (P = 0.16); I<sup>2</sup> = 50%). </p> <p>Twice as many participants withdrew due to treatment‐emergent side effects from the antipsychotic intervention arm (16%) compared to the placebo arm (7%), but we found no evidence of a harm between groups (RR 0.94, 95% CI 0.85 to 1.03; 5 trials, 174 participants; see <a href="./references#CD002795-fig-0022" title="">Analysis 3.2</a>; <a href="./references#CD002795-bbs2-0006" title="ButterfieldMI , BeckerME , ConnorKM , SutherlandS , ChurchillLE , DavidsonJR .Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. International Clinical Psychopharmacology2001;16(4):197-203. ">Butterfield 2001</a>; <a href="./references#CD002795-bbs2-0007" title="CareyP , SulimanS , GanesanK , SeedatS , SteinDJ .Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Human Psychopharmacology Clinical and Experimental2012;27:386–91. [DOI: 10.1002/hup.2238]">Carey 2012</a>; <a href="./references#CD002795-bbs2-0045" title="PadalaPR , MadisonJ , MonnahanM , MarcilW , PriceP , RamaswamyS , et al.Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. International Clinical Psychopharmacology2006;21(5):275–80. ">Padala 2006</a>; <a href="./references#CD002795-bbs2-0051" title="ReichDB , WinternitzS , HennenJ , WattsT , StanculescuC .A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. Journal of Clinical Psychiatry2004;65(12):1601-5. ">Reich 2004</a>; <a href="./references#CD002795-bbs2-0064" title="VillarrealG , HamnerMB , CañiveJM , RobertS , CalaisLA , DurklaskiV , et al.Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. American Journal of Psychiatry2016;173(12):1205-12. [DOI: 10.1176/appi.ajp.2016.15070967]">Villarreal 2016</a>). The evidence available for this outcome was of low‐certainty. </p> </section> <section id="CD002795-sec-0066"> <h5 class="title">Secondary outcome measures</h5> <p>There was evidence of a benefit for the reduction PTSD symptoms following treatment with olanzapine, risperidone or quetiapine compared to placebo for the CAPS total (MD −14.10 points, 95% CI −22.57 to −5.62; 3 trials, 129 participants; see <a href="./references#CD002795-fig-0023" title="">Analysis 3.3</a>; <a href="./references#CD002795-bbs2-0007" title="CareyP , SulimanS , GanesanK , SeedatS , SteinDJ .Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Human Psychopharmacology Clinical and Experimental2012;27:386–91. [DOI: 10.1002/hup.2238]">Carey 2012</a>; <a href="./references#CD002795-bbs2-0051" title="ReichDB , WinternitzS , HennenJ , WattsT , StanculescuC .A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. Journal of Clinical Psychiatry2004;65(12):1601-5. ">Reich 2004</a>; <a href="./references#CD002795-bbs2-0064" title="VillarrealG , HamnerMB , CañiveJM , RobertS , CalaisLA , DurklaskiV , et al.Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. American Journal of Psychiatry2016;173(12):1205-12. [DOI: 10.1176/appi.ajp.2016.15070967]">Villarreal 2016</a>). There was evidence of a benefit for the reduction PTSD symptoms for this outcome on the re‐experiencing/intrusion subscale (MD −4.73 points, 95% CI −7.55 to −1.90; see <a href="./references#CD002795-fig-0023" title="">Analysis 3.3</a>) and hyperarousal subscale (MD −5.14 points, 95% CI −8.16 to −2.11; see <a href="./references#CD002795-fig-0023" title="">Analysis 3.3</a>) of the CAPS (<a href="./references#CD002795-bbs2-0007" title="CareyP , SulimanS , GanesanK , SeedatS , SteinDJ .Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Human Psychopharmacology Clinical and Experimental2012;27:386–91. [DOI: 10.1002/hup.2238]">Carey 2012</a>; <a href="./references#CD002795-bbs2-0051" title="ReichDB , WinternitzS , HennenJ , WattsT , StanculescuC .A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. Journal of Clinical Psychiatry2004;65(12):1601-5. ">Reich 2004</a>; <a href="./references#CD002795-bbs2-0064" title="VillarrealG , HamnerMB , CañiveJM , RobertS , CalaisLA , DurklaskiV , et al.Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. American Journal of Psychiatry2016;173(12):1205-12. [DOI: 10.1176/appi.ajp.2016.15070967]">Villarreal 2016</a>). There was, however, no evidence of a benefit for the reduction of PTSD symptoms on the avoidance/numbing subscale (MD −6.01 points, 95% CI −13.72 to 1.70; see <a href="./references#CD002795-fig-0023" title="">Analysis 3.3</a>) of the CAPS (<a href="./references#CD002795-bbs2-0007" title="CareyP , SulimanS , GanesanK , SeedatS , SteinDJ .Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Human Psychopharmacology Clinical and Experimental2012;27:386–91. [DOI: 10.1002/hup.2238]">Carey 2012</a>; <a href="./references#CD002795-bbs2-0051" title="ReichDB , WinternitzS , HennenJ , WattsT , StanculescuC .A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. Journal of Clinical Psychiatry2004;65(12):1601-5. ">Reich 2004</a>; <a href="./references#CD002795-bbs2-0064" title="VillarrealG , HamnerMB , CañiveJM , RobertS , CalaisLA , DurklaskiV , et al.Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. American Journal of Psychiatry2016;173(12):1205-12. [DOI: 10.1176/appi.ajp.2016.15070967]">Villarreal 2016</a>), which is confirmed by the substantial heterogeneity found for this subscale (Chi<sup>2</sup> = 5.73, df = 2 (P = 0.06); I<sup>2</sup> = 65%). The substantial heterogeneity for this outcome is partially reflected in the unusually large and important medication effect observed in <a href="./references#CD002795-bbs2-0007" title="CareyP , SulimanS , GanesanK , SeedatS , SteinDJ .Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Human Psychopharmacology Clinical and Experimental2012;27:386–91. [DOI: 10.1002/hup.2238]">Carey 2012</a> (MD −15.10 points, 95% CI −24.47 to −5.73). Removing this trial resulted in a substantially reduced and statistically non‐significant treatment effect (MD −2.50 points, 95% CI −6.93 to 1.93), with no heterogeneity observed across the effects for the remaining trials (Chi<sup>2</sup> = 0.05, df = 1 (P = 0.82); I<sup>2</sup> = 0%). </p> <p>Furthermore, we found evidence of a beneficial effect of olanzapine and quetiapine compared to placebo in the reduction of PTSD symptoms on the symptom severity CGI‐S scale (SMD −0.55 points, 95% CI −0.94 to −0.17; 2 trials, 108 participants; see <a href="./references#CD002795-fig-0024" title="">Analysis 3.4</a>; <a href="./references#CD002795-bbs2-0007" title="CareyP , SulimanS , GanesanK , SeedatS , SteinDJ .Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Human Psychopharmacology Clinical and Experimental2012;27:386–91. [DOI: 10.1002/hup.2238]">Carey 2012</a>; <a href="./references#CD002795-bbs2-0064" title="VillarrealG , HamnerMB , CañiveJM , RobertS , CalaisLA , DurklaskiV , et al.Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. American Journal of Psychiatry2016;173(12):1205-12. [DOI: 10.1176/appi.ajp.2016.15070967]">Villarreal 2016</a>), with no evidence of a benefit on the self‐rated DTS (SMD −0.47 points, 95% CI −1.06 to 0.11; 3 trials, 119 participants; see <a href="./references#CD002795-fig-0025" title="">Analysis 3.5</a>; <a href="./references#CD002795-bbs2-0006" title="ButterfieldMI , BeckerME , ConnorKM , SutherlandS , ChurchillLE , DavidsonJR .Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. International Clinical Psychopharmacology2001;16(4):197-203. ">Butterfield 2001</a>; <a href="./references#CD002795-bbs2-0007" title="CareyP , SulimanS , GanesanK , SeedatS , SteinDJ .Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Human Psychopharmacology Clinical and Experimental2012;27:386–91. [DOI: 10.1002/hup.2238]">Carey 2012</a>; <a href="./references#CD002795-bbs2-0064" title="VillarrealG , HamnerMB , CañiveJM , RobertS , CalaisLA , DurklaskiV , et al.Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. American Journal of Psychiatry2016;173(12):1205-12. [DOI: 10.1176/appi.ajp.2016.15070967]">Villarreal 2016</a>), including the re‐experiencing/intrusion subscale (MD 0.51 points, 95% CI −0.58 to 1.61; 1 trial, 15 participants; see <a href="./references#CD002795-fig-0025" title="">Analysis 3.5</a>), avoidance/numbing subscale (MD −0.30 points, 95% CI −1.38 to 0.78; 1 trial, 15 participants; see <a href="./references#CD002795-fig-0025" title="">Analysis 3.5</a>) and hyperarousal subscale (MD −0.06 points, 95% CI −1.13 to 1.01; 1 trial, 15 participants; see <a href="./references#CD002795-fig-0025" title="">Analysis 3.5</a>) of the DTS (<a href="./references#CD002795-bbs2-0006" title="ButterfieldMI , BeckerME , ConnorKM , SutherlandS , ChurchillLE , DavidsonJR .Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. International Clinical Psychopharmacology2001;16(4):197-203. ">Butterfield 2001</a>). We also found moderate heterogeneity for the total score on the self‐rated measures (Chi<sup>2</sup> = 3.75, df = 2 (P = 0.15); I<sup>2</sup> = 47%). </p> <p>There was evidence of a benefit of olanzapine and quetiapine compared to placebo in the reduction of depression symptoms (SMD −0.62 points, 95% CI −1.01 to −0.23; 2 trials, 108 participants; see <a href="./references#CD002795-fig-0026" title="">Analysis 3.6</a>; <a href="./references#CD002795-bbs2-0007" title="CareyP , SulimanS , GanesanK , SeedatS , SteinDJ .Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Human Psychopharmacology Clinical and Experimental2012;27:386–91. [DOI: 10.1002/hup.2238]">Carey 2012</a>; <a href="./references#CD002795-bbs2-0064" title="VillarrealG , HamnerMB , CañiveJM , RobertS , CalaisLA , DurklaskiV , et al.Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. American Journal of Psychiatry2016;173(12):1205-12. [DOI: 10.1176/appi.ajp.2016.15070967]">Villarreal 2016</a>) on the HAM‐D and MADRS. There was no evidence of a beneficial effect of quetiapine on the reduction of anxiety symptoms in participants with PTSD compared to placebo (MD −3.03 points, 95% CI −6.21 to 0.15, 1 trial, 80 participants; see <a href="./references#CD002795-fig-0027" title="">Analysis 3.7</a>; <a href="./references#CD002795-bbs2-0064" title="VillarrealG , HamnerMB , CañiveJM , RobertS , CalaisLA , DurklaskiV , et al.Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. American Journal of Psychiatry2016;173(12):1205-12. [DOI: 10.1176/appi.ajp.2016.15070967]">Villarreal 2016</a>), as measured by the HAM‐A. Similarly, we found no evidence of a beneficial effect of olanzapine compared to placebo for the reduction of functional disability on the Sheehan Disability Scale (SDS) (MD −6.57 points, 95% CI −14.74 to 1.61; 2 trials, 43 participants; see <a href="./references#CD002795-fig-0028" title="">Analysis 3.8</a>; <a href="./references#CD002795-bbs2-0006" title="ButterfieldMI , BeckerME , ConnorKM , SutherlandS , ChurchillLE , DavidsonJR .Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. International Clinical Psychopharmacology2001;16(4):197-203. ">Butterfield 2001</a>; <a href="./references#CD002795-bbs2-0007" title="CareyP , SulimanS , GanesanK , SeedatS , SteinDJ .Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Human Psychopharmacology Clinical and Experimental2012;27:386–91. [DOI: 10.1002/hup.2238]">Carey 2012</a>). Substantial heterogeneity was also observed for the two trials investigating functional disability measured by the SDS (Chi<sup>2</sup> = 2.53, df = 1 (P = 0.11); I<sup>2</sup> = 61%). </p> <p>Although differences in dropout rates due to any cause in the medication (38%) and placebo (51%) arms were evident, no evidence of a difference was found across the four trials with 133 participants (see <a href="./references#CD002795-fig-0029" title="">Analysis 3.9</a>; <a href="./references#CD002795-bbs2-0006" title="ButterfieldMI , BeckerME , ConnorKM , SutherlandS , ChurchillLE , DavidsonJR .Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. International Clinical Psychopharmacology2001;16(4):197-203. ">Butterfield 2001</a>; <a href="./references#CD002795-bbs2-0045" title="PadalaPR , MadisonJ , MonnahanM , MarcilW , PriceP , RamaswamyS , et al.Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. International Clinical Psychopharmacology2006;21(5):275–80. ">Padala 2006</a>; <a href="./references#CD002795-bbs2-0051" title="ReichDB , WinternitzS , HennenJ , WattsT , StanculescuC .A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. Journal of Clinical Psychiatry2004;65(12):1601-5. ">Reich 2004</a>; <a href="./references#CD002795-bbs2-0064" title="VillarrealG , HamnerMB , CañiveJM , RobertS , CalaisLA , DurklaskiV , et al.Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. American Journal of Psychiatry2016;173(12):1205-12. [DOI: 10.1176/appi.ajp.2016.15070967]">Villarreal 2016</a>). </p> </section> </section> <section id="CD002795-sec-0067"> <h4 class="title">Comparison 4: Benzodiazepines versus placebo</h4> <section id="CD002795-sec-0068"> <h5 class="title">Primary outcome measures</h5> <p>We found no studies that looked at the number of participants who responded to alprazolam versus placebo. </p> <p>No participants dropped out due to treatment‐emergent side effects in the alprazolam and placebo groups (see <a href="./references#CD002795-fig-0030" title="">Analysis 4.1</a>; <a href="./references#CD002795-bbs2-0005" title="BraunP , GreenbergD , DasbergH , LererB .Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. Journal of Clinical Psychiatry1990;51(6):236-8. ">Braun 1990</a>). There is therefore no evidence of a harm in dropouts due to adverse events. </p> </section> <section id="CD002795-sec-0069"> <h5 class="title">Secondary outcomes measures</h5> <p>We found no information that assessed most of the additional outcomes; but the dropout rate was similar for the alprazolam (43%) and placebo groups (33%) (see <a href="./references#CD002795-fig-0031" title="">Analysis 4.2</a>; <a href="./references#CD002795-bbs2-0005" title="BraunP , GreenbergD , DasbergH , LererB .Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. Journal of Clinical Psychiatry1990;51(6):236-8. ">Braun 1990</a>). </p> </section> </section> <section id="CD002795-sec-0070"> <h4 class="title">Comparison 5: Dopamine beta‐hydroxylase inhibitors versus placebo</h4> <section id="CD002795-sec-0071"> <h5 class="title">Primary outcome measures</h5> <p>We found no studies that looked at the number of participants who responded to nepicastat versus placebo. </p> <p>There was no evidence of a harm in the number of participants who withdrew due to treatment‐emergent side effects for the nepicastat (63%) and placebo groups (57%), even though the dropout rates were substantial in both groups (RR 1.10, 95% CI 0.77 to 1.58; 1 trial, 91 participants; see <a href="./references#CD002795-fig-0032" title="">Analysis 5.1</a>; <a href="./references#CD002795-bbs2-0042" title="NCT00659230.Nepicastat for Posttraumatic Stress Disorder (PTSD) in OIF/OEF Veterans (Nepicastat). clinicaltrials.gov/ct2/show/NCT00659230 (first received 06 May 2008). ">NCT00659230</a>). </p> </section> <section id="CD002795-sec-0072"> <h5 class="title">Secondary outcome measures</h5> <p>We found no evidence of a benefit of nepicastat on CAPS total symptom severity (MD −5.27 points, 95% CI −16.72 to 6.18; see <a href="./references#CD002795-fig-0033" title="">Analysis 5.2</a>), or on the re‐experiencing/intrusion subscale (MD 2.63 points, 95% CI −1.67 to 6.93; see <a href="./references#CD002795-fig-0033" title="">Analysis 5.2</a>), avoidance/numbing subscale (MD 0.58 points, 95% CI −4.57 to 5.73; see <a href="./references#CD002795-fig-0033" title="">Analysis 5.2</a>), or hyperarousal subscale (MD 2.05 points, 95% CI −1.82 to 5.92; see <a href="./references#CD002795-fig-0033" title="">Analysis 5.2</a>) of the CAPS for reducing PTSD symptoms, in one trial with 86 participants (<a href="./references#CD002795-bbs2-0042" title="NCT00659230.Nepicastat for Posttraumatic Stress Disorder (PTSD) in OIF/OEF Veterans (Nepicastat). clinicaltrials.gov/ct2/show/NCT00659230 (first received 06 May 2008). ">NCT00659230</a>). </p> <p>Overall there were 12 (24%) dropouts in the nepicastat group and nine (18%) dropouts in the placebo group (see <a href="./references#CD002795-fig-0034" title="">Analysis 5.3</a>; <a href="./references#CD002795-bbs2-0042" title="NCT00659230.Nepicastat for Posttraumatic Stress Disorder (PTSD) in OIF/OEF Veterans (Nepicastat). clinicaltrials.gov/ct2/show/NCT00659230 (first received 06 May 2008). ">NCT00659230</a>). </p> </section> </section> <section id="CD002795-sec-0073"> <h4 class="title">Comparison 6: Ganaxolone versus placebo</h4> <section id="CD002795-sec-0074"> <h5 class="title">Primary outcome measures</h5> <p>We found no studies that looked at the number of participants who responded to ganaxolone versus placebo. </p> <p>There was no evidence of a harm for the number of participants who withdrew due to treatment‐emergent side effects (RR 0.60, 95% CI 0.10 to 3.45; 1 trial, 112 participants; see <a href="./references#CD002795-fig-0035" title="">Analysis 6.1</a>; <a href="./references#CD002795-bbs2-0050" title="RasmussonAM , MarxCE , JainS , FarfelGM , TsaiJ , SunX , et al.A randomized controlled trial of ganaxolone in posttraumatic stress disorder. Psychopharmacology2017;234(15):2245–57. [DOI: 10.1007/s00213-017-4649-y]">Rasmusson 2017</a>). </p> </section> <section id="CD002795-sec-0075"> <h5 class="title">Secondary outcome measures</h5> <p>No evidence of a benefit was observed for ganaxolone medication on CAPS total symptom severity (MD −2.50 points, 95% CI −10.92 to 5.92; 1 trial, 99 participants; see <a href="./references#CD002795-fig-0036" title="">Analysis 6.2</a>; <a href="./references#CD002795-bbs2-0050" title="RasmussonAM , MarxCE , JainS , FarfelGM , TsaiJ , SunX , et al.A randomized controlled trial of ganaxolone in posttraumatic stress disorder. Psychopharmacology2017;234(15):2245–57. [DOI: 10.1007/s00213-017-4649-y]">Rasmusson 2017</a>), or on re‐experiencing/intrusion subscale (MD −0.80 points, 95% CI −4.09 to 2.49; see <a href="./references#CD002795-fig-0036" title="">Analysis 6.2</a>), avoidance/numbing subscale (MD −1.60 points, 95% CI −5.74 to 2.54; see <a href="./references#CD002795-fig-0036" title="">Analysis 6.2</a>), or hyperarousal subscale (MD −1.10 points, 95% CI −3.96 to 1.76; see <a href="./references#CD002795-fig-0036" title="">Analysis 6.2</a>) on the CAPS for reducing PTSD symptoms. Similarly, no evidence of a benefit of ganaxolone versus placebo was observed for the reduction in PTSD symptoms on the PCL scale (self‐rated measure) (SMD −0.17 points, 95% CI −0.59 to 0.25; 1 trial, 86 participants; see <a href="./references#CD002795-fig-0037" title="">Analysis 6.3</a>; <a href="./references#CD002795-fig-0038" title="">Analysis 6.4</a>; <a href="./references#CD002795-bbs2-0050" title="RasmussonAM , MarxCE , JainS , FarfelGM , TsaiJ , SunX , et al.A randomized controlled trial of ganaxolone in posttraumatic stress disorder. Psychopharmacology2017;234(15):2245–57. [DOI: 10.1007/s00213-017-4649-y]">Rasmusson 2017</a>). </p> <p>In addition, we found no evidence of a difference in dropouts due to any cause for the ganaxolone intervention arm (33%) compared to the placebo arm (17%) (see <a href="./references#CD002795-fig-0039" title="">Analysis 6.5</a>; <a href="./references#CD002795-bbs2-0050" title="RasmussonAM , MarxCE , JainS , FarfelGM , TsaiJ , SunX , et al.A randomized controlled trial of ganaxolone in posttraumatic stress disorder. Psychopharmacology2017;234(15):2245–57. [DOI: 10.1007/s00213-017-4649-y]">Rasmusson 2017</a>), even though more dropouts were observed in the medication arm. </p> </section> </section> <section id="CD002795-sec-0076"> <h4 class="title">Comparison 7: GR205171 versus placebo</h4> <section id="CD002795-sec-0077"> <h5 class="title">Primary outcome measures</h5> <p>There was no evidence of a benefit of GR205171 compared to placebo for the number of participants with PTSD who responded to treatment (RR 0.78, 95% CI 0.42 to 1.44; 1 trial, 39 participants; see <a href="./references#CD002795-fig-0040" title="">Analysis 7.1</a>; <a href="./references#CD002795-bbs2-0039" title="MathewSJ , VythilingamM , MurroughaJW , ZarateCA , FederaA , LuckenbaughDA , et al.A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. European Neuropsychopharmacology2011;21(3):221–9. ">Mathew 2011</a>). </p> <p>No participants dropped out due to treatment‐emergent side effects in the GR205171 and placebo groups (see <a href="./references#CD002795-fig-0041" title="">Analysis 7.2</a>; <a href="./references#CD002795-bbs2-0039" title="MathewSJ , VythilingamM , MurroughaJW , ZarateCA , FederaA , LuckenbaughDA , et al.A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. European Neuropsychopharmacology2011;21(3):221–9. ">Mathew 2011</a>). </p> </section> <section id="CD002795-sec-0078"> <h5 class="title">Secondary outcome measures</h5> <p>There was no evidence of a benefit for GR205171 compared to placebo in the reduction of PTSD symptoms on the CAPS total (MD −7.60 points, 95% CI −22.59 to 7.39; 1 trial, 39 participants; see <a href="./references#CD002795-fig-0042" title="">Analysis 7.3</a>; <a href="./references#CD002795-bbs2-0039" title="MathewSJ , VythilingamM , MurroughaJW , ZarateCA , FederaA , LuckenbaughDA , et al.A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. European Neuropsychopharmacology2011;21(3):221–9. ">Mathew 2011</a>). </p> <p>Twice as many participants dropped out due to any cause from the placebo arm (48%) compared to the GR205171 intervention arm (18%) (see <a href="./references#CD002795-fig-0043" title="">Analysis 7.4</a>; <a href="./references#CD002795-bbs2-0039" title="MathewSJ , VythilingamM , MurroughaJW , ZarateCA , FederaA , LuckenbaughDA , et al.A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. European Neuropsychopharmacology2011;21(3):221–9. ">Mathew 2011</a>). </p> </section> </section> <section id="CD002795-sec-0079"> <h4 class="title">Comparison 8: GSK561679 versus placebo</h4> <section id="CD002795-sec-0080"> <h5 class="title">Primary outcome measures</h5> <p>There was no evidence of a benefit of GSK561679 on treatment efficacy in participants with PTSD compared to placebo (RR 1.08, 95% CI 0.88 to 1.31; 1 trial, 128 participants; see <a href="./references#CD002795-fig-0044" title="">Analysis 8.1</a>; <a href="./references#CD002795-bbs2-0023" title="DunlopBW , BinderEB , IosifescuD , MathewSJ , NeylanTC , PapeJC , et al.Corticotropin-releasing factor receptor 1 antagonism Is ineffective for women with posttraumatic stress disorder. Biological Psychiatry2017;82(12):866–74. [DOI: http://dx.doi.org/10.1016/j.biopsych.2017.06.024]">Dunlop 2017</a>). </p> <p>We found no studies that looked at the number of participants who dropped out due to treatment‐emergent side effects. </p> </section> <section id="CD002795-sec-0081"> <h5 class="title">Secondary outcome measures</h5> <p>We found no studies that looked at the secondary outcome measures of GSK561679 compared to placebo. </p> </section> </section> <section id="CD002795-sec-0082"> <h4 class="title">Comparison 9: Hypnotics versus placebo</h4> <section id="CD002795-sec-0083"> <h5 class="title">Primary outcome measures</h5> <p>We found no studies that looked at the number of participants who responded to eszopiclone versus placebo. </p> <p>We found no studies that looked at the number of participants who dropped out due to treatment‐emergent side effects. </p> </section> <section id="CD002795-sec-0084"> <h5 class="title">Secondary outcome measures</h5> <p>There was no evidence of a benefit of eszopiclone in reducing PTSD symptoms on the CAPS total (MD −1.00 points, 95% CI −19.57 to 17.57; 1 trial, 16 participants; see <a href="./references#CD002795-fig-0045" title="">Analysis 9.1</a>; <a href="./references#CD002795-bbs2-0022" title="DowdSM , ZaltaAK , BurgessHJ , AdkinsEC , Valdespino-HaydenZ , PollackMH .Double-blind randomized controlled study of the efficacy, safety and tolerability of eszopiclone vs placebo for the treatment of patients with post-traumatic stress disorder and insomnia. World Journal of Psychiatry2020;10(3):21-8. [DOI: 10.5498/wjp.v10.i3.21]">Dowd 2020</a>) or on the CGI‐S (SMD −0.09 points, 95% CI −1.08 to 0.90; 1 trial, 16 participants; see <a href="./references#CD002795-fig-0046" title="">Analysis 9.2</a>; <a href="./references#CD002795-bbs2-0022" title="DowdSM , ZaltaAK , BurgessHJ , AdkinsEC , Valdespino-HaydenZ , PollackMH .Double-blind randomized controlled study of the efficacy, safety and tolerability of eszopiclone vs placebo for the treatment of patients with post-traumatic stress disorder and insomnia. World Journal of Psychiatry2020;10(3):21-8. [DOI: 10.5498/wjp.v10.i3.21]">Dowd 2020</a>). </p> <p>There was also no evidence of a benefit of eszopiclone compared to placebo for the reduction in depression symptoms on the MADRS (SMD −2.67 points, 95% CI −12.68 to 7.34; 1 trial, 16 participants; see <a href="./references#CD002795-fig-0047" title="">Analysis 9.3</a>; <a href="./references#CD002795-bbs2-0022" title="DowdSM , ZaltaAK , BurgessHJ , AdkinsEC , Valdespino-HaydenZ , PollackMH .Double-blind randomized controlled study of the efficacy, safety and tolerability of eszopiclone vs placebo for the treatment of patients with post-traumatic stress disorder and insomnia. World Journal of Psychiatry2020;10(3):21-8. [DOI: 10.5498/wjp.v10.i3.21]">Dowd 2020</a>). </p> <p>We found no evidence of a difference for dropouts due to any cause for the eszopiclone (46%) and placebo (25%) group, even though dropouts were higher in the medication arm (see <a href="./references#CD002795-fig-0048" title="">Analysis 9.4</a>; <a href="./references#CD002795-bbs2-0022" title="DowdSM , ZaltaAK , BurgessHJ , AdkinsEC , Valdespino-HaydenZ , PollackMH .Double-blind randomized controlled study of the efficacy, safety and tolerability of eszopiclone vs placebo for the treatment of patients with post-traumatic stress disorder and insomnia. World Journal of Psychiatry2020;10(3):21-8. [DOI: 10.5498/wjp.v10.i3.21]">Dowd 2020</a>). </p> </section> </section> <section id="CD002795-sec-0085"> <h4 class="title">Comparison 10: MAOIs versus placebo</h4> <section id="CD002795-sec-0086"> <h5 class="title">Primary outcome measures</h5> <p>We found no studies that looked at the number of participants who responded to phenelzine versus placebo. </p> <p>More participants dropped out from the placebo group (17%) compared to the phenelzine group (5%) due to treatment‐emergent side effects, although we found no evidence of a harm in the dropout rates (see <a href="./references#CD002795-fig-0049" title="">Analysis 10.1</a>; <a href="./references#CD002795-bbs2-0032" title="KostenTR , FrankJB , DanE , McDougleCJ , Giller EL Jr.Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease1991;179(6):366–70. ">Kosten 1991</a>). This outcome was based was on low‐certainty evidence. </p> </section> <section id="CD002795-sec-0087"> <h5 class="title">Secondary outcome measures</h5> <p>There was evidence of a benefit of the MAOI phenelzine compared to placebo for reducing total PTSD symptoms on the IES (SMD −1.06 points, 95% CI −1.75 to −0.36; see <a href="./references#CD002795-fig-0050" title="">Analysis 10.2</a>) for 1 trial with 37 participants (<a href="./references#CD002795-bbs2-0032" title="KostenTR , FrankJB , DanE , McDougleCJ , Giller EL Jr.Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease1991;179(6):366–70. ">Kosten 1991</a>). This benefit was also apparent for the re‐experiencing/intrusion subscale (SMD −1.07 points, 95% CI −1.77 to −0.38; 1 trial, 37 participants; see <a href="./references#CD002795-fig-0050" title="">Analysis 10.2</a>; <a href="./references#CD002795-bbs2-0032" title="KostenTR , FrankJB , DanE , McDougleCJ , Giller EL Jr.Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease1991;179(6):366–70. ">Kosten 1991</a>) and the avoidance/numbing subscale (SMD −0.81 points, 95% CI −1.49 to −0.14; 1 trial, 37 participants; see <a href="./references#CD002795-fig-0050" title="">Analysis 10.2</a>; <a href="./references#CD002795-bbs2-0032" title="KostenTR , FrankJB , DanE , McDougleCJ , Giller EL Jr.Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease1991;179(6):366–70. ">Kosten 1991</a>) on the IES. </p> <p>There was no evidence of a benefit of phenelzine compared to placebo on the reduction in depression symptoms on the HAM‐D (MD −2.80 points, 95% CI −7.15 to 1.55; 1 trial, 37 participants; see <a href="./references#CD002795-fig-0051" title="">Analysis 10.3</a>). There was evidence for the reduction in anxiety symptoms on the Covi Anxiety Scale (SMD −0.67 points, 95% CI −1.34 to −0.01; 1 trial, 37 participants; see <a href="./references#CD002795-fig-0052" title="">Analysis 10.4</a>; <a href="./references#CD002795-bbs2-0032" title="KostenTR , FrankJB , DanE , McDougleCJ , Giller EL Jr.Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease1991;179(6):366–70. ">Kosten 1991</a>), however, based on a marginally significant effect (P = 0.05). </p> <p>We found no evidence of a difference for dropouts due to any cause for the phenelzine (21%) and placebo (11%) groups (see <a href="./references#CD002795-fig-0053" title="">Analysis 10.5</a>; <a href="./references#CD002795-bbs2-0032" title="KostenTR , FrankJB , DanE , McDougleCJ , Giller EL Jr.Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease1991;179(6):366–70. ">Kosten 1991</a>). </p> </section> </section> <section id="CD002795-sec-0088"> <h4 class="title">Comparison 11: NaSSAs versus placebo</h4> <section id="CD002795-sec-0089"> <h5 class="title">Primary outcome measures</h5> <p>There was evidence of a benefit of mirtazapine in improving PTSD symptoms compared to placebo (RR 0.45, 95% CI 0.22 to 0.94; 1 trial, 26 participants (<a href="./references#CD002795-bbs2-0014" title="DavidsonJR , WeislerRH , ButterfieldMI , CasatCD , ConnorKM , BarnettS , et al.Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biological Psychiatry2003;53(2):188-91. ">Davidson 2003</a>); see <a href="./references#CD002795-fig-0054" title="">Analysis 11.1</a>). This was based on low‐certainty evidence. </p> <p>There was no evidence of a harm in the number of participants who withdrew due to treatment‐emergent side effects for the mirtazapine (18%) and placebo groups (5%) (RR 0.87, 95% CI 0.68 to 1.11; 1 trial, 36 participants; see <a href="./references#CD002795-fig-0055" title="">Analysis 11.2</a>; <a href="./references#CD002795-bbs2-0014" title="DavidsonJR , WeislerRH , ButterfieldMI , CasatCD , ConnorKM , BarnettS , et al.Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biological Psychiatry2003;53(2):188-91. ">Davidson 2003</a>), based on moderate‐certainty evidence. </p> </section> <section id="CD002795-sec-0090"> <h5 class="title">Secondary outcome measures</h5> <p>There was no evidence of beneficial effect of mirtazapine for reducing PTSD symptoms on the CAPS total (MD −3.20 points, 95% CI −14.74 to 8.34; 1 trial, 61 participants; see <a href="./references#CD002795-fig-0056" title="">Analysis 11.3</a>; <a href="./references#CD002795-bbs2-0021" title="DavisLL , PilkintonP , LinC , ParkerP , EstesS , BartolucciA .A randomized, placebo-controlled trial of mirtazapine for the treatment of posttraumatic stress disorder in v eterans. Journal of Clinical Psychiatry2020;81(6):e1-8. [DOI: 10.4088/JCP.20m13267]">Davis 2020</a>), or on the re‐experiencing/intrusion subscale (MD −2.50 points, 95% CI −6.32 to 1.32; see <a href="./references#CD002795-fig-0056" title="">Analysis 11.3</a>), on avoidance/numbing subscale (MD −0.50 points, 95% CI −6.22 to 5.22; see <a href="./references#CD002795-fig-0056" title="">Analysis 11.3</a>), or hyperarousal subscale (MD −0.20 points, 95% CI −3.51 to 3.11; see <a href="./references#CD002795-fig-0056" title="">Analysis 11.3</a>) on the CAPS for reducing PTSD symptoms. Similarly, we found no evidence of a benefit of an effect for reducing PTSD symptoms on the self‐rated DTS (SMD −0.31 points, 95% CI −1.02 to 0.41; 2 trials, 87 participants; see <a href="./references#CD002795-fig-0058" title="">Analysis 11.5</a>; <a href="./references#CD002795-bbs2-0014" title="DavidsonJR , WeislerRH , ButterfieldMI , CasatCD , ConnorKM , BarnettS , et al.Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biological Psychiatry2003;53(2):188-91. ">Davidson 2003</a>; <a href="./references#CD002795-bbs2-0021" title="DavisLL , PilkintonP , LinC , ParkerP , EstesS , BartolucciA .A randomized, placebo-controlled trial of mirtazapine for the treatment of posttraumatic stress disorder in v eterans. Journal of Clinical Psychiatry2020;81(6):e1-8. [DOI: 10.4088/JCP.20m13267]">Davis 2020</a>). We also detected moderate heterogeneity on the self‐rated DTS measures (Chi<sup>2</sup> = 2.26, df = 1 (P = 0.13); I<sup>2</sup> = 56%). There was, however, evidence of a benefit of mirtazapine for reducing PTSD symptoms on the SPRINT and CGI‐S (SMD −0.43 points, 95% CI −0.87 to −0.00; 2 trials, 87 participants; see <a href="./references#CD002795-fig-0057" title="">Analysis 11.4</a>; <a href="./references#CD002795-bbs2-0014" title="DavidsonJR , WeislerRH , ButterfieldMI , CasatCD , ConnorKM , BarnettS , et al.Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biological Psychiatry2003;53(2):188-91. ">Davidson 2003</a>; <a href="./references#CD002795-bbs2-0021" title="DavisLL , PilkintonP , LinC , ParkerP , EstesS , BartolucciA .A randomized, placebo-controlled trial of mirtazapine for the treatment of posttraumatic stress disorder in v eterans. Journal of Clinical Psychiatry2020;81(6):e1-8. [DOI: 10.4088/JCP.20m13267]">Davis 2020</a>). </p> <p>There was no evidence of a benefit of mirtazapine compared to placebo for the reduction of depression symptoms on the HADS‐D and MADRS (SMD −0.26 points, 95% CI −1.39 to 0.88; 2 trials, 87 participants; see <a href="./references#CD002795-fig-0059" title="">Analysis 11.6</a>; <a href="./references#CD002795-bbs2-0014" title="DavidsonJR , WeislerRH , ButterfieldMI , CasatCD , ConnorKM , BarnettS , et al.Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biological Psychiatry2003;53(2):188-91. ">Davidson 2003</a>; <a href="./references#CD002795-bbs2-0021" title="DavisLL , PilkintonP , LinC , ParkerP , EstesS , BartolucciA .A randomized, placebo-controlled trial of mirtazapine for the treatment of posttraumatic stress disorder in v eterans. Journal of Clinical Psychiatry2020;81(6):e1-8. [DOI: 10.4088/JCP.20m13267]">Davis 2020</a>). There was evidence of a benefit of mirtazapine for reducing anxiety symptoms on the HADS‐A scale (SMD −0.88 points, 95% CI −1.77 to −0.00; 1 trial, 25 participants; see <a href="./references#CD002795-fig-0060" title="">Analysis 11.7</a>; <a href="./references#CD002795-bbs2-0014" title="DavidsonJR , WeislerRH , ButterfieldMI , CasatCD , ConnorKM , BarnettS , et al.Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biological Psychiatry2003;53(2):188-91. ">Davidson 2003</a>), however, based on a marginally significant effect (P = 0.05). </p> <p>There was no evidence of a difference in the number of participants who withdrew due to any cause for the mirtazapine (17%) and placebo (19%) groups (see <a href="./references#CD002795-fig-0061" title="">Analysis 11.8</a>; <a href="./references#CD002795-bbs2-0014" title="DavidsonJR , WeislerRH , ButterfieldMI , CasatCD , ConnorKM , BarnettS , et al.Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biological Psychiatry2003;53(2):188-91. ">Davidson 2003</a>; <a href="./references#CD002795-bbs2-0021" title="DavisLL , PilkintonP , LinC , ParkerP , EstesS , BartolucciA .A randomized, placebo-controlled trial of mirtazapine for the treatment of posttraumatic stress disorder in v eterans. Journal of Clinical Psychiatry2020;81(6):e1-8. [DOI: 10.4088/JCP.20m13267]">Davis 2020</a>; <a href="./references#CD002795-bbs2-0008" title="ChungMY , MinKH , JunYJ , KimSS , KimWC , JunEM .Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Human Psychopharmacology2004;19(7):489–94. [DOI: 10.1002/hup.615]">Chung 2004</a>). </p> </section> </section> <section id="CD002795-sec-0091"> <h4 class="title">Comparison 12: NK‐1 receptor antagonists versus placebo</h4> <section id="CD002795-sec-0092"> <h5 class="title">Primary outcome measures</h5> <p>We found no studies that looked at the number of participants who responded to orvepitant versus placebo. </p> <p>We found no studies that looked at the number of participants who dropped out due to treatment‐emergent side effects. </p> </section> <section id="CD002795-sec-0093"> <h5 class="title">Secondary outcome measures</h5> <p>We found no studies that looked at most secondary outcomes measures of orvepitant compared to placebo, but the proportion of dropouts was high in participants receiving orvepitant (78%) and placebo (65%), but no evidence of a difference was found (RR 0.58, 95% CI 0.32 to 1.04; 1 trial, 129 participants; see <a href="./references#CD002795-fig-0062" title="">Analysis 12.1</a>; <a href="./references#CD002795-bbs2-0043" title="NCT01000493.Orvepitant (GW823296) in adult Post Traumatic Stress Disorder. clinicaltrials.gov/ct2/show/NCT01000493 (first received 23 October 2009). ">NCT01000493</a>). </p> </section> </section> <section id="CD002795-sec-0094"> <h4 class="title">Comparison 13: RIMAs versus placebo</h4> <section id="CD002795-sec-0095"> <h5 class="title">Primary outcome measures</h5> <p>There was no evidence of a benefit of brofaromine on treatment efficacy in participants with PTSD compared to placebo (RR 0.80, 95% CI 0.44 to 1.44; 2 trials, 178 participants; see <a href="./references#CD002795-fig-0063" title="">Analysis 13.1</a>; <a href="./references#CD002795-bbs2-0002" title="BakerDG , DiamondBI , GilletteG , HamnerM , KatzelnickD , KellerT , et al.A double-blind randomized placebo-controlled multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology1995;122(4):386-9. ConnorKM , HidalgoRB , CrockettB , MalikM , KatzRJ , DavidsonJR .Predictors of treatment response in patients with posttraumatic stress disorder. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2001;25(2):337-45. ">Baker 1995</a>; <a href="./references#CD002795-bbs2-0031" title="ConnorKM , HidalgoRB , CrockettB , MalikM , KatzRJ , DavidsonJR .Predictors of treatment response in patients with posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2001;25(2):337–45. KatzRJ , LottMH , ArbusP , CrocqL , HerlobsenP , LingjaerdeO , et al.Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety1994;1(4):169–74. [DOI: https://doi.org/10.1002/anxi.3070010404 ]">Katz 1994</a>). We noted moderate heterogeneity for this outcome (Chi<sup>2</sup> = 2.33, df = 1 (P = 0.13); I<sup>2</sup> = 57%). </p> <p>There was also no evidence of a harm in the number of participants who withdrew due to treatment‐emergent side effects for the brofaromine group (5%) compared to the placebo group (2%) (see <a href="./references#CD002795-fig-0064" title="">Analysis 13.2</a>; <a href="./references#CD002795-bbs2-0002" title="BakerDG , DiamondBI , GilletteG , HamnerM , KatzelnickD , KellerT , et al.A double-blind randomized placebo-controlled multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology1995;122(4):386-9. ConnorKM , HidalgoRB , CrockettB , MalikM , KatzRJ , DavidsonJR .Predictors of treatment response in patients with posttraumatic stress disorder. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2001;25(2):337-45. ">Baker 1995</a>; <a href="./references#CD002795-bbs2-0031" title="ConnorKM , HidalgoRB , CrockettB , MalikM , KatzRJ , DavidsonJR .Predictors of treatment response in patients with posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2001;25(2):337–45. KatzRJ , LottMH , ArbusP , CrocqL , HerlobsenP , LingjaerdeO , et al.Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety1994;1(4):169–74. [DOI: https://doi.org/10.1002/anxi.3070010404 ]">Katz 1994</a>). </p> </section> <section id="CD002795-sec-0096"> <h5 class="title">Secondary outcome measures</h5> <p>There was no evidence of a benefit of a reduction in PTSD symptoms following treatment with brofaromine compared to placebo for CAPS total (MD −5.06 points, 95% CI −15.93 to 5.81, 2 trials, 178 participants; see <a href="./references#CD002795-fig-0065" title="">Analysis 13.3</a>; <a href="./references#CD002795-bbs2-0002" title="BakerDG , DiamondBI , GilletteG , HamnerM , KatzelnickD , KellerT , et al.A double-blind randomized placebo-controlled multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology1995;122(4):386-9. ConnorKM , HidalgoRB , CrockettB , MalikM , KatzRJ , DavidsonJR .Predictors of treatment response in patients with posttraumatic stress disorder. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2001;25(2):337-45. ">Baker 1995</a>; <a href="./references#CD002795-bbs2-0031" title="ConnorKM , HidalgoRB , CrockettB , MalikM , KatzRJ , DavidsonJR .Predictors of treatment response in patients with posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2001;25(2):337–45. KatzRJ , LottMH , ArbusP , CrocqL , HerlobsenP , LingjaerdeO , et al.Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety1994;1(4):169–74. [DOI: https://doi.org/10.1002/anxi.3070010404 ]">Katz 1994</a>). </p> <p>There was also no evidence of a difference for the number of participants who withdrew due to any cause from the brofaromine (30%) and placebo groups (29%) (see <a href="./references#CD002795-fig-0066" title="">Analysis 13.4</a>; <a href="./references#CD002795-bbs2-0031" title="ConnorKM , HidalgoRB , CrockettB , MalikM , KatzRJ , DavidsonJR .Predictors of treatment response in patients with posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2001;25(2):337–45. KatzRJ , LottMH , ArbusP , CrocqL , HerlobsenP , LingjaerdeO , et al.Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety1994;1(4):169–74. [DOI: https://doi.org/10.1002/anxi.3070010404 ]">Katz 1994</a>). </p> </section> </section> <section id="CD002795-sec-0097"> <h4 class="title">Comparison 14: SARIs versus placebo</h4> <section id="CD002795-sec-0098"> <h5 class="title">Primary outcome measures</h5> <p>We found no studies that looked at the number of participants who responded to nefazodone versus placebo. </p> <p>More participants dropped out of the nefazodone group due to treatment‐emergent side effects (19%) compared to placebo group (7%), but no evidence of a harm in dropout rates was observed (<a href="./references#CD002795-fig-0067" title="">Analysis 14.1</a>; <a href="./references#CD002795-bbs2-0019" title="DavisLL , AmbroseS , EnglishB , DaforeME , FarleyJ , Bartolucci Al, et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder. In: 20th Annual Meeting, International Society for Traumatic Stress Studies, December 6 - 9, New Orleans, LA. 2001. DavisLL , JewellME , AmbroseS , FarleyJ , EnglishB , BartolucciA , et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. Journal of Clinical Psychopharmacology2004;24(3):291-7. [DOI: 10.1097/01.jcp.0000125685.82219.1a]">Davis 2004</a>). </p> </section> <section id="CD002795-sec-0099"> <h5 class="title">Secondary outcome measures</h5> <p>The review found no evidence of a benefit of nefazodone on total CAPS symptom severity (MD −5.60 points, 95% CI −21.26 to 10.06; 1 trial, 41 participants; see <a href="./references#CD002795-fig-0068" title="">Analysis 14.2</a>; <a href="./references#CD002795-bbs2-0019" title="DavisLL , AmbroseS , EnglishB , DaforeME , FarleyJ , Bartolucci Al, et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder. In: 20th Annual Meeting, International Society for Traumatic Stress Studies, December 6 - 9, New Orleans, LA. 2001. DavisLL , JewellME , AmbroseS , FarleyJ , EnglishB , BartolucciA , et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. Journal of Clinical Psychopharmacology2004;24(3):291-7. [DOI: 10.1097/01.jcp.0000125685.82219.1a]">Davis 2004</a>), as well as for the re‐experiencing/intrusion subscale (MD −1.30 points, 95% CI −6.80 to 4.20; 1 trial, 41 participants; see <a href="./references#CD002795-fig-0068" title="">Analysis 14.2</a>; <a href="./references#CD002795-bbs2-0019" title="DavisLL , AmbroseS , EnglishB , DaforeME , FarleyJ , Bartolucci Al, et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder. In: 20th Annual Meeting, International Society for Traumatic Stress Studies, December 6 - 9, New Orleans, LA. 2001. DavisLL , JewellME , AmbroseS , FarleyJ , EnglishB , BartolucciA , et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. Journal of Clinical Psychopharmacology2004;24(3):291-7. [DOI: 10.1097/01.jcp.0000125685.82219.1a]">Davis 2004</a>), avoidance/numbing subscale (MD −1.60 points, 95% CI −9.23 to 6.03; 1 trial, 41 participants; see <a href="./references#CD002795-fig-0068" title="">Analysis 14.2</a>; <a href="./references#CD002795-bbs2-0019" title="DavisLL , AmbroseS , EnglishB , DaforeME , FarleyJ , Bartolucci Al, et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder. In: 20th Annual Meeting, International Society for Traumatic Stress Studies, December 6 - 9, New Orleans, LA. 2001. DavisLL , JewellME , AmbroseS , FarleyJ , EnglishB , BartolucciA , et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. Journal of Clinical Psychopharmacology2004;24(3):291-7. [DOI: 10.1097/01.jcp.0000125685.82219.1a]">Davis 2004</a>), or hyperarousal subscale (MD −2.90 points, 95% CI −8.40 to 2.60; 1 trial, 41 participants; see <a href="./references#CD002795-fig-0068" title="">Analysis 14.2</a>; <a href="./references#CD002795-bbs2-0019" title="DavisLL , AmbroseS , EnglishB , DaforeME , FarleyJ , Bartolucci Al, et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder. In: 20th Annual Meeting, International Society for Traumatic Stress Studies, December 6 - 9, New Orleans, LA. 2001. DavisLL , JewellME , AmbroseS , FarleyJ , EnglishB , BartolucciA , et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. Journal of Clinical Psychopharmacology2004;24(3):291-7. [DOI: 10.1097/01.jcp.0000125685.82219.1a]">Davis 2004</a>) on the CAPS. </p> <p>More participants dropped out of the nefazodone group due to any cause (32%) compared to the placebo group (13%) (see <a href="./references#CD002795-fig-0069" title="">Analysis 14.3</a>; <a href="./references#CD002795-bbs2-0019" title="DavisLL , AmbroseS , EnglishB , DaforeME , FarleyJ , Bartolucci Al, et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder. In: 20th Annual Meeting, International Society for Traumatic Stress Studies, December 6 - 9, New Orleans, LA. 2001. DavisLL , JewellME , AmbroseS , FarleyJ , EnglishB , BartolucciA , et al.A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. Journal of Clinical Psychopharmacology2004;24(3):291-7. [DOI: 10.1097/01.jcp.0000125685.82219.1a]">Davis 2004</a>; <a href="./references#CD002795-bbs2-0053" title="SayginMZ , SungurMZ , SabolEU , CetinkayaP .Nefazodone versus sertraline in treatment of posttraumatic stress disorder. Bulletin of Clinical Psychopharmacology2002;12(1):1-5. ">Saygin 2002</a>). </p> </section> </section> <section id="CD002795-sec-0100"> <h4 class="title">Comparison 15: SNRIs versus placebo</h4> <section id="CD002795-sec-0101"> <h5 class="title">Primary outcome measures</h5> <p>We found no studies that looked at the number of participants who responded to venlafaxine versus placebo. </p> <p>There was no evidence of a harm for the number of participants who withdrew due to treatment‐emergent side effects for the venlafaxine (4%) versus placebo (3%) groups (see <a href="./references#CD002795-fig-0070" title="">Analysis 15.1</a>; <a href="./references#CD002795-bbs2-0016" title="DavidsonJ , BaldwinD , SteinDJ , KuperE , BenattiaI , AhmedS , et al.Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Archives of General Psychiatry2006;63(10):1158-65. ">Davidson 2006a</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>), based on very low‐certainty evidence. The smaller of the two studies contributed to this. We also noted considerable heterogeneity, however, for this outcome (Chi<sup>2</sup> = 12.98, df = 1 (P &lt; 0.001); I<sup>2</sup> = 92%). </p> </section> <section id="CD002795-sec-0102"> <h5 class="title">Secondary outcome measures</h5> <p>There was evidence of a benefit of the SNRI venlafaxine compared to placebo for reducing total PTSD symptoms on the CAPS total (MD −8.11 points, 95% CI −12.29 to −3.92; 2 trials, 687 participants; see <a href="./references#CD002795-fig-0071" title="">Analysis 15.2</a>; <a href="./references#CD002795-bbs2-0016" title="DavidsonJ , BaldwinD , SteinDJ , KuperE , BenattiaI , AhmedS , et al.Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Archives of General Psychiatry2006;63(10):1158-65. ">Davidson 2006a</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>), as well as for the re‐experiencing/intrusion subscale (MD −1.95 points, 95% CI −3.36 to −0.54; 2 trials, 687 participants; see <a href="./references#CD002795-fig-0071" title="">Analysis 15.2</a>; <a href="./references#CD002795-bbs2-0016" title="DavidsonJ , BaldwinD , SteinDJ , KuperE , BenattiaI , AhmedS , et al.Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Archives of General Psychiatry2006;63(10):1158-65. ">Davidson 2006a</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>), avoidance/numbing subscale (MD −3.42 points, 95% CI −5.23 to −1.61; 2 trials, 687 participants; see <a href="./references#CD002795-fig-0071" title="">Analysis 15.2</a>; <a href="./references#CD002795-bbs2-0016" title="DavidsonJ , BaldwinD , SteinDJ , KuperE , BenattiaI , AhmedS , et al.Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Archives of General Psychiatry2006;63(10):1158-65. ">Davidson 2006a</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>), or hyperarousal subscale (MD −2.29 points, 95% CI −3.67 to −0.91; 2 trials, 687 participants; see <a href="./references#CD002795-fig-0071" title="">Analysis 15.2</a>; <a href="./references#CD002795-bbs2-0016" title="DavidsonJ , BaldwinD , SteinDJ , KuperE , BenattiaI , AhmedS , et al.Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Archives of General Psychiatry2006;63(10):1158-65. ">Davidson 2006a</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>) of the CAPS. We also found evidence of a benefit of venlafaxine compared to placebo for reducing PTSD symptoms on the CGI‐S (SMD −0.31 points, 95% CI −0.46 to −0.16; 2 trials, 687 participants; see <a href="./references#CD002795-fig-0072" title="">Analysis 15.3</a>; <a href="./references#CD002795-bbs2-0016" title="DavidsonJ , BaldwinD , SteinDJ , KuperE , BenattiaI , AhmedS , et al.Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Archives of General Psychiatry2006;63(10):1158-65. ">Davidson 2006a</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>). Moreover, we found evidence of a benefit of venlafaxine on total DTS symptom severity (SMD −0.26 points, 95% CI −0.47 to −0.05; 1 trial, 358 participants; see <a href="./references#CD002795-fig-0073" title="">Analysis 15.4</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>), as well as for the re‐experiencing/intrusion subscale (MD −0.23 points, 95% CI −0.44 to −0.02; 1 trial, 358 participants; see <a href="./references#CD002795-fig-0073" title="">Analysis 15.4</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>), avoidance/numbing subscale (MD −0.23 points, 95% CI −0.44 to −0.02; 1 trial, 358 participants; see <a href="./references#CD002795-fig-0073" title="">Analysis 15.4</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>), or hyperarousal subscale (MD −0.24 points, 95% CI −0.45 to −0.03; 1 trial, 358 participants; see <a href="./references#CD002795-fig-0073" title="">Analysis 15.4</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>) on the DTS. </p> <p>Furthermore, there was no evidence of a benefit of venlafaxine compared to placebo on the reduction in depression symptoms on the HAM‐D (SMD −0.20 points, 95% CI −0.42 to 0.02; 1 trial, 329 participants; see <a href="./references#CD002795-fig-0074" title="">Analysis 15.5</a>; <a href="./references#CD002795-bbs2-0016" title="DavidsonJ , BaldwinD , SteinDJ , KuperE , BenattiaI , AhmedS , et al.Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Archives of General Psychiatry2006;63(10):1158-65. ">Davidson 2006a</a>). There was, however, evidence of a benefit of venlafaxine on the reduction in functional disability measured with the SDS (MD −2.01 points, 95% CI −3.30 to −0.72; 2 trials, 687 participants; <a href="./references#CD002795-fig-0075" title="">Analysis 15.6</a>; <a href="./references#CD002795-bbs2-0016" title="DavidsonJ , BaldwinD , SteinDJ , KuperE , BenattiaI , AhmedS , et al.Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Archives of General Psychiatry2006;63(10):1158-65. ">Davidson 2006a</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>)) . </p> <p>We found no evidence of a difference in the number of participants who withdrew due to any cause (see <a href="./references#CD002795-fig-0076" title="">Analysis 15.7</a>; <a href="./references#CD002795-bbs2-0016" title="DavidsonJ , BaldwinD , SteinDJ , KuperE , BenattiaI , AhmedS , et al.Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Archives of General Psychiatry2006;63(10):1158-65. ">Davidson 2006a</a>), which is confirmed by the similar dropout rates in both groups (30% versus 33%). </p> </section> </section> <section id="CD002795-sec-0103"> <h4 class="title">Comparison 16: SSRIs versus placebo</h4> <section id="CD002795-sec-0104"> <h5 class="title">Primary outcome measures</h5> <p>There was evidence of a benefit of fluoxetine, paroxetine and sertraline compared to placebo in participants with PTSD (RR 0.66, 95% CI 0.59 to 0.74; 8 trials, 1078 participants; see <a href="./references#CD002795-fig-0077" title="">Analysis 16.1</a>; <a href="./references#CD002795-bbs2-0004" title="BradyK , PearlsteinT , AsnisGM , BakerD , RothbaumB , SikesCR , et al.Efficacy and safety of sertraline treatment of posttraumatic stress disorder. Archives of General Psychiatry2000;283(14):1837-44. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry2001;158(12):1974-81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. GaffneyM .Factor analysis of treatment response in posttraumatic stress disorder. Journal of Traumatic Stress2003;16(1):77-80. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59-65. RapaportMH , FarfelG , ClaryCM .Quality of life improvement in PTSD with sertraline treatment: results of a multicenter, placebo-controlled trial. International Journal of Neuropsychopharmacology2000;3(Suppl 1):294. ">Brady 2000</a>; <a href="./references#CD002795-bbs2-0009" title="BarnettSD , TharwaniHM , HertzbergMA , SutherlandSM , ConnorKM , DavidsonJR .Tolerability of fluoxetine in posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2002;26(2):363-7. ConnorKM , SutherlandSM , TuplerLA , MalikML , DavidsonJR .Fluoxetine in post-traumatic stress disorder: randomized, double-blind study. British Journal of Psychiatry1999;175:17-22. MalikML , ConnorKM , SutherlandSM , SmithRD , DavisonRM , DavidsonJR .Quality-of-life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo- controlled trial of fluoxetine. Journal of Traumatic Stress1999;12(2):387-93. ">Connor 1999a</a>; <a href="./references#CD002795-bbs2-0029" title="HertzbergMA , FeldmanME , BeckhamJC , KudlerHS , DavidsonJR .Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Annals of Clinical Psychiatry2000;12(2):101-5. ">Hertzberg 2000</a>; <a href="./references#CD002795-bbs2-0034" title="Food and Drugs Administration (FDA).Paxil (paroxetine) [NDA 20-031/S-029 Paxil (Paroxetine hydrochloride) tablets; GlaxoSmithKline; Post-traumatic Stress Disorder]. www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf (accessed 26 November 2021). GlaxoSmithKline.A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Posttraumatic Stress Disorder (PTSD). GSK - clinical study register [www.gsk-clinicalstudyregister.com]:Study ID: PAR 29060 651 (BRL-02960). MarshallRD , BeebeKL , OldhamM , ZaninelliR .Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. American Journal of Psychiatry2001;158(12):1982-8. ">Marshall 2001</a>; <a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a>; <a href="./references#CD002795-bbs2-0046" title="PanahiY , MoghaddamBR , SahebkarA , NazariMA , BeiraghdarF , KaramiG , et al.A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder. Psychological Medicine2011;41(10):2159–66. [DOI: 10.1017/S0033291711000201]">Panahi 2011</a>; <a href="./references#CD002795-bbs2-0059" title="GlaxoSmithKline.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). GSK - Clinical Study Register [www.gsk-clinicalstudyregister.com]2000:Study ID:GSK 29060/648. TuckerP , ZaninelliR , YehudaR , RuggieroL , DillinghamK , PittsCD .Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry2001;62(11):860-8. ">Tucker 2001</a>; <a href="./references#CD002795-bbs2-0066" title="AmitalD , ZoharJ , KotlerM , BleichA , MiodovnikH , NevoA , et al.A placebo-controlled study of sertraline in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):269. AmitalD , ZoharJ , KotlerM , BleichA , MiodovnikH , NevoA , et al.A placebo-controlled trial pilot study of sertraline in PTSD. In: Annual Meeting of the American Psychiatric Association. American Psychiatric Association, 1999:157. ZoharJ , AmitalD , MiodownikC , KotlerM , BleichA , LaneRM .Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. Journal of Clinical Psychopharmacology2002;22(2):190-5. ">Zohar 2002</a>), based on moderate‐certainty evidence. Fluoxetine, paroxetine and sertraline therefore improved PTSD symptoms. We also noted evidence of a benefit for the number of participants who responded to treatment for the individual SSRI paroxetine (RR 0.64, 95% CI 0.55 to 0.74; 3 trials. 728 participants; see <a href="./references#CD002795-fig-0078" title="">Analysis 16.2</a>; <a href="./references#CD002795-bbs2-0034" title="Food and Drugs Administration (FDA).Paxil (paroxetine) [NDA 20-031/S-029 Paxil (Paroxetine hydrochloride) tablets; GlaxoSmithKline; Post-traumatic Stress Disorder]. www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf (accessed 26 November 2021). GlaxoSmithKline.A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Posttraumatic Stress Disorder (PTSD). GSK - clinical study register [www.gsk-clinicalstudyregister.com]:Study ID: PAR 29060 651 (BRL-02960). MarshallRD , BeebeKL , OldhamM , ZaninelliR .Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. American Journal of Psychiatry2001;158(12):1982-8. ">Marshall 2001</a>; <a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a>; <a href="./references#CD002795-bbs2-0059" title="GlaxoSmithKline.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). GSK - Clinical Study Register [www.gsk-clinicalstudyregister.com]2000:Study ID:GSK 29060/648. TuckerP , ZaninelliR , YehudaR , RuggieroL , DillinghamK , PittsCD .Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry2001;62(11):860-8. ">Tucker 2001</a>), for sertraline (RR 0.68, 95% CI 0.56 to 0.81; 3 trials, 285 participants; see <a href="./references#CD002795-fig-0078" title="">Analysis 16.2</a>; <a href="./references#CD002795-bbs2-0004" title="BradyK , PearlsteinT , AsnisGM , BakerD , RothbaumB , SikesCR , et al.Efficacy and safety of sertraline treatment of posttraumatic stress disorder. Archives of General Psychiatry2000;283(14):1837-44. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry2001;158(12):1974-81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. GaffneyM .Factor analysis of treatment response in posttraumatic stress disorder. Journal of Traumatic Stress2003;16(1):77-80. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59-65. RapaportMH , FarfelG , ClaryCM .Quality of life improvement in PTSD with sertraline treatment: results of a multicenter, placebo-controlled trial. International Journal of Neuropsychopharmacology2000;3(Suppl 1):294. ">Brady 2000</a>; <a href="./references#CD002795-bbs2-0046" title="PanahiY , MoghaddamBR , SahebkarA , NazariMA , BeiraghdarF , KaramiG , et al.A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder. Psychological Medicine2011;41(10):2159–66. [DOI: 10.1017/S0033291711000201]">Panahi 2011</a>; <a href="./references#CD002795-bbs2-0066" title="AmitalD , ZoharJ , KotlerM , BleichA , MiodovnikH , NevoA , et al.A placebo-controlled study of sertraline in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):269. AmitalD , ZoharJ , KotlerM , BleichA , MiodovnikH , NevoA , et al.A placebo-controlled trial pilot study of sertraline in PTSD. In: Annual Meeting of the American Psychiatric Association. American Psychiatric Association, 1999:157. ZoharJ , AmitalD , MiodownikC , KotlerM , BleichA , LaneRM .Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. Journal of Clinical Psychopharmacology2002;22(2):190-5. ">Zohar 2002</a>), but not for fluoxetine (RR 0.73, 95% CI 0.19 to 2.82; 2 trials, 65 participants; see <a href="./references#CD002795-fig-0078" title="">Analysis 16.2</a>; <a href="./references#CD002795-bbs2-0009" title="BarnettSD , TharwaniHM , HertzbergMA , SutherlandSM , ConnorKM , DavidsonJR .Tolerability of fluoxetine in posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2002;26(2):363-7. ConnorKM , SutherlandSM , TuplerLA , MalikML , DavidsonJR .Fluoxetine in post-traumatic stress disorder: randomized, double-blind study. British Journal of Psychiatry1999;175:17-22. MalikML , ConnorKM , SutherlandSM , SmithRD , DavisonRM , DavidsonJR .Quality-of-life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo- controlled trial of fluoxetine. Journal of Traumatic Stress1999;12(2):387-93. ">Connor 1999a</a>; <a href="./references#CD002795-bbs2-0029" title="HertzbergMA , FeldmanME , BeckhamJC , KudlerHS , DavidsonJR .Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Annals of Clinical Psychiatry2000;12(2):101-5. ">Hertzberg 2000</a>). The failure to detect a treatment effect for fluoxetine may reflect the small samples, and hence the low power of this comparison. </p> <p>The proportion of dropouts due to adverse events was higher amongst participants receiving the SSRIs fluoxetine, paroxetine and sertraline (9%) compared to placebo (7%) (see <a href="./references#CD002795-fig-0079" title="">Analysis 16.3</a>; <a href="./references#CD002795-bbs2-0004" title="BradyK , PearlsteinT , AsnisGM , BakerD , RothbaumB , SikesCR , et al.Efficacy and safety of sertraline treatment of posttraumatic stress disorder. Archives of General Psychiatry2000;283(14):1837-44. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry2001;158(12):1974-81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. GaffneyM .Factor analysis of treatment response in posttraumatic stress disorder. Journal of Traumatic Stress2003;16(1):77-80. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59-65. RapaportMH , FarfelG , ClaryCM .Quality of life improvement in PTSD with sertraline treatment: results of a multicenter, placebo-controlled trial. International Journal of Neuropsychopharmacology2000;3(Suppl 1):294. ">Brady 2000</a>; <a href="./references#CD002795-bbs2-0009" title="BarnettSD , TharwaniHM , HertzbergMA , SutherlandSM , ConnorKM , DavidsonJR .Tolerability of fluoxetine in posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2002;26(2):363-7. ConnorKM , SutherlandSM , TuplerLA , MalikML , DavidsonJR .Fluoxetine in post-traumatic stress disorder: randomized, double-blind study. British Journal of Psychiatry1999;175:17-22. MalikML , ConnorKM , SutherlandSM , SmithRD , DavisonRM , DavidsonJR .Quality-of-life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo- controlled trial of fluoxetine. Journal of Traumatic Stress1999;12(2):387-93. ">Connor 1999a</a>; <a href="./references#CD002795-bbs2-0012" title="DavidsonJ , LondborgP , PearlsteinT , RothbaumB , BradyK , FarfelG .Double-blind, randomized, 28-week continuation study of sertraline and placebo in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):292. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo controlled study. American Journal of Psychiatry2001;158(12):1974–81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. DavidsonJR , RothbaumBO , Van der KolkBA , SikesCR , FarfelGM .Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Archives of General Psychiatry2001;58(5):485-92. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59–65. ">Davidson 2001a</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>; <a href="./references#CD002795-bbs2-0026" title="GSK 29060 627.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). https://www.gsk-studyregister.com/en/trial-details/?id=29060/648. ">GSK 29060 627</a>; <a href="./references#CD002795-bbs2-0029" title="HertzbergMA , FeldmanME , BeckhamJC , KudlerHS , DavidsonJR .Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Annals of Clinical Psychiatry2000;12(2):101-5. ">Hertzberg 2000</a>; <a href="./references#CD002795-bbs2-0033" title="LiW , Ma Y-B, YangQ , LiBL , Meng Q-G, ZhangY .Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study. International Journal of Psychiatry in Clinical Practice2017;21(2):151-5. [DOI: 10.1080/13651501.2017.1291838]">Li 2017</a>; <a href="./references#CD002795-bbs2-0034" title="Food and Drugs Administration (FDA).Paxil (paroxetine) [NDA 20-031/S-029 Paxil (Paroxetine hydrochloride) tablets; GlaxoSmithKline; Post-traumatic Stress Disorder]. www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf (accessed 26 November 2021). GlaxoSmithKline.A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Posttraumatic Stress Disorder (PTSD). GSK - clinical study register [www.gsk-clinicalstudyregister.com]:Study ID: PAR 29060 651 (BRL-02960). MarshallRD , BeebeKL , OldhamM , ZaninelliR .Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. American Journal of Psychiatry2001;158(12):1982-8. ">Marshall 2001</a>; <a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a>; <a href="./references#CD002795-bbs2-0036" title="MartenyiF , BrownEB , ZhangH , PrakashA , KokeSC .Fluoxetine versus placebo in posttraumatic stress disorder. Journal of Clinical Psychiatry2002;63(3):199-206. ">Martenyi 2002a</a>; <a href="./references#CD002795-bbs2-0044" title="NCT01681849.Neural circuits in women with abuse and Posttraumatic Stress Disorder. clinicaltrials.gov/ct2/show/NCT01681849 (first received 10 September 2012). ">NCT01681849</a>; <a href="./references#CD002795-bbs2-0046" title="PanahiY , MoghaddamBR , SahebkarA , NazariMA , BeiraghdarF , KaramiG , et al.A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder. Psychological Medicine2011;41(10):2159–66. [DOI: 10.1017/S0033291711000201]">Panahi 2011</a>; <a href="./references#CD002795-bbs2-0059" title="GlaxoSmithKline.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). GSK - Clinical Study Register [www.gsk-clinicalstudyregister.com]2000:Study ID:GSK 29060/648. TuckerP , ZaninelliR , YehudaR , RuggieroL , DillinghamK , PittsCD .Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry2001;62(11):860-8. ">Tucker 2001</a>; <a href="./references#CD002795-bbs2-0066" title="AmitalD , ZoharJ , KotlerM , BleichA , MiodovnikH , NevoA , et al.A placebo-controlled study of sertraline in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):269. AmitalD , ZoharJ , KotlerM , BleichA , MiodovnikH , NevoA , et al.A placebo-controlled trial pilot study of sertraline in PTSD. In: Annual Meeting of the American Psychiatric Association. American Psychiatric Association, 1999:157. ZoharJ , AmitalD , MiodownikC , KotlerM , BleichA , LaneRM .Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. Journal of Clinical Psychopharmacology2002;22(2):190-5. ">Zohar 2002</a>), based on moderate‐certainty evidence. In addition, a difference in treatment‐emergent side effects was evident for the separate SSRI paroxetine (RR 1.55, 95% CI 1.05 to 2.29; 5 trials, 1101 participants; see <a href="./references#CD002795-fig-0080" title="">Analysis 16.4</a>; <a href="./references#CD002795-bbs2-0026" title="GSK 29060 627.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). https://www.gsk-studyregister.com/en/trial-details/?id=29060/648. ">GSK 29060 627</a>; <a href="./references#CD002795-bbs2-0034" title="Food and Drugs Administration (FDA).Paxil (paroxetine) [NDA 20-031/S-029 Paxil (Paroxetine hydrochloride) tablets; GlaxoSmithKline; Post-traumatic Stress Disorder]. www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf (accessed 26 November 2021). GlaxoSmithKline.A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Posttraumatic Stress Disorder (PTSD). GSK - clinical study register [www.gsk-clinicalstudyregister.com]:Study ID: PAR 29060 651 (BRL-02960). MarshallRD , BeebeKL , OldhamM , ZaninelliR .Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. American Journal of Psychiatry2001;158(12):1982-8. ">Marshall 2001</a>; <a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a>; <a href="./references#CD002795-bbs2-0044" title="NCT01681849.Neural circuits in women with abuse and Posttraumatic Stress Disorder. clinicaltrials.gov/ct2/show/NCT01681849 (first received 10 September 2012). ">NCT01681849</a>; <a href="./references#CD002795-bbs2-0059" title="GlaxoSmithKline.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). GSK - Clinical Study Register [www.gsk-clinicalstudyregister.com]2000:Study ID:GSK 29060/648. TuckerP , ZaninelliR , YehudaR , RuggieroL , DillinghamK , PittsCD .Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry2001;62(11):860-8. ">Tucker 2001</a>), but not for the SSRI fluoxetine (RR 0.86, 95% CI 0.25 to 2.96; 3 trials, 367 participants; see <a href="./references#CD002795-fig-0080" title="">Analysis 16.4</a>; <a href="./references#CD002795-bbs2-0009" title="BarnettSD , TharwaniHM , HertzbergMA , SutherlandSM , ConnorKM , DavidsonJR .Tolerability of fluoxetine in posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2002;26(2):363-7. ConnorKM , SutherlandSM , TuplerLA , MalikML , DavidsonJR .Fluoxetine in post-traumatic stress disorder: randomized, double-blind study. British Journal of Psychiatry1999;175:17-22. MalikML , ConnorKM , SutherlandSM , SmithRD , DavisonRM , DavidsonJR .Quality-of-life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo- controlled trial of fluoxetine. Journal of Traumatic Stress1999;12(2):387-93. ">Connor 1999a</a>; <a href="./references#CD002795-bbs2-0029" title="HertzbergMA , FeldmanME , BeckhamJC , KudlerHS , DavidsonJR .Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Annals of Clinical Psychiatry2000;12(2):101-5. ">Hertzberg 2000</a>; <a href="./references#CD002795-bbs2-0036" title="MartenyiF , BrownEB , ZhangH , PrakashA , KokeSC .Fluoxetine versus placebo in posttraumatic stress disorder. Journal of Clinical Psychiatry2002;63(3):199-206. ">Martenyi 2002a</a>) or for the SSRI sertraline (RR 1.34; 95% CI 0.87 to 2.05; 6 trials, 931 participants; see <a href="./references#CD002795-fig-0080" title="">Analysis 16.4</a>; <a href="./references#CD002795-bbs2-0004" title="BradyK , PearlsteinT , AsnisGM , BakerD , RothbaumB , SikesCR , et al.Efficacy and safety of sertraline treatment of posttraumatic stress disorder. Archives of General Psychiatry2000;283(14):1837-44. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry2001;158(12):1974-81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. GaffneyM .Factor analysis of treatment response in posttraumatic stress disorder. Journal of Traumatic Stress2003;16(1):77-80. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59-65. RapaportMH , FarfelG , ClaryCM .Quality of life improvement in PTSD with sertraline treatment: results of a multicenter, placebo-controlled trial. International Journal of Neuropsychopharmacology2000;3(Suppl 1):294. ">Brady 2000</a>; <a href="./references#CD002795-bbs2-0012" title="DavidsonJ , LondborgP , PearlsteinT , RothbaumB , BradyK , FarfelG .Double-blind, randomized, 28-week continuation study of sertraline and placebo in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):292. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo controlled study. American Journal of Psychiatry2001;158(12):1974–81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. DavidsonJR , RothbaumBO , Van der KolkBA , SikesCR , FarfelGM .Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Archives of General Psychiatry2001;58(5):485-92. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59–65. ">Davidson 2001a</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>; <a href="./references#CD002795-bbs2-0033" title="LiW , Ma Y-B, YangQ , LiBL , Meng Q-G, ZhangY .Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study. International Journal of Psychiatry in Clinical Practice2017;21(2):151-5. [DOI: 10.1080/13651501.2017.1291838]">Li 2017</a>; <a href="./references#CD002795-bbs2-0046" title="PanahiY , MoghaddamBR , SahebkarA , NazariMA , BeiraghdarF , KaramiG , et al.A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder. Psychological Medicine2011;41(10):2159–66. [DOI: 10.1017/S0033291711000201]">Panahi 2011</a>; <a href="./references#CD002795-bbs2-0066" title="AmitalD , ZoharJ , KotlerM , BleichA , MiodovnikH , NevoA , et al.A placebo-controlled study of sertraline in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):269. AmitalD , ZoharJ , KotlerM , BleichA , MiodovnikH , NevoA , et al.A placebo-controlled trial pilot study of sertraline in PTSD. In: Annual Meeting of the American Psychiatric Association. American Psychiatric Association, 1999:157. ZoharJ , AmitalD , MiodownikC , KotlerM , BleichA , LaneRM .Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. Journal of Clinical Psychopharmacology2002;22(2):190-5. ">Zohar 2002</a>). </p> </section> <section id="CD002795-sec-0105"> <h5 class="title">Secondary outcomes measures</h5> <p>There was evidence of a benefit of the SSRIs compared to placebo for reducing total PTSD symptoms on the CAPS (MD −4.91 points, 95% CI −7.48 to −2.34, 15 trials, 2615 participants; see <a href="./references#CD002795-fig-0081" title="">Analysis 16.5</a>; <a href="./references#CD002795-bbs2-0004" title="BradyK , PearlsteinT , AsnisGM , BakerD , RothbaumB , SikesCR , et al.Efficacy and safety of sertraline treatment of posttraumatic stress disorder. Archives of General Psychiatry2000;283(14):1837-44. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry2001;158(12):1974-81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. GaffneyM .Factor analysis of treatment response in posttraumatic stress disorder. Journal of Traumatic Stress2003;16(1):77-80. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59-65. RapaportMH , FarfelG , ClaryCM .Quality of life improvement in PTSD with sertraline treatment: results of a multicenter, placebo-controlled trial. International Journal of Neuropsychopharmacology2000;3(Suppl 1):294. ">Brady 2000</a>; <a href="./references#CD002795-bbs2-0012" title="DavidsonJ , LondborgP , PearlsteinT , RothbaumB , BradyK , FarfelG .Double-blind, randomized, 28-week continuation study of sertraline and placebo in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):292. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo controlled study. American Journal of Psychiatry2001;158(12):1974–81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. DavidsonJR , RothbaumBO , Van der KolkBA , SikesCR , FarfelGM .Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Archives of General Psychiatry2001;58(5):485-92. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59–65. ">Davidson 2001a</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>; <a href="./references#CD002795-bbs2-0026" title="GSK 29060 627.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). https://www.gsk-studyregister.com/en/trial-details/?id=29060/648. ">GSK 29060 627</a>; <a href="./references#CD002795-bbs2-0034" title="Food and Drugs Administration (FDA).Paxil (paroxetine) [NDA 20-031/S-029 Paxil (Paroxetine hydrochloride) tablets; GlaxoSmithKline; Post-traumatic Stress Disorder]. www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf (accessed 26 November 2021). GlaxoSmithKline.A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Posttraumatic Stress Disorder (PTSD). GSK - clinical study register [www.gsk-clinicalstudyregister.com]:Study ID: PAR 29060 651 (BRL-02960). MarshallRD , BeebeKL , OldhamM , ZaninelliR .Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. American Journal of Psychiatry2001;158(12):1982-8. ">Marshall 2001</a>; <a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a>; <a href="./references#CD002795-bbs2-0044" title="NCT01681849.Neural circuits in women with abuse and Posttraumatic Stress Disorder. clinicaltrials.gov/ct2/show/NCT01681849 (first received 10 September 2012). ">NCT01681849</a>; <a href="./references#CD002795-bbs2-0047" title="Food and Drug Administration (FDA).Review and evaluation of clinical data [Pfizer NDA application: Sertraline (Zoloft) for PTSD]. www.accessdata.fda.gov/drugsatfda_docs/nda/99/19-839S026_Zoloft_Clinr_P1.pdf1999;(accessed 28 November 2021). Pfizer.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. ">Pfizer588</a>; <a href="./references#CD002795-bbs2-0048" title="Food and Drug Adminstration (FDA).Review and evaluation of clinical data [Pfizer NDA application: Sertraline (Zoloft) for PTSD]. www.accessdata.fda.gov/drugsatfda_docs/nda/99/19-839S026_Zoloft_Clinr_P1.pdf1999;(accessed 28 November 2021). FriedmanMJ , MarmarCR , BakerDG , SikesCR , FarfelGM .Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. Journal of Clinical Psychiatry2007;68(5):711-20. Pfizer.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. ">Pfizer589</a>; <a href="./references#CD002795-bbs2-0055" title="Food and Drug Administration (FDA).NDA 20-031/S-029 Paxil (paroxetine hydrochloride) tablets; GlaxoSmithKline; Post-traumatic Stress Disorder. www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf;(accessed 28 November 2021). GlaxoSmithKline.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). GSK - clinical study register [www.gsk-clinicalstudyregister.com]:Study ID: 29060/627. SmithKline Beecham.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. SteinDJ , DavidsonJ , SeedatS , BeebeK .Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies. Expert Opinion on Pharmacotherapy2003;4(10):1829-38. ">SKB627</a>; <a href="./references#CD002795-bbs2-0056" title="SmithKline Beecham.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. ">SKB650</a>; <a href="./references#CD002795-bbs2-0059" title="GlaxoSmithKline.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). GSK - Clinical Study Register [www.gsk-clinicalstudyregister.com]2000:Study ID:GSK 29060/648. TuckerP , ZaninelliR , YehudaR , RuggieroL , DillinghamK , PittsCD .Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry2001;62(11):860-8. ">Tucker 2001</a>; <a href="./references#CD002795-bbs2-0060" title="TuckerP , Potter-KimballR , WyattDB , ParkerDE , BurginC , JonesDE , et al.Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. General Psychopharmacology2003;37(3):135-49. ">Tucker 2003</a>; <a href="./references#CD002795-bbs2-0063" title="Van der Kolk, SpinazzolaJ , BlausteinM , HopperJ , HopperE , KornD , et al.A randomized clinical trial of EMDR, fluoxetine and pill placebo in the treatment of PTSD: treatment effects and long-term maintenance. Draft manuscript2004. Van der KolkBA , SpinazzolaJ , BlausteinME , HopperJW , HopperEK , KornDL , et al.A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. Journal of Clinical Psychiatry2007;68(1):37-46. ">Van der Kolk 2007</a>; <a href="./references#CD002795-bbs2-0066" title="AmitalD , ZoharJ , KotlerM , BleichA , MiodovnikH , NevoA , et al.A placebo-controlled study of sertraline in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):269. AmitalD , ZoharJ , KotlerM , BleichA , MiodovnikH , NevoA , et al.A placebo-controlled trial pilot study of sertraline in PTSD. In: Annual Meeting of the American Psychiatric Association. American Psychiatric Association, 1999:157. ZoharJ , AmitalD , MiodownikC , KotlerM , BleichA , LaneRM .Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. Journal of Clinical Psychopharmacology2002;22(2):190-5. ">Zohar 2002</a>). However, there was considerable heterogeneity in effect size estimates for this outcome (Chi<sup>2</sup> = 29.51, df = 14 (P = 0.009); I<sup>2</sup> = 53%). The SSRIs were also superior to placebo on both the re‐experiencing/intrusion subscale (MD −1.86 points, 95% CI −2.82 to −0.90; see <a href="./references#CD002795-fig-0081" title="">Analysis 16.5</a>), avoidance/numbing subscale (MD −3.68 points, 95% CI −4.82 to −2.54; see <a href="./references#CD002795-fig-0081" title="">Analysis 16.5</a>), and hyperarousal subscale (MD −2.45 points, 95% CI −3.30 to −1.59; see <a href="./references#CD002795-fig-0081" title="">Analysis 16.5</a>) on the CAPS in 8 trials with 1813 participants (<a href="./references#CD002795-bbs2-0004" title="BradyK , PearlsteinT , AsnisGM , BakerD , RothbaumB , SikesCR , et al.Efficacy and safety of sertraline treatment of posttraumatic stress disorder. Archives of General Psychiatry2000;283(14):1837-44. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry2001;158(12):1974-81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. GaffneyM .Factor analysis of treatment response in posttraumatic stress disorder. Journal of Traumatic Stress2003;16(1):77-80. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59-65. RapaportMH , FarfelG , ClaryCM .Quality of life improvement in PTSD with sertraline treatment: results of a multicenter, placebo-controlled trial. International Journal of Neuropsychopharmacology2000;3(Suppl 1):294. ">Brady 2000</a>; <a href="./references#CD002795-bbs2-0012" title="DavidsonJ , LondborgP , PearlsteinT , RothbaumB , BradyK , FarfelG .Double-blind, randomized, 28-week continuation study of sertraline and placebo in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):292. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo controlled study. American Journal of Psychiatry2001;158(12):1974–81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. DavidsonJR , RothbaumBO , Van der KolkBA , SikesCR , FarfelGM .Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Archives of General Psychiatry2001;58(5):485-92. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59–65. ">Davidson 2001a</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>; <a href="./references#CD002795-bbs2-0026" title="GSK 29060 627.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). https://www.gsk-studyregister.com/en/trial-details/?id=29060/648. ">GSK 29060 627</a>; <a href="./references#CD002795-bbs2-0034" title="Food and Drugs Administration (FDA).Paxil (paroxetine) [NDA 20-031/S-029 Paxil (Paroxetine hydrochloride) tablets; GlaxoSmithKline; Post-traumatic Stress Disorder]. www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf (accessed 26 November 2021). GlaxoSmithKline.A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Posttraumatic Stress Disorder (PTSD). GSK - clinical study register [www.gsk-clinicalstudyregister.com]:Study ID: PAR 29060 651 (BRL-02960). MarshallRD , BeebeKL , OldhamM , ZaninelliR .Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. American Journal of Psychiatry2001;158(12):1982-8. ">Marshall 2001</a>; <a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a>; <a href="./references#CD002795-bbs2-0059" title="GlaxoSmithKline.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). GSK - Clinical Study Register [www.gsk-clinicalstudyregister.com]2000:Study ID:GSK 29060/648. TuckerP , ZaninelliR , YehudaR , RuggieroL , DillinghamK , PittsCD .Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry2001;62(11):860-8. ">Tucker 2001</a>; <a href="./references#CD002795-bbs2-0060" title="TuckerP , Potter-KimballR , WyattDB , ParkerDE , BurginC , JonesDE , et al.Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. General Psychopharmacology2003;37(3):135-49. ">Tucker 2003</a>). </p> <p>The pattern of symptom severity on the CAPS for the separate SSRI medications was similar to that observed for treatment efficacy, with both paroxetine MD −6.32 points, 95% CI −11.49 to −1.14; 6 trials, 1375 participants; see <a href="./references#CD002795-fig-0082" title="">Analysis 16.6</a>; <a href="./references#CD002795-bbs2-0026" title="GSK 29060 627.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). https://www.gsk-studyregister.com/en/trial-details/?id=29060/648. ">GSK 29060 627</a>; <a href="./references#CD002795-bbs2-0034" title="Food and Drugs Administration (FDA).Paxil (paroxetine) [NDA 20-031/S-029 Paxil (Paroxetine hydrochloride) tablets; GlaxoSmithKline; Post-traumatic Stress Disorder]. www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf (accessed 26 November 2021). GlaxoSmithKline.A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Posttraumatic Stress Disorder (PTSD). GSK - clinical study register [www.gsk-clinicalstudyregister.com]:Study ID: PAR 29060 651 (BRL-02960). MarshallRD , BeebeKL , OldhamM , ZaninelliR .Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. American Journal of Psychiatry2001;158(12):1982-8. ">Marshall 2001</a>; <a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a>; <a href="./references#CD002795-bbs2-0055" title="Food and Drug Administration (FDA).NDA 20-031/S-029 Paxil (paroxetine hydrochloride) tablets; GlaxoSmithKline; Post-traumatic Stress Disorder. www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf;(accessed 28 November 2021). GlaxoSmithKline.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). GSK - clinical study register [www.gsk-clinicalstudyregister.com]:Study ID: 29060/627. SmithKline Beecham.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. SteinDJ , DavidsonJ , SeedatS , BeebeK .Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies. Expert Opinion on Pharmacotherapy2003;4(10):1829-38. ">SKB627</a>; <a href="./references#CD002795-bbs2-0056" title="SmithKline Beecham.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. ">SKB650</a>; <a href="./references#CD002795-bbs2-0059" title="GlaxoSmithKline.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). GSK - Clinical Study Register [www.gsk-clinicalstudyregister.com]2000:Study ID:GSK 29060/648. TuckerP , ZaninelliR , YehudaR , RuggieroL , DillinghamK , PittsCD .Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry2001;62(11):860-8. ">Tucker 2001</a>) and sertraline (MD −4.45 points, 95% CI −7.17 to −1.73; 6 trials, 1133 participants; see <a href="./references#CD002795-fig-0082" title="">Analysis 16.6</a>; <a href="./references#CD002795-bbs2-0004" title="BradyK , PearlsteinT , AsnisGM , BakerD , RothbaumB , SikesCR , et al.Efficacy and safety of sertraline treatment of posttraumatic stress disorder. Archives of General Psychiatry2000;283(14):1837-44. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry2001;158(12):1974-81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. GaffneyM .Factor analysis of treatment response in posttraumatic stress disorder. Journal of Traumatic Stress2003;16(1):77-80. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59-65. RapaportMH , FarfelG , ClaryCM .Quality of life improvement in PTSD with sertraline treatment: results of a multicenter, placebo-controlled trial. International Journal of Neuropsychopharmacology2000;3(Suppl 1):294. ">Brady 2000</a>; <a href="./references#CD002795-bbs2-0012" title="DavidsonJ , LondborgP , PearlsteinT , RothbaumB , BradyK , FarfelG .Double-blind, randomized, 28-week continuation study of sertraline and placebo in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):292. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo controlled study. American Journal of Psychiatry2001;158(12):1974–81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. DavidsonJR , RothbaumBO , Van der KolkBA , SikesCR , FarfelGM .Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Archives of General Psychiatry2001;58(5):485-92. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59–65. ">Davidson 2001a</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>; <a href="./references#CD002795-bbs2-0047" title="Food and Drug Administration (FDA).Review and evaluation of clinical data [Pfizer NDA application: Sertraline (Zoloft) for PTSD]. www.accessdata.fda.gov/drugsatfda_docs/nda/99/19-839S026_Zoloft_Clinr_P1.pdf1999;(accessed 28 November 2021). Pfizer.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. ">Pfizer588</a>; <a href="./references#CD002795-bbs2-0048" title="Food and Drug Adminstration (FDA).Review and evaluation of clinical data [Pfizer NDA application: Sertraline (Zoloft) for PTSD]. www.accessdata.fda.gov/drugsatfda_docs/nda/99/19-839S026_Zoloft_Clinr_P1.pdf1999;(accessed 28 November 2021). FriedmanMJ , MarmarCR , BakerDG , SikesCR , FarfelGM .Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. Journal of Clinical Psychiatry2007;68(5):711-20. Pfizer.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. ">Pfizer589</a>; <a href="./references#CD002795-bbs2-0066" title="AmitalD , ZoharJ , KotlerM , BleichA , MiodovnikH , NevoA , et al.A placebo-controlled study of sertraline in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):269. AmitalD , ZoharJ , KotlerM , BleichA , MiodovnikH , NevoA , et al.A placebo-controlled trial pilot study of sertraline in PTSD. In: Annual Meeting of the American Psychiatric Association. American Psychiatric Association, 1999:157. ZoharJ , AmitalD , MiodownikC , KotlerM , BleichA , LaneRM .Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. Journal of Clinical Psychopharmacology2002;22(2):190-5. ">Zohar 2002</a>), demonstrating evidence of a benefit of a reduction in PTSD symptoms. We also noted considerable heterogeneity for the individual SSRI paroxetine (Chi<sup>2</sup> = 21.87, df = 5 (P &lt; 0.001); I<sup>2</sup> = 77%). There was once again insufficient evidence to determine whether fluoxetine was effective in reducing total PTSD (MD −0.90 points, 95% CI −12.31 to 10.51; 1 trial, 59 participants; see <a href="./references#CD002795-fig-0082" title="">Analysis 16.6</a>; <a href="./references#CD002795-bbs2-0063" title="Van der Kolk, SpinazzolaJ , BlausteinM , HopperJ , HopperE , KornD , et al.A randomized clinical trial of EMDR, fluoxetine and pill placebo in the treatment of PTSD: treatment effects and long-term maintenance. Draft manuscript2004. Van der KolkBA , SpinazzolaJ , BlausteinME , HopperJW , HopperEK , KornDL , et al.A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. Journal of Clinical Psychiatry2007;68(1):37-46. ">Van der Kolk 2007</a>), as well as citalopram (MD 4.78 points, 95% CI −15.95 to 25.51; 1 trial, 35 participants; see <a href="./references#CD002795-fig-0082" title="">Analysis 16.6</a>; <a href="./references#CD002795-bbs2-0060" title="TuckerP , Potter-KimballR , WyattDB , ParkerDE , BurginC , JonesDE , et al.Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. General Psychopharmacology2003;37(3):135-49. ">Tucker 2003</a>), compared to placebo. </p> <p>There was evidence of a benefit of the SSRIs fluoxetine, paroxetine and sertraline compared to placebo for the reduction of PTSD symptoms on the CGI‐S (SMD −0.32 points, 95% CI −0.55 to −0.09; 6 trials, 862 participants; see <a href="./references#CD002795-fig-0083" title="">Analysis 16.7</a>; <a href="./references#CD002795-bbs2-0009" title="BarnettSD , TharwaniHM , HertzbergMA , SutherlandSM , ConnorKM , DavidsonJR .Tolerability of fluoxetine in posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2002;26(2):363-7. ConnorKM , SutherlandSM , TuplerLA , MalikML , DavidsonJR .Fluoxetine in post-traumatic stress disorder: randomized, double-blind study. British Journal of Psychiatry1999;175:17-22. MalikML , ConnorKM , SutherlandSM , SmithRD , DavisonRM , DavidsonJR .Quality-of-life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo- controlled trial of fluoxetine. Journal of Traumatic Stress1999;12(2):387-93. ">Connor 1999a</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>; <a href="./references#CD002795-bbs2-0026" title="GSK 29060 627.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). https://www.gsk-studyregister.com/en/trial-details/?id=29060/648. ">GSK 29060 627</a>; <a href="./references#CD002795-bbs2-0029" title="HertzbergMA , FeldmanME , BeckhamJC , KudlerHS , DavidsonJR .Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Annals of Clinical Psychiatry2000;12(2):101-5. ">Hertzberg 2000</a>; <a href="./references#CD002795-bbs2-0033" title="LiW , Ma Y-B, YangQ , LiBL , Meng Q-G, ZhangY .Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study. International Journal of Psychiatry in Clinical Practice2017;21(2):151-5. [DOI: 10.1080/13651501.2017.1291838]">Li 2017</a>; <a href="./references#CD002795-bbs2-0046" title="PanahiY , MoghaddamBR , SahebkarA , NazariMA , BeiraghdarF , KaramiG , et al.A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder. Psychological Medicine2011;41(10):2159–66. [DOI: 10.1017/S0033291711000201]">Panahi 2011</a>). There was considerable heterogeneity in effect size estimates for this outcome (Chi<sup>2</sup> = 10.24, df = 5 (P = 0.07); I<sup>2</sup> = 51%). There was no evidence of a benefit of the SSRIs compared to placebo for a reduction in total PTSD symptoms on the DTS (SMD 0.11, 95% CI −0.50 to 0.72; 10 trials, 1698 participants; see <a href="./references#CD002795-fig-0084" title="">Analysis 16.8</a>; <a href="./references#CD002795-bbs2-0004" title="BradyK , PearlsteinT , AsnisGM , BakerD , RothbaumB , SikesCR , et al.Efficacy and safety of sertraline treatment of posttraumatic stress disorder. Archives of General Psychiatry2000;283(14):1837-44. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry2001;158(12):1974-81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. GaffneyM .Factor analysis of treatment response in posttraumatic stress disorder. Journal of Traumatic Stress2003;16(1):77-80. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59-65. RapaportMH , FarfelG , ClaryCM .Quality of life improvement in PTSD with sertraline treatment: results of a multicenter, placebo-controlled trial. International Journal of Neuropsychopharmacology2000;3(Suppl 1):294. ">Brady 2000</a>; <a href="./references#CD002795-bbs2-0009" title="BarnettSD , TharwaniHM , HertzbergMA , SutherlandSM , ConnorKM , DavidsonJR .Tolerability of fluoxetine in posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2002;26(2):363-7. ConnorKM , SutherlandSM , TuplerLA , MalikML , DavidsonJR .Fluoxetine in post-traumatic stress disorder: randomized, double-blind study. British Journal of Psychiatry1999;175:17-22. MalikML , ConnorKM , SutherlandSM , SmithRD , DavisonRM , DavidsonJR .Quality-of-life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo- controlled trial of fluoxetine. Journal of Traumatic Stress1999;12(2):387-93. ">Connor 1999a</a>; <a href="./references#CD002795-bbs2-0015" title="DavidsonJT , ConnorKM , HertzbergMA , WeislerRH , WilsonWH , PayneVM .Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study. Journal of Clinical Psychopharmacology2005;25(2):166–9. [DOI: 10.1097/01.jcp.0000155817.21467.6c]">Davidson 2005</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>; <a href="./references#CD002795-bbs2-0026" title="GSK 29060 627.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). https://www.gsk-studyregister.com/en/trial-details/?id=29060/648. ">GSK 29060 627</a>; <a href="./references#CD002795-bbs2-0029" title="HertzbergMA , FeldmanME , BeckhamJC , KudlerHS , DavidsonJR .Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Annals of Clinical Psychiatry2000;12(2):101-5. ">Hertzberg 2000</a>; <a href="./references#CD002795-bbs2-0033" title="LiW , Ma Y-B, YangQ , LiBL , Meng Q-G, ZhangY .Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study. International Journal of Psychiatry in Clinical Practice2017;21(2):151-5. [DOI: 10.1080/13651501.2017.1291838]">Li 2017</a>; <a href="./references#CD002795-bbs2-0046" title="PanahiY , MoghaddamBR , SahebkarA , NazariMA , BeiraghdarF , KaramiG , et al.A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder. Psychological Medicine2011;41(10):2159–66. [DOI: 10.1017/S0033291711000201]">Panahi 2011</a>; <a href="./references#CD002795-bbs2-0056" title="SmithKline Beecham.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. ">SKB650</a>; <a href="./references#CD002795-bbs2-0060" title="TuckerP , Potter-KimballR , WyattDB , ParkerDE , BurginC , JonesDE , et al.Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. General Psychopharmacology2003;37(3):135-49. ">Tucker 2003</a>), and this is confirmed by the substantial heterogeneity found between trials (Chi<sup>2</sup> = 295.12, df = 9 (P &lt; 0.001); I<sup>2</sup> = 97%). We did however observe evidence of a benefit of four trials of sertraline for the re‐experiencing/intrusion subscale (MD −0.30 points, 95% CI −0.58 to −0.03; 5 trials, 986 participants; see <a href="./references#CD002795-fig-0084" title="">Analysis 16.8</a>; <a href="./references#CD002795-bbs2-0004" title="BradyK , PearlsteinT , AsnisGM , BakerD , RothbaumB , SikesCR , et al.Efficacy and safety of sertraline treatment of posttraumatic stress disorder. Archives of General Psychiatry2000;283(14):1837-44. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry2001;158(12):1974-81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. GaffneyM .Factor analysis of treatment response in posttraumatic stress disorder. Journal of Traumatic Stress2003;16(1):77-80. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59-65. RapaportMH , FarfelG , ClaryCM .Quality of life improvement in PTSD with sertraline treatment: results of a multicenter, placebo-controlled trial. International Journal of Neuropsychopharmacology2000;3(Suppl 1):294. ">Brady 2000</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>; <a href="./references#CD002795-bbs2-0026" title="GSK 29060 627.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). https://www.gsk-studyregister.com/en/trial-details/?id=29060/648. ">GSK 29060 627</a>; <a href="./references#CD002795-bbs2-0033" title="LiW , Ma Y-B, YangQ , LiBL , Meng Q-G, ZhangY .Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study. International Journal of Psychiatry in Clinical Practice2017;21(2):151-5. [DOI: 10.1080/13651501.2017.1291838]">Li 2017</a>; <a href="./references#CD002795-bbs2-0046" title="PanahiY , MoghaddamBR , SahebkarA , NazariMA , BeiraghdarF , KaramiG , et al.A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder. Psychological Medicine2011;41(10):2159–66. [DOI: 10.1017/S0033291711000201]">Panahi 2011</a>), and avoidance/numbing subscale (MD −0.31 points, 95% CI −0.58 to −0.04; 5 trials, 985 participants; see <a href="./references#CD002795-fig-0084" title="">Analysis 16.8</a>; <a href="./references#CD002795-bbs2-0004" title="BradyK , PearlsteinT , AsnisGM , BakerD , RothbaumB , SikesCR , et al.Efficacy and safety of sertraline treatment of posttraumatic stress disorder. Archives of General Psychiatry2000;283(14):1837-44. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry2001;158(12):1974-81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. GaffneyM .Factor analysis of treatment response in posttraumatic stress disorder. Journal of Traumatic Stress2003;16(1):77-80. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59-65. RapaportMH , FarfelG , ClaryCM .Quality of life improvement in PTSD with sertraline treatment: results of a multicenter, placebo-controlled trial. International Journal of Neuropsychopharmacology2000;3(Suppl 1):294. ">Brady 2000</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>; <a href="./references#CD002795-bbs2-0026" title="GSK 29060 627.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). https://www.gsk-studyregister.com/en/trial-details/?id=29060/648. ">GSK 29060 627</a>; <a href="./references#CD002795-bbs2-0033" title="LiW , Ma Y-B, YangQ , LiBL , Meng Q-G, ZhangY .Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study. International Journal of Psychiatry in Clinical Practice2017;21(2):151-5. [DOI: 10.1080/13651501.2017.1291838]">Li 2017</a>; <a href="./references#CD002795-bbs2-0046" title="PanahiY , MoghaddamBR , SahebkarA , NazariMA , BeiraghdarF , KaramiG , et al.A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder. Psychological Medicine2011;41(10):2159–66. [DOI: 10.1017/S0033291711000201]">Panahi 2011</a>), but not for the hyperarousal subscale (MD −0.48 points, 95% CI −0.98 to 0.01; 4 trials, 805 participants; see <a href="./references#CD002795-fig-0084" title="">Analysis 16.8</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>; <a href="./references#CD002795-bbs2-0026" title="GSK 29060 627.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). https://www.gsk-studyregister.com/en/trial-details/?id=29060/648. ">GSK 29060 627</a>; <a href="./references#CD002795-bbs2-0033" title="LiW , Ma Y-B, YangQ , LiBL , Meng Q-G, ZhangY .Effect and safety of sertraline for treat posttraumatic stress disorder: a multicenter randomised controlled study. International Journal of Psychiatry in Clinical Practice2017;21(2):151-5. [DOI: 10.1080/13651501.2017.1291838]">Li 2017</a>; <a href="./references#CD002795-bbs2-0046" title="PanahiY , MoghaddamBR , SahebkarA , NazariMA , BeiraghdarF , KaramiG , et al.A randomized, double-blind, placebo-controlled trial on the efficacy and tolerability of sertraline in Iranian veterans with post-traumatic stress disorder. Psychological Medicine2011;41(10):2159–66. [DOI: 10.1017/S0033291711000201]">Panahi 2011</a>) on the DTS. Substantial heterogeneity was also found for each of the subscales (I<sup>2</sup> = 75%, I<sup>2</sup> = 74%, I<sup>2</sup> = 90% respectively). </p> <p>There was no evidence of a benefit of citalopram, paroxetine or sertraline compared to placebo on the reduction in depression symptoms on the BDI‐R and HAM‐D (SMD −0.20 points, 95% CI −0.44 to 0.04; 3 trials, 270 participants; see <a href="./references#CD002795-fig-0085" title="">Analysis 16.9</a>; <a href="./references#CD002795-bbs2-0004" title="BradyK , PearlsteinT , AsnisGM , BakerD , RothbaumB , SikesCR , et al.Efficacy and safety of sertraline treatment of posttraumatic stress disorder. Archives of General Psychiatry2000;283(14):1837-44. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry2001;158(12):1974-81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. GaffneyM .Factor analysis of treatment response in posttraumatic stress disorder. Journal of Traumatic Stress2003;16(1):77-80. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59-65. RapaportMH , FarfelG , ClaryCM .Quality of life improvement in PTSD with sertraline treatment: results of a multicenter, placebo-controlled trial. International Journal of Neuropsychopharmacology2000;3(Suppl 1):294. ">Brady 2000</a>; <a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a>; <a href="./references#CD002795-bbs2-0060" title="TuckerP , Potter-KimballR , WyattDB , ParkerDE , BurginC , JonesDE , et al.Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. General Psychopharmacology2003;37(3):135-49. ">Tucker 2003</a>). Similarly, there was no evidence of a benefit of paroxetine or sertraline compared to placebo on the reduction in anxiety symptoms on the HAM‐A (MD −0.22 points, 95% CI −1.84 to 1.41; 3 trials, 606 participants; see <a href="./references#CD002795-fig-0086" title="">Analysis 16.10</a>; <a href="./references#CD002795-bbs2-0012" title="DavidsonJ , LondborgP , PearlsteinT , RothbaumB , BradyK , FarfelG .Double-blind, randomized, 28-week continuation study of sertraline and placebo in posttraumatic stress disorder. International Journal of Neuropsychopharmacology2000;3(Suppl 1):292. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo controlled study. American Journal of Psychiatry2001;158(12):1974–81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. DavidsonJR , RothbaumBO , Van der KolkBA , SikesCR , FarfelGM .Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Archives of General Psychiatry2001;58(5):485-92. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59–65. ">Davidson 2001a</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>; <a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a>). In contrast, we found evidence of a benefit of fluoxetine, paroxetine and sertraline compared to placebo on the reduction in functional disability measured by the SDS (MD −2.10 points, 95% CI −3.00 to −1.21; 6 trials, 1336 participants; see <a href="./references#CD002795-fig-0087" title="">Analysis 16.11</a>; <a href="./references#CD002795-bbs2-0009" title="BarnettSD , TharwaniHM , HertzbergMA , SutherlandSM , ConnorKM , DavidsonJR .Tolerability of fluoxetine in posttraumatic stress disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry2002;26(2):363-7. ConnorKM , SutherlandSM , TuplerLA , MalikML , DavidsonJR .Fluoxetine in post-traumatic stress disorder: randomized, double-blind study. British Journal of Psychiatry1999;175:17-22. MalikML , ConnorKM , SutherlandSM , SmithRD , DavisonRM , DavidsonJR .Quality-of-life and posttraumatic stress disorder: a pilot study assessing changes in SF-36 scores before and after treatment in a placebo- controlled trial of fluoxetine. Journal of Traumatic Stress1999;12(2):387-93. ">Connor 1999a</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>; <a href="./references#CD002795-bbs2-0026" title="GSK 29060 627.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). https://www.gsk-studyregister.com/en/trial-details/?id=29060/648. ">GSK 29060 627</a>; <a href="./references#CD002795-bbs2-0029" title="HertzbergMA , FeldmanME , BeckhamJC , KudlerHS , DavidsonJR .Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Annals of Clinical Psychiatry2000;12(2):101-5. ">Hertzberg 2000</a>; <a href="./references#CD002795-bbs2-0034" title="Food and Drugs Administration (FDA).Paxil (paroxetine) [NDA 20-031/S-029 Paxil (Paroxetine hydrochloride) tablets; GlaxoSmithKline; Post-traumatic Stress Disorder]. www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf (accessed 26 November 2021). GlaxoSmithKline.A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Posttraumatic Stress Disorder (PTSD). GSK - clinical study register [www.gsk-clinicalstudyregister.com]:Study ID: PAR 29060 651 (BRL-02960). MarshallRD , BeebeKL , OldhamM , ZaninelliR .Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. American Journal of Psychiatry2001;158(12):1982-8. ">Marshall 2001</a>; <a href="./references#CD002795-bbs2-0059" title="GlaxoSmithKline.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). GSK - Clinical Study Register [www.gsk-clinicalstudyregister.com]2000:Study ID:GSK 29060/648. TuckerP , ZaninelliR , YehudaR , RuggieroL , DillinghamK , PittsCD .Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry2001;62(11):860-8. ">Tucker 2001</a>). </p> <p>We observed similar dropout rates in the medication (33%) and placebo arms (28%); see <a href="./references#CD002795-fig-0088" title="">Analysis 16.12</a>. We also observed substantial heterogeneity in effect size estimates for this outcome (Chi<sup>2</sup> = 74.38, df = 20 (P &lt; 0.001); I<sup>2</sup> = 73%). </p> <p>Finally, there was no evidence of a benefit of the SSRI fluoxetine compared to placebo for a reduction in PTSD symptoms on the CAPS after long‐term treatment (MD 9.62 points; 95% CI −3.53 to 22.77; 1 trial, 16 participants; see <a href="./references#CD002795-fig-0089" title="">Analysis 16.13</a>; <a href="./references#CD002795-bbs2-0035" title="MarshallR , BlancoC , Lewis-FernandezR , SimpsonB , LinSH , GarciaW , et al.Randomized controlled trial of paroxetine in adults with chronic PTSD. In: 18th Annual Meeting, International Society for Traumatic Stress Studies, November 7 - 10, Baltimore, MD. 2002. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , LinS , GarciaW , et al.A controlled trial of paroxetine for chronic PTSD, dissociation and interpersonal problems in mostly minority adults. Draft manuscript2004. MarshallRD , Lewis-FernandezR , BlancoC , SimpsonHB , Lin S-H, VermesD , et al.A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depression and Anxiety2007;24(2):77–84. [DOI: 10.1002/da]">Marshall 2007</a>). </p> </section> </section> <section id="CD002795-sec-0106"> <h4 class="title">Comparison 17: TCAs versus placebo</h4> <section id="CD002795-sec-0107"> <h5 class="title">Primary outcome measures</h5> <p>There was evidence of a benefit of amitriptyline on treatment efficacy in participants with PTSD compared to placebo (RR 0.60, 95% CI 0.38 to 0.96; 1 trial, 40 participants; see <a href="./references#CD002795-fig-0090" title="">Analysis 17.1</a>; <a href="./references#CD002795-bbs2-0011" title="DavidsonJR , KudlerH , SmithR , MahorneySL , LipperS , HammettE , et al.Treatment of posttraumatic stress disorder with amitriptyline and placebo. Archives of General Psychiatry1990;47(3):259-66. DavidsonJR , KudlerHS , SaundersWB , EricksonL , SmithRD , SteinRM , et al.Predicting response to amitriptyline in posttraumatic stress disorder. American Journal of Psychiatry1993;150(7):1024-9. ">Davidson 1990</a>) based on low‐certainty evidence. </p> <p>There was no evidence of a harm for the number of participants who withdrew due to treatment‐emergent side effects in the amitriptyline, desipramine and imipramine groups (23%) compared to the placebo groups (18%) (see <a href="./references#CD002795-fig-0091" title="">Analysis 17.2</a>; <a href="./references#CD002795-bbs2-0011" title="DavidsonJR , KudlerH , SmithR , MahorneySL , LipperS , HammettE , et al.Treatment of posttraumatic stress disorder with amitriptyline and placebo. Archives of General Psychiatry1990;47(3):259-66. DavidsonJR , KudlerHS , SaundersWB , EricksonL , SmithRD , SteinRM , et al.Predicting response to amitriptyline in posttraumatic stress disorder. American Journal of Psychiatry1993;150(7):1024-9. ">Davidson 1990</a>; <a href="./references#CD002795-bbs2-0032" title="KostenTR , FrankJB , DanE , McDougleCJ , Giller EL Jr.Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease1991;179(6):366–70. ">Kosten 1991</a>; <a href="./references#CD002795-bbs2-0052" title="ReistC , KauffmannCD , Chicz DemetA , ChenCC , DemetEM .REM latency, dexamethasone suppression test, and thyroid releasing hormone stimulation test in posttraumatic stress disorder. Progress in Neuropsychopharmacology and Biological Psychiatry1995;19(3):433-43. ReistC , KauffmannCD , HaierRJ , SangdahlC , DeMetEM , Chicz-DeMetA , et al.A controlled trial of desipramine in 18 men with posttraumatic stress disorder. American Journal of Psychiatry1989;146(4):513-6. ">Reist 1989</a>), based on moderate‐certainty evidence. </p> </section> <section id="CD002795-sec-0108"> <h5 class="title">Secondary outcomes measures</h5> <p>We found no evidence of a benefit for amitriptyline and imipramine compared to placebo for reducing total IES symptom severity (SMD −0.54 points, 95% CI −1.18 to 0.10; 2 trials, 74 participants; see <a href="./references#CD002795-fig-0092" title="">Analysis 17.3</a>; <a href="./references#CD002795-bbs2-0011" title="DavidsonJR , KudlerH , SmithR , MahorneySL , LipperS , HammettE , et al.Treatment of posttraumatic stress disorder with amitriptyline and placebo. Archives of General Psychiatry1990;47(3):259-66. DavidsonJR , KudlerHS , SaundersWB , EricksonL , SmithRD , SteinRM , et al.Predicting response to amitriptyline in posttraumatic stress disorder. American Journal of Psychiatry1993;150(7):1024-9. ">Davidson 1990</a>; <a href="./references#CD002795-bbs2-0032" title="KostenTR , FrankJB , DanE , McDougleCJ , Giller EL Jr.Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease1991;179(6):366–70. ">Kosten 1991</a>), as well as for the re‐experiencing/intrusion subscale (SMD −0.44 points, 95% CI −0.99 to 0.11; 2 trials, 74 participants; see <a href="./references#CD002795-fig-0092" title="">Analysis 17.3</a>; <a href="./references#CD002795-bbs2-0011" title="DavidsonJR , KudlerH , SmithR , MahorneySL , LipperS , HammettE , et al.Treatment of posttraumatic stress disorder with amitriptyline and placebo. Archives of General Psychiatry1990;47(3):259-66. DavidsonJR , KudlerHS , SaundersWB , EricksonL , SmithRD , SteinRM , et al.Predicting response to amitriptyline in posttraumatic stress disorder. American Journal of Psychiatry1993;150(7):1024-9. ">Davidson 1990</a>; <a href="./references#CD002795-bbs2-0032" title="KostenTR , FrankJB , DanE , McDougleCJ , Giller EL Jr.Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease1991;179(6):366–70. ">Kosten 1991</a>) and avoidance/numbing subscale (SMD −0.23 points, 95% CI −1.51 to 1.04; 2 trials, 74 participants; see <a href="./references#CD002795-fig-0092" title="">Analysis 17.3</a>; <a href="./references#CD002795-bbs2-0011" title="DavidsonJR , KudlerH , SmithR , MahorneySL , LipperS , HammettE , et al.Treatment of posttraumatic stress disorder with amitriptyline and placebo. Archives of General Psychiatry1990;47(3):259-66. DavidsonJR , KudlerHS , SaundersWB , EricksonL , SmithRD , SteinRM , et al.Predicting response to amitriptyline in posttraumatic stress disorder. American Journal of Psychiatry1993;150(7):1024-9. ">Davidson 1990</a>; <a href="./references#CD002795-bbs2-0032" title="KostenTR , FrankJB , DanE , McDougleCJ , Giller EL Jr.Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease1991;179(6):366–70. ">Kosten 1991</a>) on the IES. We noted moderate heterogeneity for the total IES symptom severity outcome (Chi<sup>2</sup> = 1.83, df = 1 (P = 0.18); I<sup>2</sup> = 45%) and substantial heterogeneity for the avoidance/numbing subscale of the IES (Chi<sup>2</sup> = 7.16, df = 1 (P = 0.007); I<sup>2</sup> = 86%). </p> <p>There was no evidence of a benefit of amitriptyline or imipramine compared to placebo on the reduction in depression symptoms on the HAM‐D (SMD −0.67 points, 95% CI −1.58 to 0.25; 2 trials, 74 participants (<a href="./references#CD002795-bbs2-0011" title="DavidsonJR , KudlerH , SmithR , MahorneySL , LipperS , HammettE , et al.Treatment of posttraumatic stress disorder with amitriptyline and placebo. Archives of General Psychiatry1990;47(3):259-66. DavidsonJR , KudlerHS , SaundersWB , EricksonL , SmithRD , SteinRM , et al.Predicting response to amitriptyline in posttraumatic stress disorder. American Journal of Psychiatry1993;150(7):1024-9. ">Davidson 1990</a>; <a href="./references#CD002795-bbs2-0032" title="KostenTR , FrankJB , DanE , McDougleCJ , Giller EL Jr.Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease1991;179(6):366–70. ">Kosten 1991</a>) see <a href="./references#CD002795-fig-0093" title="">Analysis 17.4</a>) . There was also substantial heterogeneity for this outcome (Chi<sup>2</sup> = 3.60, df = 1 (P = 0.06); I<sup>2</sup> = 72%). We did, however, observe evidence of a benefit of amitriptyline on a reduction of anxiety symptoms on the HAM‐A (MD −7.60 points, 95% CI −12.74 to −2.46; 1 trial, 33 participants; see <a href="./references#CD002795-fig-0094" title="">Analysis 17.5</a>; <a href="./references#CD002795-bbs2-0011" title="DavidsonJR , KudlerH , SmithR , MahorneySL , LipperS , HammettE , et al.Treatment of posttraumatic stress disorder with amitriptyline and placebo. Archives of General Psychiatry1990;47(3):259-66. DavidsonJR , KudlerHS , SaundersWB , EricksonL , SmithRD , SteinRM , et al.Predicting response to amitriptyline in posttraumatic stress disorder. American Journal of Psychiatry1993;150(7):1024-9. ">Davidson 1990</a>). We found no evidence of a benefit for the TCA imipramine on a reduction in anxiety symptoms on the Covi Anxiety Scale (SMD −0.46 points, 95% CI −1.08 to 0.17; 1 trial, 41 participants; see <a href="./references#CD002795-fig-0095" title="">Analysis 17.6</a>; <a href="./references#CD002795-bbs2-0032" title="KostenTR , FrankJB , DanE , McDougleCJ , Giller EL Jr.Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease1991;179(6):366–70. ">Kosten 1991</a>). </p> <p>In addition, more participants dropped out of the amitriptyline and imipramine groups (34%) due to any cause (see <a href="./references#CD002795-fig-0096" title="">Analysis 17.7</a>; <a href="./references#CD002795-bbs2-0011" title="DavidsonJR , KudlerH , SmithR , MahorneySL , LipperS , HammettE , et al.Treatment of posttraumatic stress disorder with amitriptyline and placebo. Archives of General Psychiatry1990;47(3):259-66. DavidsonJR , KudlerHS , SaundersWB , EricksonL , SmithRD , SteinRM , et al.Predicting response to amitriptyline in posttraumatic stress disorder. American Journal of Psychiatry1993;150(7):1024-9. ">Davidson 1990</a>; <a href="./references#CD002795-bbs2-0032" title="KostenTR , FrankJB , DanE , McDougleCJ , Giller EL Jr.Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease1991;179(6):366–70. ">Kosten 1991</a>). </p> </section> </section> <section id="CD002795-sec-0109"> <h4 class="title">Comparison 18: Total effect of medication versus placebo</h4> <p>There was evidence of a benefit across all medication classes (RR 0.74, 95% CI 0.64 to 0.85; 19 trials, 1822 participants; see <a href="./references#CD002795-fig-0097" title="">Analysis 18.1</a>). There was also evidence that medication class explained a substantial proportion of variability in treatment efficacy when assessed across all trials providing data on this outcome (Chi<sup>2</sup> = 19.59, df = 6 (P = 0.003); I<sup>2</sup> = 69.4%; see <a href="./references#CD002795-fig-0097" title="">Analysis 18.1</a>). </p> <p>We found no evidence of a harm for the proportion of dropouts due to adverse events across all medication classes compared to placebo (RR 0.98; 95% CI 0.91 to 1.08; participants; 37 trials, 4212 participants; see <a href="./references#CD002795-fig-0098" title="">Analysis 18.2</a>); which is confirmed by the low dropout rate in the medication (10%) and placebo arm (7%). For this analysis, we excluded data from one study reporting on sertraline, because this study also reported data for the SNRI venlafaxine (<a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>). </p> <p>We noted evidence of reductions in symptom severity for participants who received medication in 34 short‐term trials from which it was possible to retrieve data for this outcome (MD ‐4.79, 95% CI −6.64 to −2.94; 34 trials, 4639 participants; see <a href="./references#CD002795-fig-0099" title="">Analysis 18.3</a>). For this analysis, data from one study reporting on sertraline were excluded, because this study also reported data for the SNRI venlafaxine (<a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>). </p> <p>The proportion of dropouts due to any cause across both the medication and placebo groups was similar (32% and 29%, respectively) and was comparable across subgroups (Chi<sup>2</sup> = 23.93, df = 14 (P = 0.05), I<sup>2</sup> = 41.5%; see <a href="./references#CD002795-fig-0100" title="">Analysis 18.4</a>). For this analysis data from one study were excluded, with an additional arm of phenelzine to give preference to imipramine (<a href="./references#CD002795-bbs2-0032" title="KostenTR , FrankJB , DanE , McDougleCJ , Giller EL Jr.Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease1991;179(6):366–70. ">Kosten 1991</a>). </p> </section> <section id="CD002795-sec-0110"> <h4 class="title">Comparison 19: Head‐to‐head comparisons</h4> <p>More participants dropped out of the reboxetine group (45%) compared to the fluvoxamine group (15%) due to treatment‐emergent side effects (see <a href="./references#CD002795-fig-0101" title="">Analysis 19.1</a>; <a href="./references#CD002795-bbs2-0058" title="SpivakB , StrousRD , ShakedG , ShabashE , KotlerM , WeizmanA .Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. Journal of Clinical Psychopharmacology2006;26(2):152–6. [DOI: 10.1097/01.jcp.0000203195.65710.f0]">Spivak 2006</a>). </p> <p>It is unclear if there was evidence of a benefit of the reduction of symptom severity in the two head‐to‐head comparisons of nefazodone and sertraline (SMD −0.19 points, 95% CI −0.63 to 0.25; 2 trials, 80 participants; see <a href="./references#CD002795-fig-0102" title="">Analysis 19.2</a>; <a href="./references#CD002795-bbs2-0041" title="McRaeAL , BradyKT , MellmanTA , SonnSC , KilleenTK , TimmermanMA , et al.Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depression and Anxiety2004;19(3):190–6. [DOI: 10.1002/da.20008]">McRae 2004</a>; <a href="./references#CD002795-bbs2-0053" title="SayginMZ , SungurMZ , SabolEU , CetinkayaP .Nefazodone versus sertraline in treatment of posttraumatic stress disorder. Bulletin of Clinical Psychopharmacology2002;12(1):1-5. ">Saygin 2002</a>), nor in the single‐trial comparison of venlafaxine and sertraline (SMD −0.01 points, 95% CI −0.22 to 0.20; 1 trial, 352 participants; see <a href="./references#CD002795-fig-0102" title="">Analysis 19.2</a>; <a href="./references#CD002795-bbs2-0017" title="DavidsonJ , RothbaumBO , TuckerP , AsnisG , BenattiaI , MusgnungJJ .Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. Journal of Clinical Psychopharmacology2006;26(3):259-67. ">Davidson 2006b</a>), and the single trial comparing reboxetine and fluvoxamine (SMD 0.67 points, 95% CI −0.11 to 1.45; 1 trial, 28 participants; see <a href="./references#CD002795-fig-0102" title="">Analysis 19.2</a>; <a href="./references#CD002795-bbs2-0058" title="SpivakB , StrousRD , ShakedG , ShabashE , KotlerM , WeizmanA .Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. Journal of Clinical Psychopharmacology2006;26(2):152–6. [DOI: 10.1097/01.jcp.0000203195.65710.f0]">Spivak 2006</a>). </p> <p>There was no evidence of a benefit of nefazodone compared to sertraline for the reduction of depression symptoms on the MADRS (SMD −0.09 points, 95% CI −0.86 to 0.68; 1 trial, 26 participants; see <a href="./references#CD002795-fig-0103" title="">Analysis 19.3</a>; <a href="./references#CD002795-bbs2-0041" title="McRaeAL , BradyKT , MellmanTA , SonnSC , KilleenTK , TimmermanMA , et al.Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depression and Anxiety2004;19(3):190–6. [DOI: 10.1002/da.20008]">McRae 2004</a>) or of reboxetine and fluvoxamine on the HAM‐D (SMD 0.67 points, 95% CI −0.11 to 1.45; 1 trial, 28 participants; see <a href="./references#CD002795-fig-0103" title="">Analysis 19.3</a>; <a href="./references#CD002795-bbs2-0058" title="SpivakB , StrousRD , ShakedG , ShabashE , KotlerM , WeizmanA .Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. Journal of Clinical Psychopharmacology2006;26(2):152–6. [DOI: 10.1097/01.jcp.0000203195.65710.f0]">Spivak 2006</a>). We also found no evidence of a benefit of nefazodone compared to sertraline on the reduction in anxiety symptoms on the HAM‐A (MD −3.23 points, 95% CI −10.90 to 4.44, 1 trial, 26 participants; see <a href="./references#CD002795-fig-0104" title="">Analysis 19.4</a>; <a href="./references#CD002795-bbs2-0041" title="McRaeAL , BradyKT , MellmanTA , SonnSC , KilleenTK , TimmermanMA , et al.Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depression and Anxiety2004;19(3):190–6. [DOI: 10.1002/da.20008]">McRae 2004</a>), or for reboxetine and fluvoxamine on the HAM‐A (MD 1.80 points, 95% CI −1.30 to 4.90; 1 trial, 28 participants; see <a href="./references#CD002795-fig-0104" title="">Analysis 19.4</a>; <a href="./references#CD002795-bbs2-0058" title="SpivakB , StrousRD , ShakedG , ShabashE , KotlerM , WeizmanA .Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. Journal of Clinical Psychopharmacology2006;26(2):152–6. [DOI: 10.1097/01.jcp.0000203195.65710.f0]">Spivak 2006</a>). </p> </section> <section id="CD002795-sec-0111"> <h4 class="title">Comparison 20: Subgroup analyses ‐ Methodological criteria</h4> <p>We found evidence of a benefit in the analysis of treatment response for single‐centre trials and for multi‐centre trials (Chi<sup>2</sup> = 0.77, df = 1 (P = 0.38); I<sup>2</sup> = 0%; see <a href="./references#CD002795-fig-0105" title="">Analysis 20.1</a>). Symptom severity in the 22 trials which took place across multiple centres for which the CAPS total score was available was reduced to a greater extent than in the eight trials conducted within single centres (Chi<sup>2</sup> = 1.24, df = 1 (P = 0.27); I<sup>2</sup> = 19.1%; see <a href="./references#CD002795-fig-0106" title="">Analysis 20.2</a>). </p> <p>There was evidence of a benefit in treatment response based on source of funding and to a lesser extent for non‐industry‐funded trials (Chi<sup>2</sup> = 0.42, df = 1 (P = 0.52); I<sup>2</sup> = 0%; see <a href="./references#CD002795-fig-0107" title="">Analysis 20.3</a>) on the CGI‐I. This was also observed in the analysis of the reduction of PTSD symptoms for industry‐funded trials versus non‐industry‐funded trials (Chi<sup>2</sup> = 3.15, df = 1 (P = 0.08), I<sup>2</sup> = 68.2%; see <a href="./references#CD002795-fig-0108" title="">Analysis 20.4</a>). </p> </section> <section id="CD002795-sec-0112"> <h4 class="title">Comparison 21: Subgroup analyses ‐ Clinical criteria</h4> <p>There was evidence of a benefit of treatment response for trials which included depressed participants compared to those trials which did not (Chi<sup>2</sup> = 2.57, df = 1 (P = 0.11), I<sup>2</sup> = 61.1%; see <a href="./references#CD002795-fig-0109" title="">Analysis 21.1</a>). For the outcome of symptom severity, there was evidence of a benefit of the reduction of PTSD symptoms in trials which included depressed participants, as in those trials which did not (Chi<sup>2</sup> = 0.94, df = 1 (P = 0.33), I<sup>2</sup> = 0%; see <a href="./references#CD002795-fig-0110" title="">Analysis 21.2</a>). </p> <p>We found evidence of a benefit between groups for trials including war trauma compared to trials without war trauma (Chi<sup>2</sup> = 0.06, df = 1 (P = 0.81); I<sup>2</sup> = 0%; see <a href="./references#CD002795-fig-0111" title="">Analysis 21.3</a>). RCTs which contained participants without war trauma demonstrated evidence of a reduction in symptom severity following medication treatment compared with trials containing participants with war trauma exposure (Chi<sup>2</sup> = 4.21, df = 1 (P = 0.04), I<sup>2</sup> = 76.3%; see <a href="./references#CD002795-fig-0112" title="">Analysis 21.4</a>). The finding of a beneficial effect in the reduction of symptom severity between trials with few war veterans versus those with many was not surprising, given the general characterisation of the war trauma subgroup of PTSD sufferers as more treatment‐resistant than other subgroups. </p> </section> <section id="CD002795-sec-0113"> <h4 class="title">Comparison 22: Sensitivity analyses</h4> <p>The comparison of the analysis of treatment efficacy for non‐response as opposed to response on the CGI‐I (or equivalent) revealed similar outcomes for both the overall short‐term efficacy of medication (RR 0.72; 95% CI 0.62 to 0.83; 20 trials, 1847 participants; see <a href="./references#CD002795-fig-0113" title="">Analysis 22.1</a>), as well as for the efficacy of the NaSSA mirtazapine (RR 0.45; 95% CI 0.22 to 0.94; 1 trial, 26 participants; see <a href="./references#CD002795-fig-0113" title="">Analysis 22.1</a>), the SSRIs (RR 0.66; 95% CI 0.59 to 0.74; 8 trials, 1078 participants; see <a href="./references#CD002795-fig-0113" title="">Analysis 22.1</a>), and the TCA amitriptyline in treating PTSD (RR 0.60, 95% CI 0.38 to 0.96; 1 trial, 40 participants; see <a href="./references#CD002795-fig-0113" title="">Analysis 22.1</a>). However, the use of treatment non‐response as a summary statistic indicates that the anticonvulsants, antipsychotics, experimental medications and MAOIs were no more effective than placebo. </p> <p>The number of participants responding to medication was significantly higher compared to placebo in both the worst‐case scenario (RR 0.83, 95% CI 0.69 to 1.00; 13 trials, 1555 participants; see <a href="./references#CD002795-fig-0114" title="">Analysis 22.2</a>), where those participants from the medication group who were not included in the analysis were regarded as non‐responders, and in the best‐case scenario (RR 1.41, 95% CI 1.12 to 1.78; 13 trials, 1498 participants; see <a href="./references#CD002795-fig-0115" title="">Analysis 22.3</a>), in which those participants excluded from the placebo control were regarded as non‐responders. The overlap in the confidence intervals for these two outcomes indicates that loss to follow‐up is unlikely to have influenced assumptions about the overall efficacy of medication. </p> </section> <section id="CD002795-sec-0114"> <h4 class="title">Comparison 23: Publication bias</h4> <p>The distribution of trials on a funnel plot for treatment response (see <a href="#CD002795-fig-0004">Figure 4</a>) and symptom severity (see <a href="#CD002795-fig-0005">Figure 5</a>) demonstrate no evidence for substantial publication bias. </p> <div class="figure" id="CD002795-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 13 Comparison 13: SSRIs versus placebo, outcome: 13.1 Clinical Global Impressions scale improvement item (CGI‐I). Note: The left side favours the SSRI arm and the right side favours the placebo arm." data-id="CD002795-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 13 Comparison 13: SSRIs versus placebo, outcome: 13.1 Clinical Global Impressions scale improvement item (CGI‐I). Note: The left side favours the SSRI arm and the right side favours the placebo arm. </p> </div> </div> </div> <div class="figure" id="CD002795-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 15 Comparison 13: SSRIs versus placebo, outcome: 15.5 Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms. Note: The left side favours the SSRI arm and the right side favours the placebo arm." data-id="CD002795-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 15 Comparison 13: SSRIs versus placebo, outcome: 15.5 Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms. Note: The left side favours the SSRI arm and the right side favours the placebo arm. </p> </div> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002795-sec-0115" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002795-sec-0115"></div> <section id="CD002795-sec-0116"> <h3 class="title" id="CD002795-sec-0116">Summary of main results</h3> <p>For the primary outcome measure of PTSD response to treatment, this review found evidence of beneficial effect for the SSRIs (i.e. citalopram, fluoxetine, paroxetine, and sertraline), based on moderate‐certainty evidence. We also found evidence of beneficial effect for the NaSSA mirtazapine and the TCA amitriptyline. The remaining medication classes (i.e. anticonvulsant, antipsychotic, GR205171, GSK561679, and RIMA groups), did not, however, provide evidence of a benefit. </p> <p>Individuals diagnosed with PTSD who were treated with individual SSRI agents, and in particular the SSRI paroxetine, were more likely to withdraw from treatment due to treatment‐related adverse events. Nevertheless, the absolute proportion of individuals dropping out from treatment due to treatment‐related adverse events was low (9%), with the difference in dropouts from the control group of two percentage points unlikely to be clinically significant, based on moderate‐certainty evidence. </p> <p>For the secondary outcome measure of PTSD symptom reduction on the CAPS there was also evidence of a benefit of efficacy for the SSRIs, the antipsychotics, and the SNRI venlafaxine. Medication was significantly more effective than placebo across the re‐experiencing/intrusion, avoidance/numbing, and hyperarousal cluster assessed by the CAPS for the SSRIs and the SNRIs. We also found evidence of a benefit for reducing PTSD symptoms on the CGI‐S for the SSRIs, the SNRI venlafaxine and for the antipsychotics. This was also evidence for the SSRIs, the SNRI venlafaxine, and the MAOIs on the self‐rated IES or the DTS. Direct comparisons of sertraline and nefazodone, of venlafaxine and sertraline, and of reboxetine and fluvoxamine indicated that these medications were not effective in reducing PTSD symptom severity. Moreover, the reduction of PTSD was not observed in the long‐term trials included in the review. </p> <p>We found evidence of efficacy for reducing depression symptoms only observed for the antipsychotic group. For the reduction of anxiety symptoms, evidence of a benefit was observed for the MAOI, NaSSA and TCA groups. In addition, the SSRIs and the SNRI venlafaxine were the only medications showing a treatment effect on the SDS. </p> <p>The review also found evidence of a difference of dropouts due to any cause for the SARI nefazodone and the TCAs, although dropout rates were low (24%, 28%, respectively). Subgroup analysis of trials where depression was and was not an inclusion criterion found differences in efficacy (i.e. for the number of participants who responded to treatment). We also found evidence of a benefit in response or reduction or both for single versus multi‐site studies and for industry‐funded versus non‐industry‐funded studies. We also found that war veterans are more resistant to pharmacotherapy than other patient groups, in terms of treatment response and reduction of symptom severity. </p> <p>When studies were combined, evidence of a benefit was found on the CGI‐I and CAPS across all medications. Further, no evidence of a harm was found across studies that reported this, and dropouts due to any cause were similar across the medication classes.Also, no publication bias was observed for the SSRI group versus the placebo group. We could not assess the remaining medication classes due to lack of sufficient trials. </p> </section> <section id="CD002795-sec-0117"> <h3 class="title" id="CD002795-sec-0117">Overall completeness and applicability of evidence</h3> <section id="CD002795-sec-0118"> <h4 class="title">Completeness of evidence</h4> <p>Although it has been suggested that the SSRIs are more effective than older antidepressants (<a href="./references#CD002795-bbs2-0208" title="DowB , KlineN .Antidepressant treatment of posttraumatic stress disorder and major depression in veterans. Annals of Clinical Psychiatry1997;9(1):1-5.">Dow 1997</a>; <a href="./references#CD002795-bbs2-0273" title="PenavaSJ , OttoMW , PollackMH , RosenbaumJF .Current status of pharmacotherapy for PTSD: an effect size analysis of controlled studies. Depression and Anxiety1996;4(5):240-2.">Penava 1996</a>), class membership did not contribute significantly to the variation observed in symptom severity outcomes between trials, and the confidence intervals for the summary statistic of responder status on the SSRI trials overlapped with the NaSSA mirtazapine and the TCA amitriptyline, probably reflecting insufficient power for this comparison to reach statistical significance. Similarly, direct comparisons of sertraline and nefazodone, of venlafaxine and sertraline, and of reboxetine and fluvoxamine, did not demonstrate differences between these treatments in reducing PTSD symptoms. Although the SSRIs have been argued and have shown superior tolerability in comparison to older medication classes in this review, it is important to be aware of the need for careful monitoring after initiation of individual SSRI agents (<a href="./references#CD002795-bbs2-0190" title="Committee on Safety of Medicines.Report of the CSM expert working group on the safety of selective serotonin reuptake inhibitor antidepressants. https://www.neuroscience.ox.ac.uk/publications/4740472005.">CSM 2005</a>). Nevertheless, the SSRI trials constitute the bulk of the evidence for the efficacy of medication in treating PTSD, both in the number of studies and their size. It is therefore reasonable to support the expert consensus (<a href="./references#CD002795-bbs2-0162" title="BallengerJC , DavidsonJR , LecrubierY , NuttDJ , FoaEB , KesslerRC , et al.Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. Journal of Clinical Psychiatry2000;61(Suppl 5):60-6.">Ballenger 2000</a>; <a href="./references#CD002795-bbs2-0163" title="BallengerJC , DavidsonJR , LecrubierY , NuttDJ , MarshallRD , NemeroffCB , et al.Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety. Journal of Clinical Psychiatry2004;65(Suppl 1):55-62.">Ballenger 2004</a>; <a href="./references#CD002795-bbs2-0218" title="FoaEB , DavidsonJR , FrancesA .The expert consensus guideline series: treatment of posttraumatic stress disorder: the expert consensus panel for PTSD. Journal of Clinical Psychiatry1999;60(Suppl. 16):1-75.">Foa 1999</a>; <a href="./references#CD002795-bbs2-0271" title="NICE.Post-traumatic stress disorder: management (NG116). Clinical guideline Published: December 2018. National Institute for Health and Care Excellence2018.">NICE 2018</a>) that SSRIs constitute the first‐line medication choice for PTSD. </p> <p>In addition, industry‐funded trials found a larger reduction in CAPS total score than in non‐industry‐funded trials, which could be a potential bias because published trials sponsored by pharmaceutical companies appear more likely to report positive findings than trials that are not supported by for‐profit companies (<a href="./references#CD002795-bbs2-0153" title="Als-NielsenB , ChenW , GluudC , KjaergardLL .Association of funding and conclusions in randomized drug trials - A reflection of treatment effect or adverse events?JAMA2003;290(7):921-8.">Als‐Nielsen 2003</a>; <a href="./references#CD002795-bbs2-0160" title="BakerCB , JohnsrudMT , CrismonML , RosenheckRA , WoodsSW .Quantitative analysis of sponsorship bias in economic studies of antidepressants. British Journal of Psychiatry2003;183:498-506.">Baker 2003</a>). </p> </section> <section id="CD002795-sec-0119"> <h4 class="title">Applicability of evidence</h4> <p>Studies included men and women across a wide age range. Furthermore, the existing evidence base of RCTs includes a heterogeneous sample of participants with a range of different traumas, trauma duration and severity, and comorbidity. Nevertheless, people with PTSD who are recruited to clinical trials may not be representative of those with PTSD in the community (<a href="./references#CD002795-bbs2-0221" title="FrancoS , HoertelN , McMahonK , WangS , Rodríguez-FernándezJM , PeyreH , et al.Generalizability of pharmacologic and psychotherapy clinical trial results for posttraumatic stress disorder to community samples. Journal of Clinical Psychiatry2016;77(8):975-81. [DOI: doi: 10.4088/JCP.15m10060]">Franco 2016</a>). Given the high prevalence and enormous personal and societal costs of PTSD, there are still relatively few RCTs of pharmacotherapy for PTSD, with some notable gaps. With a few exceptions (<a href="./references#CD002795-bbs2-0002" title="BakerDG , DiamondBI , GilletteG , HamnerM , KatzelnickD , KellerT , et al.A double-blind randomized placebo-controlled multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology1995;122(4):386-9. ConnorKM , HidalgoRB , CrockettB , MalikM , KatzRJ , DavidsonJR .Predictors of treatment response in patients with posttraumatic stress disorder. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry2001;25(2):337-45. ">Baker 1995</a>; <a href="./references#CD002795-bbs2-0005" title="BraunP , GreenbergD , DasbergH , LererB .Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. Journal of Clinical Psychiatry1990;51(6):236-8. ">Braun 1990</a>; <a href="./references#CD002795-bbs2-0011" title="DavidsonJR , KudlerH , SmithR , MahorneySL , LipperS , HammettE , et al.Treatment of posttraumatic stress disorder with amitriptyline and placebo. Archives of General Psychiatry1990;47(3):259-66. DavidsonJR , KudlerHS , SaundersWB , EricksonL , SmithRD , SteinRM , et al.Predicting response to amitriptyline in posttraumatic stress disorder. American Journal of Psychiatry1993;150(7):1024-9. ">Davidson 1990</a>; <a href="./references#CD002795-bbs2-0028" title="HertzbergMA , ButterfieldMI , FeldmanME , BeckhamJC , SutherlandSM , ConnorKM , et al.A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biological Psychiatry1999;45(9):1226-9. ">Hertzberg 1999</a>; <a href="./references#CD002795-bbs2-0029" title="HertzbergMA , FeldmanME , BeckhamJC , KudlerHS , DavidsonJR .Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Annals of Clinical Psychiatry2000;12(2):101-5. ">Hertzberg 2000</a>; <a href="./references#CD002795-bbs2-0052" title="ReistC , KauffmannCD , Chicz DemetA , ChenCC , DemetEM .REM latency, dexamethasone suppression test, and thyroid releasing hormone stimulation test in posttraumatic stress disorder. Progress in Neuropsychopharmacology and Biological Psychiatry1995;19(3):433-43. ReistC , KauffmannCD , HaierRJ , SangdahlC , DeMetEM , Chicz-DeMetA , et al.A controlled trial of desipramine in 18 men with posttraumatic stress disorder. American Journal of Psychiatry1989;146(4):513-6. ">Reist 1989</a>), trials have excluded people with comorbid substance use. Although outside the scope of the current review, there is also a need for additional work on the pharmacotherapy for the prevention of PTSD (<a href="./references#CD002795-bbs2-0154" title="AmosT , SteinDJ , IpserJC .Pharmacological interventions for preventing post-traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews2014, Issue Issue 7. Art. No.: CD006239. Art. No: CD006239. [DOI: 10.1002/14651858.CD006239.pub2]">Amos 2014</a>). </p> </section> </section> <section id="CD002795-sec-0120"> <h3 class="title" id="CD002795-sec-0120">Quality of the evidence</h3> <p>Sixteen RCTs had a high risk of bias related to at least one aspect of study design, with the most commonly‐observed weakness relating to attrition bias (<a href="./references#CD002795-bbs2-0006" title="ButterfieldMI , BeckerME , ConnorKM , SutherlandS , ChurchillLE , DavidsonJR .Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. International Clinical Psychopharmacology2001;16(4):197-203. ">Butterfield 2001</a>; <a href="./references#CD002795-bbs2-0008" title="ChungMY , MinKH , JunYJ , KimSS , KimWC , JunEM .Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Human Psychopharmacology2004;19(7):489–94. [DOI: 10.1002/hup.615]">Chung 2004</a>; <a href="./references#CD002795-bbs2-0010" title="ConnorKM , DavidsonJR , WeislerRH , ZhangW , AbrahamK .Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology2006;184:21–5. [DOI: 10.1007/s00213-005-0265-3]">Connor 2006</a>; <a href="./references#CD002795-bbs2-0020" title="DavisLL , DavidsonJR , WardC , BartolucciA , BowdenCL , PettyF .Divalproex in the treatment of posttraumatic tress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. Journal of Clinical Psychopharmacology2008;28(21):84–8. [DOI: 10.1097/jcp.0b013e318160f83b]">Davis 2008</a>; <a href="./references#CD002795-bbs2-0024" title="FederA , ParidesMK , MurroughJW , PerezAM , MorganJE , SaxenaS , et al.Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder. A randomized clinical trial. JAMA Psychiatry2014;71(6):681-8. [DOI: 10.1001/jamapsychiatry.2014.62]">Feder 2014</a>; <a href="./references#CD002795-bbs2-0028" title="HertzbergMA , ButterfieldMI , FeldmanME , BeckhamJC , SutherlandSM , ConnorKM , et al.A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biological Psychiatry1999;45(9):1226-9. ">Hertzberg 1999</a>; <a href="./references#CD002795-bbs2-0032" title="KostenTR , FrankJB , DanE , McDougleCJ , Giller EL Jr.Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. Journal of Nervous and Mental Disease1991;179(6):366–70. ">Kosten 1991</a>; <a href="./references#CD002795-bbs2-0037" title="MartenyiF , BrownEB , ZhangH , KokeSC , PrakashA .Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. British Journal of Psychiatry2002;181:315-20. ">Martenyi 2002b</a>; <a href="./references#CD002795-bbs2-0044" title="NCT01681849.Neural circuits in women with abuse and Posttraumatic Stress Disorder. clinicaltrials.gov/ct2/show/NCT01681849 (first received 10 September 2012). ">NCT01681849</a>; <a href="./references#CD002795-bbs2-0051" title="ReichDB , WinternitzS , HennenJ , WattsT , StanculescuC .A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. Journal of Clinical Psychiatry2004;65(12):1601-5. ">Reich 2004</a>; <a href="./references#CD002795-bbs2-0053" title="SayginMZ , SungurMZ , SabolEU , CetinkayaP .Nefazodone versus sertraline in treatment of posttraumatic stress disorder. Bulletin of Clinical Psychopharmacology2002;12(1):1-5. ">Saygin 2002</a>; <a href="./references#CD002795-bbs2-0057" title="SmajkicA , WeineS , Djuric-BijedicZ , BoskailoE , LewisJ , PavkovicI .Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms. Journal of Traumatic Stress2001;14(3):445-52. ">Smajkic 2001</a>; <a href="./references#CD002795-bbs2-0058" title="SpivakB , StrousRD , ShakedG , ShabashE , KotlerM , WeizmanA .Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. Journal of Clinical Psychopharmacology2006;26(2):152–6. [DOI: 10.1097/01.jcp.0000203195.65710.f0]">Spivak 2006</a>; <a href="./references#CD002795-bbs2-0062" title="Van der KolkBA , DreyfussD , MichaelsM , SheraD , BerkowitzR , FislerR , et al.Fluoxetine treatment in posttraumatic stress disorder. Journal of Clinical Psychiatry1994;55(12):517-22. ">Van der Kolk 1994</a>; <a href="./references#CD002795-bbs2-0064" title="VillarrealG , HamnerMB , CañiveJM , RobertS , CalaisLA , DurklaskiV , et al.Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. American Journal of Psychiatry2016;173(12):1205-12. [DOI: 10.1176/appi.ajp.2016.15070967]">Villarreal 2016</a>). Lack of blinding for outcome assessors may also have influenced the detection of treatment effects in three trials (<a href="./references#CD002795-bbs2-0008" title="ChungMY , MinKH , JunYJ , KimSS , KimWC , JunEM .Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Human Psychopharmacology2004;19(7):489–94. [DOI: 10.1002/hup.615]">Chung 2004</a>; <a href="./references#CD002795-bbs2-0053" title="SayginMZ , SungurMZ , SabolEU , CetinkayaP .Nefazodone versus sertraline in treatment of posttraumatic stress disorder. Bulletin of Clinical Psychopharmacology2002;12(1):1-5. ">Saygin 2002</a>; <a href="./references#CD002795-bbs2-0057" title="SmajkicA , WeineS , Djuric-BijedicZ , BoskailoE , LewisJ , PavkovicI .Sertraline, paroxetine, and venlafaxine in refugee posttraumatic stress disorder with depression symptoms. Journal of Traumatic Stress2001;14(3):445-52. ">Smajkic 2001</a>). There was also evidence for selective reporting bias in <a href="./references#CD002795-bbs2-0020" title="DavisLL , DavidsonJR , WardC , BartolucciA , BowdenCL , PettyF .Divalproex in the treatment of posttraumatic tress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. Journal of Clinical Psychopharmacology2008;28(21):84–8. [DOI: 10.1097/jcp.0b013e318160f83b]">Davis 2008</a>, <a href="./references#CD002795-bbs2-0024" title="FederA , ParidesMK , MurroughJW , PerezAM , MorganJE , SaxenaS , et al.Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder. A randomized clinical trial. JAMA Psychiatry2014;71(6):681-8. [DOI: 10.1001/jamapsychiatry.2014.62]">Feder 2014</a> and <a href="./references#CD002795-bbs2-0064" title="VillarrealG , HamnerMB , CañiveJM , RobertS , CalaisLA , DurklaskiV , et al.Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. American Journal of Psychiatry2016;173(12):1205-12. [DOI: 10.1176/appi.ajp.2016.15070967]">Villarreal 2016</a>. Even though the SSRIs were the best‐studied medication class, we rated most of these trials as unclear for randomisation procedures. </p> <p>Judgements of the primary outcome measure of response to treatment with the SSRIs were based on evidence rated as being of moderate certainty. Additional research may therefore impact effect size and confidence intervals (see <a href="./full#CD002795-tbl-0006">summary of findings Table 6</a>). Findings of treatment efficacy for the NaSSA mirtazapine and for the TCA amitriptyline were based on evidence rated as being of low‐certainty (see <a href="./full#CD002795-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD002795-tbl-0007">summary of findings Table 7</a>), indicating that data from additional studies may also change the effect size and confidence intervals for these medication classes. The most common reasons for downgrading the quality of studies were imprecise effect estimates, low response rates, small sample size, a rating of high or unclear bias for study design (based on 50% attrition rates across groups, detection, and selective reporting bias), and heterogeneity between the medication and placebo groups. </p> <p>Although a recent guideline noted that, with few exceptions, the overall effect size for medication trials for PTSD failed to exceed the limit of 0.5 defined as indicative of clinical efficacy (<a href="./references#CD002795-bbs2-0271" title="NICE.Post-traumatic stress disorder: management (NG116). Clinical guideline Published: December 2018. National Institute for Health and Care Excellence2018.">NICE 2018</a>), we would caution that there is no direct translation between the effect size statistic and assessments of clinical efficacy. The findings here of efficacy for the primary outcome measure of CGI‐I response rate support the clinical consensus that medication does have an important role in the treatment of PTSD. </p> <p>Trials tested in this review where depression was or was not an inclusion criterion were able to account for the substantial proportion of participants who do not appear to respond to medication. The finding that symptom severity is reduced to a greater extent in multi‐centre than in the single‐centre trials should be interpreted with caution, due to the marginal significance of this finding. The finding of an association between the presence of participants with comorbid major depression and treatment efficacy suggests that medications are likely to exert their effects on PTSD via a reduction in depressive symptoms. This review also found evidence that war veterans are more resistant to pharmacotherapy than other patient groups, for response and the reduction of symptom severity. However, several RCTs with war veteran samples were excluded from this review (<a href="./references#CD002795-bbs2-0071" title="BartzokisG , LuPH , TurnerJ , MintzJ , SaundersCS .Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biological Psychiatry2005;57(5):474-9. ">Bartzokis 2005</a>; <a href="./references#CD002795-bbs2-0090" title="HamnerM , UlmerH , HorneD .Buspirone potentiation of antidepressants in the treatment of PTSD. Depression and Anxiety1997;5(3):137-9. ">Hamner 1997</a>; <a href="./references#CD002795-bbs2-0092" title="HamnerMB , FaldowskiRA , UlmerHG , FruehBC , HuberMG , AranaGW .Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. International Clinical Psychopharmacology2003;18(1):1-8. ">Hamner 2003</a>; <a href="./references#CD002795-bbs2-0100" title="MonnellyEP , CirauloDA , KnappC , KeaneT .Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. Journal of Clinical Psychopharmacology2003;23(2):193-6. ">Monnelly 2003</a>; <a href="./references#CD002795-bbs2-0120" title="RaskindMA , PeskindER , KanterED , PetrieEC , RadantA , ThompsonCE , et al.Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. American Journal of Psychiatry2003;160(2):371-3. ">Raskind 2003</a>; <a href="./references#CD002795-bbs2-0128" title="SteinMB , KlineNA , MatloffJL .Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. American Journal of Psychiatry2002;159(10):1777-9. ">Stein 2002</a>) (see <a href="./references#CD002795-sec-0159" title="">Characteristics of excluded studies</a>), and it was not possible to classify certain large‐scale unpublished trials according to trauma type (<a href="./references#CD002795-bbs2-0055" title="Food and Drug Administration (FDA).NDA 20-031/S-029 Paxil (paroxetine hydrochloride) tablets; GlaxoSmithKline; Post-traumatic Stress Disorder. www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-031S029.pdf;(accessed 28 November 2021). GlaxoSmithKline.A 12-week, double-blind, placebo-controlled, parallel group study to assess the efficacy and tolerability of paroxetine in patients suffering from posttraumatic stress disorder (PTSD). GSK - clinical study register [www.gsk-clinicalstudyregister.com]:Study ID: 29060/627. SmithKline Beecham.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. SteinDJ , DavidsonJ , SeedatS , BeebeK .Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies. Expert Opinion on Pharmacotherapy2003;4(10):1829-38. ">SKB627</a>; <a href="./references#CD002795-bbs2-0056" title="SmithKline Beecham.Unpublished data. Appendix 14 of 2nd consultation draft for the NICE (2005) PTSD guidelines. ">SKB650</a>). Given the heterogeneous phenomenology of PTSD, it remains crucial to determine the factors which do predict response to medication, and to delineate whether certain medications are more effective for particular symptom sets (including symptoms such as psychosis (<a href="./references#CD002795-bbs2-0232" title="HamnerMB .Clozapine treatment for a veteran with comorbid psychosis and PTSD (letter). American Journal of Psychiatry1996;153(6):841.">Hamner 1996</a>), dissociation (<a href="./references#CD002795-bbs2-0216" title="FichtnerCG , KuhlmanDT , GruenfeldMJ , HughesJR .Decreased episodic violence and increased control of dissociation in a carbamazepine-treated case of multiple personality. Biological Psychiatry1990;27(9):1045-52.">Fichtner 1990</a>; <a href="./references#CD002795-bbs2-0264" title="MarshallRD , SchneierFR , FallonBA , KnightCB , AbbateLA , GoetzD , et al.An open trial of paroxetine in patients with noncombat-related posttraumatic stress disorder. Journal of Clinical Psychopharmacology1998;18(1):10-8.">Marshall 1998b</a>) and vulnerability to stress (<a href="./references#CD002795-bbs2-0187" title="ConnorKM , DavidsonJR , WeislerRH , AhearnE .A pilot study of mirtazapine in post-traumatic stress disorder. International Clinical Psychopharmacology1999;14(1):29-31.">Connor 1999b</a>)). Future RCTs and meta‐analyses should attempt to address such questions in greater detail. </p> </section> <section id="CD002795-sec-0121"> <h3 class="title" id="CD002795-sec-0121">Potential biases in the review process</h3> <p>We conducted an extensive search for studies meeting rigorous inclusion criteria and made repeated efforts to obtain missing data from the trial investigators. Nevertheless, there were insufficient data available to assess the extent to which selective publication may have introduced bias into the findings for medication classes other than the SSRIs, where no publication bias was observed (see <a href="#CD002795-fig-0004">Figure 4</a>; <a href="#CD002795-fig-0005">Figure 5</a>). </p> <p>Furthermore, the inherent problems of meta‐analysis should be borne in mind (<a href="./references#CD002795-bbs2-0159" title="Bailar JC 3rd.The promise and problems of meta-analysis. New England Journal of Medicine1999;337(8):559-61.">Bailar 1997</a>); certainly, these are by no means a substitute for primary clinical research. This is especially the case when there is evidence that trials with negative outcomes are not being published. Also, the context of clinical practice differs from that of controlled trials in many respects, not least being the inclusion of more complex participants (including those with possible 'secondary gain' from symptoms, a group that has been specifically excluded from some RCTs) (<a href="./references#CD002795-bbs2-0004" title="BradyK , PearlsteinT , AsnisGM , BakerD , RothbaumB , SikesCR , et al.Efficacy and safety of sertraline treatment of posttraumatic stress disorder. Archives of General Psychiatry2000;283(14):1837-44. DavidsonJ , PearlsteinT , LondborgP , BradyKT , RothbaumB , BellJ , et al.Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry2001;158(12):1974-81. DavidsonJR , LandermanLR , FarfelGM , ClaryCM .Characterizing the effects of sertraline in post-traumatic stress disorder. Psychological Medicine2002;32(4):661-70. GaffneyM .Factor analysis of treatment response in posttraumatic stress disorder. Journal of Traumatic Stress2003;16(1):77-80. RapaportMH , EndicottJ , ClaryCM .Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. Journal of Clinical Psychiatry2002;63(1):59-65. RapaportMH , FarfelG , ClaryCM .Quality of life improvement in PTSD with sertraline treatment: results of a multicenter, placebo-controlled trial. International Journal of Neuropsychopharmacology2000;3(Suppl 1):294. ">Brady 2000</a>). </p> </section> <section id="CD002795-sec-0122"> <h3 class="title" id="CD002795-sec-0122">Agreements and disagreements with other studies or reviews</h3> <p>The findings of this review are consistent with findings from other systematic reviews and meta‐analyses in identifying the SSRIs as first‐line agents for the treatment of PTSD (<a href="./references#CD002795-bbs2-0245" title="HoskinsM , PearceJ , BethellA , DankovaL , BarbuiC , TolWA , et al.Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. British Journal of Psychiatry2015;206(2):93–100. [DOI: 10.1192/bjp.bp.114.148551]">Hoskins 2015</a>; <a href="./references#CD002795-bbs2-0246" title="IpserJC , SteinDJ .Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). International Journal of Neuropsychopharmacology2012;15(6):825–40. [DOI: org/10.1017/S1461145711001209]">Ipser 2012</a>). This review classified medications based on their putative mechanisms of action (taken from CCMD antidepressant classification map) (<a href="./references#CD002795-bbs2-0200" title="DaviesSJ , ChampionC , DawsonS , SharpJ , ChurchillR .The Subway Map - a new way to visualize antidepressant classification (a Cochrane CCDAN initiative). In: 14th ICGP and 19th JSNP Joint Congress; 3 October. Tsukuba, Japan, 2014: 78. [Abstract P14]. 2015.">Davies 2015</a>), and these do not necessarily map onto the drug classification schemes used in other reviews. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002795-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD002795-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#CD002795-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002795-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#CD002795-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD002795-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#CD002795-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 13 Comparison 13: SSRIs versus placebo, outcome: 13.1 Clinical Global Impressions scale improvement item (CGI‐I). Note: The left side favours the SSRI arm and the right side favours the placebo arm." data-id="CD002795-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 13 Comparison 13: SSRIs versus placebo, outcome: 13.1 Clinical Global Impressions scale improvement item (CGI‐I). Note: The left side favours the SSRI arm and the right side favours the placebo arm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#CD002795-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 15 Comparison 13: SSRIs versus placebo, outcome: 15.5 Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms. Note: The left side favours the SSRI arm and the right side favours the placebo arm." data-id="CD002795-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 15 Comparison 13: SSRIs versus placebo, outcome: 15.5 Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms. Note: The left side favours the SSRI arm and the right side favours the placebo arm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#CD002795-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Alpha‐blockers versus placebo, Outcome 1: Dropout rate due to treatment‐emergent adverse effects" data-id="CD002795-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Alpha‐blockers versus placebo, Outcome 1: Dropout rate due to treatment‐emergent adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Alpha‐blockers versus placebo, Outcome 2: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms" data-id="CD002795-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Alpha‐blockers versus placebo, Outcome 2: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Alpha‐blockers versus placebo, Outcome 3: Self‐rated scales" data-id="CD002795-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Alpha‐blockers versus placebo, Outcome 3: Self‐rated scales</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Alpha‐blockers versus placebo, Outcome 4: Depression scale (typically Hamilton Depression)" data-id="CD002795-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Alpha‐blockers versus placebo, Outcome 4: Depression scale (typically Hamilton Depression) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Alpha‐blockers versus placebo, Outcome 5: Dropout rate due to any cause" data-id="CD002795-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Alpha‐blockers versus placebo, Outcome 5: Dropout rate due to any cause</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticonvulsants versus placebo, Outcome 1: Clinical Global Impressions Scale Improvement Item (CGI‐I)" data-id="CD002795-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Anticonvulsants versus placebo, Outcome 1: Clinical Global Impressions Scale Improvement Item (CGI‐I) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticonvulsants versus placebo, Outcome 2: Dropout rate due to treatment emergent adverse effects" data-id="CD002795-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Anticonvulsants versus placebo, Outcome 2: Dropout rate due to treatment emergent adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticonvulsants versus placebo, Outcome 3: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms" data-id="CD002795-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Anticonvulsants versus placebo, Outcome 3: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticonvulsants versus placebo, Outcome 4: Symptom severity: Other measures" data-id="CD002795-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Anticonvulsants versus placebo, Outcome 4: Symptom severity: Other measures</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticonvulsants versus placebo, Outcome 5: Self‐rated scales" data-id="CD002795-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Anticonvulsants versus placebo, Outcome 5: Self‐rated scales</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticonvulsants versus placebo, Outcome 6: Depression scale (typically Hamilton Depression)" data-id="CD002795-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Anticonvulsants versus placebo, Outcome 6: Depression scale (typically Hamilton Depression) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticonvulsants versus placebo, Outcome 7: Anxiety ‐ Hamilton Anxiety Scale" data-id="CD002795-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Anticonvulsants versus placebo, Outcome 7: Anxiety ‐ Hamilton Anxiety Scale </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticonvulsants versus placebo, Outcome 8: Anxiety ‐ Other scales" data-id="CD002795-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Anticonvulsants versus placebo, Outcome 8: Anxiety ‐ Other scales</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticonvulsants versus placebo, Outcome 9: Sheehan Disability Scale" data-id="CD002795-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Anticonvulsants versus placebo, Outcome 9: Sheehan Disability Scale</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticonvulsants versus placebo, Outcome 10: Dropout rate due to any cause" data-id="CD002795-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Anticonvulsants versus placebo, Outcome 10: Dropout rate due to any cause </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antipsychotics versus placebo, Outcome 1: Clinical Global Impressions Scale Improvement Item (CGI‐I)" data-id="CD002795-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Antipsychotics versus placebo, Outcome 1: Clinical Global Impressions Scale Improvement Item (CGI‐I) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antipsychotics versus placebo, Outcome 2: Drop‐out rate due to treatment emergent adverse effects" data-id="CD002795-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Antipsychotics versus placebo, Outcome 2: Drop‐out rate due to treatment emergent adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antipsychotics versus placebo, Outcome 3: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms" data-id="CD002795-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Antipsychotics versus placebo, Outcome 3: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antipsychotics versus placebo, Outcome 4: Symptom severity: Other measures" data-id="CD002795-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Antipsychotics versus placebo, Outcome 4: Symptom severity: Other measures</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antipsychotics versus placebo, Outcome 5: Self‐rated scales" data-id="CD002795-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Antipsychotics versus placebo, Outcome 5: Self‐rated scales</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antipsychotics versus placebo, Outcome 6: Depression Scale (typically Hamilton Depression)" data-id="CD002795-fig-0026" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Antipsychotics versus placebo, Outcome 6: Depression Scale (typically Hamilton Depression) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antipsychotics versus placebo, Outcome 7: Anxiety ‐ Hamilton Anxiety Scale" data-id="CD002795-fig-0027" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Antipsychotics versus placebo, Outcome 7: Anxiety ‐ Hamilton Anxiety Scale </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antipsychotics versus placebo, Outcome 8: Sheehan Disability Scale" data-id="CD002795-fig-0028" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Antipsychotics versus placebo, Outcome 8: Sheehan Disability Scale</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Antipsychotics versus placebo, Outcome 9: Drop‐out rate due to any cause" data-id="CD002795-fig-0029" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Antipsychotics versus placebo, Outcome 9: Drop‐out rate due to any cause</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Benzodiazepines versus placebo, Outcome 1: Drop‐out rate due to treatment emergent adverse effects" data-id="CD002795-fig-0030" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Benzodiazepines versus placebo, Outcome 1: Drop‐out rate due to treatment emergent adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Benzodiazepines versus placebo, Outcome 2: Drop‐out rate due to any cause" data-id="CD002795-fig-0031" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Benzodiazepines versus placebo, Outcome 2: Drop‐out rate due to any cause </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Dopamine beta‐hydroxylase inhibitors versus placebo, Outcome 1: Drop‐out rate due to treatment emergent adverse effects" data-id="CD002795-fig-0032" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Dopamine beta‐hydroxylase inhibitors versus placebo, Outcome 1: Drop‐out rate due to treatment emergent adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Dopamine beta‐hydroxylase inhibitors versus placebo, Outcome 2: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms" data-id="CD002795-fig-0033" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Dopamine beta‐hydroxylase inhibitors versus placebo, Outcome 2: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Dopamine beta‐hydroxylase inhibitors versus placebo, Outcome 3: Drop‐out rate due to any cause" data-id="CD002795-fig-0034" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Dopamine beta‐hydroxylase inhibitors versus placebo, Outcome 3: Drop‐out rate due to any cause </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Ganaxolone versus placebo, Outcome 1: Drop‐out rate due to treatment emergent adverse effects" data-id="CD002795-fig-0035" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Ganaxolone versus placebo, Outcome 1: Drop‐out rate due to treatment emergent adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Ganaxolone versus placebo, Outcome 2: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms" data-id="CD002795-fig-0036" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Ganaxolone versus placebo, Outcome 2: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Ganaxolone versus placebo, Outcome 3: Symptom severity: Other measures" data-id="CD002795-fig-0037" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Ganaxolone versus placebo, Outcome 3: Symptom severity: Other measures</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Ganaxolone versus placebo, Outcome 4: Self‐rated scales" data-id="CD002795-fig-0038" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Ganaxolone versus placebo, Outcome 4: Self‐rated scales</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Ganaxolone versus placebo, Outcome 5: Drop‐out rate due to any cause" data-id="CD002795-fig-0039" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Ganaxolone versus placebo, Outcome 5: Drop‐out rate due to any cause</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: GR205171 versus placebo, Outcome 1: Clinical Global Impressions Scale Improvement Item (CGI‐I)" data-id="CD002795-fig-0040" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: GR205171 versus placebo, Outcome 1: Clinical Global Impressions Scale Improvement Item (CGI‐I) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: GR205171 versus placebo, Outcome 2: Drop‐out rate due to treatment emergent adverse effects" data-id="CD002795-fig-0041" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: GR205171 versus placebo, Outcome 2: Drop‐out rate due to treatment emergent adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: GR205171 versus placebo, Outcome 3: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms" data-id="CD002795-fig-0042" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: GR205171 versus placebo, Outcome 3: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: GR205171 versus placebo, Outcome 4: Drop‐out rate due to any cause" data-id="CD002795-fig-0043" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: GR205171 versus placebo, Outcome 4: Drop‐out rate due to any cause</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: GSK561679 versus placebo, Outcome 1: Clinical Global Impressions Scale Improvement Item (CGI‐I)" data-id="CD002795-fig-0044" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: GSK561679 versus placebo, Outcome 1: Clinical Global Impressions Scale Improvement Item (CGI‐I) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Hypnotics versus placebo, Outcome 1: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms" data-id="CD002795-fig-0045" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Hypnotics versus placebo, Outcome 1: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Hypnotics versus placebo, Outcome 2: Symptom severity: Other measures" data-id="CD002795-fig-0046" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Hypnotics versus placebo, Outcome 2: Symptom severity: Other measures</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Hypnotics versus placebo, Outcome 3: Depression Scale (typically Hamilton Depression)" data-id="CD002795-fig-0047" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Hypnotics versus placebo, Outcome 3: Depression Scale (typically Hamilton Depression) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-009.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Hypnotics versus placebo, Outcome 4: Drop‐out rate due to any cause" data-id="CD002795-fig-0048" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-009.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-009.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9: Hypnotics versus placebo, Outcome 4: Drop‐out rate due to any cause</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-009.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: MAOIs versus placebo, Outcome 1: Drop‐out rate due to treatment emergent adverse effects" data-id="CD002795-fig-0049" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: MAOIs versus placebo, Outcome 1: Drop‐out rate due to treatment emergent adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: MAOIs versus placebo, Outcome 2: Self‐rated scales" data-id="CD002795-fig-0050" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: MAOIs versus placebo, Outcome 2: Self‐rated scales</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: MAOIs versus placebo, Outcome 3: Depression Scale (typically Hamilton Depression)" data-id="CD002795-fig-0051" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: MAOIs versus placebo, Outcome 3: Depression Scale (typically Hamilton Depression) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-010.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: MAOIs versus placebo, Outcome 4: Anxiety ‐ Other scales" data-id="CD002795-fig-0052" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-010.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-010.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10: MAOIs versus placebo, Outcome 4: Anxiety ‐ Other scales</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-010.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-010.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: MAOIs versus placebo, Outcome 5: Drop‐out rate due to any cause" data-id="CD002795-fig-0053" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-010.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-010.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10: MAOIs versus placebo, Outcome 5: Drop‐out rate due to any cause</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-010.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: NaSSAs versus placebo, Outcome 1: Clinical Global Impressions Scale Improvement Item (CGI‐I)" data-id="CD002795-fig-0054" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: NaSSAs versus placebo, Outcome 1: Clinical Global Impressions Scale Improvement Item (CGI‐I) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: NaSSAs versus placebo, Outcome 2: Drop‐out rate due to treatment emergent adverse effects" data-id="CD002795-fig-0055" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: NaSSAs versus placebo, Outcome 2: Drop‐out rate due to treatment emergent adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-011.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: NaSSAs versus placebo, Outcome 3: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms" data-id="CD002795-fig-0056" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-011.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-011.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11: NaSSAs versus placebo, Outcome 3: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-011.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-011.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: NaSSAs versus placebo, Outcome 4: Symptom severity: Other measures" data-id="CD002795-fig-0057" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-011.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-011.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11: NaSSAs versus placebo, Outcome 4: Symptom severity: Other measures</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-011.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-011.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: NaSSAs versus placebo, Outcome 5: Self‐rated scales" data-id="CD002795-fig-0058" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-011.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-011.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.5</div> <div class="figure-caption"> <p>Comparison 11: NaSSAs versus placebo, Outcome 5: Self‐rated scales</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-011.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-011.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: NaSSAs versus placebo, Outcome 6: Depression Scale (typically Hamilton Depression)" data-id="CD002795-fig-0059" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-011.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-011.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.6</div> <div class="figure-caption"> <p>Comparison 11: NaSSAs versus placebo, Outcome 6: Depression Scale (typically Hamilton Depression) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-011.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-011.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: NaSSAs versus placebo, Outcome 7: Anxiety ‐ Other scales" data-id="CD002795-fig-0060" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-011.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-011.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.7</div> <div class="figure-caption"> <p>Comparison 11: NaSSAs versus placebo, Outcome 7: Anxiety ‐ Other scales</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-011.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-011.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: NaSSAs versus placebo, Outcome 8: Drop‐out rate due to any cause" data-id="CD002795-fig-0061" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-011.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-011.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.8</div> <div class="figure-caption"> <p>Comparison 11: NaSSAs versus placebo, Outcome 8: Drop‐out rate due to any cause</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-011.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: NK‐1 receptor antagonists versus placebo, Outcome 1: Drop‐out rate due to any cause" data-id="CD002795-fig-0062" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: NK‐1 receptor antagonists versus placebo, Outcome 1: Drop‐out rate due to any cause </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: RIMAs versus placebo, Outcome 1: Clinical Global Impressions Scale Improvement Item (CGI‐I)" data-id="CD002795-fig-0063" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: RIMAs versus placebo, Outcome 1: Clinical Global Impressions Scale Improvement Item (CGI‐I) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: RIMAs versus placebo, Outcome 2: Drop‐out rate due to treatment emergent adverse effects" data-id="CD002795-fig-0064" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: RIMAs versus placebo, Outcome 2: Drop‐out rate due to treatment emergent adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-013.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: RIMAs versus placebo, Outcome 3: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms" data-id="CD002795-fig-0065" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-013.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-013.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: RIMAs versus placebo, Outcome 3: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-013.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-013.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: RIMAs versus placebo, Outcome 4: Drop‐out rate due to any cause" data-id="CD002795-fig-0066" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-013.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-013.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13: RIMAs versus placebo, Outcome 4: Drop‐out rate due to any cause</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-013.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: SARIs versus placebo, Outcome 1: Drop‐out rate due to treatment emergent adverse effects" data-id="CD002795-fig-0067" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: SARIs versus placebo, Outcome 1: Drop‐out rate due to treatment emergent adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-014.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: SARIs versus placebo, Outcome 2: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms" data-id="CD002795-fig-0068" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-014.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-014.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: SARIs versus placebo, Outcome 2: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-014.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-014.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: SARIs versus placebo, Outcome 3: Drop‐out rate due to any cause" data-id="CD002795-fig-0069" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-014.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-014.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14: SARIs versus placebo, Outcome 3: Drop‐out rate due to any cause</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-014.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: SNRIs versus placebo, Outcome 1: Drop‐out rate due to treatment emergent adverse effects" data-id="CD002795-fig-0070" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: SNRIs versus placebo, Outcome 1: Drop‐out rate due to treatment emergent adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-015.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: SNRIs versus placebo, Outcome 2: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms" data-id="CD002795-fig-0071" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-015.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-015.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15: SNRIs versus placebo, Outcome 2: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-015.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-015.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: SNRIs versus placebo, Outcome 3: Symptom severity: Other measures" data-id="CD002795-fig-0072" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-015.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-015.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15: SNRIs versus placebo, Outcome 3: Symptom severity: Other measures</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-015.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-015.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: SNRIs versus placebo, Outcome 4: Self‐rated scales" data-id="CD002795-fig-0073" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-015.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-015.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.4</div> <div class="figure-caption"> <p>Comparison 15: SNRIs versus placebo, Outcome 4: Self‐rated scales</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-015.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-015.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: SNRIs versus placebo, Outcome 5: Depression Scale (typically Hamilton Depression)" data-id="CD002795-fig-0074" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-015.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-015.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.5</div> <div class="figure-caption"> <p>Comparison 15: SNRIs versus placebo, Outcome 5: Depression Scale (typically Hamilton Depression) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-015.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-015.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: SNRIs versus placebo, Outcome 6: Sheehan Disability Scale" data-id="CD002795-fig-0075" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-015.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-015.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.6</div> <div class="figure-caption"> <p>Comparison 15: SNRIs versus placebo, Outcome 6: Sheehan Disability Scale</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-015.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-015.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: SNRIs versus placebo, Outcome 7: Drop‐out rate due to any cause" data-id="CD002795-fig-0076" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-015.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-015.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.7</div> <div class="figure-caption"> <p>Comparison 15: SNRIs versus placebo, Outcome 7: Drop‐out rate due to any cause</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-015.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-016.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: SSRIs versus placebo, Outcome 1: Clinical Global Impressions Scale Improvement Item (CGI‐I)" data-id="CD002795-fig-0077" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-016.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16: SSRIs versus placebo, Outcome 1: Clinical Global Impressions Scale Improvement Item (CGI‐I) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-016.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: SSRIs versus placebo, Outcome 2: CGI: Individual SSRI agents" data-id="CD002795-fig-0078" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-016.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16: SSRIs versus placebo, Outcome 2: CGI: Individual SSRI agents</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-016.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: SSRIs versus placebo, Outcome 3: Drop‐out rate due to treatment emergent adverse effects" data-id="CD002795-fig-0079" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-016.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.3</div> <div class="figure-caption"> <p>Comparison 16: SSRIs versus placebo, Outcome 3: Drop‐out rate due to treatment emergent adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-016.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: SSRIs versus placebo, Outcome 4: Drop‐out rate due to treatment emergent adverse effects: Individual SSRI agents" data-id="CD002795-fig-0080" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-016.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.4</div> <div class="figure-caption"> <p>Comparison 16: SSRIs versus placebo, Outcome 4: Drop‐out rate due to treatment emergent adverse effects: Individual SSRI agents </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-016.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: SSRIs versus placebo, Outcome 5: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms" data-id="CD002795-fig-0081" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-016.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.5</div> <div class="figure-caption"> <p>Comparison 16: SSRIs versus placebo, Outcome 5: Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-016.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: SSRIs versus placebo, Outcome 6: CAPS: Individual SSRI agents" data-id="CD002795-fig-0082" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-016.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.6</div> <div class="figure-caption"> <p>Comparison 16: SSRIs versus placebo, Outcome 6: CAPS: Individual SSRI agents</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-016.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: SSRIs versus placebo, Outcome 7: Symptom severity: Other measures" data-id="CD002795-fig-0083" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-016.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.7</div> <div class="figure-caption"> <p>Comparison 16: SSRIs versus placebo, Outcome 7: Symptom severity: Other measures</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-016.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: SSRIs versus placebo, Outcome 8: Self‐rated scales" data-id="CD002795-fig-0084" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-016.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.8</div> <div class="figure-caption"> <p>Comparison 16: SSRIs versus placebo, Outcome 8: Self‐rated scales</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-016.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: SSRIs versus placebo, Outcome 9: Depression Scale (typically Hamilton Depression)" data-id="CD002795-fig-0085" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-016.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.9</div> <div class="figure-caption"> <p>Comparison 16: SSRIs versus placebo, Outcome 9: Depression Scale (typically Hamilton Depression) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-016.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: SSRIs versus placebo, Outcome 10: Anxiety ‐ Hamilton Anxiety Scale" data-id="CD002795-fig-0086" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-016.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.10</div> <div class="figure-caption"> <p>Comparison 16: SSRIs versus placebo, Outcome 10: Anxiety ‐ Hamilton Anxiety Scale</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-016.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: SSRIs versus placebo, Outcome 11: Sheehan Disability Scale" data-id="CD002795-fig-0087" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-016.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.11</div> <div class="figure-caption"> <p>Comparison 16: SSRIs versus placebo, Outcome 11: Sheehan Disability Scale</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-016.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: SSRIs versus placebo, Outcome 12: Drop‐out rate due to any cause" data-id="CD002795-fig-0088" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-016.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.12</div> <div class="figure-caption"> <p>Comparison 16: SSRIs versus placebo, Outcome 12: Drop‐out rate due to any cause</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-016.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: SSRIs versus placebo, Outcome 13: Continuation trials" data-id="CD002795-fig-0089" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-016.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.13</div> <div class="figure-caption"> <p>Comparison 16: SSRIs versus placebo, Outcome 13: Continuation trials</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-016.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-017.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: TCAs versus placebo, Outcome 1: Clinical Global Impressions Scale Improvement Item (CGI‐I)" data-id="CD002795-fig-0090" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-017.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-017.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17: TCAs versus placebo, Outcome 1: Clinical Global Impressions Scale Improvement Item (CGI‐I) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-017.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-017.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: TCAs versus placebo, Outcome 2: Drop‐out rate due to treatment emergent adverse effects" data-id="CD002795-fig-0091" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-017.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-017.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17: TCAs versus placebo, Outcome 2: Drop‐out rate due to treatment emergent adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-017.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-017.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: TCAs versus placebo, Outcome 3: Self‐rated scales" data-id="CD002795-fig-0092" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-017.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-017.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.3</div> <div class="figure-caption"> <p>Comparison 17: TCAs versus placebo, Outcome 3: Self‐rated scales</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-017.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-017.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: TCAs versus placebo, Outcome 4: Depression Scale (typically Hamilton Depression)" data-id="CD002795-fig-0093" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-017.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-017.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.4</div> <div class="figure-caption"> <p>Comparison 17: TCAs versus placebo, Outcome 4: Depression Scale (typically Hamilton Depression) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-017.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-017.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: TCAs versus placebo, Outcome 5: Anxiety ‐ Hamilton Anxiety Scale" data-id="CD002795-fig-0094" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-017.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-017.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.5</div> <div class="figure-caption"> <p>Comparison 17: TCAs versus placebo, Outcome 5: Anxiety ‐ Hamilton Anxiety Scale</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-017.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-017.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: TCAs versus placebo, Outcome 6: Anxiety ‐ Other scales" data-id="CD002795-fig-0095" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-017.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-017.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.6</div> <div class="figure-caption"> <p>Comparison 17: TCAs versus placebo, Outcome 6: Anxiety ‐ Other scales</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-017.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-017.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: TCAs versus placebo, Outcome 7: Drop‐out rate due to any cause" data-id="CD002795-fig-0096" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-017.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-017.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.7</div> <div class="figure-caption"> <p>Comparison 17: TCAs versus placebo, Outcome 7: Drop‐out rate due to any cause</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-017.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-018.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Total effect of medication versus placebo, Outcome 1: Clinical Global Impressions ‐ Improvement (CGI‐I) or similar) scale: no. of responders" data-id="CD002795-fig-0097" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-018.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-018.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18: Total effect of medication versus placebo, Outcome 1: Clinical Global Impressions ‐ Improvement (CGI‐I) or similar) scale: no. of responders </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-018.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-018.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Total effect of medication versus placebo, Outcome 2: Drop‐out rate due to treatment emergent adverse effects" data-id="CD002795-fig-0098" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-018.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-018.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.2</div> <div class="figure-caption"> <p>Comparison 18: Total effect of medication versus placebo, Outcome 2: Drop‐out rate due to treatment emergent adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-018.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-018.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Total effect of medication versus placebo, Outcome 3: Clinically Administered PTSD Scale (CAPS): CAPS Total" data-id="CD002795-fig-0099" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-018.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-018.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.3</div> <div class="figure-caption"> <p>Comparison 18: Total effect of medication versus placebo, Outcome 3: Clinically Administered PTSD Scale (CAPS): CAPS Total </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-018.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-018.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: Total effect of medication versus placebo, Outcome 4: Drop‐out rate due to any cause" data-id="CD002795-fig-0100" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-018.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-018.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.4</div> <div class="figure-caption"> <p>Comparison 18: Total effect of medication versus placebo, Outcome 4: Drop‐out rate due to any cause </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-018.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-019.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: Head‐to‐head comparisons, Outcome 1: Drop‐out rate due to treatment emergent adverse effects" data-id="CD002795-fig-0101" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-019.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-019.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19: Head‐to‐head comparisons, Outcome 1: Drop‐out rate due to treatment emergent adverse effects </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-019.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-019.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: Head‐to‐head comparisons, Outcome 2: Clinician administered scales: Symptom severity" data-id="CD002795-fig-0102" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-019.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-019.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.2</div> <div class="figure-caption"> <p>Comparison 19: Head‐to‐head comparisons, Outcome 2: Clinician administered scales: Symptom severity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-019.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-019.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: Head‐to‐head comparisons, Outcome 3: Comorbid symptoms: Depression" data-id="CD002795-fig-0103" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-019.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-019.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.3</div> <div class="figure-caption"> <p>Comparison 19: Head‐to‐head comparisons, Outcome 3: Comorbid symptoms: Depression</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-019.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-019.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: Head‐to‐head comparisons, Outcome 4: Comorbid symptoms: Anxiety (Hamilton Anxiety Scale)" data-id="CD002795-fig-0104" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-019.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-019.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.4</div> <div class="figure-caption"> <p>Comparison 19: Head‐to‐head comparisons, Outcome 4: Comorbid symptoms: Anxiety (Hamilton Anxiety Scale) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-019.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-020.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: Subgroup analyses ‐ Methodological criteria, Outcome 1: Single versus multi‐centre trials (CGI‐I: No. of responders)" data-id="CD002795-fig-0105" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-020.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-020.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20: Subgroup analyses ‐ Methodological criteria, Outcome 1: Single versus multi‐centre trials (CGI‐I: No. of responders) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-020.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-020.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: Subgroup analyses ‐ Methodological criteria, Outcome 2: Single versus multi‐centre trials (CAPS: Total score)" data-id="CD002795-fig-0106" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-020.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-020.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.2</div> <div class="figure-caption"> <p>Comparison 20: Subgroup analyses ‐ Methodological criteria, Outcome 2: Single versus multi‐centre trials (CAPS: Total score) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-020.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-020.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: Subgroup analyses ‐ Methodological criteria, Outcome 3: Industry versus non‐industry funded trials (CGI‐I: No. of responders)" data-id="CD002795-fig-0107" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-020.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-020.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.3</div> <div class="figure-caption"> <p>Comparison 20: Subgroup analyses ‐ Methodological criteria, Outcome 3: Industry versus non‐industry funded trials (CGI‐I: No. of responders) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-020.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-020.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: Subgroup analyses ‐ Methodological criteria, Outcome 4: Industry versus non‐industry funded trials (CAPS: Total score)" data-id="CD002795-fig-0108" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-020.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-020.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.4</div> <div class="figure-caption"> <p>Comparison 20: Subgroup analyses ‐ Methodological criteria, Outcome 4: Industry versus non‐industry funded trials (CAPS: Total score) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-020.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-021.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Subgroup analyses ‐ Clinical criteria, Outcome 1: Inclusion of major depression vs. non‐inclusion: (CGI‐I: No. of responders)" data-id="CD002795-fig-0109" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-021.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-021.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21: Subgroup analyses ‐ Clinical criteria, Outcome 1: Inclusion of major depression vs. non‐inclusion: (CGI‐I: No. of responders) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-021.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-021.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Subgroup analyses ‐ Clinical criteria, Outcome 2: Inclusion of major depression vs. non‐inclusion: (CAPS: Total score)" data-id="CD002795-fig-0110" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-021.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-021.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.2</div> <div class="figure-caption"> <p>Comparison 21: Subgroup analyses ‐ Clinical criteria, Outcome 2: Inclusion of major depression vs. non‐inclusion: (CAPS: Total score) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-021.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-021.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Subgroup analyses ‐ Clinical criteria, Outcome 3: Inclusion of war veterans versus non‐inclusion: (CGI‐I: No. of responders)" data-id="CD002795-fig-0111" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-021.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-021.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.3</div> <div class="figure-caption"> <p>Comparison 21: Subgroup analyses ‐ Clinical criteria, Outcome 3: Inclusion of war veterans versus non‐inclusion: (CGI‐I: No. of responders) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-021.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-021.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: Subgroup analyses ‐ Clinical criteria, Outcome 4: Inclusion of war veterans versus non‐inclusion: (CAPS: Total score)" data-id="CD002795-fig-0112" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-021.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-021.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.4</div> <div class="figure-caption"> <p>Comparison 21: Subgroup analyses ‐ Clinical criteria, Outcome 4: Inclusion of war veterans versus non‐inclusion: (CAPS: Total score) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-021.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-022.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: Sensitivity analyses, Outcome 1: Clinical Global Impressions Scale Improvement Item (CGI‐I): non‐response" data-id="CD002795-fig-0113" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-022.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-022.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22: Sensitivity analyses, Outcome 1: Clinical Global Impressions Scale Improvement Item (CGI‐I): non‐response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-022.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-022.02" target="_blank"><b></b></a></p> </div><img alt='Comparison 22: Sensitivity analyses, Outcome 2: "Worst case" loss to follow up analysis' data-id="CD002795-fig-0114" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-022.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-022.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.2</div> <div class="figure-caption"> <p>Comparison 22: Sensitivity analyses, Outcome 2: "Worst case" loss to follow up analysis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-022.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002795-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/urn:x-wiley:14651858:media:CD002795:CD002795-CMP-022.03" target="_blank"><b></b></a></p> </div><img alt='Comparison 22: Sensitivity analyses, Outcome 3: "Best case" loss to follow up analysis' data-id="CD002795-fig-0115" src="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-022.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_t/tCD002795-CMP-022.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.3</div> <div class="figure-caption"> <p>Comparison 22: Sensitivity analyses, Outcome 3: "Best case" loss to follow up analysis</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/media/CDSR/CD002795/image_n/nCD002795-CMP-022.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002795-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Comparison 1: Alpha‐blockers versus placebo for posttraumatic stress disorder (PTSD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 1: Alpha‐blockers versus placebo for posttraumatic stress disorder (PTSD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population</b> : adults (aged 18‐85)<br/><b>Settings</b> : multi‐centre trials<br/><b>Intervention</b> : alpha‐blocker<br/><b>Comparison</b>: placebo </p> <p><b>Follow‐up:</b> not specified </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With alpha‐blockers</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies that looked at the number of participants who responded to prazosin compared to placebo. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment tolerability, as measured by Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.99</b><br/>(0.91 to 1.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>304<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>No evidence of a difference in dropout rates were found in the alpha‐blocker group (13%) and placebo group (12%) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>118 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>117 per 1000</b><br/>(108 to 128) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>118 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>117 per 1000</b><br/>(107 to 127) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : confidence interval;<b>RR</b> : risk ratio. <b>N/A:</b> Not applicable. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to serious risk of bias (concerns with randomisation procedures). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Comparison 1: Alpha‐blockers versus placebo for posttraumatic stress disorder (PTSD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#CD002795-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002795-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Comparison 2: Antipsychotics versus placebo for posttraumatic stress disorder (PTSD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 2: Antipsychotics versus placebo for posttraumatic stress disorder (PTSD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population</b> : adults (aged 18‐85)<br/><b>Settings</b> : single and multi‐centre trials<br/><b>Intervention</b> : antipsychotics<br/><b>Comparison</b>: placebo </p> <p><b>Follow‐up</b>: not specified </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With</b> antipsychotics </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.51</b> <br/>(0.16 to 1.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>43<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no evidence of a benefit of the number of participants in the antipsychotic groups (71%) compared to the placebo groups (37%) who responded and improved on the CGI‐I scale </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>368 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>188 per 1000</b><br/>(59 to 615) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>443 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>226 per 1000</b><br/>(71 to 740) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment tolerability, as measured by Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.98</b> <br/>(0.92 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>348<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Twice as many participants withdrew from the antipsychotic groups (16%) compared to the placebo groups (7%), but no important difference in dropout rates was found </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>71 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>66 per 1000</b><br/>(60 to 73) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to serious risk of bias (concerns with randomisation procedures).<br/><sup>b</sup>Downgraded by one level due to serious imprecision (wide confidence intervals).<br/><sup>c</sup>Downgraded by one level due to moderate heterogeneity (I<sup>2</sup> of 50%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Comparison 2: Antipsychotics versus placebo for posttraumatic stress disorder (PTSD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#CD002795-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002795-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Comparison 3: MAOIs versus placebo for posttraumatic stress disorder (PTSD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 3: MAOIs versus placebo for posttraumatic stress disorder (PTSD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population</b> : adults (aged 18‐85)<br/><b>Settings</b> : multi‐centre trial<br/><b>Intervention</b> : MAOI<br/><b>Comparison</b>: placebo </p> <p><b>Follow‐up</b>: not specified </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With MAOIs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies that looked at the number of participants who responded to phenelzine versus placebo. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment tolerability, as measured by Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.14</b> <br/>(0.90 to 1.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>37<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>More participants dropped out from the placebo group (17%) compared to the MAOI group (5%), but we found no difference in dropout rates </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>190 per 1000</b><br/>(150 to 238) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>190 per 1000</b><br/>(150 to 239) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : confidence interval;<b>RR</b> : risk ratio. <b>N/A:</b> Not applicable. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to serious risk of bias (concerns with randomisation procedures).<br/><sup>b</sup>Downgraded by one level due to serious imprecision (wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Comparison 3: MAOIs versus placebo for posttraumatic stress disorder (PTSD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#CD002795-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002795-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Comparison 4: NaSSAs versus placebo for posttraumatic stress disorder (PTSD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 4: NaSSAs versus placebo for posttraumatic stress disorder (PTSD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population</b> : adults (aged 18‐85)<br/><b>Settings</b> : single‐centre trial<br/><b>Intervention</b> : NaSSA<br/><b>Comparison</b>: placebo </p> <p><b>Follow‐up:</b> not specified </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With NaSSAs</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment efficacy ‐ Treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.45</b> <br/>(0.22 to 0.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>26<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence of a benefit for the number of participants with PTSD who responded to treatment (65%) compared to placebo (22%). This is also indicated by the Risk Ratio of 0.45 which indicates that there is a statistically significantly greater number of people in the NaSSA group compared to the placebo group who improved on the CGI‐I scale </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/>(49 to 209) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>222 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/>(49 to 209) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment tolerability, as measured by Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.87</b> <br/>(0.68 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>36<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The proportion of dropouts due to adverse events was high in participants receiving the NaSSA (18%) relative to placebo (5%), but there was no </p> <p>evidence of a harm between the numbers of participants that dropped out due to adverse events </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b><br/>(20 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>178 per 1000</b><br/>(20 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>CAPS:</b> Clinically Administered PTSD Scale;<b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to serious risk of bias (concerns with randomisation procedures).<br/><sup>b</sup>Downgraded by one level due to serious imprecision (wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Comparison 4: NaSSAs versus placebo for posttraumatic stress disorder (PTSD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#CD002795-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002795-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Comparison 5: SNRIs versus placebo for posttraumatic stress disorder (PTSD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 5: SNRIs versus placebo for posttraumatic stress disorder (PTSD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population</b> : adults (aged 18‐85)<br/><b>Settings</b> : multi‐centre trials<br/><b>Intervention</b> : SNRIs<br/><b>Comparison</b>: placebo </p> <p><b>Follow‐up:</b> for one study at week 24 or at the time of discontinuation if before week 24; the remaining study did not specify follow‐up </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With SNRIs</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We found no studies that looked at the number of participants who responded to venlafaxine versus placebo. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment tolerability, as measured by Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.98</b> <br/>(0.88 to 1.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>687<br/>(2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Dropout rates due to adverse events were low in the SNRI (4%) and placebo groups (3%)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>25 per 1000</b><br/>(23 to 29) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b><br/>(24 to 30) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : confidence interval;<b>RR</b> : risk ratio. <b>N/A:</b> Not applicable. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to serious risk of bias (concerns with randomisation procedures).<br/><sup>b</sup>Downgraded by two levels due to considerable heterogeneity (I<sup>2</sup> of 92%). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Comparison 5: SNRIs versus placebo for posttraumatic stress disorder (PTSD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#CD002795-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002795-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Comparison 6: SSRIs versus placebo for posttraumatic stress disorder (PTSD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 6: SSRIs versus placebo for posttraumatic stress disorder (PTSD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population</b> : adults (aged 18‐85)<br/><b>Settings</b> : single and multi‐centre trials<br/><b>Intervention</b> : SSRIs<br/><b>Comparison</b>: placebo </p> <p><b>Follow‐up:</b> for 1 study at week 10 and for another study 14 days after the last dose of study drug; the remaining studies did not specify follow‐up </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With SSRIs</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.66</b> <br/>(0.59 to 0.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1078<br/>(8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence of a benefit for the number of participants with PTSD who responded to treatment for the SSRI group (58%) compared to the placebo group (35%). This is also indicated by the Risk Ratio of 0.66 which indicates that there is a statistically significantly greater number of people in the SSRI group compared to the placebo group who improved on the CGI‐I scale </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>348 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>229 per 1000</b><br/>(205 to 257) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>328 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>216 per 1000</b><br/>(194 to 243) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment tolerability, as measured by Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.98</b> <br/>(0.96 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>2399<br/>(14 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>A similar proportion withdrew due to treatment adverse events (9% versus 7%)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>66 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>65 per 1000</b><br/>(64 to 66) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b><br/>(48 to 50) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to serious risk of bias (concerns with randomisation procedures). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Comparison 6: SSRIs versus placebo for posttraumatic stress disorder (PTSD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#CD002795-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002795-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Comparison 7: TCAs versus placebo for posttraumatic stress disorder (PTSD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 7: TCAs versus placebo for posttraumatic stress disorder (PTSD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population</b> : adults (aged 18‐85)<br/><b>Settings</b> : single and multi‐centre trials<br/><b>Intervention</b> : TCAs<br/><b>Comparison</b>: placebo </p> <p><b>Follow‐up:</b> not specified </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>With TCAs</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.60</b> <br/>(0.38 to 0.96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>40<br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence of a benefit for the number of participants with PTSD who responded to treatment in the TCA group (50%) compared to the placebo group (17%). This is also indicated by the Risk Ratio of 0.60, which indicates that there is a statistically significantly greater number of people in the TCA group compared to the placebo group who improved on the CGI‐I scale </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/>(63 to 160) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b><br/>(63 to 160) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Treatment tolerability, as measured by Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.92</b> <br/>(0.81 to 1.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>141<br/>(3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>We found no evidence of a difference in dropout rates between the TCA groups (23%) and placebo groups (18%) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>182 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>167 per 1000</b><br/>(147 to 191) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale;<b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level due to serious risk of bias (concerns with randomisation procedures).<br/><sup>b</sup>Downgraded by one level due to serious imprecision (wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Comparison 7: TCAs versus placebo for posttraumatic stress disorder (PTSD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/full#CD002795-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Alpha‐blockers versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Dropout rate due to treatment‐emergent adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.91, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 CAPS: Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐5.13, 5.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Self‐rated scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.41, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Depression scale (typically Hamilton Depression) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Reduction of depression symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐2.11, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Dropout rate due to any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.65, 1.62]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Alpha‐blockers versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Anticonvulsants versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Clinical Global Impressions Scale Improvement Item (CGI‐I) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.63, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Dropout rate due to treatment emergent adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 CAPS: Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐6.54, 5.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 CAPS subscale: Re‐experiencing/intrusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐3.74, 4.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 CAPS subscale: Avoidance/numbing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐8.65, 7.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.4 CAPS subscale: Hyperarousal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [‐2.57, 2.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Symptom severity: Other measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Reduction of PTSD symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.31, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Self‐rated scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Reduction of PTSD symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.75, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Depression scale (typically Hamilton Depression) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Reduction of depression symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.57, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Depression Scale ‐ Change scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.32 [‐0.81, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Anxiety ‐ Hamilton Anxiety Scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Reduction of anxiety symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.66 [‐3.66, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Anxiety ‐ Other scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 Reduction of anxiety symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [‐0.21, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Sheehan Disability Scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 Reduction of functional disability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [‐1.48, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Dropout rate due to any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.61, 1.06]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Anticonvulsants versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Antipsychotics versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Clinical Global Impressions Scale Improvement Item (CGI‐I) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.16, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Drop‐out rate due to treatment emergent adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.85, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 CAPS: Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.10 [‐22.57, ‐5.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 CAPS subscale: Re‐experiencing/intrusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.73 [‐7.55, ‐1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.3 CAPS subscale: Avoidance/numbing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.01 [‐13.72, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.4 CAPS subscale: Hyperarousal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.14 [‐8.16, ‐2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Symptom severity: Other measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Reduction of PTSD symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.55 [‐0.94, ‐0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Self‐rated scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.47 [‐1.06, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 Self‐rated subscale: Re‐experiencing/Intrusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [‐0.58, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.3 Self‐rated subscale: Avoidance/numbing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.38, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.4 Self‐rated subscale: Hyperarousal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐1.13, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Depression Scale (typically Hamilton Depression) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 Reduction of depression symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.62 [‐1.01, ‐0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Anxiety ‐ Hamilton Anxiety Scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 Reduction of anxiety symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.03 [‐6.21, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Sheehan Disability Scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 Reduction of functional disability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.57 [‐14.74, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Drop‐out rate due to any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.54, 1.14]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Antipsychotics versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Benzodiazepines versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Drop‐out rate due to treatment emergent adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Drop‐out rate due to any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.39, 1.89]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Benzodiazepines versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Dopamine beta‐hydroxylase inhibitors versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Drop‐out rate due to treatment emergent adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.77, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 CAPS: Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.27 [‐16.72, 6.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 CAPS subscale: Re‐experiencing/intrusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.63 [‐1.67, 6.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.3 CAPS subscale: Avoidance/numbing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [‐4.57, 5.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.4 CAPS subscale: Hyperarousal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [‐1.82, 5.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Drop‐out rate due to any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.64, 3.00]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Dopamine beta‐hydroxylase inhibitors versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Ganaxolone versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Drop‐out rate due to treatment emergent adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.10, 3.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 CAPS: Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.50 [‐10.92, 5.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 CAPS subscale: Re‐experiencing/intrusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐4.09, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.3 CAPS subscale: Avoidance/numbing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐5.74, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.4 CAPS subscale: Hyperarousal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐3.96, 1.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Symptom severity: Other measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 Reduction of PTSD symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.59, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Self‐rated scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4.1 Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.59, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Drop‐out rate due to any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.94, 3.92]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Ganaxolone versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">GR205171 versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Clinical Global Impressions Scale Improvement Item (CGI‐I) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.42, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Drop‐out rate due to treatment emergent adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.1 CAPS: Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.60 [‐22.59, 7.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Drop‐out rate due to any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.03, 2.41]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">GR205171 versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">GSK561679 versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Clinical Global Impressions Scale Improvement Item (CGI‐I) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.88, 1.31]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">GSK561679 versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Hypnotics versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 CAPS Total Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐19.57, 17.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Symptom severity: Other measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 Reduction of PTSD symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐1.08, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Depression Scale (typically Hamilton Depression) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3.1 Reduction of depression symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.67 [‐12.68, 7.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.4 Drop‐out rate due to any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [0.59, 5.79]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Hypnotics versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">MAOIs versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Drop‐out rate due to treatment emergent adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.90, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Self‐rated scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.06 [‐1.75, ‐0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.2 Self‐rated subscale: Re‐experiencing/Intrusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.07 [‐1.77, ‐0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.3 Self‐rated subscale: Avoidance/numbing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.81 [‐1.49, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Depression Scale (typically Hamilton Depression) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.1 Reduction of depression symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.80 [‐7.15, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.4 Anxiety ‐ Other scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4.1 Reduction of anxiety symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.67 [‐1.34, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.5 Drop‐out rate due to any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.67, 1.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">MAOIs versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">NaSSAs versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Clinical Global Impressions Scale Improvement Item (CGI‐I) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.22, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Drop‐out rate due to treatment emergent adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.68, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.3 Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.1 CAPS Total Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.20 [‐14.74, 8.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.2 CAPS subscale: Re‐experiencing/intrusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.50 [‐6.32, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.3 CAPS subscale: Avoidance/numbing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐6.22, 5.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3.4 CAPS subscale: Hyperarousal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐3.51, 3.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.4 Symptom severity: Other measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4.1 Reduction of PTSD symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐0.87, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.5 Self‐rated scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5.1 Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐1.02, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.6 Depression Scale (typically Hamilton Depression) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.6.1 Reduction of depression symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐1.39, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.7 Anxiety ‐ Other scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.7.1 Reduction of anxiety symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.88 [‐1.77, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.8 Drop‐out rate due to any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.8.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.48, 1.52]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">NaSSAs versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">NK‐1 receptor antagonists versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Drop‐out rate due to any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.32, 1.04]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">NK‐1 receptor antagonists versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">RIMAs versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Clinical Global Impressions Scale Improvement Item (CGI‐I) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.44, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Drop‐out rate due to treatment emergent adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.91, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3.1 CAPS Total Score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.06 [‐15.93, 5.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.4 Drop‐out rate due to any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.49, 2.22]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">RIMAs versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">SARIs versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Drop‐out rate due to treatment emergent adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.70, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.1 CAPS: Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.60 [‐21.26, 10.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.2 CAPS subscale: Re‐experiencing/intrusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐6.80, 4.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.3 CAPS subscale: Avoidance/numbing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐9.23, 6.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2.4 CAPS subscale: Hyperarousal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.90 [‐8.40, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.3 Drop‐out rate due to any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.68, 0.97]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">SARIs versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">SNRIs versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 Drop‐out rate due to treatment emergent adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.88, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.2 Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2.1 CAPS: Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.11 [‐12.29, ‐3.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2.2 CAPS subscale: Re‐experiencing/intrusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.95 [‐3.36, ‐0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2.3 CAPS subscale: Avoidance/numbing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.42 [‐5.23, ‐1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2.4 CAPS subscale: Hyperarousal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.29 [‐3.67, ‐0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.3 Symptom severity: Other measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3.1 Reduction of PTSD symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.46, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.4 Self‐rated scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4.1 Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.47, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4.2 Self‐rated subscale: Re‐experiencing/Intrusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.44, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4.3 Self‐rated subscale: Avoidance/numbing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.44, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.4.4 Self‐rated subscale: Hyperarousal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.45, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.5 Depression Scale (typically Hamilton Depression) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5.1 Reduction of depression symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.42, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.5.2 Depression Scale ‐ Change scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.43, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.6 Sheehan Disability Scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.6.1 Reduction of functional disability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.01 [‐3.30, ‐0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.7 Drop‐out rate due to any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.7.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.90, 1.21]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">SNRIs versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">SSRIs versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.1 Clinical Global Impressions Scale Improvement Item (CGI‐I) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1078</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.59, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.2 CGI: Individual SSRI agents <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2.1 Fluoxetine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.19, 2.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2.2 Paroxetine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>728</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.55, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2.3 Sertraline versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.56, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.3 Drop‐out rate due to treatment emergent adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.96, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.4 Drop‐out rate due to treatment emergent adverse effects: Individual SSRI agents <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4.1 Fluoxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.25, 2.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4.2 Paroxetine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.05, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4.3 Sertraline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.87, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.5 Clinically Administered PTSD Scale (CAPS): reduction of PTSD symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5.1 CAPS: Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.91 [‐7.48, ‐2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5.2 CAPS subscale: Re‐experiencing/intrusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.86 [‐2.82, ‐0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5.3 CAPS subscale: Avoidance/numbing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.68 [‐4.82, ‐2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5.4 CAPS subscale: Hyperarousal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1813</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.45 [‐3.30, ‐1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.6 CAPS: Individual SSRI agents <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6.1 Citalopram versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.78 [‐15.95, 25.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6.2 Fluoxetine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐12.31, 10.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6.3 Paroxetine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.32 [‐11.49, ‐1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6.4 Sertraline versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.45 [‐7.17, ‐1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.7 Symptom severity: Other measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.7.1 Reduction of PTSD symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.32 [‐0.55, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.8 Self‐rated scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.8.1 Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.50, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.8.2 Self‐rated subscale: Re‐experiencing/Intrusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.58, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.8.3 Self‐rated subscale: Avoidance/numbing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.58, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.8.4 Self‐rated subscale: Hyperarousal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐0.98, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.9 Depression Scale (typically Hamilton Depression) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.9.1 Reduction of depression symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.44, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.9.2 Depression Scale ‐ Change scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1551</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.43, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.10 Anxiety ‐ Hamilton Anxiety Scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.10.1 Reduction of anxiety symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐1.84, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.11 Sheehan Disability Scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.11.1 Reduction of functional disability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.10 [‐3.00, ‐1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.12 Drop‐out rate due to any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.12.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.87, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.13 Continuation trials <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.13.1 Symptom severity on the CAPS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.62 [‐3.53, 22.77]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">SSRIs versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">TCAs versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.1 Clinical Global Impressions Scale Improvement Item (CGI‐I) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.38, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.2 Drop‐out rate due to treatment emergent adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.81, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.3 Self‐rated scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3.1 Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.54 [‐1.18, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3.2 Self‐rated subscale: Re‐experiencing/Intrusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.44 [‐0.99, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3.3 Self‐rated subscale: Avoidance/numbing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐1.51, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.4 Depression Scale (typically Hamilton Depression) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4.1 Reduction of depression symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.67 [‐1.58, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.5 Anxiety ‐ Hamilton Anxiety Scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.5.1 Reduction of anxiety symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.60 [‐12.74, ‐2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.6 Anxiety ‐ Other scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.6.1 Reduction of anxiety symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐1.08, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.7 Drop‐out rate due to any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.7.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.62, 0.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">TCAs versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Total effect of medication versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar) scale: no. of responders <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1822</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.64, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1.1 Anticonvulsants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.63, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1.2 Antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.16, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1.3 MAOIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.44, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1.4 GR205171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.42, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1.5 GSK561679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.88, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1.6 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1078</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.59, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1.7 TCAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.37, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.2 Drop‐out rate due to treatment emergent adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.96, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.1 Alpha‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.91, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.2 Anticonvulsants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.3 Antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.85, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.4 Benzodiazepines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.89, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.5 Dopamine beta‐hydroxylase inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.54, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.6 Ganaxolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.94, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.7 GR205171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.91, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.8 MAOIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.91, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.9 NaSSAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.68, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.10 SARIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.70, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.11 SNRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.88, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.12 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2047</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.96, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.13 TCAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.81, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.3 Clinically Administered PTSD Scale (CAPS): CAPS Total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.79 [‐6.64, ‐2.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3.1 Alpha‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐5.13, 5.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3.2 Anticonvulsants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐6.54, 5.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3.3 Antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.10 [‐22.57, ‐5.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3.4 Dopamine beta‐hydroxylase inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.27 [‐16.72, 6.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3.5 Ganaxolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.50 [‐10.92, 5.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3.6 GR205171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.60 [‐22.59, 7.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3.7 Hypnotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐19.57, 17.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3.8 MAOIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.06 [‐15.93, 5.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3.9 NaSSAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.38 [‐10.32, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3.10 SARIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.60 [‐21.26, 10.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3.11 SNRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.11 [‐12.29, ‐3.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3.12 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.84 [‐7.64, ‐2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.4 Drop‐out rate due to any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.90, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4.1 Alpha‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.89, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4.2 Anticonvulsants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.90, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4.3 Antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.93, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4.4 Benzodiazepines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.39, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4.5 Dopamine beta‐hydroxylase inhibitors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.75, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4.6 Ganaxolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.65, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4.7 GR205171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.03, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4.8 Hypnotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.39, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4.9 MAOIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.71, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4.10 NaSSAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.88, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4.11 NK‐1 receptor antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.32, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4.12 SARIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.68, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4.13 SNRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.90, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4.14 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.87, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4.15 TCAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.62, 0.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Total effect of medication versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Head‐to‐head comparisons</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.1 Drop‐out rate due to treatment emergent adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1.1 Reboxetine versus fluvoxamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.42, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.2 Clinician administered scales: Symptom severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2.1 Nefazodone versus sertraline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.63, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2.2 Venlafaxine versus sertraline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.22, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2.3 Reboxetine versus fluvoxamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [‐0.11, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.3 Comorbid symptoms: Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3.1 Nefazodone versus sertraline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.86, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3.2 Reboxetine versus fluvoxamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [‐0.11, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.4 Comorbid symptoms: Anxiety (Hamilton Anxiety Scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.4.1 Nefazodone versus sertraline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.23 [‐10.90, 4.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.4.2 Reboxetine versus fluvoxamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [‐1.30, 4.90]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Head‐to‐head comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Subgroup analyses ‐ Methodological criteria</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.1 Single versus multi‐centre trials (CGI‐I: No. of responders) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1.1 Single centre trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.55, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1.2 Multi‐centre trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.63, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.2 Single versus multi‐centre trials (CAPS: Total score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2.1 Single centre trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>269</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.04 [‐7.91, 3.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2.2 Multi‐centre trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3636</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.60 [‐7.84, ‐3.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.3 Industry versus non‐industry funded trials (CGI‐I: No. of responders) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3.1 Industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.25, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3.2 Non‐industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.00, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.4 Industry versus non‐industry funded trials (CAPS: Total score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.4.1 Industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.29 [‐9.09, ‐3.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.4.2 Non‐industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.43 [‐5.64, 0.79]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Subgroup analyses ‐ Methodological criteria</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Subgroup analyses ‐ Clinical criteria</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.1 Inclusion of major depression vs. non‐inclusion: (CGI‐I: No. of responders) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.1 Trials including patients with major depressive disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.60, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.2 Trials excluding patients with major depressive disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.10, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.2 Inclusion of major depression vs. non‐inclusion: (CAPS: Total score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2.1 Trials including patients with major depressive disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1959</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.40 [‐9.36, ‐3.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2.2 Trials excluding patients with major depressive disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>866</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.34 [‐14.51, ‐4.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.3 Inclusion of war veterans versus non‐inclusion: (CGI‐I: No. of responders) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3.1 Trials including war veterans</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.59, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3.2 Trials without war veterans</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1264</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.58, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.4 Inclusion of war veterans versus non‐inclusion: (CAPS: Total score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.4.1 Trials including war veterans</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.65 [‐7.27, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.4.2 Trials without war veterans</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1653</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.26 [‐10.76, ‐5.76]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Subgroup analyses ‐ Clinical criteria</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002795-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Sensitivity analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.1 Clinical Global Impressions Scale Improvement Item (CGI‐I): non‐response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1847</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.62, 0.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.1 Anticonvulsants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.46, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.2 Antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.16, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.3 MAOIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.44, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.4 GR205171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.42, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.5 GSK561679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.88, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.6 NASSAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.22, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.7 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1078</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.59, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.8 TCAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.38, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.2 "Worst case" loss to follow up analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1555</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.69, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2.1 Anticonvulsants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.84, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2.2 Antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.27, 3.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2.3 MAOIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.07, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2.4 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.62, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2.5 TCAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.45, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.3 "Best case" loss to follow up analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [1.12, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3.1 Anticonvulsants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.72, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3.2 Antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.42, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3.3 MAOIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.06, 3.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3.4 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1022</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [1.43, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3.5 TCAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [1.13, 10.81]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Sensitivity analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002795.pub3/references#CD002795-tbl-0029">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002795.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD002795-note-0021">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002795-note-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002795-note-0019">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD002795-note-0017">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD002795-note-0016">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD002795-note-0020">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD002795-note-0015">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD002795-note-0014">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD002795-note-0012">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD002795-note-0013">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002795\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002795\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002795\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002795\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002795\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002795\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002795\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002795\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002795\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002795\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002795\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002795\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002795\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002795\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002795\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002795\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002795\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002795\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=sogqpCtr&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002795.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002795.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002795.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002795.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002795.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714154241"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002795.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714154245"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002795.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d67b8e98e937d',t:'MTc0MDcxNDE1NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 